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Abstract 
Signal Transducer and Activator of Transcription 3 (STAT3) is a transcription factor 
constitutively activated in cancer, leading to survival, proliferation, angiogenesis and 
metastasis. STAT3 inhibitors possess anti-cancer properties, however, the 
selectivity and potency of current inhibitors must be improved. This thesis 
characterises a novel STAT3 inhibitor, VS-43. VS-43 is a potent and selective 
STAT3 inhibitor, able to inhibit cancer cell growth and induce apoptosis in cancer 
cell lines.  VS-43 is shown to inhibit STAT3 DNA binding and downstream target 
expression. VS-43 is also able to synergise with cisplatin, and this combination is 
more synergistic than the combination of cisplatin with other STAT3 inhibitors.  
Cisplatin acts via the formation of adducts with the cellular DNA, and the interstrand 
crosslink (ICL) is the most toxic of the cisplatin lesions. Resistance to cisplatin can 
occur via enhanced repair of ICLs. Therefore, the effect of STAT3 inhibition on ICL 
repair was investigated. STAT3 inhibitors are shown to block the unhooking of 
cisplatin-induced ICLs and down-regulate the expression of the ICL repair factors 
EME1, MUS81, BRCA1 and FANCD2. Binding of STAT3 to the MUS81 and EME1 
promoters was demonstrated using ChIP assays, suggesting direct transcriptional 
regulation of the MUS81-EME1 nuclease by STAT3. In contrast, STAT3 inhibitors 
did not synergise with melphalan and did not block melphalan-ICL unhooking. 
siRNA knockdown of MUS81 or EME1 demonstrated that the MUS81-EME1 
nuclease is selectively involved in cisplatin-ICL repair. 
This thesis presents VS-43 as a promising novel STAT3 inhibitor, and provides 
mechanistic insight into how STAT3 inhibitors synergise with cisplatin through the 
regulation of ICL unhooking. Understanding the differences in the repair of different 
ICLs will be essential for the design of future chemotherapy combinations. 
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Chapter 1 Introduction 
1.1 The epidemiology of cancer  
Globally, 14.1 million people were diagnosed with cancer in 2012. It is estimated 
that 8.2 million deaths occurred in 2012 due to cancer: 22,000 per day (American 
Cancer Society, 2015). In the UK alone, 352,197 new cases of cancer were 
diagnosed in 2013, and there were 163,444 deaths related to cancer (Cancer 
Statistics for the UK, Cancer Research UK webpage. Available from: 
http://www.cancerresearchuk.org/health-professional/cancer-statistics [accessed 
August 2016]). By 2030, the American Cancer Society estimates that the number of 
new cancer cases will have increased to 21.7 million per year and the number of 
cancer-related deaths will be 13 million per year. This, however, may still be a huge 
underestimate due to the increasing number of people adopting behaviours that 
increase the risk of cancer such as smoking, lack of activity and a poor diet. 
Globally, the most common cancer is prostate cancer in men and breast cancer in 
women (American Cancer Society, 2015). The twenty most common types of cancer 
and their incidence in the UK are shown in Figure 1-1.  
Together, breast, lung, prostate and bowel cancer contribute to 53% of all cancers 
in the UK. Worldwide, cancer incidence varies with geographical location due to 
different population age ranges, access to medical care and screening programmes, 
and the presence of risk factors in different regions. For example, worldwide, 16% of 
cancers are caused by infections, however this is as high as 23% in developing 
regions compared with only 7% in developed countries (American Cancer Society, 
2015). Even though survival rates have improved considerably over the past 40 
years (from 25% to 50% survival 10 years post diagnosis), cancer is still a 
devastating disease, and 1 in 2 people born after 1960 will be diagnosed with 
cancer in their lifetime (Ahmad et al., 2015).  
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According to Cancer Research UK, 42% of cancer incidences are classed as 
preventable. Smoking is the highest cause of preventable cancer in the UK, 
accounting for 19% of new cancer cases each year. Other lifestyle factors 
contributing to preventable cancers include a poor diet, lack of exercise, excessive 
alcohol consumption, and lack of sun protection. Occupational exposure to radiation 
or carcinogens such as asbestos, and infections with carcinogenic organisms also 
contribute to preventable cancers (Statistics on Preventable Cancers, Cancer 
Research UK webpage. Available from: http://www.cancerresearchuk.org/health-
professional/cancer-statistics/risk/preventable-cancers [accessed August 2016]). 
Given the current global burden of cancer and the ever-growing incidence of this 
disease, continued research into new treatments is critical.  
The epidemiology of prostate and lung cancer will be discussed in more detail as 
prostate and lung cancer cell lines are predominantly used in this thesis.  
 
Figure 1-1: The twenty most common cancers in the UK, and their incidence. 
Figure obtained from: Cancer Incidence for Common Cancers, Cancer Research 
UK. Available from: http://www.cancerresearchuk.org/health-professional/cancer-
statistics/incidence/common-cancers-compared#heading-Zero [accessed August 
2016].  
The 20 Most Common Cancers in 2013
Number of New Cases, UK
Cancer Site Male Female Persons
Breast (C50) 344 53,352 53,696
Prostate (C61) 47,300 47,300
Lung (C33-C34) 24,481 21,044 45,525
Bowel (C18-C20) 22,957 18,155 41,112
Malignant Melanoma (C43) 7,152 7,357 14,509
Non-Hodgkin Lymphoma 
(C82-C86)
7,259 6,154 13,413
Kidney (C64-C66,C68) 7,455 4,418 11,873
Brain, Other CNS & 
Intracranial Tumours (C70-
C72, C75.1-C75.3, D32-D33, 
D35.2-D35.4, D42-D43, D44.3-
D44.5)
5,164 5,460 10,624
Bladder (C67) 7,465 2,876 10,341
Pancreas (C25) 4,716 4,692 9,408
Leukaemia (C91-C95) 5,585 3,716 9,301
Uterus (C54-C55) 0 9,022 9,022
Oesophagus (C15) 5,852 2,932 8,784
Oral (C00-C06,C09-C10,C12-
C14)
5,103 2,488 7,591
Ovary (C56-C57.4) 0 7,284 7,284
Stomach (C16) 4,564 2,503 7,067
Myeloma (C90) 3,142 2,355 5,497
Liver (C22) 3,491 1,922 5,413
Thyroid (C73) 880 2,361 3,241
Cervix (C53) 3,207 3,207
Other Sites 18,584 17,799 36,383
Data in this chart do not sum to the all cancers combined total provided elsewhere, because 'Brain, other CNS (central nervous system) and intracranial' includes 
tumours that are malignant, benign and of uncertain or unknown behaviour but only the malignant tumours are included in 'all cancers combined' total. 
Data in this chart do not sum to the all cancers combined total provided elsewhere, because 'Brain, other CNS (central nervous system) and intracranial' includes 
tumours that are malignant, benign and of uncertain or unknown behaviour but only the malignant tumours are included in 'all cancers combined' total. 
Source: cruk.org/cancerstats
You are welcome to reuse this Cancer Research UK statistics content for your own work. 
Credit us as authors by referencing Cancer Research UK as the primary source. 
Suggested style: Cancer Research UK, full URL of the page, Accessed [month] [year].
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1.1.1 Prostate cancer 
In 2012 there were 1.1 million new cases of prostate cancer and 307,500 deaths 
due to prostate cancer worldwide. Prostate cancer is most prevalent in the 
economically developed world, with two thirds of all cases occurring in these regions 
where only 17% of the worlds population lives. Northern Europe and North America 
have some of the highest incidence rates for prostate cancer, however this may be 
correlated to a greater use of prostate specific antigen (PSA) testing in these 
regions and therefore, greater detection rates. The main risk factor for prostate 
cancer is age (American Cancer Society, 2015). Prostate cancer is the fifth greatest 
cause of death globally, however death rates are decreasing due to earlier 
detection. Between 2010-2011, 10-year survival for men with prostate cancer was 
84%, however the number of deaths occurring in the UK was still 11,287 in 2014. 
Inherited factors contribute to 5-9% of prostate cancers (Prostate Cancer Statistic, 
Cancer Research UK webpage. Available from: 
http://www.cancerresearchuk.org/health-professional/cancer-statistics/statistics-by-
cancer-type/prostate-cancer [accessed August 2016]), with some mutations, for 
example BRCA2 mutations, being responsible for tumourigenesis. The relative risk 
of developing prostate cancer is 7.33% in men carrying a BRCA2 mutation under 
the age of 65 (Consortium, 1999). However, obesity and consumption of processed 
meat have also been suggested to impact incidence of prostate cancer (American 
Cancer Society, 2015).  
1.1.2 Lung Cancer 
In 2012 there were 1.8 million new cases of lung cancer, with again, North America 
and Northern Europe having the highest incidence rates. Lung cancer is responsible 
for the most cancer-related deaths in men, and the second most cancer-related 
deaths in women, with an estimated 1.6 million deaths in 2012 (American Cancer 
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Society, 2015). In the UK in 2013, there were 45,525 new cases of lung cancer and 
38,895 deaths. Only 5% of patients with lung cancer survive for 10 years post-
diagnosis. The largest risk factor for developing lung cancer is smoking due to the 
carcinogens in tobacco smoke and global incidence rates reflect this. For example, 
Scotland has one of the highest incidence rates of lung cancer in the world and as a 
country, is also one of the largest consumers of cigarettes (Lung Cancer Statistics, 
Cancer Research UK webpage. Available from: 
http://www.cancerresearchuk.org/health-professional/cancer-statistics/statistics-by-
cancer-type/lung-cancer [accessed August 2016]). The high mortality rate 
associated with lung cancer is due to the commonly late diagnosis of this disease, 
due to lack of symptoms until the cancer is more advanced. The most common form 
of lung cancer is non-small cell lung cancer (NSCLC), which accounts for 87% of 
cases. Small-cell lung cancer accounts for approximately 12% of cases (Types of 
Lung Cancer, Cancer Research UK webpage. Available from: 
http://www.cancerresearchuk.org/about-cancer/type/lung-cancer/about/types-of-
lung-cancer [accessed August 2016]).  
1.2 The biology of cancer 
Cancer is a disease of uncontrolled cellular replication, and it places immense strain 
on the human body either physically, by creating obstructions or putting pressure on 
a particular organ, or through the deregulation of essential processes such as 
hormone production, immune response, and haematogenesis. Due to genetic 
heterogeneity, no two cancers are the same. As illustrated in Figure 1-2, due to the 
accumulation of genetic mutations in a tumour over time, sub-clones appear within a 
single tumour, and the sub-clones present can differ between patients with the same 
cancer type, between different regions in a single tumour, and also between the 
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primary tumour and metastases (Jamal-Hanjani et al., 2015). Therefore cancer is a 
collection of diseases, and accordingly, many different treatments are required. 
 
Figure 1-2: Types of tumour heterogeneity. A) Interpatient, B) intratumour, C) 
intermetastatic and D) intrametastatic. Taken from (Jamal-Hanjani et al., 2015). 
 
1.2.1 The hallmarks of cancer and genomic instability  
In 2000, Hanahan and Weinberg identified six key traits which enable 
tumourigenesis, and coined these “The Hallmarks of Cancer” (Hanahan et al., 
2000). These traits are shown in Figure 1-3.  
As cancer is a disease of uncontrolled replication, it is not surprising that the ability 
to sustain proliferative signalling is one of the most important cancer hallmarks. 
Cancer cells deregulate the signals for proliferation, driving the cell cycle through 
aberrant production of growth factors and their receptors. Independence from these  
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Figure 1-3: The six Hallmarks of Cancer. Proliferation, evasion of growth 
suppression, invasion and metastasis, replicative immortality, angiogenesis and 
survival. Taken from (Hanahan and Weinberg, 2011). 
growth signals can also arise when components of signalling pathways become 
constitutively activated (Hanahan and Weinberg, 2011). Genes driving cancer 
growth in this way are known as oncogenes. An oncogene exists in the normal cell’s 
DNA in its pre-tumourigenic form, the proto-oncogene. Once mutated the gene 
becomes over-activated or over-expressed, ultimately driving tumourigenesis. 
Oncogenes are dominant, in that only one mutated allele is required to allow cancer 
progression. For instance, approximately half of all melanomas have activating 
somatic mutations in the B-Raf oncogene. B-Raf is a member of the MAP-kinase 
signalling cascade, and constitutive activation of this pathway drives cellular 
proliferation (Davies and Samuels, 2010).  
In order to continue proliferating, the cancer cell must be able to escape from the 
signals that restrict proliferation. These growth suppressive signals are often 
provided by tumour suppressor genes. When tumour suppressors are inactivated by 
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mutation, deregulation of key cell processes such as the cell cycle occurs. Tumour 
suppressors are recessive cancer genes in that both alleles must be mutated in 
order to loose complete function of the gene and allow cancer progression (Stratton, 
2011).  
A key example of a tumour suppressor is p53 which is mutated in more than half of 
cancers (Brady and Attardi, 2010). P53 is referred to as the “guardian of the 
genome”, putting a brake on cell cycle progression when DNA damage is detected, 
and inducing apoptosis if that damage is irreparable (Lane, 1992). When p53 
function is disrupted through mutation, the cancer cell is able to rapidly progress 
through the cell cycle, acquiring even more mutations as DNA damage is no longer 
repaired before DNA replication.  
The third hallmark is “resisting cell death”. The role of the mutated p53 tumour 
suppressor gene in evading apoptosis has already been discussed, but tumour cells 
can also up-regulate the expression of anti-apoptotic regulators such as the bcl2 
family of proteins (Hanahan and Weinberg, 2011). 
A normal cell can perform a limited number of divisions (known as the Hayflick limit 
(Shay and Wright, 2000)) before it either enters senescence (a non-replicative but 
viable state), or undergoes apoptosis. However, a cancer cell must continue 
replicating. The replicative lifetime of a cell is determined by the length of the 
telomeres - repetitive DNA sequences protecting the ends of chromosomes from 
recombination and degradation. Each replicative cycle slightly shortens the 
telomeres, and once too short, the DNA is no longer protected and the cell is no 
longer viable. Some cancer cells are able circumvent telomere shortening by 
expressing greater levels of the enzyme telomerase which allows for continued 
replication (Blasco, 2005). 
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The combination of the first four hallmarks: sustaining proliferation, evading growth 
suppression, resisting cell death and obtaining replicative immortality, therefore, all 
contribute to the continued survival and replication of the cancer cell. The fifth 
hallmark of cancer, angiogenesis, concerns supplying the growing tumour with the 
required nutrients and oxygen it needs. Angiogenesis is the development of new 
vasculature, and is usually only temporarily switched on for processes such as 
wound healing. However, in cancer, angiogenesis is switched on in the pre-
tumourigenic stage, and remains switched on in order to continue expanding the 
vasculature serving the tumour’s growth. Expression of the vascular endothelial 
growth factor (VEGF) and its receptors can induce angiogenesis (Hanahan and 
Folkman, 1996; Hanahan and Weinberg, 2011). 
The final original hallmark is related to the ability of the tumour to spread to other 
regions of the body: invasion and metastasis. Loss of cell-cell adhesion molecules in 
the primary tumour, such as E-cadherin, allows for epithelial-mesenchymal 
transition (EMT) and individual cells can then enter the tumour vasculature, and be 
carried around the body. Tumour cells then leave the vasculature and develop new 
tumours at the metastasis site (Talmadge and Fidler, 2010). 
These six hallmarks were later expanded upon in 2011 to include two further 
hallmarks: evading immune destruction and reprogramming energy metabolism. As 
tumour proliferation is deregulated, the cellular energy demands are higher and 
therefore metabolism must adapt. Cancer cells derive most of their energy from 
glycolysis, even in the presence of oxygen. This phenomenon has been coined the 
Warburg effect. As glycolysis is substantially less efficient at producing ATP than 
oxidative phosphorylation, the reason why cancer cells undergo this metabolic 
switch is not fully understood. One hypothesis is that glycolytic intermediates are 
used for the synthesis of nucleotides and amino acids in order to maintain rapid 
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tumour cell division (Vander Heiden et al., 2009). The second emerging hallmark, 
evading immune destruction, allows the tumour to continue growing without being 
detected and eliminated by the immune system. A tumour may do this through the 
production of immunosuppressive factors or the recruitment of immunosuppressive 
inflammatory cells to the tumour microenvironment (Hanahan and Weinberg, 2011). 
Two enabling characteristics for the development of a tumour have also been 
identified: genome instability, which provides the genetic alterations required for 
many of the cancer hallmarks, and tumour-promoting inflammation, which can 
supply growth factors and enzymes to facilitate hallmark development (Hanahan 
and Weinberg, 2011). 
Cancer cells have inherent genomic instability due to the loss of cell cycle 
checkpoints and continued proliferation in the presence of unrepaired DNA damage. 
This damage may be a result of errors in replication, but is also linked to reactive 
oxygen species and free radicals generated during the reprogrammed metabolism 
of the cancer cells (Dang, 2012). If a cell acquires mutations in DNA repair genes, 
the cell becomes less able to correct DNA damage and the stability of the genome 
worsens.  
The hallmarks of cancer are underpinned by genomic instability. Genetic changes 
can occur via three pathways: aneuploidy (an abnormal number of chromosomes), 
chromosomal rearrangements such as translocations, or point mutations in specific 
genes. Mutations can be hereditary, acquired by exposure to external mutagens or 
a product of random mutations acquired during DNA replication. Cells can acquire 
two types of mutation: passenger and driver mutations. Passenger mutations have 
no direct role in tumourigenesis, whereas driver mutations directly contribute to 
tumour development by allowing the cell some form of growth advantage, 
contributing to one of the hallmarks (Stratton, 2011). Mutations will begin to 
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accumulate even before birth due to intrinsic mutational processes. Throughout 
adulthood, environmental and lifestyle-induced mutations will occur. Further 
mutations can arise when a cancer cell acquires a mutator phenotype, and also 
after treatment with chemotherapy, leading eventually to a chemotherapy resistant 
tumour (Figure 1-4) (Stratton, 2013).  
Mutations can arise when DNA damage is incorrectly repaired. On average, tens of 
thousands of DNA damages occur each day in just one cell. This damage can exist 
in various forms; a list of the approximate frequencies of some types of DNA 
damage is shown in Table 1-1. 
Epigenetic mutations can also contribute to cancer development. For example, 
methylation of CpG islands can inhibit the transcription of certain genes. If this 
 
Figure 1-4: Accumulation of mutations from a fertilised egg to a chemotherapy 
resistant tumour cell. Taken from (Stratton, 2013). 
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Table 1-1: Approximate numbers of DNA damages per cell per day. 
Summarised from (Bernstein et al., 2013). 
Damage Approximate frequency (per cell per day) 
Oxidative 10,000 
Depurination 10,000 
Depyrimidination 700 
Single-strand breaks 55,000 
Double-strand breaks 10-50 per cell cycle 
Methylation  3000 
Cytosine deamination 200 
occurs in a tumour suppressor gene or a DNA repair gene, this could be considered 
a driver mutation (Bernstein et al., 2013).   
Exogenous carcinogens can cause DNA mutations. As discussed previously, 
tobacco smoke is the leading cause of lung cancer. The reason for this being that 
tobacco smoke contains several carcinogens including nitrosamines, benzopyrenes 
and formaldehyde (Cunningham et al., 2011; Hecht, 2003). As well as chemical 
carcinogens, biological carcinogens such as Helicobacter pylori also exist. Infection 
with this bacterium increases production of reactive oxygen species in the stomach, 
resulting in DNA damage such as oxidation of guanines. Infection with Helicobacter 
pylori, therefore, is a significant risk factor for stomach cancer (Wiseman and 
Halliwell, 1996). Solar UV radiation is another natural carcinogen, which plays a 
huge role in the development of melanomas due to the formation of cyclopyridine 
dimers (CPDs) and 6-4 photoproducts in the cellular DNA. The increasing use of 
commercial tanning sunbeds has also been closely linked to melanomas, with 
individuals who begin using sunbeds under the age of 30 having a 75% greater 
chance of developing melanoma (Kanavy and Gerstenblith, 2011).  
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It is estimated that approximately five driver mutations are required for 
tumourigenesis (Stratton, 2011), and so given the huge amount of DNA damage 
that occurs daily from a number of sources, it is understandable why cancer is so 
prevalent in the human population.  
1.3 Treatments for cancer 
Surgery is one of the most common treatments for cancer, and is often used when 
the tumour is confined to one area. Other therapies include radiotherapy, 
chemotherapy, hormone therapy, biological therapy, and in the case of 
haematological malignancies, bone marrow or stem cell transplant may be used in 
conjunction with high dose chemotherapy or radiotherapy.  
In this thesis, the main cell lines used are prostate and non-small cell lung cancer; 
therefore, the treatments currently available for these types of cancer will be 
discussed in further detail.  
1.3.1 Treatments for prostate cancer 
The main treatments for prostate cancer in the UK are surgery, radiotherapy and 
hormone therapy.  Radiotherapy can be administered externally or internally and 
can cure the cancer if it has not yet spread outside of the prostate gland. Hormone 
therapy works by reducing the level of testosterone in patients, as prostate cancer 
requires testosterone to continue growing. Hormone therapy drugs include anti-
androgens, GnRH blockers, cytochrome p17 blockers and luteinising hormone 
blockers. Prostate cancers may respond initially to these treatments however they 
can become hormone-refractory and alternative treatments may be required. The 
average time to progression after hormone therapy is between 18-24 months 
(Recine and Sternberg, 2015). Once resistant to hormone-based treatments 
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metastases can occur and radiotherapy may be used to relieve the painful 
symptoms of prostate cancer metastases in the bones (Zustovich and Fabiani, 
2014). At this stage chemotherapy drugs will also be considered for the treatment of 
advanced prostate cancer. Drugs currently used include Docetaxel, Paclitaxel, and 
Cabazitaxel (microtubule inhibitors), Estramustine (both a microtubule inhibitor and 
alkylating agent), and Mitoxantrone and Epirubicin (DNA intercalating 
Topoisomerase II inhibitors). All of these drugs act to block cancer cell proliferation. 
Whether chemotherapy should be given to patients before they become hormone-
refractory is currently debated (Recine and Sternberg, 2015).  
Other treatments sometimes used for hormone-refractory prostate cancer include 
steroids, cryotherapy, and High Intensity Focused Ultrasound (HIFU) (Treatment 
Options for Prostate Cancer, Cancer Research UK webpage. Available from: 
http://www.cancerresearchuk.org/about-cancer/type/prostate-
cancer/treatment/types/treatment-options-for-prostate-cancer [accessed August 
2016]). 
1.3.2 Treatments for lung cancer 
Current treatments approved for lung cancer patients in the UK include surgery, 
radiotherapy and chemotherapy. Surgery is only used for non-small cell lung cancer 
(NSCLC) as small-cell lung cancers (SCLC) have often already spread by the time 
of diagnosis. In surgery, one of three procedures can be carried out depending on 
the tumour size and location. A section, lobe, or whole lung can be removed. 
Radiotherapy can be used internally or more commonly externally to treat lung 
cancer (Types of Treatment for Lung Cancer, Cancer Research UK webpage. 
Available from: http://www.cancerresearchuk.org/about-cancer/type/lung-
cancer/treatment/which-treatment-for-lung-cancer [accessed August 2016]).  
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Chemotherapy is the most effective choice of treatment for those with SCLC or for 
where a cancer has metastasised around the body to multiple locations. Different 
chemotherapy combinations are used depending on whether a patient has SCLC or 
NSCLC. For SCLC, most primary treatment combinations include either cisplatin or 
carboplatin. However, if a cancer becomes resistant to these therapies and recurs, 
secondary chemotherapy combinations must be used (Table 1-2). For NSCLC, 
chemotherapy is used after surgery, alongside radiotherapy or for advanced NSCLC 
that has metastasised (Types of Treatment for Lung Cancer, Cancer Research UK. 
Available from: http://www.cancerresearchuk.org/about-cancer/type/lung-
cancer/treatment/which-treatment-for-lung-cancer [accessed August 2016]). Again, 
chemotherapy drug combinations almost always include cisplatin or carboplatin 
combined with another agent (Table 1-3). Therefore, platinum agents are the most 
commonly used class of chemotherapy drugs in the treatment of lung cancer. Which 
other chemotherapy agent is combined with platinum may be determined by the 
histology of the tumour (Fennell et al., 2016). However, platinum-based therapy is 
not curative. Novel platinum agents may be required in the future to overcome 
acquired resistance to platinum chemotherapy as up to 63% and 68% of NSCLC 
tumour cultures display resistance to cisplatin and carboplatin, respectively (Chang, 
2011).  
Biologically targeted therapeutics may be used for NSCLC, including Erlotinib, 
Gefitinib, and Afatinib. These are all Tyrosine Kinase Inhibitors (TKIs) that target 
EGFR (Epidermal Growth Factor Receptor). Crizotinib and ceritinib are TKI’s that 
target the EML4-ALK fusion protein and are also approved treatments for some 
NSCLCs.  Overactive EGFR and ALK activity are known to contribute to 
carcinogenesis of NSCLC, therefore, these proteins are valid targets for directed 
biological therapy. However, the incidence of driver mutations in these proteins is 
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only 10% and 4% for EGFR and ALK, respectively. Therefore, approximately 85% of 
NSCLC patients cannot be treated with these targeted agents and depend upon 
platinum-based therapy (Fennell et al., 2016).  
 
Table 1-2: Primary and secondary chemotherapy drug combinations for small 
cell lung cancer. (Types of Treatment for Lung Cancer, Cancer Research UK. 
Available from: http://www.cancerresearchuk.org/about-cancer/type/lung-
cancer/treatment/which-treatment-for-lung-cancer [accessed August 2016] 
Small Cell Lung Cancer 
Primary Chemotherapy Cisplatin + Etoposide (EP) 
Carboplatin + Etoposide 
Carboplatin + Gemcitabine 
Secondary Chemotherapy  Cyclophosphamide + Doxorubicin + Vincristine (CAV) 
CAV + Etoposide (CAVE) 
 
Doxorubicin + Cyclophosphamide + Etoposide (ACE) 
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Table 1-3: Chemotherapy drug combinations for non-small cell lung 
cancer.(Types of Treatment for Lung Cancer, Cancer Research UK. Available from: 
http://www.cancerresearchuk.org/about-cancer/type/lung-cancer/treatment/which-
treatment-for-lung-cancer [accessed August 2016] 
Non-Small Cell Lung Cancer 
 
 
After Surgery 
 
 
 
Cisplatin/Carboplatin +… 
Vinorelbine 
Gemcitabine 
Paclitaxel 
Docetaxel 
 
Alongside Radiotherapy  
Doxorubicin 
Etoposide 
Pemetrexed 
 
 
Advanced or Metastatic NSCLC 
 
 
Cisplatin/Carboplatin +… 
Gemcitabine 
Paclitaxel 
Vinorelbine 
Docetaxel 
Pemetrexed 
Combinations of chemotherapy with radiotherapy are also used, and other less 
commonly used treatments include Radiofrequency Ablation (RFA) where the heat 
from microwaves is targeted to the cancer cells, or Photodynamic Therapy (PDT) 
where a photosensitising drug is administered followed by exposure to a laser light 
source (Types of Treatment for Lung Cancer, Cancer Research UK webpage, 
available from: http://www.cancerresearchuk.org/about-cancer/type/lung-
cancer/treatment/which-treatment-for-lung-cancer [accessed August 2016]). 
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1.4 Cancer chemotherapy 
In the early 1900s, the German chemist Paul Ehrlich described the term 
“chemotherapy” as the use of chemicals to treat disease (DeVita and Chu, 2008). 
The discovery of the first chemotherapy agent arose from the observation that 
soldiers exposed to sulphur mustard gas had depleted bone marrow and lymphoid 
cells. In 1942, pharmacologists Goodman and Gilman at the Yale School of 
Medicine hypothesised that these gases might also act on tumours of the 
hematopoietic system. Having demonstrated therapeutic benefit in a mouse model, 
a more stable nitrogen mustard was tested in its first cancer patient. The nitrogen 
mustard compound (mechlorethamine) was administered intravenously to an 
individual with non-Hodgkins lymphoma, and marked regression of the patient’s 
cancer was observed (Gilman and Philips, 1946). Whilst the cancer did return after 
a short remission period, this discovery paved the way for the use of chemical 
compounds in the treatment of cancer (Chabner and Roberts, 2005; DeVita and 
Chu, 2008). 
The second class of chemotherapy compounds to be developed was the anti-
folates. Shortly after the Second World War it was noted that folic acid could 
stimulate the proliferation of some leukemia cells, and that deficiency in folic acid 
produced similar effects on the hematopoietic system as was previously observed 
for nitrogen mustards (Farber, 1949). One of the first anti-folate drugs developed 
was methotrexate, which is still used in the clinic today, and since then other anti-
folates have been developed including pemetrexed. These compounds act by 
inhibiting the enzyme required for folic acid synthesis, which itself is a precursor for 
thymidine. Therefore, inhibition of the folic acid pathway inhibits DNA replication 
(Bertino, 2009; DeVita and Chu, 2008). Methotrexate was noted to have anti-tumour 
effects in a range of cancers including ovarian, breast, head and neck and bladder 
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cancer. It was even suggested to completely cure some patients with 
choriocarcinoma, a rare malignancy of the placenta (Chiu Li et al., 1958).  
The development of the purine analogues quickly followed in the early 1950s. This 
class of compounds included mercaptopurine, which is still used today to treat some 
forms of leukemia. The first form of “targeted cancer therapy” was also brought to 
light in the 1950s, when scientists at the University of Wisconsin observed that rat 
hepatocellular cancer cells uptake higher levels of uracil than normal cells. They 
modified uracil by adding a fluorine atom, creating 5-fluorouracil (5-FU) which was 
demonstrated to have anti-tumour activity in a variety of solid cancers. 5-FU is still 
one of the most commonly used chemotherapy drugs in the clinic today (DeVita and 
Chu, 2008).  
In 1963 the natural alkaloids from the Vinca rosea plant were identified to have anti-
proliferative effects on tumour cells through their ability to inhibit the polymerisation 
of microtubules which is essential for mitosis (Bensch and Malawista, 1968; 
Johnson et al., 1963). This class of compounds included vincristine, which was later 
administered as part of one of the earliest combination chemotherapy treatment 
regimes alongside methotrexate, prednisone and mercaptopurine. This treatment 
demonstrated long-lasting remission in children with acute lymphoblastic leukemia 
(Chabner and Roberts, 2005). Another microtubule-targeting chemotherapy agent 
discovered in the 1960’s was paclitaxel, but due to its difficulty to synthesise and 
relative insolubility, it wasn’t until 1989 that this drug was demonstrated to have 
significant anti-tumour activity in ovarian cancer (Chabner and Roberts, 2005). The 
camptothecin class of natural chemotherapy compounds was also discovered in the 
1960’s but like paclitaxel, these compounds took time to demonstrate clinical 
efficacy due to their instability. In 1996, irinotecan was the first camptothecin to gain 
FDA approval for the treatment of colorectal cancer. Irinotecan works by targeting 
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DNA topoisomerase I (Saltz et al., 2000). This will be reviewed in more detail in the 
following sections.  
Another major class of chemotherapy agents discovered in this period was the 
platinum compounds, which form adducts and crosslinks with the DNA, blocking 
replication and transcription. Cisplatin was the first of this class, discovered in 1965 
(Rosenberg et al., 1969, 1965) and later approved by the FDA in 1978. In a bid to 
overcome cisplatin’s adverse effects including nephrotoxicity, second and third 
generation platinum compounds have been developed such as carboplatin and 
oxaliplatin.  During the 1970’s the chloroethyl nitrosoureas, a group of DNA-
alkylating chemotherapy agents, were also developed. However, in the 1980’s, 
there was little development of new chemotherapy agents that didn’t fit into one of 
the already identified groups: antimetabolites, alkylators, crosslinkers, anti-mitotics 
and topoisomerase inhibitors. Therefore, more recently there has been a change of 
direction, with drug discovery focussing more on targeted cancer therapy such as 
monoclonal antibodies and tyrosine kinase inhibitors. However, traditional 
chemotherapy is still very much at the core of cancer treatment, and therefore, 
these agents will be discussed in further detail, with a focus on those which act 
through targeting the cancer cell DNA. 
1.5 DNA as an anti-cancer target 
DNA is the most successful anti-cancer target, as demonstrated by the number of 
traditional chemotherapy agents discussed above which target this molecule. The 
double helical structure of DNA, and the pairing of adenine with thymine and 
cytosine with guanine, was resolved in 1953 by geneticists James Watson and 
Francis Crick (Watson and Crick, 1953), so at the time of the development of the 
earliest chemotherapy agents, the details of their molecular target were unknown. 
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Since then, the importance of what is known as the “central dogma” has emerged. 
This concept was first described by Francis Crick in 1958, and detailed the transfer 
of information between DNA, RNA and protein (Crick, 1970). The information 
encoded by DNA is first transcribed by RNA polymerase to form messenger RNA, 
which is subsequently translated into proteins by ribosomes. Therefore, intact and 
functional DNA is crucial for the survival of a cell, and so agents that disrupt the 
integrity of the cellular DNA exert their toxicity in this way.  
Agents which target the DNA are not, however, selective in their activity. Every cell 
contains DNA and is dependent upon its integrity for survival. Accumulation of DNA 
damage will halt the cell cycle and if left unrepaired, eventually cause apoptosis, 
whether the cell is a cancer cell or not. DNA-targeting chemotherapy agents do, 
however, gain some degree of selectivity through the more rapid proliferation of 
cancer cells versus most normal tissues. Cancer cells typically lose cell cycle 
regulation and so continue to replicate their DNA even with accumulated DNA 
damage, leading to replication-induced DSBs and ultimately cell death. Therefore, 
exposure to DNA-damaging agents can more effectively push cancer cells into 
apoptosis than normal cells. However, the basis of this selectivity also means that 
the adverse effects of DNA-damaging agents are often associated with areas of the 
body with a high cellular proliferation rate (Hurley, 2002).  
Nonetheless, DNA damaging agents are still the most frequently used drugs in 
cancer therapy, although they are more often administered as part of a combination 
regimen to lower the individual drug toxicities (see Table 1-2 and Table 1-3) for 
treatment combinations in lung cancer). Future directions for overcoming the 
adverse effects associated with DNA-damaging agents rely on the development of 
targeting modules so that the effect of these compounds on normal tissues is 
minimised.  Examples of these include antibody-drug conjugates (ADCs) which 
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carry a cytotoxic compound to the tumour cell by binding to antigens expressed 
selectively on tumour cells, such as Kadcyla® (trastuzumab emtansine), which is 
used in HER2 positive breast cancers. Liposomal or nanoparticle formulations of 
chemotherapy drugs may also be used. These can be coated in tumour-targeting 
ligands (Thomas and Pommier, 2016). The liposomal form of irinotecan was 
approved for use in advanced metastatic pancreatic cancer in 2015 (Drummond et 
al., 2006), and works via a passive accumulation of the liposomes in the tumour 
tissue due to the enhanced permeability and retention, “EPR”, effect (Greish, 2010).  
1.6 DNA-interacting drugs 
As described above, many chemotherapy agents interact with the DNA to exert their 
cytotoxic effects. Drugs may covalently bond to the DNA in the minor or major 
groove, or may intercalate into the DNA helix. There are four main ways in which a 
bifunctional alkylating agent can interact with the DNA and these are illustrated in 
Figure 1-5. Initially, the agent may bind to the DNA in one region, forming a 
monoadduct. This may be converted in a second step to an adduct with two 
contacts to the DNA – either an intrastrand crosslink where the drug contacts two 
bases of the same strand, or an interstrand crosslink (ICL) where the drug bridges 
two bases on opposite strands of the DNA. The second step is the rate limiting step 
and so monoadducts are often more common than crosslinks. A fourth type of 
adduct that may form is a DNA-protein crosslink (McHugh et al., 2001).  
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Figure 1-5: The four DNA binding modes for bifunctional agents: monoadduct, 
DNA-protein crosslink, intrastrand crosslink or interstrand crosslink (ICL). Adapted 
from (McHugh et al., 2001). 
One of the largest group of DNA-interacting drugs is the alkylating agents. These 
include both mono-functional and bi-functional agents which transfer alkyl groups 
ranging from small methyl adducts to larger bulky adducts onto the DNA bases.  
Both types of agents are used in the clinic such as the monofunctional alkylators, 
procarbazine and temozolomide, and the bifunctional nitrogen mustards melphalan 
and chlorambucil (D. Fu et al., 2012).  
The platinum class of chemotherapy agents are considered “alkylating-like”, in that 
they perform similar reactions with the DNA but do not contain alkyl groups. 
Platinum agents consist of a central platinum ion surrounded by ligands that can be 
displaced by nucleophilic atoms in the DNA bases. This displacement allows 
platinum agents to form covalent bonds with one base (mono-functional) or two 
bases (bi-functional) (Colvin et al., 2003).  
As well as agents that form mono-adducts and crosslinks, agents that can inhibit 
topoisomerase complexes are used in cancer therapy. Topoisomerases are 
required to induce transient breaks in the genome in order to avoid supercoiling and 
Monoadduct 
DNA-Protein 
Crosslink 
Intrastrand Crosslink Interstrand Crosslink (ICL) 
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“knots” in the DNA when regions are unwound for transcription or replication. 
Therefore, inhibition of these enzymes results in abnormal DNA structures and 
stalling of DNA replication and transcription. The camptothecins, for example 
irinotecan, stabilise the topoisomerase I-DNA complex, therefore inhibiting re-
ligation of the cleaved DNA and inducing DSBs. Doxorubicin is able to act similarly 
on the topoisomerase II-DNA complex, doing so through its intercalation into the 
DNA double helix (Pommier et al., 2010), and etoposide, a non-intercalating 
topoisomerase II poison, likely inhibits topoisomerase II through direct protein-drug 
interactions (Nitiss, 2009).  
The final class of DNA-interacting chemotherapeutics are the nucleoside analogues, 
for example, gemcitabine, which is an analogue of cytidine. Upon entering the cell, 
nucleoside analogues like gemcitabine are phosphorylated and incorporated into the 
DNA during replication instead of the natural nucleotides. This causes termination of 
elongation, DNA strand breaks and subsequently apoptosis. Gemcitabine also 
potentiates its own effect by inhibiting ribonucleotide reductase, an enzyme involved 
in synthesis of deoxyribonucleotides from ribonucleotides. This lowers the level of 
competing deoxyribonucleotides in the cell, and ensures that a greater amount of 
gemcitabine is incorporated into the DNA (Galmarini et al., 2002; Mini et al., 2006).  
Therefore, there are several mechanisms by which chemotherapy drugs may 
interact with DNA and as a result interfere with the correct functioning of this 
molecule, and this has been exploited from the very beginning of cancer therapy.  
1.6.1 Crosslinking agents 
Nitrogen mustards, mitomycin C, platinums and psoralens are all successful 
chemotherapy agents that are still used in the clinic today. These drugs have one 
thing in common: they produce DNA interstrand crosslinks (ICLs). ICLs are 
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considered to be one of the most toxic DNA lesions possible, as they covalently link 
the two DNA strands and as such, cannot be bypassed during replication or 
transcription. Therefore, these essential processes are blocked by unrepaired ICLs, 
and stalling of replication forks at these structures results in DSBs and eventual 
apoptosis (McHugh et al., 2001; Muniandy et al., 2010). The contribution of the ICL 
in the toxicity of these agents was demonstrated by Clingen et al. Mono-functional 
melphalan was demonstrated to have an IC50 4-fold higher than bi-functional 
melphalan, and the novel crosslinker SJG-136 was 60-fold more potent as a bi-
functional agent than its mono-functional counterpart (Clingen et al., 2005). As the 
mono-functional forms of these drugs can only form monoadducts, whereas the bi-
functional forms are able to produce ICLs, this suggests that the ICL is a critical 
cytotoxic lesion. It is estimated that just 20 unrepaired ICLs can cause cell death in 
sensitive cell lines (Lawley and Phillips, 1996). Therefore, agents that produce ICLs 
are highly effective for chemotherapy.  
1.6.1.1 Cisplatin 
The first of the platinum class of agents, cis-platinum diamminodichloride (cisplatin), 
was initially synthesised in 1844 by Michael Peyrone and named Peyrone’s 
Chloride. 50 years passed before the structure of cisplatin was elucidated in 1893 
by Alfred Werner (Desoize and Madoulet, 2002; Florea and Büsselberg, 2011).  
More than 70 years then passed before cisplatin was re-discovered serendipitously 
in 1965. Rosenberg et al. intended to observe the effects of an electric current on 
bacterial processes using platinum electrodes. Instead, they noticed an effect on the 
replication of the bacteria and identified that this was in fact due to several platinum-
based compounds that had formed in the media (Rosenberg et al., 1965). Later, 
they demonstrated the anti-cancer effects of these platinum-based compounds in 
mice – one of which was cisplatin (Rosenberg et al., 1969).  Cisplatin was given to 
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the first cancer patient in a phase I clinical trial in 1971, and this was followed by 
positive results from trials in ovarian and testicular cancer patients (Lebwohl and 
Canetta, 1998). 
Cisplatin was eventually approved for use by the FDA in 1978 and today, more than 
170 years after its initial discovery, cisplatin is one of the most commonly used 
drugs for treating lung, ovarian, testicular, head and neck, cervical, bladder and 
germ cell cancers. It is typically administered every 3-4 weeks intravenously. As 
cisplatin is given systemically many side effects can occur with a tendency for a 
lower tolerance of the drug as age increases. This has been suggested to be due to 
an inverse relationship between the ability of cells to repair ICLs and the patients 
age (McHugh et al., 2001). 10% of patients typically experience at least one of the 
more common side effects of cisplatin which include: vulnerability to infections due 
to a lower white blood cell count, tiredness and a shortness of breath due to a lower 
red blood cell count, bruising due to the effect of cisplatin on platelets, nausea, 
some high-range hearing loss and kidney damage. Less than 10% of patients will 
experience one of the less common side effects such as amenorrhoea, fertility 
problems, loss of appetite and taste, tinnitus, or numbness (Cisplatin, Cancer 
Research UK webpage, available from: http://www.cancerresearchuk.org/about-
cancer/cancers-in-general/treatment/cancer-drugs/cisplatin [accessed August 
2016]). Strategies exist to manage some of these side effects such as increasing 
drug elimination with intravenous hydration, and alleviation of nausea by 
administration of antiemetics (Florea and Büsselberg, 2011).  
Due to these side effects, cisplatin is often administered in combination with other 
drugs that have non-overlapping toxicities (see treatment of lung cancer, section 
1.3.2) as this allows lower doses of each component of the combination to be used 
to obtain the same therapeutic effect. Development of other platinum chemotherapy 
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drugs was also intended to reduce the side effects observed with cisplatin. These 
include oxaliplatin and carboplatin, now widely used in colon cancer and ovarian 
cancer, respectively (Florea and Büsselberg, 2011).  
1.6.1.1.1 Molecular mechanism of cisplatin 
Cisplatin has been suggested to enter the cell by one of three processes: passive 
diffusion across the membrane, facilitated transportation through the copper 
transporter CTR1 or active transport via ATPases such as the Na+/K+ ATPase (Basu 
and Krishnamurthy, 2010).  
Once inside the cell, cisplatin undergoes two spontaneous hydrolysis reactions, 
displacing the chloride ions for water molecules (Figure 1-6). Hydrolysis is only 
favourable inside the cell as the chloride ion concentration is 25-fold lower in the 
cytoplasm than it is in the bloodstream (Basu and Krishnamurthy, 2010). It is in this 
hydrolysed form, cis-[Pt(NH3)2(H2O)2]2+, that the now electrophilic cisplatin may 
interact with and form adducts to the cellular DNA. Cisplatin binds to the nucleophilic 
N7 of purine bases to form monoadducts and subsequently crosslinks. The most 
common adduct formed is the intrastrand crosslink at either 5’-GpG-3’ (65%) or 5’-
ApG-3’ (25%) sites. ICLs constitute up to 8% of cisplatin-DNA adducts and form at 
5’-GpC-3’ sites, crosslinking the N7 of the opposite guanines (Figure 1-7) (Muniandy 
et al., 2010).  
 
Figure 1-6: Chemical structure of cisplatin before and after hydrolysis.  
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Figure 1-7: Structure of a cisplatin ICL. Cisplatin covalently bonds to the N7 of 
each cross-linked Guanine. Taken from (Wilson and Seidman, 2010). 
 
1.6.1.2 Melphalan 
The discovery of the nitrogen mustards as chemotherapy agents occurred 
serendipitously in the 1940s as a result of observations with the chemical warfare 
agent sulphur mustard, as was discussed in section 1.4. These were the first 
chemotherapy drugs to be discovered, and so the development of derivatives of the 
first nitrogen mustard occurred soon after its discovery. In 1954, melphalan was first 
synthesised when searching for new anti-tumour drugs derived from phenylalanine 
(Bergel and Stock, 1954). Melphalan, previously known as sarcolysine, was 
demonstrated to completely inhibit tumour growth in mouse sarcoma models. A year 
later, similar experiments with melphalan demonstrated complete tumour regression 
in 240 mice with sarcoma (Larionov et al., 1955), providing further evidence towards 
the usefulness of this compound in the fight against cancer. Throughout the late 
1950s and early 1960s clinical trials with melphalan were carried out and in 1964 
melphalan was approved by the FDA.  
Today, melphalan is primarily used to treat multiple myeloma. Melphalan is 
administered either intravenously or with oral tablets. As with cisplatin, melphalan 
has many side effects due to the action of the drug on the normal cells of the body. 
The most common side effects with melphalan are similar to those of cisplatin, 
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including tiredness, vulnerability to infection and bruising, which are all due to the 
effects of chemotherapy on the components of the blood. 33% of patients receiving 
melphalan may experience nausea and at least 10% of patients receiving melphalan 
may experience a loss in fertility. Less common side effects associated with 
melphalan include hair loss, mouth ulcers or development of a second cancer, 
although this is very rare (Melphalan (Alkeran), Cancer Research UK webpage, 
available from: http://www.cancerresearchuk.org/about-cancer/cancers-in-
general/treatment/cancer-drugs/melphalan [accessed August 2016]).  
As with cisplatin, melphalan can be administered as part of a combination of drugs. 
In myeloma, melphalan can be given with prednisolone, thalidomide or bortezomib, 
which may help to reduce side effects. Myeloma patients are also treated with 
melphalan in a high dose setting in combination with a stem cell transplant.  
1.6.1.2.1 Molecular mechanism of melphalan 
The mechanism of cellular uptake of melphalan has not been extensively 
investigated. However, melphalan uptake has been suggested to occur via an active 
process, using amino acid transporters due to the structural similarities between 
melphalan and amino acids (Goldenberg et al., 1979). Competitive inhibition of 
melphalan uptake has been demonstrated by leucine, which was also able to 
reduce the anti-tumour effect of melphalan (Vistica et al., 1979).   
Nitrogen mustards can form monoadducts, intrastrand crosslinks and interstrand 
crosslinks. However, melphalan, unlike cisplatin and other nitrogen mustards such 
as mechlorethamine, does not readily form intrastrand crosslinks. This is proposed 
to be due to the interaction of melphalan with different regions of the DNA, drawing 
the reactive chlorine atom away from the conformation favourable for intrastrand 
crosslink formation (Bauer and Povirk, 1997). The inability of melphalan to form 
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intrastrand crosslinks highlights the importance of ICLs in the toxicity of crosslinking 
drugs. Cells treated with doses of mechlorethamine and melphalan that produce 
similar peak levels of ICLs are more sensitive to melphalan than to 
mechlorethamine (Ross et al., 1978). As mechlorethamine also produces many 
more intrastrand crosslinks than ICLs, and the kinetics of ICL repair indicate more 
persistent ICLs for melphalan, this may suggest that the ICL is the most cytotoxic 
crosslink (Bauer and Povirk, 1997). 
To form DNA-adducts, nitrogen mustards become electrophilic through the loss of 
one chloride atom, and subsequently covalently bind to the N7 atom of a guanine 
residue. These adducts constitute 90-95% of nitrogen mustard-DNA adducts. The 
remaining 5-10% of adducts are ICLs (Muniandy et al., 2010), however early 
experiments with melphalan suggested that up to 30-40% of melphalan-DNA 
adducts may be ICLs (Hansson et al., 1987), therefore there may be differences 
between the proportion of adducts formed by different nitrogen mustards. The 
formation of a crosslink can occur through a second covalent linkage to another 
guanine N7 on the opposite strand of DNA (Muniandy et al., 2010; Rajski and 
Williams, 1998). This mechanism is shown in Figure 1-8 for mechlorethamine, which 
has a simpler methyl group compared to the phenylalanine group in melphalan. This 
reaction is particularly slow for melphalan in comparison with other nitrogen 
mustards, however, the resulting ICLs are considerably more stable (Bauer and 
Povirk, 1997).   
For nitrogen mustards, as the chlorine atoms are separated by 5 atoms, the 
crosslinked guanines are separated by another base pair, with these adducts 
occurring at 5’-GpNpC-3’ sites. The differences between nitrogen mustard and 
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cisplatin ICLs in terms of structure and helical distortion are discussed in detail in 
the introduction to Chapter 6.  
In addition to DNA-DNA crosslinks, nitrogen mustards can also crosslink DNA to 
proteins. This includes chromatin remodelling factors, DNA repair proteins and 
transcriptional regulation factors.  
These crosslinks occur between the guanine N7 and cysteine residues on cellular 
proteins, although, these interactions are not well characterised. However, the DNA-
protein crosslinks induced by nitrogen mustards such as melphalan may also 
contribute towards the cytotoxicity of these compounds (Loeber et al., 2009).   
 
 
Figure 1-8: Formation of nitrogen mustard monoadducts (1) and interstrand 
crosslinks (2) between two N7 guanine atoms. The differences in the R group for 
mechlorethamine and melphalan are highlighted. Adapted from (Rajski and 
Williams, 1998). 
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1.7 Drug resistance 
Unfortunately, treatment with chemotherapy agents rarely results in a complete 
cure, as acquired resistance to treatment will occur. Drug resistance is one of the 
most common reasons for patient discontinuation of treatment with a particular 
agent (Luqmani, 2005). Resistance to chemotherapy agents can be intrinsic to the 
tumour. It is estimated that 1 in 106-107 cells in a tumour will have intrinsic 
resistance to a chemotherapy drug. Given that there are at least 109 cells in a 
clinically detectable tumour, there could be 1000 drug-resistant cells capable of 
evading chemotherapy. Therefore, the size of the tumour at the onset of 
chemotherapy is proportional to the chance of intrinsic resistance (Luqmani, 2005). 
Therefore, treatment with a chemotherapy agent in this setting puts selective 
pressure on the tumour, with the result being that the intrinsically resistant cancer 
cells survive and continue to proliferate. Another form of resistance can develop 
after treatment with an agent. An initial response to the agent will be achieved, but 
relapse will occur. This is known as acquired resistance, and is also product of 
natural selection of the tumour cells that are able to evade the cytotoxic actions of 
the chemotherapy drug. With acquired resistance, however, the ability to evade the 
tumour develops only after exposure to the chemotherapy agent in question due to 
acquired mutations. 
Several methods can be used in order to overcome resistance to chemotherapy 
drugs. These include administering higher doses of the chemotherapy whilst 
controlling side-effects with other drugs in the combination treatment, developing 
novel combination therapies to target resistance pathways directly, or developing 
new chemotherapy drugs that do not have the same resistance mechanisms 
(Giaccone, 2000).  
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1.7.1 Cisplatin resistance  
Although many types of cancer are initially sensitive to cisplatin, high levels of 
relapse are seen. For example, in NSCLC initial response rate is only 20% due to 
inherent resistance to cisplatin whereas SCLC tumours are initially very sensitive to 
cisplatin (80-95% response rate) and only after prolonged exposure will relapse 
occur, with rates of up to 95% reported. 70-80% of advanced ovarian cancer 
patients typically respond to cisplatin therapy initially, however, relapse due to 
cisplatin resistance occurs in 56% (Giaccone, 2000). Resistance to cisplatin is 
determined in clinical scenarios by the time to progression in the absence of 
chemotherapy. For example in ovarian cancer, patients that relapse more than 6 
months after finishing platinum therapy are considered platinum-sensitive, whereas 
patients that relapse within 6 months from finishing platinum therapy are considered 
resistant (Giaccone, 2000).  
As discussed previously, cisplatin exerts its toxicity through the adducts it forms with 
the cancer cell DNA. There is a direct correlation between cisplatin sensitivity and 
extent of platinated DNA in ovarian cancer patient samples (Reed et al., 1987) and 
therefore, any process which interferes with the ability of cisplatin to interact with the 
DNA could result in clinical resistance. This may include changes in cisplatin 
accumulation within the cell either through enhanced efflux or reduced uptake, 
inactivation of cisplatin inside the cell, or enhanced DNA repair. The various factors 
that can contribute to cisplatin resistance are summarised in Figure 1-9 (Siddik, 
2003). Ironically, many of the mechanisms behind resistance to chemotherapy 
drugs like cisplatin are likely to have evolved in order to protect normal cells against 
natural carcinogens and toxins (Luqmani, 2005). However, these proposed 
resistance mechanisms, of which many have been demonstrated in cell line models, 
may not occur in patients. Some proposed mechanisms such as expression of the 
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GST-π enzyme and the ATP7a transporter have been correlated with cisplatin 
resistance in patient samples (Bai et al., 1996; Yang et al., 2015), however, data 
from this research group has suggested that in ovarian cancer patients, cisplatin 
resistance is acquired through enhanced ICL repair. The level of ICLs formed in 
paired cisplatin-naïve and cisplatin-treated samples was equal, implying that 
upstream factors such as cisplatin accumulation or detoxification are not responsible 
for the acquired resistance found in ovarian cancer patients (Wynne et al., 2007). 
The mechanisms contributing to cisplatin resistance will be explored in more detail 
in the introduction to Chapter 4.  
 
Figure 1-9: Factors contributing to the development of resistance of cisplatin. 
Taken from (Siddik, 2003). 
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1.7.1.1 Biomarkers for cisplatin sensitivity 
One approach to tackle failure of cisplatin therapy is to select for those patients 
most likely to respond well using biomarkers for cisplatin sensitivity. This method 
would improve response rates, save money, and also benefit the non-responding 
patients greatly as time would not be wasted on platinum-based therapy, increasing 
the chance of finding an effective treatment sooner.  
Biomarkers can be screened for histologically by staining tumour sections, or 
genetically by identifying mutations in target genes associated with sensitivity or 
resistance to cisplatin. One such potential biomarker is ERCC1, a component of the 
XPF-ERCC1 nucleotide excision repair nuclease. This nuclease is essential for the 
repair of both intrastrand crosslinks (repaired by NER) and ICLs (repaired by a 
unique pathway), and its role in these repair pathways will be covered in sections 
1.8.1.2.2 and 1.8.2.2. Patients classified as clinically resistant to cisplatin have been 
shown to exhibit significantly higher levels of ERCC1 (Dabholkar et al., 1992). 
Additionally, single nucleotide polymorphisms in the ERCC1 gene, which reduces 
expression of the ERCC1 protein, are correlated with survival following platinum-
based therapy, and patients expressing higher levels of ERCC1 prior to platinum-
based therapy have a reduced overall survival (Ting et al., 2013).  
In order to assess the usefulness of ERCC1 as a biomarker for cisplatin treatment, a 
phase III trial was carried out in 364 NSCLC patients and the results were reported 
in 2007. The control group received cisplatin and docetaxel therapy, whereas the 
remainder of the patients received docetaxel and gemcitabine if they had high 
ERCC1 levels, and cisplatin and docetaxel if they had low ERCC1 levels, as 
determined by ERCC1 mRNA expression. In the control group 39.3% of patients 
obtained an objective response whereas in the stratified treatment group (both high 
and low ERCC1), 50.7% of patients obtained an objective response. This is the first 
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large scale demonstration that ERCC1 status could be used to successfully assign 
patients to cisplatin-based treatment schedules (Cobo et al., 2007). However, not all 
studies have found a correlation between ERCC1 and cisplatin sensitivity, though 
this may be due to the combination of cisplatin with other drugs making consistent 
analysis of correlation more complex (Rose and Huang, 2014). Also, the technical 
issue of ERCC1 antibodies lacking specificity for the active isoform of ERCC1 over 
other inactive isoforms remains to be overcome if ERCC1 status is to be determined 
histologically, as this factor may be responsible for the difficulty in validation of 
ERCC1 as a biomarker for cisplatin sensitivity (Friboulet et al., 2013). Therefore, 
there is potential in the use of ERCC1 as a biomarker for the selection of patients 
who would benefit from cisplatin treatment, and this avenue must be explored 
further in order to improve response to cisplatin.  
ERCC1 is by far the most well characterised potential biomarker for cisplatin 
sensitivity, however, the expression of other factors has also been correlated with 
cisplatin sensitivity. These include the NER factor, XPA, and transporters involved in 
the uptake and efflux of cisplatin including the copper transporters CTR1 and CTR2, 
and the ATP7a and ATP7b ATPase transporters. Additionally, low levels of the 
glutathione-S-transferase pi (GSTπ) enzyme have been correlated with cisplatin 
sensitivity, due to decreased inactivation of cisplatin (Rose and Huang, 2014). 
However, all of these factors require more clinical evidence in order to demonstrate 
their potential use as biomarkers for cisplatin sensitivity. 
1.7.2 Melphalan resistance 
Many of the mechanisms of resistance reported for melphalan are similar to those 
reported for cisplatin, and act by interfering with the ability of melphalan to form DNA 
adducts.  
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Melphalan can be inactivated in the cell through the action of GST enzymes, 
however whilst the GST-π isoform is involved in detoxification of cisplatin, the 
microsomal GST (MGSTII) isoform is reportedly involved in melphalan 
detoxification, and its introduction into cells can confer resistance to melphalan 
(Harkey et al., 2005). As with cisplatin, expression of thiol-containing molecules 
such as metallothioneins can also reduce melphalan sensitivity (Kelley et al., 1988) 
by covalently binding to and inactivating melphalan directly (Yu et al., 1995).  
Reduced accumulation of melphalan in the cell is another mechanism by which 
resistance can occur. Decreased uptake of melphalan in cells with reduced levels of 
amino acid transporters such as CD98 is correlated with resistance (Harada et al., 
2000; Moscow et al., 1993). Alternatively, enhanced efflux of GSH-conjugated 
melphalan mediated by the multidrug resistance protein, MRP1, has been reported 
(Barnouin et al., 1998), and a correlation between expression of the multidrug 
resistance transporter, MDR1, decreased intracellular accumulation and reduced 
sensitivity to melphalan has been observed (Kuhne et al., 2009). Therefore, both 
uptake and efflux of melphalan may contribute to cellular melphalan resistance.  
Direct effects on the formation and repair of melphalan-DNA adducts has also been 
linked to cellular melphalan resistance. In resistant cell lines a 50% decrease in 
melphalan-DNA binding was observed, and 50% less melphalan-ICLs were present 
when compared to the parental cell line (Parsons et al., 1981). In patient samples, 
whilst no difference in the formation of ICLs was observed after ex vivo treatment 
with melphalan, cells from individuals previously exposed to melphalan were able to 
more effectively repair melphalan-ICLs than cells from melphalan-naïve individuals, 
and the ability to repair melphalan-ICLs negatively correlated with ex vivo melphalan 
sensitivity (Spanswick et al., 2002). This suggests that resistance to melphalan in 
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myeloma patients is due to DNA repair processes rather than an “upstream” 
mechanism such as melphalan accumulation or inactivation.  
Therefore, melphalan resistance may occur via many processes that interfere with 
the ability of melphalan to bind cancer cell DNA. However, most of these resistance 
mechanisms have only been demonstrated in vitro, and so their clinical relevance is 
as yet undetermined. A role for DNA repair in melphalan resistance currently has 
the most support from clinical data. Whether the melphalan resistance pathways 
discussed here can be exploited to develop novel biomarkers for melphalan 
sensitivity has not yet been thoroughly investigated.  
1.7.3 Chemotherapy cross-resistance 
The mechanisms of resistance to cisplatin and melphalan have significant cross 
over. This is true for many chemotherapy drugs, and therefore, a phenomenon 
known as “cross-resistance” can occur. This is when a patient that has been treated 
with one drug and has subsequently developed acquired resistance to that drug, will 
now fail to respond to another chemotherapy drug due to similar resistance 
mechanisms.  
This is common within a class of chemotherapy agents. For instance, cells resistant 
to cisplatin often demonstrate cross-resistance to carboplatin (Eckstein, 2011). 
Similarly, cross-resistance within the nitrogen mustard class can also exist in vitro 
(Goldenberg, 1975). This can be overcome by the development of similar agents 
that have alternative mechanisms of resistance. For example, some cisplatin 
resistant cells are not cross-resistant to oxaliplatin (Eckstein, 2011; Raymond et al., 
2002).  
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Cross-resistance can also occur between classes of drugs if a common resistance 
mechanism is shared. For example high levels of cellular glutathione has been 
implicated in cross-resistance to a group of chemotherapy agents including cisplatin, 
melphalan, carboplatin, etoposide and doxorubicin. This was proposed to be due to 
inactivation of these compounds by glutathione (Hamaguchi et al., 1993). Similarly, 
overexpression of metallothionein confers resistance to cisplatin, melphalan and 
chlorambucil (Kelley et al., 1988). Cross-resistance has also been observed 
between nitrogen mustards (mechlorethamine, chlorambucil and melphalan), 
cisplatin and MMC. These are all crosslinking agents and so cells exhibiting cross-
resistance to these agents may have enhanced DNA repair pathways common to 
the repair of these crosslinks (Bramson et al., 1995). However, not all cells that are 
able to repair interstrand crosslinks induced by one agent are able to repair ICLs 
induced by all crosslinkers, as was demonstrated by this research group (Spanswick 
et al., 2012). Therefore, the molecular events responsible for cross-resistance to 
crosslinking chemotherapy drugs requires further investigation.  
Due to cross-resistance, selection of a second chemotherapy agent after resistance 
has emerged must be considered carefully so as to avoid selecting a drug the 
patient is already cross-resistant to. However, exploitation of cross-resistance may 
also provide the potential to develop agents that interfere with common resistance 
pathways, such as DNA repair or drug inactivation, allowing re-sensitisation of 
patients to more than one chemotherapy drug.  
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1.8 DNA repair  
As described in section 1.2.1, the human genome is constantly under attack from 
both exogenous and endogenous sources, producing adducts, intercalations, nicks 
and breaks in the genetic material. If accumulating DNA damage is not repaired, the 
cell may undergo apoptosis, or depending on the proliferation status of the cell, the 
damage may contribute to the development of cancer or the aging process 
(Bernstein et al., 2013) (Figure 1-10). 
 
 
Figure 1-10: Fates of cells after DNA damage: cell death, cancer, and aging. 
Taken from (Bernstein et al., 2013).  
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Many thousands of individual DNA damages occur each day (as was summarised in 
Table 1-1). Fortunately, the cell has evolved a comprehensive defence mechanism 
in the form of several DNA repair pathways in order to cope with endogenous DNA 
damages. In a normal cell, upon detection of DNA damage, the cell cycle is halted 
at one of the checkpoints (either prior to S phase DNA replication or prior to 
mitosis), and DNA repair is allowed to occur before the cell cycle proceeds again. In 
cancer cells, these checkpoints are often lost (mainly due to mutations in the p53 
and pRb tumour suppressors) and so this allows DNA damage to accumulate and 
results in enhanced mutation rates (Lapenna and Giordano, 2009). The signalling 
network from detection of DNA damage to arrest of the cell cycle is shown in Figure 
1-11.  
 
Figure 1-11: DNA damage detection by the ATR and ATM kinases, and the 
resulting arrest in cell cycle due to inhibition of cyclin-dependent kinases. 
Taken from (Lapenna and Giordano, 2009). 
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Many DNA damages induced by exogenous agents are also repaired via these 
pathways, which at least in part accounts for the resistance to DNA damaging 
chemotherapy drugs observed, as discussed previously. Defects in these repair 
processes can result in persistent DNA damage, which causes errors in replication 
leading to mutations. If a mutation is in a significant region of a driver gene, this 
event can spark tumourigenesis. Therefore DNA repair pathways are critical in 
preventing the development of cancer.  
1.8.1 Major mechanisms of repair 
1.8.1.1 Double strand break repair 
Double strand breaks (DSBs) arise when both strands of the DNA are broken close 
together, resulting in two free DNA ends which are able to dissociate away from 
each other (Jackson, 2002). An estimated 10 DSBs occur in each cell, each day 
(Lieber, 2010).  DSBs can be caused intentionally by endogenous processes such 
as VDJ recombination in antibody production (Bassing et al., 2002) as well as 
crossover during meiosis which produces greater genetic diversity (Youds and 
Boulton, 2011), or unintentionally by endogenous species such as reactive oxygen 
species generated during aerobic respiration (Lieber, 2010). Exogenous factors 
such as exposure to ionizing radiation and topoisomerase inhibitors also induce 
DSBs. If left unrepaired or incorrectly repaired, DSBs can induce mutations, 
amplifications, deletions and translocations, and just one DSB can cause cell death 
if the break occurs in an essential gene. Equally, mis-repaired DSBs can result in 
tumourigenesis if an oncogene or tumour suppressor is affected (Khanna and 
Jackson, 2001). Therefore, several repair mechanisms exist depending on the 
situation, for example cell cycle phase (Jackson, 2002). The three forms of DSB 
repair and in which scenarios they are used will be discussed. 
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1.8.1.1.1 Homologous recombination 
Where a second copy of the damaged gene is available, for example in S phase 
immediately after DNA replication, a process known as homologous recombination 
(HR) can be utilised (Figure 1-12). This type of repair will be employed particularly 
for DSBs arising from collapsed replication forks (Lieber, 2010). Here, detection of 
the DSB by ATM and ATR leads to phosphorylation of key repair proteins such as 
BRCA1, p53 and H2AX. BRCA1 acts as a scaffold for other HR proteins (Walsh, 
2015). The RAD50/MRE11/NBS1 nuclease then digests the two ends of the DSB in 
a 5’-3’ direction (known as end resection), creating single-stranded overhangs with 
3’OH ends which are substrates for RPA binding. Recombination mediators such as 
BRCA2 are able to facilitate the displacement of RPA and loading of RAD51 onto 
the single strand regions, forming a nucleoprotein filament. Rad51 is a recombinase 
and so is able to search for a homologous sequence (in S phase this is provided by 
the sister chromatid, often in close proximity due to the action of cohesins) and 
initiate strand invasion of the template DNA. This forms a “D-loop” structure and 
allows for highly accurate re-synthesising of the damaged DNA followed by ligation. 
(Hoeijmakers, 2001; San Filippo et al., 2008). Changes can however occur when 
the branched holliday junction structures are resolved to separate the two DNA 
molecules during the last step of HR.  These structures can be cleaved in two ways 
by structure-specific endonucleases such as MUS81-EME1 (Heyer, 2004), and 
depending on the orientation of the incisions made, a cross-over of genetic material 
can occur. Alternatively, dissolution of the holliday junctions by the BLM helicase 
and topoisomerase III can occur, resulting exclusively in non-crossover products, 
and subsequently a more accurate repair process (Li and Heyer, 2008; San Filippo 
et al., 2008). Crossover can however be beneficial, for instance during meiosis 
where this process helps to produce genetic diversity in offspring.  
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Figure 1-12: Simplified model for homologous recombination. Taken from 
(Weterings and Chen, 2008). 
 
1.8.1.1.2 Single strand annealing 
A second method of DSB repair also involves homology, however, this method 
occurs between repetitive DNA on the same chromosome. This is known as single 
strand annealing (SSA, Figure 1-13) and depending on the length of the repetitive 
sequences, can be classed as long-homology SSA or micro-homology SSA. As with 
HR, the first stage of SSA involves resection of the DSB site. However, unlike HR, 
Rad51 is not required for SSA whereas Rad52 is. Rad52 is thought to bind to the 
ends of the single strand overhangs as a heptameric ring structure, and promotes 
association of the two complimentary regions (Valerie and Povirk, 2003). Therefore, 
instead of strand invasion occurring to copy back the missing DNA, when two 
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repetitive sequences are present, these are paired together, and the resulting 
single-strand ”tails” of DNA are cleaved by nucleases such as XPF-ERCC1. This 
method deletes the genetic information between the two sites, including one of the 
repeated sequences (San Filippo et al., 2008). Long-homology SSA likely follows 
this pathway however it has been suggested that micro-homology SSA may occur in 
a manner similar to non-homologous end joining (see next section) (Valerie and 
Povirk, 2003).  
 
Figure 1-13: Model for single strand annealing homologous recombination. 
Taken from (Valerie and Povirk, 2003). 
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1.8.1.1.3 Non-homologous end joining 
When a second copy of the gene is not present in the cell and no repetitive regions 
flank the DSB, non-homologous end joining (NHEJ, Figure 1-14) can be used to 
repair the DSB. For this reason, NHEJ is thought to be the prevalent method of DSB 
repair for two-sided DSBs rather than replication-induced DSBs, and also in G1 
phase. This pathway involves direct joining of the DNA either side of the DSB. The 
Ku70/80 complex is largely involved in this process, as it has extremely high affinity 
for DNA ends and so immediately after DSB induction, Ku70/80 encapsulates the 
two free DNA ends in its ring-like structure and acts as a scaffold to recruit the other 
members of the NHEJ machinery. The kinase DNA-PKcs (DNA-dependent protein 
kinase catalytic subunit) is recruited by Ku70/80, and is able to bridge the two DNA 
ends together. Autophosphorylation of DNA-PKcs induces a conformation change in 
the NHEJ complex, which allows the processing enzymes and ligase to access the 
site. Ligase IV/XRCC4 is then recruited to the repair site, which performs the final 
ligation step. However, in order to generate compatible ends for ligation, either 
resection or gap-filling is often necessary. Gap-filling may be carried out by DNA 
polymerases µ and λ, or by Human terminal deoxynucleotidyltransferase (TdT); all 
of these enzymes are recruited to the DSB site by Ku70/80. For resection of the 
overhangs, the nuclease Artemis is required. Phosphate groups may also need to 
be added at the 5’-end as this is required for successful ligation of the two DNA 
ends. Once the DNA ends have been processed into ligatable ends, the Ligase 
IV/XRCC4 is able to complete NHEJ. Due to this end-processing step, NHEJ results 
in insertions or deletions of genetic information at the site of the repaired DSB. For 
this reason, NHEJ is considered a less accurate mechanism for DSB repair 
(Weterings and Chen, 2008).  
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Figure 1-14: Simplified model for NHEJ. Taken from (Weterings and Chen, 2008). 
 
1.8.1.2 Excision repair 
There are three main types of excision repair: base excision, nucleotide excision 
and mismatch repair. These repair pathways deal with damage to bases where 
DSBs are not present.  
1.8.1.2.1 Base excision repair 
Base excision repair (BER) is employed by the cell to remove adducts to single 
bases such as alkylations, base oxidations, depurination/depyrimidations and 
deaminations, and this can be achieved through two routes: removal of the single 
affected nucleotide (known as short-patch BER) or removal of a length of 
nucleotides surrounding the damage site (known as long-patch BER). The core 
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mechanism for the single-adduct removal BER pathway is illustrated in Figure 1-15. 
Recognition of the damage is performed by a DNA glycosylase specific for the 
particular lesion, for example Uracil DNA Glycosylase (UNG) recognises 
misincorporated uracil nucleotides, and OGG1 recognises 8-oxo-guanine lesions 
(Krokan et al., 2000). This recognition is followed by excision of the affected base by 
the glycosylase enzyme. The glycosylase flips the affected nucleotide out of the 
DNA helix and excises the nucleotide by cleaving the N-glycosidic bond, leaving an 
abasic site. Spontaneous hydrolysis of the affected nucleotide can also result in an 
abasic site. The backbone is then nicked either up or down-stream of the lesion by 
an AP endonuclease (such as APEX1) or an AP lyase (which can be provided by 
bifunctional glycosylase enzymes such as OGG1 (Jacobs and Schär, 2012)), 
respectively. When BER is required after induction of a SSB, PARP and 
polynucleotide kinase (PNK) may be required to process the break for BER. In 
short-patch BER the resulting abasic site filled by DNA polymerase β adding in a 
single nucleotide, followed by ligation of the DNA backbone by DNA ligase III 
(Krokan et al., 2000).  
For long-patch BER, between 2-10 nucleotides are replaced via processive 
polymerisation by DNA Pol δ in a PCNA-dependent manner. This results in a 
displaced DNA flap, therefore the FEN1 endonuclease is required to cleave the flap 
before ligation of the newly synthesised DNA by DNA ligase I (Hoeijmakers, 2001; 
Robertson et al., 2009). What determines whether short- or long-patch BER takes 
place is not fully understood, however, the glycosylase used to remove the lesion, 
the cell cycle stage, and the ATP concentration have all been suggested to play a 
role in this decision (Krokan et al., 2000; Robertson et al., 2009). 
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Figure 1-15: Mechanism of base excision repair. Taken from (Hoeijmakers, 
2001). 
 
1.8.1.2.2 Nucleotide excision repair 
Where bulkier adducts are present, nucleotide excision repair (NER) is employed 
(Figure 1-16).  NER can repair intrastrand crosslinks, UV-induced lesion such as 6-4 
pyrimidine-pyrimidone (6,4-PP) photoproducts and cylopyrimidine dimers, as well as 
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some more complex oxidative lesions. NER is also viewed to be critical for ICL 
repair alongside other repair pathways (Nouspikel, 2009).  
NER can only repair bulky adducts due to the machinery responsible for damage 
detection in this pathway - the XPC complex. XPC is only able to recognise lesions 
that considerably distort the double helix. Upon DNA damage, XPC becomes 
polyubiquitinated, which is thought to stimulate it’s binding to DNA. Where smaller 
helix distortions are present, the damage binding complex DDB1/2 will bind the 
lesion first and induce a larger helical distortion, which allows for XPC recognition. 
During this process, DDB polyubiquitinates XPC and also auto-polyubiquitinates 
itself. The result of this is handover of repair from DDB1/2 to XPC through 
enhancement of XPC binding to DNA and proteasomal degradation of DDB2. The 
TFIIH complex of proteins is recruited and two components of this complex, XPB 
and XPD unwind the DNA around the lesion using their helicase and ATPase 
activities to create a “denaturation bubble”. XPA binding is known to be critical for 
the NER process but it is not fully understood whether XPA has a role in damage 
recognition or in determination of the damaged strand for excision purposes. The 
single-strand binding protein, RPA, binds to the now exposed DNA strands in order 
to stabilise this intermediate. The next stage involves excision at both the 5’ and 3’ 
ends, which is carried out by the endonucleases XPF-ERCC1 and XPG, 
respectively. A 25-30 nucleotide fragment is excised by this process and DNA 
polymerase δ/ε/κ, along with PCNA, synthesises across the gap using the 
undamaged strand as a template. The excision of the fragment may be coupled to 
re-synthesis across the gap, beginning as soon as the 5’ incision has been made. 
This prevents the exposure of large single-stranded regions during the repair 
process and, therefore, prevents further DNA damage signalling (Marteijn et al., 
2014). DNA ligase I/III is then recruited to complete re-synthesis and ligation 
(Friedberg, 2001; Nouspikel, 2009).  
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Figure 1-16: Mechanism of nucleotide excision repair. Taken from (Marteijn et 
al., 2014).  
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Bulky adducts can also be detected by the RNA polymerase whilst transcribing – 
this is known as transcription-coupled repair (TCR). When RNA polymerase stalls at 
a lesion, two factors are recruited to induce RNA polymerase backtracking which 
allows repair factors access to the damage site: these are CSA and CSB. The repair 
process post recognition follows the same pathway as classical NER, with the 
exception that the XPC and DDB proteins are no longer required (Hoeijmakers, 
2001; Marteijn et al., 2014).  
Defects in many of the NER genes leads to Xeroderma Pigmentosum (XP) 
syndromes. These are autosomal recessive diseases, of which there are eight 
complementation groups with varying symptoms. One of the most common 
symptoms is the high sensitivity to sunlight and subsequent high predisposition to 
skin cancers. The median age of onset for skin cancer in the XP population is just 8 
years, at least 50 years lower than the age of onset for the normal population 
(Friedberg, 2001). This is due to the inability of these patients to repair UV-induced 
DNA damage, thus leading to acquired mutations and eventually tumourigenesis. 
Other internal cancers are also more common in XP individuals due to their inability 
to repair lesions produced by internalised carcinogens such as tobacco smoke and 
other pollutants (Nouspikel, 2009).  
Cockayne Syndrome (CS) is caused by a mutation in CSA or CSB and is 
characterised by extreme photosensitivity, and neurological and growth problems. 
The average life expectancy for a patient with CS is just 12 years. This disease is 
caused by an inability to perform TCR (Marteijn et al., 2014). Therefore the 
importance of NER, both global and transcription-coupled, is evident from the 
severity of the diseases that occur due to failures in this pathway. 
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1.8.1.2.3   Mismatch repair 
Where the lesion in question is an incorrect nucleotide inserted by error during 
polymerisation of the DNA, or an insertion/deletion loop (IDL) the mismatch repair 
system (MMR) is required. This pathway is shown in Figure 1-17. Here the MutSα 
complex (MSH2 and MSH6) is the primary recognition protein complex. For larger 
IDLs, the MutSβ (MSH2 and MSH3) complex is required for recognition. MutSα 
recruits MutLα (composed of MLH1 and PMS2) and together they form a sliding 
clamp that uses ATP to move up or down-stream from the mismatch in search of a 
strand discrimination signal, thought to be in the form of a strand nick. At this site 
the Exo1 exonuclease is loaded onto the DNA and subsequently, degradation of the 
intervening DNA between the nick and the mismatch occurs. Exo1 is a 5’-3’ 
exonuclease, however, it is also able to perform digestion of the DNA in a 3’-5’ 
manner with the aid of PCNA and the endonuclease function of MutLα which 
creates a nick 5’ to the mismatch site that Exo1 can digest from. This digestion may 
occur from multiple Exo1-loading events. Exo1 is blocked from digesting 5’-3’ away 
from the mismatch in this scenario by the replication factor RFC. The resulting gap 
is filled and ligated with DNA polymerase δ and ligase I. The importance of the MMR 
pathway in genome protection is highlighted by it’s link with hereditary non-polyposis 
colon cancer. Individuals with mutations in MSH2 or MLH1 are predisposed to 
developing colon cancer (Jiricny, 2006; Li, 2008).	
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Figure 1-17: Model of the mismatch repair pathway. Taken from (Jiricny, 2006). 
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1.8.1.3 Lesion bypass and tolerance 
In some scenarios, damage is not recognised by the appropriate repair systems and 
so upon DNA replication, bypass of this lesion must occur for the cell to avoid 
replication fork breakdown and successfully divide. There are two mechanisms for 
lesion bypass, both of which are summarised in Figure 1-18. The first mechanism 
involves the polymerisation of DNA past a lesion. This process is carried out by Y-
family polymerases as the high fidelity polymerases used for general DNA 
replication are not capable of replicating past an adduct. Y-family polymerases such, 
as DNA Pol η, have significant structural differences which allows them to bypass 
the damaged bases albeit with higher error than the general DNA polymerases. 
These structural differences render the catalytic site wider and more able to 
incorporate damaged nucleotides and dimers such as CPDs. Often two bypass 
polymerases will cooperate: one performing the nucleotide insertion opposite the 
damaged base and the other performing the extension stage (Prakash et al., 2005). 
Rad6-Rad18 mediated mono-ubiquitination of the PCNA sliding clamp is thought to 
play a key role in the switch from general polymerases to bypass polymerases after 
encountering a replication-blocking lesion (Waters et al., 2009). Extension past the 
damaged nucleotide can result in mutations. For example, if an abasic site is 
present, TLS polymerases prefer to insert an adenine. If the correct sequence 
should have been CG and the guanine was lost, the mutation induced would be 
AT (Helleday et al., 2014).		
Defects in lesion bypass can occur in individuals with mutated DNA polymerase η, 
which results in the XPV complementation group of xeroderma pigmentosum. These 
individuals exhibit hypersensitivity to UV light and a high predisposition to skin 
cancer due to their inability to bypass UV-induced lesions rather than a defect in 
NER (Friedberg, 2001).  
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Figure 1-18: Lesion bypass can occur by polymerase switch or template 
switch mechanisms. Taken from (Hoeijmakers, 2001). 
The second mechanism for lesion bypass is via the template switch. Here, the 
normal polymerase is able to replicate the DNA accurately by using a process called 
recombinatorial strand exchange whereby the undamaged newly synthesised strand 
of DNA is used as a template. Regression of the replication fork can also provide an 
undamaged template for the normal DNA polymerase to copy from (Hoeijmakers, 
2001). It is thought that the choice between TLS and template switching is 
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influenced by the ubiquitination status of PCNA, with monoubiquitinated PCNA 
stimulating TLS through the interaction with ubiquitin binding domains on the Y-
family polymerases, and polyubiquitinated PCNA stimulating template switching. 
The mechanism for the latter is not yet fully understood, however, binding of a 
translocase-like protein, ZRANB3, to PCNA’s polyubiquitin chains is suggested to 
promote replication fork regression (Cipolla et al., 2016; Sale, 2012). However, in 
both TLS and template switching the damage is not removed. 	
1.8.2 ICL repair  
ICLs can be formed endogenously from aldehydes and the ingestion of alcohol and 
lipids (Clauson et al., 2013) and so a repair system has evolved to protect cells from 
these lesions.  
However the repair of interstrand crosslinks is not yet fully elucidated. This is due to 
the complexity of these lesions and the requirement for many repair pathways to 
work together in order to achieve their repair. For example, the NER process alone 
is able to repair intrastrand crosslinks as only one strand is affected, so the 
unaffected strand is available as a template for repair. However, ICLs involve both 
strands of the DNA, which makes forming the “denaturation bubble” impossible, and 
also means there is no intact template strand for repair.  Components of the NER 
machinery are, however, still important for ICL repair as will be discussed.  
1.8.2.1 Model for ICL repair in E.coli 
ICL repair was first investigated in the prokaryotic E.coli system and this led to the 
basic repair model, known as the Cole model (Figure 1-19) (Cole, 1973). In this 
model incisions are made either side of the ICL by the Uvr endonucleases 
(components of the E.coli NER system) and DNA Pol I exonuclease activity. This is 
known as unhooking where the ICL and attached excised fragment are flipped out of 
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the DNA helix. Recombination events dependent upon RecA lead to the repair of 
the incised strand and further incisions on the opposite strand remove the ICL from 
the DNA. The resulting gap is filled and ligation reactions complete the repair 
process. This model is in agreement with the sensitivity of Uvr and RecA mutants to 
crosslinking agents (Cole et al., 1976).  Where recombination is not possible it has 
been suggested that after the unhooking stage, bypass polymerases may replicate 
past the unhooked ICL, before classical NER processes remove the lesion, treating 
it as a bulky adduct (Berardini et al., 1997).  
 
Figure 1-19: Cole Model for ICL repair in E.coli.  
 
Incisions 
ICL Unhooking 
Strand Invasion and Homology-
directed Repair of Incised Strand 
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Synthesis and Ligation 
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1.8.2.2 Model for ICL repair in mammalian cells 
Mammalian ICL repair is considerably more complicated than repair in E.coli 
however the key stages remain constant, with the unhooking of the ICL being the 
critical event.  
Detection of the ICL can occur either by damage-recognition proteins, by stalling of 
transcription, or by stalling of replication. Which recognition method is utilised will 
depend on the cell cycle stage and the cellular processes occurring at the time of 
detection.  
For replication-independent repair (Figure 1-20), where recognition proteins from 
other repair pathways such as NER contribute to ICL detection it seems there is a 
certain degree of lesion specificity. This specificity may be related to the differences 
in helix distortion various crosslinking agents cause. For instance psoralen ICLs are 
readily bound by the XPC recognition protein whereas XPC negative cells are not 
sensitive to cisplatin (Muniandy et al., 2010). The protein HMGB1 has also been 
suggested to bind cisplatin-induced ICLs (Kasparkova et al., 2003), as has the 
Fanconi Anemia factor FANCM and components of the MMR system (Fink et al., 
1998; Niedernhofer, 2007). Therefore, the initial replication-independent recognition 
of the ICL is currently not well understood, but may involve several recognition 
factors.  
Post-detection, it is thought that the typical NER machinery is recruited for the 
unhooking of the ICL, with the XPF-ERCC1 complex being critical for this process. 
Cells deficient in XPF or ERCC1 are considerably more sensitive to crosslinking 
agents than other NER mutants (Andersson et al., 1996) and are deficient in ICL 
unhooking (De Silva et al., 2000).  The role of other nucleases in the unhooking 
stage has also been discussed with a common model suggesting that a scaffold 
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protein, SLX4, orchestrates ICL unhooking by recruiting XPF-ERCC1 as well as the 
MUS81-EME1 nuclease (Muñoz et al., 2009). SLX4 is also thought to stimulate the 
activity of these nucleases (Muñoz et al., 2009), and cells deficient in either 
nuclease or the SLX4 scaffold express sensitivity to ICL-inducing agents (Abraham 
et al., 2003; Hanada et al., 2006; Sengerová et al., 2011). The exact mechanism of 
unhooking is yet to be confirmed, however, this stage of ICL repair will be discussed 
in more detail in the introduction to Chapter 5. After the crosslink is unhooked, 
bypass polymerases synthesise past the damage site.  
 
Figure 1-20: One model for replication-independent ICL repair in mammalian 
cells. Taken from (Clauson et al., 2013). 
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In replication-dependent repair (Figure 1-21), the replication fork stalls 20-40 
nucleotides before the ICL, causing disassembly of the replicative helicase and 
allowing the fork to approach to within 1 nucleotide of the ICL. The Fanconi 
Anaemia (FA) pathway is activated through monoubiquitination of the FANCD2/I 
complex which is essential for replication-coupled ICL repair, most likely in order to 
recruit structure-specific nucleases to the ICL (Knipscheer et al., 2009). ICL 
unhooking then proceeds as described for replication-independent repair, and gap 
filling occurs through translesion synthesis. 
However, ICL unhooking at a replication fork results in the formation of a DSB. 
Replication is therefore restarted through homologous recombination. This model is 
supported by evidence showing that recombination defective cells (cells negative for 
BRCA1 or RAD51 paralogs XRCC2 and XRCC3) are highly sensitive to crosslinking 
agents. However, it should be noted that BRCA1 is also thought to have a HR-
independent additional role in the early stages of ICL repair, which will be discussed 
in Chapter 5 (Bunting et al., 2012; De Silva et al., 2000). 
There is a second model for replication-dependent ICL repair, which involves the 
convergence of two replication forks on one ICL. As the replicative helicase cannot 
be re-loaded during S-phase, convergence of two replication forks on an ICL 
negates the need to restart replication after one fork has collapsed. However, this is 
likely to only occur during late S-phase due to the distance between replication forks 
(Zhang and Walter, 2014).  
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Figure 1-21: One model for replication-dependent ICL repair. Taken from 
(Clauson et al., 2013). 
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1.8.3 Fanconi’s Anemia and the FA complementation groups 
Briefly discussed already, the FA pathway assumes a significant role in the repair of 
ICLs. This pathway comprises the FANC proteins, which were discovered through 
genetic studies of individuals with a rare autosomal recessive disease, Fanconi’s 
Anaemia. Discovered in 1927 by Guido Fanconi, a Swiss paediatrician, FA is 
characterised by bone marrow failure, congenital abnormalities and increased risk of 
cancer development (de Winter and Joenje, 2009). The occurrence rate is 
approximately 1 in 360,000 and the median survival only 20 years. 9% of FA 
patients develop leukemia, >90% of these are AML, and the median diagnosis age 
is just 14, however, FA patients are also susceptible to solid tumours (Crossan and 
Patel, 2012). Currently, the only treatment for FA is hematopoietic stem cell 
transplantation which treats the bone marrow failure, however, this does not 
alleviate the patient’s susceptibility to solid tumours or growth defects (Risitano et 
al., 2016). FA is a disease of genomic instability, and as such, FA individuals are 
incredibly sensitive to crosslinking agents (Sasaki, 1975). This characteristic can be 
used to diagnose FA through chromosomal breakage analysis after treatment of 
patient blood cells with MMC or diepoxybutane (Oostra et al., 2012). However, this 
sensitivity also presents one of the hurdles when treating cancer in FA patients, as 
ICL-inducing agents cannot be used due to increased toxicity.   
Complementation analysis and cell fusion studies were employed to discover the 
key genes involved in the FA phenotype and this resulted in the discovery of 19 FA-
associated genes: FANCA, B, C, D1, D2, E, F, G, I, J, L, M, N, O, P, Q, R, S, T) 
(Dong et al., 2015; Moldovan and D’Andrea, 2009; Walden and Deans, 2014). 
Some of the FA genes are better known by other names, such as BRCA2 
(FANCD1), RAD51C (FANCO), SLX4 (FANCP) and BRCA1 (FANCS) as they were 
discovered to be FA genes after their initial discovery as DNA repair proteins. Many 
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of the FA proteins are part of a larger complex, the FA core complex (FANCA, B, C, 
E, F, G, L, M), which is responsible for the monoubiquitination of the FANCD2/I 
complex.  
The most commonly mutated FA gene is FANCA, contributing to 65% of FA cases. 
Mutations in FANCA, C and G together account for 85% of FA cases, with the most 
common form of mutation being an intragenic deletion. The remaining FA 
complementation groups are considerably rarer (Dong et al., 2015). 
1.8.3.1 Roles of the FANC proteins in ICL repair 
Upon detection of an ICL at a replication fork (which may occur via the FANCM DNA 
binding protein and its cofactors (Kim et al., 2008; Walden and Deans, 2014)), the 
ATR kinase is activated. ATR phosphorylates the FANCD2/I complex, and the core 
FA complex E3 ubiquitin ligase protein FANCL monoubiquitinates FANCD2/I. The 
importance of the core FA complex in the functioning of the FA pathway is 
highlighted by the fact that the majority of FA patients have mutations in core 
complex proteins, and mutation of these factors results in a loss of FANCD2/I 
ubiquitination and FA pathway activity (Crossan and Patel, 2012; Dong et al., 2015). 
Ubiquitination of FANCD2 is considered essential for FA pathway activation, as it 
allows the FANCD2/I complex to bind chromatin at DNA damage foci which contain 
the damage marker γH2AX and repair factors including BRCA1 and RAD51 
(Moldovan and D’Andrea, 2009). Once bound at the DNA damage foci, FANCD2/I 
may take part in several stages of ICL repair. In terms of early repair events, 
FANCD2 is thought to be required for efficient recruitment of the unhooking 
nucleases via interaction with the SLX4 (FANCP) scaffolding protein (Klein Douwel 
et al., 2014), whereas in later stages of ICL repair, FANCD2 is thought to recruit 
BRCA2 (FANCD1) for HR (Wang et al., 2004). Other FANC proteins involved in ICL 
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repair through regulation of homologous recombination include BRCA1, Rad51C 
and PALB2 (a BRCA2 interacting protein required or HR) (Bunting et al., 2012; 
Moldovan and D’Andrea, 2009; Vaz et al., 2010). The roles of the FA proteins in ICL 
repair are illustrated in Figure 1-22. Therefore the importance of the Fanconi 
Anemia pathway in multiple stages of ICL repair is clear.  
 
 
Figure 1-22: Role of the Fanconi Anaemia proteins in initiation of ICL repair. 
Taken from (Clauson et al., 2013). 
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1.9 The STAT3 signalling pathway  
1.9.1 Introduction to the STAT transcription factors 
There are seven signal transducer and activator of transcription (STAT) proteins 
within the STAT family of transcription factors: STAT1, 2, 3, 4, 5a, 5b, and 6. These 
proteins relay signals from extracellular ligands binding to cell surface receptors in 
the plasma membrane, to the nucleus where they initiate a cellular response to that 
signal through the regulation of gene expression. The STATs were first identified as 
mediators of IFN-triggered gene expression. The promoters of genes regulated by 
IFNs revealed a consensus motif (TT(N)5AA) that was required for expression from 
those promoters. Proteins bound to this motif were biochemically isolated and 
purified, and the STAT1 and STAT2 genes were identified. STAT3 was later 
identified with a cDNA library screen using the SH2 domain of STAT1 aiming to 
identify further STAT family members (Clevenger, 2004; Zhong et al., 1994). 
The general domain structure of STAT proteins is shown in Figure 1-23. The key 
domains are the DNA binding domain which allows these proteins to bind the DNA 
in order to regulate the transcription of genes, the transactivation domain (TAD) 
which contains tyrosine and serine phosphorylation residues that control the 
activation of these proteins, and the SH2 domain which allows binding to 
phosphorylated tyrosine kinase receptors and dimerisation of STAT monomers.  
The N-terminal region is essential for the interaction of both STAT3 and STAT5 with 
the CBP/p300 transcriptional activating proteins, and the coiled-coil and DNA 
binding domains contain interaction sites for other transcription factors such as c-
Jun and the glucocorticoid receptor. These interactions allow for the formation of 
“enhanceosomes” which facilitate the recruitment of RNA polymerase to allow for 
transcription from that site (Bromberg, 2001; Clevenger, 2004; Hou et al., 2008; 
Lerner et al., 2003; Zhang et al., 1999).  
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Although the STATs have similar structural properties and are considered one 
family of proteins, they function in the regulation of diverse processes. The function 
of each STAT family member in normal cell processes has been investigated with 
knockout studies in mice. STAT1 knockout mice do not respond to interferon 
signalling and are highly susceptible to infections, whereas mice lacking STAT4 or 
STAT6 have impaired IL-12 and IL-14-mediated T-cell proliferation, respectively. 
STAT5A knockout mice have defective development of the mammary gland, and 
both STAT5A and STAT5B female knockout mice are infertile.  Deletion of STAT2 
and STAT3 in mice is embryonic lethal and so these family members have been 
studied with tissue-specific cre-lox-mediated deletion. Therefore, both STAT2 and 
STAT3 are required for normal embryo development, and in addition to this, STAT3 
knockout keratinocytes display reduced migration, suggesting a role for STAT3 in 
would healing (Akira, 1999; Bowman et al., 2000). Additionally, STAT proteins can 
have opposing effects. Through IFNγ signalling, STAT1 functions as a tumour 
suppressor, enhancing the expression of genes involved in apoptosis and cell cycle 
arrest, and suppressing the expression of pro-survival genes. On the other hand, 
STAT3 promotes the expression of pro-survival and cell cycle progression genes, 
and is therefore considered an oncogene (Regis et al., 2008).  
 
 
Figure 1-23: STAT Family protein domains. Adapted from (Aggarwal et al., 2006). 
Activating phosphorylations occur on tyrosine 705 and serine 727 of the 
transactivation (TAD) domain. 
 
Coiled-Coil	Domain	 DNA	Binding	 Linker	 SH2	 TAD	N	 C	
				P					P	
Adapted	from	aggarwal	2006,	annals	of	the	
academy	of	new	york	sciences.		
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1.9.2 STAT3 signalling  
The third member of the STAT family, STAT3, was discovered in 1994 (Zhong et al., 
1994) as a response factor activated by interleukin-6 (IL6) and epidermal growth 
factor (EGF). 
The STAT3 pathway is activated by cytokines or growth factors binding their 
respective receptors, which subsequently dimerise and become phosphorylated. 
These phospho-residues on the intracellular domains of the transmembrane 
receptors are substrates for binding by STAT3 monomers via the SH2 domain. 
Once bound, the STAT3 monomers are phosphorylated on the Tyrosine-705 
residue (by the tyrosine kinase activity of the receptor itself for growth factor 
receptors, or by an associated kinase such as the Janus Kinase 2 (JAK2) for 
cytokine receptors), causing dissociation from the receptor, and dimerisation with 
another phospho-STAT3 monomer. The p-STAT3Tyr705 dimer is translocated into the 
nucleus where it binds to consensus sequences within gene promoters, regulating 
transcription (Figure 1-24). Where tandem consensus sequences are present, 
multiple STAT3 dimers may bind, and form tetramers through interaction of the N-
terminal domains (Zhang and Darnell, 2001).   
A further phosphorylation event on residue Serine-727 does not impact DNA binding 
but allows a greater level of STAT3 activation (Wen and Darnell, 1997). There has 
also been some evidence that unphosphorylated STAT3 dimers are able to 
translocate into the nucleus, however, only phosphorylated dimers are retained 
there to activate transcription. Therefore, in this model, phosphorylation results in 
nuclear retention of STAT3 rather than translocation, and in the absence of 
phosphorylation, STAT3 is able to shuttle between the nucleus and cytoplasm (Liu 
et al., 2005; Mitchell and John, 2005; Pranada et al., 2004). However, activated 
STAT3 dimers have been reported to translocate into the nucleus at a faster rate 
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than non-activated STAT3, which may suggest an alternative mechanism for the 
accumulation of activated STAT3 in the nucleus (Herrmann et al., 2007).  
The N-terminal and coiled coil domains of STAT3 are required for nuclear 
translocation of STAT3, which is thought to be mediated by the α3/β1-importin 
heterodimer (Cimica et al., 2011; Liu et al., 2005; Pranada et al., 2004). Evidence 
also exists for the interaction of STAT3 with the α5 importin (Ma and Cao, 2006), 
therefore, this mechanism is not yet fully elucidated. Nuclear export of STAT3 is 
thought to occur after dephosphorylation by nuclear phosphatases, which renders 
STAT3 a substrate for exportin-1 mediated transport (Herrmann et al., 2007). 
 
 
Figure 1-24: STAT3 Signalling Pathway. Adapted from (Johnston and Grandis, 
2011).  
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As well as STAT3 homodimers, STAT3:STAT1 heterodimers have been observed 
(Zhong et al., 1994), and in the inflammatory response, where STAT3 and STAT1 
have opposing effects, STAT3 is able to sequester STAT1 in heterodimers and 
reduce STAT1-mediated gene expression (Ho and Ivashkiv, 2006). Whether this 
occurs in tumourigenesis, where STAT3 and STAT1 also exhibit opposing functions, 
is not yet know.   
1.9.2.1 STAT3 upstream activators 
The two main events that feed into STAT3 activation are stimulation of either the IL-
6-receptor/JAK2 cytokine signalling pathway or the EGF-receptor growth factor 
signalling pathway (Zhong et al., 1994). Src-family kinases have also been shown to 
stimulate STAT3 activation, both directly and as downstream mediators of RTK 
signalling (Silva, 2004), and G-protein coupled receptors are also able to activate 
STAT3 through their interaction with Src (Ram and Iyengar, 2001). As well as EGF 
and IL-6, many other growth factors and cytokines including PDGF, LIF, TGF-β, IL-
10 and IL-11 have been demonstrated to activate STAT3 (Johnston and Grandis, 
2011). As well as stimulatory molecules, cell-cell interactions through cadherins are 
able to activate the Rac-GTPase which induces IL-6 expression and subsequently 
increases STAT3 activation (Arulanandam et al., 2009). In many of these activating 
components, overexpression or activating genetic mutations has been shown to 
occur in cancers and often correlates with a poor prognosis (Allgayer et al., 2002; 
Alvarez et al., 2006; Baxter et al., 2005; Engers et al., 2007; Irby et al., 1999; 
Salgado et al., 2003).   
1.9.2.2 Negative regulation of STAT3 
Negative regulation of the STAT3 pathway can be carried out by phosphatase 
action on STAT3 or any of the phosphorylated components of the pathway; for 
instance, the SHP1 and SHP2 phosphatases remove the activating phosphorylation 
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from STAT3, terminating signalling. Alternatively, inhibitors such as PIAS3 (protein 
inhibitor of activated STAT3) can bind to STAT3 directly and block DNA binding. 
SOCS3 can also negatively regulate STAT3 signalling by acting as a negative 
feedback loop. SOCS are activated by the JAK/STAT pathway itself and function by 
binding either upstream JAK molecules, competing for STAT3 binding sites and thus 
excluding STAT3, or by binding other STAT3 signalling components and targeting 
them for proteasomal degradation by ubiquitination (Wormald and Hilton, 2004).  
As well as protein-mediated negative regulation of STAT3 signalling, miRNAs are 
able to control STAT3 activation by targeting mRNA expression. The let-7 miRNA is 
able to induce SOCS3 expression, thus inhibiting STAT3 activation indirectly. Also, 
lower levels of some STAT3-regulating miRNAs, such as miRNA-20a, are correlated 
with poorer recurrence-free survival in patients (Fan et al., 2013).  These tumour 
suppressor-like miRNAs have been shown to be down-regulated in tumour cell lines 
and patient tumour tissue compared with normal tissue (Fan et al., 2013; Patel et 
al., 2014). 
1.9.2.3 STAT3 downstream effectors 
STAT3 is an oncogene, which when constitutively activated can drive cells into 
oncogenesis. The genes that STAT3 modulates the expression of, which includes 
factors involved in proliferation, anti-apoptosis and survival, angiogenesis, and 
metastasis, mediate this outcome. Cyclin D1 and c-Myc, key regulators of the cell 
cycle, as well as anti-apoptosis proteins Bcl-xl, survivin and Mcl-1 are all regulated 
by STAT3 and these allow cancer cells to survive and proliferate (Aoki et al., 2003; 
Bromberg et al., 1999; Epling-Burnette et al., 2001; Gritsko et al., 2006; Kiuchi et al., 
1999; Masuda et al., 2002; Zushi et al., 1998). Also regulated by STAT3 are VEG-F 
and MMP-9, which ensure a good blood supply to the tumour (angiogenesis) as well 
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as the capacity for tumour cells to migrate and form metastases (Dechow et al., 
2004; Niu et al., 2002).  STAT3 also regulates the expression of other cancer-
related transcription factors such as c-Fos and HIF-1α which potentiates STAT3’s 
tumourigenic effect (Niu et al., 2008; Xu et al., 2005; Yang et al., 2003) 
1.9.3 STAT3 and cancer 
Several lines of evidence suggest a key role for STAT3 in tumourigenesis. Firstly, 
cells transformed with the oncogene, Src, depend upon activated STAT3 and 
expression of a dominant-negative STAT3 will inhibit this transformation (Bromberg 
et al., 1998). In addition, overexpressing constitutively activated STAT3 causes 
transformation in fibroblasts and tumourigenesis when these cells are injected into 
mice (Bromberg et al., 1999). Finally, high levels of constitutively activated STAT3 
are seen in many cancer types, including prostate, lung, breast, head and neck, 
ovarian, gastric, kidney, liver, skin, colorectal, pancreatic and haematological 
cancers, and in several of these, STAT3 levels are correlated with a poor prognosis 
(Aggarwal et al., 2006; Johnston and Grandis, 2011). For example, a meta analysis 
of 1314 gastric cancer patients concluded that positive pSTAT3 expression was 
significantly associated with poorer overall survival (hazard ratio = 1.87) (Yu et al., 
2015), and NSCLC patients with high STAT3 expression exhibited a 5-year overall 
survival rate of 42.3% compared with 58.8% in patients with low STAT3 expression 
(Yin et al., 2012).  
Table 1-4 summarises several immunohistochemistry experiments where the 
percentage of pSTAT3Tyr705 in human tissue samples has been analysed. As high as 
38-50% of non-small cell lung cancers (Cortas et al., 2007; Gao et al., 2007) and 
86% of recurrent prostate cancers (Abdulghani et al., 2008) express constitutively 
active STAT3, and as normal adult tissues do not harbour constitutively active 
STAT3 (activation is a transient event, tightly regulated by negative feedback 
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mechanisms (Yoshimura et al., 2007; Zhang and Lai, 2014)), this highlights the 
potential for the use of STAT3 inhibitors in the clinic.  
Table 1-4: Activated STAT3 in different tumour types, assessed by 
immunohistochemistry of human tumour samples.  
Cancer Type % with STAT3 
activated 
Reference  
Non-small cell lung 
(NSCLC) 
38-50% (Cortas et al., 2007; Gao et al., 
2007) 
Prostate:  
 
Lymph node 
metastasis  
------- 
Bone metastasis 
------- 
Recurrent human 
prostate cancers 
Up to 100% 
------ 
77% 
 
------ 
67% 
------- 
86% 
(Barton et al., 2004) 
 
(Abdulghani et al., 2008) 
 
 
 
Breast >50% (Kunigal et al., 2009) 
Cervical 25.2% (Chen et al., 2007) 
Endometrial  
 
20.8% 
 
(Chen et al., 2007) 
AML 25-44% (Benekli, 2002; Redell et al., 2011; 
Schuringa et al., 2000) 
Liver 54.3% (W. Y. Wu et al., 2011) 
Colon 55.1% (Lin et al., 2011) 
Gastric 49.5% (Yakata et al., 2007) 
Squamous cell (SCC) 56.7% (Suiqing et al., 2005) 
Basal cell (BCC) 20% (Suiqing et al., 2005) 
Pancreatic 30% (Toyonaga et al., 2003) 
Renal cell 51% (Guo et al., 2009) 
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Mutations in the STAT3 gene that lead to its constitutive activation have been 
reported. In hepatocellular adenomas, several somatic mutations in the STAT3 SH2 
domain were identified, and these mutations were shown to cause constitutive 
STAT3 activation and enhanced STAT3 phosphorylation, nuclear translocation and 
DNA binding (Pilati et al., 2011). 40% of patients with T-cells leukaemia were shown 
to have mutations in the SH2 domain of STAT3. Again, these mutations enhanced 
STAT3 dimerisation by increasing the hydrophobicity of the amino acids lining the 
SH2 pocket, and therefore, enhanced STAT3 activation and nuclear translocation 
(Koskela et al., 2012). Mutations in the TAD and DNA binding domains have also 
been reported in patients with autoimmune diseases (Flanagan et al., 2014).   
As well as activating mutations in the STAT3 gene, constitutive STAT3 activation 
can arise through mutations in the signalling machinery upstream of STAT3. For 
example, high IL-6 levels contribute significantly to the constitutive activation of 
STAT3 activation in prostate cancers (Giri et al., 2001).  Also, stimulating mutations 
occur in positive regulators of STAT3 signalling such as the EGF-receptor (EGFR) 
(Gao et al., 2007), and  the V617F activating mutation in the JAK2 kinase occurs in 
50-97% of patients with myeloproliferative neoplasms (Baxter et al., 2005; Thomas 
et al., 2015). Conversely, inhibitory mutations may occur in negative regulators of 
STAT3 such as SOCS proteins. A deletion in the suppressor of cytokine signalling 1 
(SOCS1) gene has been described in B-cell lymphomas, and inactivation of the 
SOCS1 promoter by methylation has also been described in over 50% of 
melanomas and hepatocellular carcinomas (Inagaki-Ohara et al., 2013; Yoshikawa 
et al., 2001). Methylation of the SOCS3 promoter also occurs in up to 90% of head 
and neck cancers (Inagaki-Ohara et al., 2013). Therefore, constitutive STAT3 
signalling can occur via the deregulation of several stages in the STAT3 pathway. 
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1.10 Targeting STAT3 in cancer 
As STAT3 is frequently activated in a broad spectrum of cancers and is involved in 
tumourigenesis, it is a viable target for therapeutic intervention. In vivo studies 
demonstrated that complete STAT3 knockout is embryonic lethal in mice (Takeda et 
al., 1997), however, selective knockout is tolerated by normal cells but not 
transformed cells (Schlessinger and Levy, 2005), therefore, STAT3 has potential as 
a target for novel anti-cancer therapeutics.  
STAT3 signalling can be interfered with at various stages of the pathway. The 
possible stages of intervention are illustrated in Figure 1-25. Direct inhibition of 
STAT3 can block the dimerisation of STAT3 monomers, or the binding of activated 
STAT3 to DNA. Inhibition of the STAT3 pathway could also be achieved by 
inhibition of the nuclear translocation process. Alternatively, the upstream signalling 
molecules that lead to STAT3 activation can be inhibited, including the growth factor 
and cytokine pathways, and stimulation of the factors which negatively regulate 
STAT3 would also achieve inhibition of this pathway. Each of these modes of 
intervention will be discussed in further detail. 
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1.10.1 Direct STAT3 inhibitors  
Direct targeting of STAT3 is desirable as many upstream oncogenic signalling 
pathways lead into STAT3 activation, so blocking one of these pathways may lead 
to feedback-related resistance, and sustained STAT3 signalling (Zhao et al., 2016). 
Therefore, by targeting the transcription factor directly, the central cancer-signalling 
node can be blocked. However, one of the main problems with targeting a 
transcription factor is how specificity is attained. Transcription factors have 
classically been considered “undruggable” targets, as they lack individual enzymatic 
activities to target and many share similar DNA binding mechanisms with large 
surface areas used for these interactions (Frank, 2012; Yan and Higgins, 2013). 
Nonetheless, progress has been made in the development of small molecule 
inhibitors targeting STAT3 directly.   
1.10.1.1 SH2 domain inhibitors 
STAT3 dimerisation is the first stage of STAT3 signalling where multiple signalling 
pathways converge, therefore, it represents an attractive target for interference, and 
as such, most of the STAT3 inhibitors currently reported target the SH2 domain. 
Inhibition of the SH2 domain can prevent these pockets from binding phospho-
tyrosine residues on activating receptors and other STAT3 monomers and, 
therefore, prevent both phosphorylation and dimerisation of STAT3. 
There are many natural compounds derived from various plant materials that have 
been shown to inhibit STAT3 dimerisation. Curcumin, from the Indian spice saffron, 
or Curcuma longa, is one of the most widely known natural inhibitors of STAT3. In 
its keto form it can bind to SH2 domains (Lin et al., 2010a). Curcumin has, however, 
been demonstrated to affect many other signalling pathways: it was first discovered 
as an anti-bacterial compound and since then was shown to regulate an array of 
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molecules such as hormones, blood sugars, cytokines, cholesterol, growth factors, 
antioxidants, and cyclooxygenases (Gupta et al., 2013a).  
Dried roots of Salvia miltiorrhiza contain the active component Cryptotanshinone  
which has also been shown to have anti-cancer properties through the inhibition of 
the STAT3 SH2 domain. Cryptotanshinone also has anti-bacterial and anti-
inflammatory action (Shin et al., 2009). Another natural STAT3 inhibitor, Scoparone, 
comes from the Chinese herb Artimisia capillaris. Scoparone was predicted by 
computational studies to bind the STAT3 SH2 domain. Alongside its anti-cancer 
activity, Scoparone also harbours anti-coagulant, anti-inflammatory, and vasodilator 
activities as well as being used as a common treatment for jaundice in Asia (Kim et 
al., 2013).  
One of the key limitations when using natural compounds for therapeutic purposes 
has been highlighted here: lack of specificity. Additionally, natural compounds like 
curcumin have low bioavailability (Anand et al., 2007). Therefore, the development 
of synthetic derivatives of these natural compounds has aimed to achieve specificity 
and improved bioavailability.  
High-throughput screening techniques led to the discovery of small molecule 
inhibitors of the STAT3 SH2 domain, and one of the first of these was stattic (Schust 
et al., 2006). Many other synthetic STAT3 SH2 inhibitors have since been 
discovered, including STA-21 (Song et al., 2005), S3I-201 and its derivatives 
(Siddiquee et al., 2007), 5,15-DPP (Uehara et al., 2009), the CPD compounds (Xu 
et al., 2009), STX-0119 (Matsuno et al., 2010), 17o (Page et al., 2011), XZH-5 (Liu 
et al., 2011) and many other synthetic curcumin analogues (Bill et al., 2012; Hutzen 
et al., 2009; Kumar et al., 2014; Lin et al., 2010a; Selvendiran et al., 2011). Many of 
these STAT3 inhibitors harbour anti-proliferative activity, however, most lack 
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potency or have not been demonstrated to be specific for STAT3 over the other 
STAT transcription factors.  
Given the lack of small binding pockets on transcription factors such as STAT3, 
peptides have also been designed to block the dimerisation of STAT3 monomers, 
with the rationale that biological macromolecules will be more effective competitors 
for STAT3 protein-protein interactions (Borghouts et al., 2012; Ren et al., 2003; Wei 
Zhao et al., 2010). However, peptide-based therapeutics suffer from instability due 
to cleavage of the peptide bond, and lack of selectivity in terms of tumour delivery 
versus uptake by normal cells, therefore, both targeting and the use of 
peptidomimetics should be investigated for further development of peptide-based 
inhibitors.   
1.10.1.2 DNA binding domain inhibitors 
Small molecules targeting the DNA binding domain of STAT3 are less common than 
those targeting the SH2 domain, however, these compounds have exhibited greater 
selectivity for STAT3. DNA-binding domain inhibitors block STAT3 dimers from 
binding to consensus DNA sequences and therefore, block transcription. Examples 
of DNA binding domain inhibitors include the curcumin analogues, HO-3867 and H-
4073 (Selvendiran et al., 2011, 2010), and inS3-54 and its derivatives which were 
initially identified by virtual docking of 200,000 compounds to the STAT3 DNA 
binding domain (Huang et al., 2016, 2014). A natural compound isolated from a 
particular type of fungus, galiellalactone, was also demonstrated to inhibit STAT3 
DNA binding without affecting STAT3 phosphorylation by covalently binding to 
cysteine residues in the DNA binding domain (Don-Doncow et al., 2014). A peptide 
inhibitor of the STAT3 DNA binding domain has also been described (Nagel-
Wolfrum et al., 2004), however, the shortcomings of peptide-based molecules 
remain to be addressed.  
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1.10.1.2.1 Decoy oligonucleotide inhibitors 
The DNA-binding domain of STAT3 has also been investigated as a target for 
inhibition by decoy oligonucleotides that mimic the STAT3 binding site (Leong et al., 
2003; Zhang et al., 2007), however, as with peptide-based inhibitors, cellular 
stability and delivery of oligonucleotides to the tumour is challenging. A recent 
phase 0 trial of a STAT3 decoy in head and neck cancer has begun to make 
advances in this area by using a cyclic oligonucleotide to increase stability (Sen et 
al., 2012).   
1.10.1.3 N-terminal domain inhibitors 
Peptide inhibitors targeting the N-terminal domain of STAT3 have also been 
described (Timofeeva et al., 2007). The rationale behind targeting this domain is to 
disrupt the interactions between STAT3 dimers and other transcriptional proteins, 
leading to an impaired enhanceosome formation. However, no small molecule 
inhibitors of this domain have yet been discovered.  
1.10.2 Indirect STAT3 inhibitors 
Many inhibitors that target elements upstream of STAT3 activation in the STAT3 
pathway have already been approved for use by the FDA and EMA. These indirect 
inhibitors will be discussed.  
1.10.2.1 EGFR inhibitors  
EGFR itself is activated or over-expressed in many cancers, and its signalling leads 
to STAT3 activation (see Figure 1-26a), and so in the 1980s inhibitors targeting this 
receptor were developed. EGFR can be blocked by monoclonal antibodies targeting 
the extracellular domain or by small molecule kinase inhibitors targeting the 
intracellular domain.  
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1.10.2.1.1 Tyrosine kinase inhibitors 
The first class of molecules that target the EGFR pathway are small molecules 
targeting the EGFR kinase domain. These include erlotinib and gefitinib, which 
compete with ATP for the EGFR kinase domain. This inhibits EGFR 
autophosphorylation-induced activation and therefore blocks signalling downstream 
of EGFR (see Figure 1-26b). However, acquired resistance can develop in response 
to tyrosine kinase inhibitors (TKIs) through mutations in the EGFR kinase domain. 
The T790M mutation accounts for approximately half of all cases of resistance to 
EGFR TKIs. This mutation enhances the affinity of the receptor for ATP, reducing 
the efficacy of inhibitors such as erlotinib and gefitinib (Yun et al., 2008). The 
second generation EGFR inhibitor, afatinib, was designed to overcome resistance 
by irreversibly inhibiting the EGFR kinase domain. However, T790M-mediated 
resistance to afatinib also occurs (Wu et al., 2016). Development of improved TKIs 
for patients with the T790M mutation is on-going. The third generation EGFR TKIs 
include osimertinib, which was approved in late 2015 by the FDA and in early 2016 
by the EMA for use in metastatic NSCLC patients with the T790M mutation (Wang 
et al., 2016). Olmutinib has also been recently approved for use in NSCLC in South 
Korea based on positive clinical trial results (J. S. Lee et al., 2015). Mutations 
incurring resistance to these third generation TKIs have, however, already been 
reported (Wang et al., 2016).  
1.10.2.1.2 Monoclonal antibodies 
Monoclonal antibodies (mAbs) directed against EGFR are designed to bind the 
extracellular domain of the receptor. This competes with the EGF ligand and 
therefore blocks EGF-induced activation of the EGFR pathway. This subsequently 
blocks downstream STAT3 activation (see Figure 1-26c). EGFR mAbs are also able 
to elicit cytotoxicity through antibody-dependent cellular cytotoxicity (ADCC).  
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Figure 1-26: Action of EGFR inhibitors. A) EGFR signalling to STAT3, b) tyrosine 
kinase inhibitors and c) monoclonal antibodies 
This is where the Fc domain of the antibody (the domain not bound to the target 
antigen, EGFR) is bound by Fc-receptors on immune cells and triggers and an 
immune response against the cancer cell (Adams and Weiner, 2005). Additionally, 
binding of monoclonal antibodies to EGFR is able to induce internalisation and 
subsequent degradation of the receptor, diminishing the signal to STAT3 (Sunada et 
al., 1986). The most frequently used monoclonal EGFR antibody is cetuximab 
(Ciardiello and Tortora, 2008). 
1.10.2.2 JAK2 inhibitors 
The cytokine signalling pathway can also be targeted. The inhibitor of the JAK2 
kinase, ruxolitinib, was approved in 2011 for the treatment of myeloproliferative 
cancer. This inhibitor targets the kinase domain of both wild-type JAK2 and the 
V617F mutant, competing with ATP (Mascarenhas and Hoffman, 2012; Seavey and 
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Dobrzanski, 2012). The natural compound bergamottin was also recently found to 
inhibit JAK1/2 as well as inducing levels of the STAT3-deactivating phosphatase 
SHP-1 (Kim et al., 2014).  
As with STAT3 inhibitors, many novel JAK2 inhibitors are also being developed. 
One such inhibitor is AZ1480 which underwent a phase I trial in solid tumours. This 
trial revealed that AZD1480 induced neuropsychiatric dose-limiting side effects and 
therefore, the development of this drug was discontinued. The authors hypothesised 
that these effects were due to lack of specificity of the inhibitor, highlighting the need 
for specificity in targeting the STAT3 pathway (Plimack et al., 2013). 
1.10.2.3 Src inhibitors 
The Src kinase is also reported to activate STAT3 and so theoretically, targeting Src 
would also inhibit STAT3 (Silva, 2004).The Src inhibitor, Dasatinib, was approved in 
2011 for patients with elevated Src kinase levels. However, STAT3 inhibition by 
Dasatinib is not maintained, and with prolonged dasatinib exposure, STAT3 
phosphorylation is enhanced. It is thought that other STAT3 activating pathways 
may compensate for the inhibition Src-mediated STAT3 activation (Sen et al., 2009), 
For instance, dual inhibition of JAK and Src is able to block STAT reactivation 
(Byers et al., 2009). Therefore, as many pathways converge on STAT3, it may not 
be sufficient to focus on one STAT3-activating pathway. It is for this reason that 
much research has been directed towards the direct inhibition of STAT3. 
Other Src inhibitors with FDA approval for the treatment of malignancies include 
bosotunib, ponatinib and vandetanib, which all target the Src kinase domain 
(Roskoski, 2015). However, none of these inhibitors are selective for Src, as they 
also target many other kinases. Development of novel, more selective compounds is 
underway to address this, with studies suggesting that a more selective Src inhibitor 
is more efficient at inhibiting cancer cell growth (Brandvold and Steffey, 2012). 
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1.10.2.4 Nuclear translocation inhibitors. 
Another possible target is the nuclear machinery that translocates STAT3 dimers 
into the nucleus. Translocation is thought to be mediated by the importin class of 
proteins, including importin α3, α5 and β1 (Cimica et al., 2011; Liu et al., 2005; Ma 
and Cao, 2006; Pranada et al., 2004), however, small molecule inhibitors of the 
importins have not yet been investigated for their effect on STAT3 activation. 
Importin inhibitors discovered to date include importazole, which has been 
demonstrated to exhibit toxicity against multiple myeloma cells by blocking the 
import of NF-κB, an oncogenic transcription factor (Yan et al., 2015). However, the 
effect of this inhibitor on STAT3 translocation has not yet been investigated. On the 
other hand, decoy oligonucleotides that interfere with STAT3-importin interactions 
have been shown to have anti-cancer activity (Souissi et al., 2011).  
As well as import, export of STAT3 from the nucleus could be targeted. Blocking the 
export of STAT3 with ratjadona A, an inhibitor of exportin-1, was shown to interfere 
with the STAT3 reactivation cycle. STAT3 phosphorylation occurs in the cytoplasm, 
and STAT3 dephosphorylation occurs in the nucleus, therefore, nuclear shuttling of 
STAT3 is required to maintain a persistent STAT3 signal (Herrmann et al., 2007). 
Also, the exportin-1 inibitor, selinexor, was able to inhibit STAT3 transcriptional 
activity and is currently undergoing clinical trials in various cancers (Cheng et al., 
2014). Consequently, interfering with either STAT3 nuclear import or export is a 
valid target for future research.  
1.10.2.5 Stimulators of STAT3 negative regulation 
Negative regulation of the STAT3 signalling pathway occurs through 
dephosphorylation by SHP1/SHP2, or by activation of PIAS and SOCS proteins. Up-
regulating the activity of these negative regulators could inhibit STAT3 signalling. To 
date, research into this area has focussed on natural compounds. Morin, a natural 
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compound isolated from figs, was shown to inhibit STAT3 activation by inducing the 
expression of the SHP1 phosphatase and PIAS3 (Gupta et al., 2013b). Another 
natural compound, brassinin, was demonstrated to block STAT3 signalling through 
the up-regulation of PIAS3 expression (J. H. Lee et al., 2015). The flavanoids 
naringenin and flavone were shown to inhibit STAT3 activation by up-regulating the 
expression of SOCS3 (Wiejak et al., 2013). However, no stimulators of these 
STAT3-inhibitory proteins are currently in clinical development, therefore, this 
particular area for intervention requires more research.   
1.10.3 STAT3 Inhibitors as chemosensitisers 
Resistance to chemotherapeutics is an important limitation that must be overcome. 
To achieve this, new compounds can be designed entirely, or drug combinations 
can be employed where one agent modifies the cancer cell biochemistry in order to 
re-sensitise the tumour to the chemotherapy agent.  
STAT3 inhibitors have been shown to act as both radiosensitisers, and 
chemosensitisers to a range of chemotherapy agents. The natural compound, 
curcumin, has been the focus of much research into STAT3-mediated 
chemosensitisation. Curcumin and its synthetic derivatives are able to sensitise 
cancer cell lines to a range of chemotherapy agents. These include doxorubicin, 
etoposide, camptothecin, 5-fluorouracil, vincristine, melphalan, gemcitabine, 
paclitaxel, celecoxib, oxaliplatin, thalidomide, bortezomib and cisplatin (Dhandapani 
et al., 2007; Goel and Aggarwal, 2010; Kumar et al., 2014; Lev-Ari et al., 2007; 
Notarbartolo et al., 2005; Patel et al., 2008; Ye et al., 2012).  Additionally, curcumin 
has been demonstrated to act as a chemosensitiser in murine models (Li et al., 
2007; Sreekanth et al., 2011).  
Stattic, the first synthetic SH2-domain targeting STAT3 inhibitor, has also been 
demonstrated to sensitise nasopharyngeal and ovarian cancer cells to cisplatin and 
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radiotherapy (Pan et al., 2013; Teng et al., 2013), and novel synthetic STAT3 
inhibitors such as 5,15-DPP and XZH-5 are also able to sensitise cells to cisplatin 
and doxorubicin/gemcitabine, respectively (Huang et al., 2012; Liu et al., 2012). As 
cisplatin features recurrently in these studies, the ability of STAT3 pathway inhibitors 
to chemosensitise to cisplatin will be discussed in greater detail in the introduction to 
Chapter 4. 
Many of the agents that STAT3 inhibitors chemosensitise cells to are cytotoxic due 
to the DNA damage they cause, as is the same for radiation therapy. Therefore, 
what remains to be answered is whether STAT3 inhibitors chemosensitise through 
an ability to directly modify the DNA damage response or DNA repair pathways of 
cancer cells.  
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1.11 Thesis aims and objectives 
Given the importance of the STAT3 pathway in tumourigenesis, and the interest in 
targeting this pathway therapeutically, this thesis details two projects concerning 
STAT3. First, the anti-cancer potential of a novel STAT3 inhibitor, VS-43, both as a 
single agent and in combination with cisplatin is investigated. Second, the role of 
STAT3 in DNA-ICL repair is investigated, in order to better understand the 
molecular mechanisms contributing to more effective drug combinations. 
The summarised aims for each chapter of this thesis are, therefore, as follows: 
• Chapter 3: Initial characterisation of a novel STAT3 inhibitor, VS-43. 
• Chapter 4: Determination of the effect of STAT3 inhibitors in combination 
with cisplatin, and comparison of VS-43 to known STAT3 inhibitors.  
• Chapter 5: Investigation into the molecular mechanism of sensitisation to 
cisplatin by STAT3 inhibitors, focusing on the repair of DNA-ICLs. 
• Chapter 6: Extension of STAT3 combination and mechanistic studies to 
melphalan.   
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Chapter 2 Methods and Materials  
Methods used in this thesis were assessed for hazards and COSHH risk 
assessments were carried out in order to perform the following protocols safely.  
2.1 Reagents 
Cisplatin was kindly provided as a 3.3mM aqueous solution by the UCLH Macmillan 
Centre. Melphalan, Stattic, Curcumin, and doxorubicin hydrochloride were 
purchased from Sigma-Aldrich and solubilised to 10mM in DMSO. VS-43 was 
synthesised and supplied by Professor Moses Lee, Georgia State University, USA. 
VS-43 was solubilised in DMSO to a 10mM stock solution.  
2.2 Maintenance of Cell Lines 
DU145 human prostate cancer and A549 human non-small cell lung cancer cells 
were obtained from the American Type Culture Collection (ATCC) and cultured in 
DMEM (Sigma Aldrich) supplemented with 10% FCS (Gibco) and 2mM L-glutamine 
(Sigma Aldrich). Both cell lines were grown at 37°C with 5% CO2. The RPMI8226 
human multiple myeloma cell line was cultured in RPMI 1640 medium (Sigma 
Aldrich) supplemented with 10% FCS and 2mM L-glutamine. 
Adherent cell lines (DU145 and A549) were passaged every 2-3 days by 
trypsinisation. Media was removed, cells were rinsed in 2-3mL Trypsin-EDTA 
(Sigma Aldrich), and then incubated for 5 minutes at 37°C with a further 5mL 
Trypsin-EDTA. Detached cells were collected and the trypsin was neutralised by 
adding an equal volume of culture media. Cells were pelleted by centrifugation at 
1200rpm for 5 minutes and subsequently resuspended in culture media for counting 
and seeding. Both cell lines were passaged 2-3 times per week in order to maintain 
them in exponential growth.  
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RPMI8226 suspension cells were passaged every 2-3 days by centrifuging at 
1200rpm for 5 minutes and resuspending in the appropriate culture media. These 
cells were maintained within the optimal density range of 5 x 105 and 2 x 106 
cells/mL.  
2.3 Frozen cell line stocks 
To freeze down cell line stocks for future use, one exponentially growing T75 flask 
of cells was detached by trypsinisation as for cell line maintenance (for suspension 
cell lines no trypsinisation was required). Cells were spun down at 1200rpm for 5 
minutes and subsequently resuspended in 6mL freezing media (FCS with 10% 
DMSO). This cell suspension was transferred into 6x 1mL cryovials and the vials 
were placed in a cryo freezing container (NalgeneTM) at -80°C in order to achieve a 
cooling rate of -1°C/min. After 24 hours, cryovials containing cells were transferred 
to a liquid nitrogen tank for long-term storage.   
To set up fresh cultures from frozen down stocks, cryovials were placed in a 37°C 
water bath to thaw cells quickly. 9mL of culture medium was added to the cell 
suspension, and centrifugation at 1200rpm for 5 minutes was performed to pellet the 
cells. The pellet was resuspended in culture medium and seeded into a T75 flask.  
2.4 Counting of cells 
In order to seed cells at specific densities, an improved neubauer haemocytometer 
(Appleton Woods) was used to count cells in suspension. 10µL of cell suspension 
was pipetted into the gap between the haemocytometer chamber and cover glass. 
Under a microscope, the number of cells in 5 of the larger squares on the 
haemocytometer grid were counted. Cells touching the upper and left limits of each 
square were counted whereas cells touching the lower and right limits of each 
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square were not included in the count. The total number of cells counted was 
divided by 5 to give the number of cells x 104/mL.  
2.5 Immunoblotting 
2.5.1 Seeding, Treatment and Whole Cell Protein Extraction 
Cells were seeded in 6-well plates (Corning) and grown until they reached 70% 
confluency. Cells were then drug treated and incubated for the duration of the 
treatment time at 37°C with 5% CO2.   
To harvest cells, plates were placed on ice and rinsed twice in cold PBS before 
adding 1mL cold PBS per well and collecting cells using scrapers. Samples were 
spun down at 1200rpm, 4°C for 5 minutes. The supernatant was aspirated and the 
cell pellet was resuspended in CelLytic M Lysis Buffer (Sigma Aldrich) containing 1x 
cOmpleteTM protease and PhosSTOPTM phosphatase inhibitors (Roche). Lysis was 
performed on ice for at least 30 minutes, with regular vortexing.  Samples were then 
spun down for 15 minutes at 4°C and the supernatant containing the whole-cell 
lysates collected. 
2.5.2 Protein Quantification 
The BioRad DCTM protein assay kit was used determine the concentration of protein 
in lysates. The standard curve method was used, where Bovine Serum Albumin 
(BSA) standards are included in the assay to create a curve. From this curve, a 𝑦 = 𝑚𝑥 + 𝑐 equation relating absorbance to protein concentration can be obtained. 
BSA was dissolved in water to reach 1000µg/mL, 800µg/mL, 600µg/mL, 400µg/mL, 
200µg/mL, and 100µg/mL for the standard curve. These standards were stored at     
-20°C.  
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Whole cell lysates were diluted 1:5 in distilled water and 10µL of each sample, 
including BSA standard samples, was added per well on a 96-well plate (Corning). 
Two replicates of each sample were performed. 25µL of a mixture of Reagent A and 
Reagent S (20µL of A : 1mL of S) was then added per well, followed by 200µL of 
Reagent B. Upon adding Reagent B, the contents of each well was mixed by 
pipetting. The colour was then allowed to develop by placing the plate on a rotating 
platform for 15 minutes. Absorbance at 630nm was read using the Variskan Flash 
Multimode Reader (Thermo-Scientific). Average absorbance versus BSA 
concentration was plotted for the standard curve and using the best-fit equation 
given by Microsoft Excel, the corresponding protein concentration for unknown 
samples was calculated from their absorbance.  
2.5.3 Protein Sample Preparation 
4x SDS-PAGE sample loading buffer (NuPAGE®, with 500mM DTT) was added to 
30µg of each sample lysate to obtain a final 1x concentration. Samples were then 
denatured by incubating at 95°C for 5 minutes. Samples were allowed to cool and 
spun down briefly before loading into an SDS-PAGE pre-cast gel.  
2.5.4 Immunoblotting Procedure 
Proteins were separated on pre-cast 7% Tris-Acetate or 4-12% Bis-Tris NuPAGE® 
SDS-PAGE gels with either 1x NuPAGE® Tris-Acetate, MOPS or MES running 
buffers depending on the gel and the separation required (Thermo Fisher Scientific). 
Voltage applied was 150V and 200V for Tris-Acetate and Bis-Tris gels respectively. 
Proteins were then transferred to Immobilon-P PVDF membrane (Merck Millipore) in 
an XCell transfer module using 1x transfer buffer (10x: 30.3g Tris-base, 144.1g 
glycine in 1L distilled water, pH 8.3) with 20% methanol added immediately before 
use. PVDF membrane was activated in methanol for 2 minutes and soaked in 
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transfer buffer before use. The voltage applied for the transfer was 35V for 2.5 
hours.  
Membranes were then blocked for 1 hour in 5% w/v BSA in TBS 0.1% Tween-20 
(TBS-T) (Sigma Aldrich). Membranes were incubated with primary antibodies diluted 
in 5% w/v milk or BSA overnight at 4°C on a rotating platform. A list of primary 
antibodies used can be seen in Table 2-1. After washing three times with TBS-T for 
5 minutes per wash, secondary horseradish peroxidase-coupled anti-rabbit or anti-
mouse antibodies (Cell Signaling) were incubated on membranes for 1 hour with 
rocking at room temperature. After three further TBS-T and one TBS wash, 
membranes were soaked in enhanced chemiluminesence (ECL, Amersham, GE 
Healthcare) reagent and exposed in a dark room to film.  
Where there was a need to probe for proteins of a similar molecular weight, 
duplicate gels were run where possible. In some cases, stripping of the membrane 
using Restore PLUS Western Blot Stripping Buffer (Thermo Fisher Scientific) and 
re-blocking was required before re-probing the membrane for a second protein 
target.  
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Table 2-1: Details for primary antibodies used in immunoblotting: supplier, 
species, dilution and diluting buffer. 
Primary Antibody 
Target 
Supplier Species Dilution Diluting Buffer 
pSTAT3-Tyr705 Cell Signaling Rabbit 1:1000 5% BSA in 
TBS-T 
STAT3 Cell Signaling Rabbit 1:1000 5% BSA in 
TBS-T 
pSTAT1-Tyr701 Cell Signaling Rabbit 1:1000 5% BSA in 
TBS-T 
pSTAT5-Tyr694 Cell Signaling Rabbit 1:1000 5% BSA in 
TBS-T 
β-Actin Cell Signaling Rabbit 1:2000 5% BSA in 
TBS-T 
Cleaved PARP Cell Signaling Rabbit 1:1000 5% BSA in 
TBS-T 
Cleaved Caspase-
3 
Cell Signaling Rabbit 1:1000 5% Milk in TBS-
T 
γ-H2AX Cell Signaling  Rabbit 1:500 5% BSA in 
TBS-T 
XPF Cell Signaling Rabbit 1:1000 5% BSA in 
TBS-T 
ERCC1 Cell Signaling Rabbit 1:1000 5% BSA in 
TBS-T 
MUS81 Santa Cruz 
Biotechnology 
Mouse 1:500 5% milk in TBS-
T 
EME1 Santa Cruz 
Biotechnology 
Mouse 1:500 5% milk in TBS-
T 
SLX4 Abcam Mouse 1:500 5% BSA in 
TBS-T 
FANCD2 Abcam Rabbit 1:1000 5% BSA in 
TBS-T 
BRCA1 Cell Signaling Rabbit 1:1000 5% BSA in 
TBS-T 
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2.6 Cytotoxicity Assays 
2.6.1 Sulphorhodamine B Cell Growth Inhibition Assays 
2.6.1.1 Seeding and Treatment of Cells 
DU145 and A549 cells were seeded in 96-well flat-bottomed plates (Corning) at a 
density of 2.5 x 104 cells/mL and 2 x 104 cells/mL respectively and left to adhere 
overnight before drug treatment.  
Cells were then treated with 100µL/well of drug diluted in fully complemented media. 
For combination treatments cells were treated with drug A, drug B or a successive 
combination of the two drugs. For instance, in the “Fixed Ratio” regime, cells were 
treated with VS-43 for 18 hours, media removed, and then immediately treated with 
cisplatin for 1 hour. The treatment ratio chosen for each combination was based on 
estimated GI50 values for each drug in the DU145 cell line. The same ratios were 
applied for A549 cells to allow for a direct comparison between cell lines. Non-fixed 
ratio combination treatments were also carried out in a successive manner.  
After all drug treatments, the media was replaced and plates were incubated at 
37°C with 5% CO2 for 96 hours. 
2.6.1.2 SRB Staining 
SRB (Sigma Aldrich) was used to stain the cells remaining after drug incubation. 
Cells were first fixed with 100µL 10% TCA per well for 20 minutes at 4°C, and then 
washed with distilled water four times. 100µL SRB stain (0.4% w/v SRB in 1% acetic 
acid) was added to each well and the plates were incubated for 20 minutes at room 
temperature, followed by four washes with 1% acetic acid. Excess acetic acid was 
then patted out onto tissue paper and the plates were left to dry overnight at room 
temperature. SRB was re-suspended in 100µL of 10mM Tris-base (Sigma Aldrich) 
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pH 10.5 per well the following morning and the absorbance at 540nm was read 
using the Variskan Flash Multimode Reader (Thermo-Scientific). 
2.6.2 MTT Assay 
For suspension cell lines the MTT assay is the preferable method of GI50 
determination.  
2.6.2.1 Seeding of cells and drug treatment 
RPMI8226 cells were counted and resuspended to a concentration of 1 x 105 
cells/mL in culture media. The appropriate volume of drug was then added directly 
to the cell suspension and incubated for the required time at 37°C with 5% CO2. 
After this time the cells were centrifuged at 1200rpm for 5 minutes and the media 
was aspirated. Cells were resuspended in drug-free media and plated in 96-well 
round-bottom plates (Corning) with 200µL per well. Plates were incubated for 96 
hours post drug treatment.  
2.6.2.2 Staining of viable cells with MTT 
At the end of the 96 hour incubation period 20µL of 5mg/mL MTT (Sigma Aldrich) 
was added per well and plates were incubated at 37°C with 5% CO2 for a further 4 
hours. Plates were then centrifuged at 1200rpm for 5 minutes and the media was 
aspirated from each well without disturbing the cell pellets. To resuspend the MTT 
200µL DMSO was added per well and mixed by pipetting. The absorbance at 
540nm was read using the Variskan Flash Multimode Reader (Thermo-Scientific). 
2.6.3 Quantification of Growth Inhibition 
Absorbances were normalised to the absorbance value of untreated wells and 
expressed as a percentage of the control absorbance. At least three repeats of each 
experiment were performed and the results were presented as the mean ± SEM. 
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Dose-response graphs were plotted using GraphPad Prism 6. GraphPad was also 
utilised to calculate GI50 values using non-linear regression analysis. 
2.6.4 Quantification of Drug Interactions: Chou-Talalay Combination Index 
Analysis 
To determine whether the drug combinations tested were synergistic (total effect is 
greater than the sum of the effect of the two drugs individually), the Chou-Talalay 
Combination Index (CI) method was utilised. The two types of drug combination 
ratio described by Chou were tested for the combination of VS-43 and cisplatin 
(fixed and non-fixed ratio) (Chou, 2006). For combination of other STAT3 inhibitors 
with cisplatin, and for combinations involving melphalan, only the fixed ratio 
combination method was used. 
Using the percentages for growth inhibition obtained from the SRB assay, the 
fraction affected was calculated using the equation: 
𝐹𝑟𝑎𝑐𝑡𝑖𝑜𝑛 𝐴𝑓𝑓𝑒𝑐𝑡𝑒𝑑 = !""!!"#$ !"#$%#& !"#$"%&'("!""     
Fraction Affected values were inputted into the Calcusyn software and the manual 
drug wizard was used to generate CI values.  
Table 2-2 shows the descriptions and symbols used to interpret CI values. A CI 
value of less than 0.9 indicates synergism. CI values in the region of 0.9-1.1 indicate 
an almost additive interaction. This is as described by Chou and Talalay in the 
Calcusyn manual.  
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Table 2-2: Symbols and descriptions for interpretation of CI values. (Chou, 
2006) 
Range of CI Symbol Description 
<0.1 +++++ Very strong synergism 
0.1-0.3 ++++ Strong synergism 
0.3-0.7 +++ Synergism 
0.7-0.85 ++ Moderate synergism 
0.85-0.90 + Slight synergism 
0.90-1.10 ± Nearly additive 
1.10-1.20 − Slight antagonism 
1.20-1.45 −− Moderate antagonism 
1.45-3.3 −−− Antagonism 
3.3-10 −−−− Strong antagonism 
>10 −−−−− Very strong antagonism 
 
2.7 STAT Family Specificity ELISA 
2.7.1 Treatment of Cells and Preparation of Samples 
DU145 cells were seeded in 6 well plates (Corning) and allowed to reach 70% 
confluency before treating with VS-43. Treatments of 0, 0.8, 1.2 and 2µM in culture 
media were carried out for 18 hours. For the 1 hour VS-43 treatment, 5 and 10µM 
VS-43 was used. Whole cell extracts were harvested as for immunoblotting (section 
2.5.1) and protein quantification carried out as described in section 2.5.2. 
2.7.2 ELISA Assay Procedure 
The Active Motif TransAM® STAT Family ELISA was used according to the 
manufacturers protocol (TransAM® STAT3 and STAT Family Kits, Available from: 
http://www.activemotif.com/catalog/232/transam-stat3-stat-family-kits [accessed 
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May 2016]). Components of the kit were stored at 4°C, -20°C or -80°C according to 
the manufacturers guide.  
Provided in the kit is a 96-well plate coated with oligos encoding the STAT 
consensus binding site. 30µL of complete binding buffer was added per well, 
followed by 20µL of 1µg/µL sample diluted in complete lysis buffer. Each sample 
was repeated in triplicate for each of the four STAT proteins to be observed; 
therefore, twelve wells of each sample were required. For positive control wells, the 
Nb2 (prolactin stimulated) nuclear extract was used at 5 µg/well. The plate was 
covered with plastic film and incubated for 1 hour at room temperature with gentle 
rocking.  
STAT1, STAT3, STAT5a and STAT5b primary antibodies were diluted 1:1000 in 
antibody binding buffer and 100µL of antibody added per well. The plate was 
covered again and incubated at room temperature for 1 hour without agitation. The 
plate was then washed three times with 200µL of wash buffer. 
Secondary HRP-conjugated antibody was diluted 1:1000 in antibody binding buffer 
and 100µL added per well. The plate was then covered and incubated at room 
temperature for 1 hour without agitation. During this incubation period the 
developing solution was placed at room temperature. The plate was then washed 
four times with 200µL of wash buffer. 
To develop the ELISA, 100µL of developing solution was added to each well and 
incubated away from direct light for 5 minutes to allow for colour development. To 
prevent over-development of the ELISA, 100µL of stop solution was added per well 
immediately after the 5 minutes development time. Absorbance was then read at 
450nm using the Variskan Flash Multimode Reader (Thermo-Scientific) immediately 
after the addition of stop solution.  
  131 
2.7.3 Quantification of STAT Activation and DNA binding 
Activation and DNA binding of STAT proteins after treatment with VS-43 was 
quantified as percentage activation compared to control (0µM) wells. The average 
absorbance of the technical repeats was calculated and expressed as a percentage 
of the average absorbance of the control wells for each STAT protein. Two 
biological repeats were performed and the average and SEM calculated for the 18 
hour VS-43 treatments. For the 1 hour VS-43 treatments, only one biological repeat 
was performed due to the limited size of the TransAM® ELISA kit.  
2.8 Electrophoretic Mobility Shift Assay (EMSA) 
The following protocol was performed by Dr K. Kiakos. 
Nuclear extracts from DU145 cells were prepared using the Active Motif Nuclear 
Extract kit following the manufacturer’s protocol, in the presence of 1x cOmplete 
protease and 1x phosphatase inhibitors (Roche). The concentration of protein was 
determined as with immunoblotting (section 2.5.2). 20µg of nuclear extract was 
incubated with increasing concentrations of VS-43 or Stattic for 1 hour. 
Subsequently extracts were incubated for 1 hour with 32P-labeled double-stranded 
oligonucleotide containing the high-affinity sis-inducible element (hSIE) probe SIE 
(5′-AGCTTCATTTCCCGTAAATCCCTA-3′; Eurofins MWG Operon) derived from 
the c-fos gene. Binding reactions contained 0.9 µg poly(dI-dC). Competition assays 
were performed by adding 100x excess cold SIE oligonucleotide (lane C) and non-
specific competitor (lane M; FIRE; 5’-AGCGCCTCCCCGGCCGGGG-3’). The DNA-
protein complexes were subjected to electrophoresis on a 5% non-denaturing 
polyacrylamide gel (30% acrylamide/Bis solution, Bio-Rad) in 0.5% TBE buffer 
containing 2.5% glycerol (pH 7.8) at 4°C for 2 hours. Once dried, the radioactive 
signal of the gel was visualised by exposure to Fuji medical X-ray film. 
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2.9 Single Cell Gel Electrophoresis (Comet) Assay 
2.9.1 Treatment of Cells and Preparation of Samples 
Cells were seeded in 6 well plates (Corning) and allowed to reach 70% confluency 
before treatment. Four treatment conditions were required for this assay: untreated-
unirradiated, untreated-irradiated, crosslinker treated-irradiated, and combination 
treated-irradiated. One well of a 6-well plate was used for each treatment and time-
point. Drugs were diluted in culture media for drug treatments and cells were 
washed with fresh media after treatment. To observe the formation and repair of 
cisplatin-induced ICLs, cells were harvested at four time-points: 0, 9, 24, and 48 
hours, where 0 hours is immediately after 1 hour cisplatin exposure. For melphalan-
induced ICLs, cells were harvested at 0, 16, 24 and 48 hours. 
To harvest cells for the comet assay, wells were washed briefly in trypsin-EDTA and 
incubated with 1mL trypsin-EDTA for 5 minutes. An equal volume of culture media 
was added and cells were collected and spun down at 1200rpm for 5 minutes. Cells 
were resuspended in 2ml freezing media (FCS with 10% DMSO), counted and 
aliquotted into two cryo-vials. Samples were immediately placed on ice and frozen 
at -80°C until all time-points had been harvested. 
2.9.2 Comet Assay Procedure 
The modified single cell gel electrophoresis (comet) assay was performed as 
previously described (Spanswick et al., 2010). 
Cells were diluted to 2.5 x 104 cells/mL in DMEM and irradiated on ice with 15Gy 
using the A.G.O. HS 321 kV X-ray system (untreated-unirradiated control cells were 
diluted but not irradiated). Irradiation with a set dose of X-rays delivers a fixed 
number of strand breaks to the cellular DNA. Samples were then diluted 1:3 in 1% 
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low gelling temperature molten agarose and applied to slides pre-coated with 1% 
type 1-A agarose.  
Embedded cells were lysed for 1 hour in the dark on ice in lysis buffer (100mM 
disodium EDTA, 2.5M NaCl, 10mM Tris-HCl, 1% triton X-100, pH 10.5) and then 
slides were washed four times with distilled water for 15 minutes per wash. 
Subsequently, slides were transferred to large electrophoresis tanks and incubated 
in the dark in ice-cold alkali buffer (50mM NaOH, 1mM disodium EDTA, pH 12.5) for 
45 minutes. Electrophoresis was carried out for 25 minutes at 18V in the dark. 
Slides were then removed from the tanks and placed onto racks where they were 
washed once with cold neutralisation buffer (0.5M Tris-HCl, pH 7.5) for 10 minutes 
and once with sterile PBS for 10 minutes before removing excess liquid and leaving 
to dry at room temperature overnight.  
Slides were re-hydrated for 30 minutes in distilled water and the DNA stained with 
2.5µg/ml propidium iodide (Sigma Aldrich) for 30 minutes in the dark. Slides were 
then washed twice with distilled water – for 10 and then 30 minutes, and finally dried 
in an oven at 40°C for 1 hour before reading.  
2.9.3 Analysis of Slides 
Slides were analysed using the Komet 6.0 analysis software (Andor Technology). 
Images were captured using a Nikon inverted microscope with a high-pressure 
mercury light source, 510-560 nm excitation filter, 590 nm barrier filter and an on-
line CCD camera. 25 images at 20x were taken per slide with 2 duplicate slides per 
experimental condition and time point. The tail moment is defined as the “product of 
the amount of DNA in the tail, and the mean distance of migration in the tail” (Olive 
et al., 1990). The extent of crosslinking is expressed as a percentage decrease in 
tail moment.  
  134 
The following formula was used to calculate the tail moment:  
% 𝐷𝑒𝑐𝑟𝑒𝑎𝑠𝑒 𝑖𝑛 𝑡𝑎𝑖𝑙 𝑚𝑜𝑚𝑒𝑛𝑡 =  1 − (𝑇𝑀𝑑𝑖 − 𝑇𝑀𝑐𝑢)(𝑇𝑀𝑐𝑖 − 𝑇𝑀𝑐𝑢)  × 100 
Where TMdi = tail moment of drug treated irradiated sample 
TMcu = tail moment of untreated unirradiated control 
TMci = tail moment of untreated irradiated control. 
These experiments were performed in parallel when a direct comparison between 
the crosslink unhooking in two treatment regimes was being made (for example 
cisplatin alone and VS-43 plus cisplatin treated cells were treated and harvested 
together, and run in the same electrophoresis tank with the same untreated 
controls). It should be noted that cells treated only with STAT3 inhibitors were also 
analysed for any strand breaks caused by these inhibitors, as the outcome of this 
would determine which tail moment calculation to use.  
Three repeats for each experiment were performed, with the mean and SEM of 
these data sets plotted using GraphPad Prism 6. 
2.10 Immunofluorescence 
2.10.1 Seeding and Treatment of Cells 
13mm round coverslips (VWR International) were placed into 24-well culture plates 
(Corning) and cells were seeded on top of these coverslips at a density of 2.5x104 or 
2x104 cells per well for DU145 or A549 cells, respectively.  Cells were drug treated 
24 hours after seeding once they had reached 70% confluency.  
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For experiments observing γ-H2AX foci, four time-points were considered: 0, 9, 24 
and 48 hours after cisplatin exposure, in accordance with the time-points observed 
by the comet assay. Therefore, after the allotted drug exposure time, the media was 
replaced with fresh media and cells incubated for the required amount of time before 
proceeding with the fixing and staining stages.  
2.10.2 Fixing and Staining of Cells 
Media was aspirated and cells were washed with 1mL of sterile PBS per well. Cells 
were subsequently fixed in 500µL 4% PFA (Alfa Aesar) in water for 10 minutes at 
room temperature. Two further washes with PBS were carried out before cells were 
permeabilised by adding 500µL 0.5% PBS-Triton-X100 per well for 10 minutes at 
room temperature. Blocking was carried out with 500µL 5% PBS-BSA per well for 1 
hour at room temperature. For timecourse experiments each sample was fixed and 
stored at 4°C in PBS until all samples had been fixed. Permeabilisation onwards 
was carried out for all samples together.  
Coverslips were then removed from the 24-well plate using tweezers and placed 
cell-side up on parafilm coated microscope slides.  Primary antibodies were 
prepared in 1% PBS-BSA at a dilution of 1:100, and 70µL applied to each coverslip 
for incubation at room temperature for 1 hour. For pSTAT3 detection, the same 
primary antibody as was used for immunoblotting was used here. For γH2AX foci 
detection, the Anti-phospho-Histone H2A.X (Ser139) Antibody, clone JBW301 from 
Merck Millipore was used. After primary antibody incubation, three 10 minute 0.1% 
PBS-Triton-X100 washes (70µL per wash, removed each time carefully with an 
aspirator) were then performed before applying 70µL AlexaFluor 488 anti-
Rabbit/anti-Mouse secondary antibody (Invitrogen) at 1:100 and incubating at room 
temperature for 4 hours. Three 10 minute washes in 0.1% PBS-Triton-X100 were 
carried out again before applying 70µL 1µg/mL propidium iodide (PI) and incubating 
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for 3 minutes at room temperature. Finally, three 10 minute washes in PBS were 
carried out before mounting coverslips on microscopy slides using mounting media 
(Dako). Coverslips were further secured in place with clear nail varnish. Slides were 
then stored at 4°C until the time of reading. 
2.10.3 Confocal Microscopy 
The Leica DM 2500 microscope (fitted with a Leica TCS SPE confocal head) was 
used to obtain z-stack images at 40x magnification. Leica LASX software was used 
for image collection.  
To quantify γ-H2AX foci from images obtained using the protocol above, the 
program CellProfiler (Carpenter et al., 2006) was utilised. First, ImageJ (Schneider 
et al., 2012) was used to split each captured image into the two channels (PI and 
488nm). These images were loaded into CellProfiler and each cell nucleus was 
identified from the PI channel. The number of foci within each nucleus was 
computationally counted using the 488nm channel. The number of foci was taken as 
an average from the first 30 cells measured with a detection threshold of 0.3.   
Post-capture, confocal images were arranged using Microsoft Powerpoint.  
2.11 Quantitative Reverse-Transcriptase PCR (qRT-PCR):  
2.11.1 Treatment of Cells 
One 10cm dish (Corning) of cells was prepared for each treatment and cells were 
allowed to reach 70% confluency before drug treatments. Each plate was then 
rinsed in 3mL trypsin-EDTA, then 4mL trypsin-EDTA was added and plates were 
incubated at 37°C with 5% CO2 for 5 minutes to allow cells to detach. An equal 
volume of culture media was added to neutralise the trypsin, and cells were 
subsequently spun down at 1200rpm for 5 minutes. Pellets were re-suspended in 
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10mL sterile PBS and pelleted by centrifugation again. Excess PBS was aspirated 
off and pellets resuspended in 2mL sterile PBS. This was aliquotted into sterile 
1.5mL eppendorfs and centrifuged at 8000rpm for 5 minutes at 4°C. The 
supernatant was aspirated off and the remaining pellet processed for RNA 
extraction.  
2.11.2 RNA Extraction and cDNA Generation 
RNA was extracted from cell pellets using the RNeasy Plus Mini-kit (Qiagen) 
according to the manufacturers protocol and stored at -80°C. One modification to 
the manufacturers protocol was made: each cell pellet was resuspended in lysis 
buffer using a 21G needle and 1mL syringe 6 times followed by vortexing for 30 
seconds per pellet to ensure full lysis.  
1µg RNA was used for both cDNA generation protocols. 
For the DNA Damage Signalling Array the RT2 First Strand Kit (SABiosciences-
Qiagen) was used whereas for the TaqMan gene expression analysis system the 
High Capacity cDNA Reverse Transcription Kit (Life Technologies) was used. These 
are the recommended cDNA generation kits for each of the qRT-PCR procedures. 
Both kits were used as per the instructions in the manufacturers protocols. cDNA 
was stored at -20°C. 
RNA and cDNA concentrations were determined using the NanoDrop 2000 
spectrophotometer, with an A260/A280 reading of ~2.0 for RNA and ~1.8 for cDNA 
considered as clean.  
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2.11.3 qRT-PCR Procedure and Analysis 
2.11.3.1 DNA Damage Signaling Array Procedure 
To analyse the expression of genes involved in DNA repair pathways the Human 
DNA Damage Signalling Pathway PCR Array (SABiosciences-Qiagen) was used. 
The array contains primer sets for 84 target genes and 5 house-keeping genes. In 
addition the plates include genomic DNA, reverse-transcription and positive PCR 
controls.  A full gene list of this array can be found in Appendix A. 
As stated in the manufacturers protocol, to perform the array 1248µL RNAse-free 
water, 1350µL RT2 SYBR-Green qPCR Mastermix (SABiosciences-Qiagen) and 
102µL cDNA was added to a sterile reagent reservoir and mixed thoroughly by 
pipetting.  24µL of this solution was then added per well of the array plate, and the 
plate sealed with the plastic caps provided. The plate was spun down for 10 
seconds at 1000rpm.  
qRT-PCR was performed using an Applied Biosystems 7500 RT-PCR machine. The 
qRT-PCR cycle consisted of an initial 10 minutes at 95°C followed by 45 cycles of 
95°C/60°C for 15 seconds and 1 minute respectively.   
Cycle Threshold (CT) values were calculated using a threshold of 0.1 and fold-
regulation analysis carried out using the online software found at 
http://pcrdataanalysis.sabiosciences.com/pcr/arrayanalysis.php. Three biological 
repeats were performed for each drug treatment and the CT values of these repeats 
inputted into the online analysis software directly.  
2.11.3.2 TaqMan Gene Expression Analysis Procedure 
To verify and further quantify changes in gene expression discovered by the array 
analysis system, TaqMan Gene Expression Assays (Life Technologies) were 
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employed. These assays were also used to analyse the expression of genes not 
included on the array that were of interest. Primer/probe sets for FANCD2, BRCA1, 
EME1 and MUS81 were diluted 1:10 with TaqMan 2x Universal PCR Mastermix 
(Life Technologies). cDNA was diluted in RNAse-free water to reach 50ng cDNA per 
reaction. For each reaction, 9µL cDNA and 11µL primer/probe/mastermix solution 
was added, making a total reaction volume of 20µL. Three technical repeats were 
performed on each plate, with GAPDH used as the housekeeping gene. The qRT-
PCR program was identical to that used in section 2.11.3.1.  
Fold change was calculated using the comparative CT method. For each sample the 
mean CT was calculated for the gene of interest (GOI) and for the housekeeping 
gene GAPDH. The  ΔCT was calculated using the formula:   
∆𝐶! = 𝐶!  𝑇𝑎𝑟𝑔𝑒𝑡 𝐺𝑒𝑛𝑒 −  𝐶!  𝐺𝐴𝑃𝐷𝐻 . 
ΔΔCT was calculated for each dose by using the formula:  
∆∆𝐶! = ∆𝐶!  𝑇𝑟𝑒𝑎𝑡𝑒𝑑 −  ∆𝐶!  𝑈𝑛𝑡𝑟𝑒𝑎𝑡𝑒𝑑. 
The fold difference was then calculated using the formula:  
𝐹𝑜𝑙𝑑 𝑑𝑖𝑓𝑓𝑒𝑟𝑒𝑛𝑐𝑒 = 2!∆∆!!. 
From three biological repeats, the mean fold difference and the SEM was 
calculated. Therefore, all relative mRNA levels are comparable to the untreated 
control, which is set to 1.  
 
  140 
2.12 Cell Cycle Analysis 
To assess whether the exposure of cell lines to STAT3 inhibitors significantly altered 
the cell cycle profile, flow cytometry was used. 
2.12.1 Drug Treatment of cells 
2.12.1.1 Asynchronous cell treatments 
DU145 cells were seeded in 10cm dishes and allowed to attach and reach 70% 
confluency before drug treatment. Cells were treated with 3 doses of VS-43, stattic 
and curcumin (one dose below the GI50, the approximate GI50 and one dose above 
the GI50) for 18 hours. Cells treated with drug-free medium were used as a control.  
2.12.1.2 Synchronisation and treatment of cells  
To enrich for cells in S-phase, DU145 cells were seeded in 10cm dishes and 
allowed to reach 70% confluency. One plate was harvested as a representation of 
the asynchronous cell population, and the media on the remaining plates was 
replaced with serum-free media. After a starvation period of 48 hours, another plate 
was harvested (the starved cell population), and the media on the remaining plates 
was replaced with 20% serum full media. These plates were then harvested at 
various time points after release in order to determine the optimum length of release 
to obtain the maximum percentage of S phase cells. This was found to be 18 hours 
therefore, to study the effect of STAT3 inhibitors on the cell cycle progression of 
synchronised cells, cells were released in the presence of VS-43, stattic or curcumin 
for 18 hours before harvesting. Cells released with drug-free 20% serum media 
were used as a control. 
2.12.2 Preparation of cells for flow cytometry 
After the drug treatment period, all media was removed from plates and cells were 
harvested by trypsinisation. After spinning down at 1200rpm for 5 minutes, cell 
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pellets were washed in 10mL PBS and spun down again before resuspending in 
1mL PBS. 2mL ice cold 100% ethanol was added to each sample dropwise whilst 
vortexing to avoid clumping of cells. Cells were fixed at -20°C overnight. 
Fixed samples were spun down at 1200rpm for 5 minutes at 4°C and the 
supernatant carefully aspirated. Pellets were washed with PBS before staining. To 
enable quantification of DNA content each sample was resuspended in 1mL of the 
following DNA staining solution: 
For 1 mL: 
950µL PBS 0.05% Triton-X100, 3.2µL RNase A and 50µL PI (1mg/mL) 
Samples were incubated at 37°C for 1 hour to allow for the incorporation of PI into 
cellular DNA. 
2.12.3 Collection of cell cycle data 
The BD Biosciences Fortessa X20 cell analyser was utilised for collecting cell cycle 
data. Forward and side scatter gating was used to select for a single, intact cell 
population, and 10000 events per sample were recorded. The YG610/20 laser was 
used to excite PI.  
2.12.4 Analysis of cell cycle data  
Flowjo v10 was used to analyse flow cytometry raw data. As with data collection, 
forward and side scatter profiles were used to select for a single, intact cell 
population. This population was analysed for cell cycle profile using the built-in cell 
cycle modelling tool. Specifically, the Dean-Jett-Fox model was chosen as this gave 
the best fit. The percentage of cells in G1, S and G2/M phase was then averaged 
over 3 repeats and the SEM calculated in GraphPad Prism 6.  
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2.13 siRNA knockdowns 
As a non-pharmacological control for experiments where natural and synthethic 
compounds had been utilised to inhibit STAT3, siRNA was used. siRNA was also 
used to knock down the DNA repair proteins EME1 and MUS81.   
DU145 cells were seeded in 6-well plates (Corning) and allowed to adhere and 
reach 70% confluency. Cells were then transfected with either a targeted siRNA 
(STAT3, EME1 or MUS81), or a control siRNA targeted against luciferase (both 
SMARTpool ON-TARGETplus siRNAs purchased from Dharmacon, GE 
Healthcare). The final concentration of siRNA used was 10nM with 3µL of 
DharmaFECT 1 transfection reagent (Dharmacon, GE Healthcare) per well.  
In detail, siRNAs were resuspended in 1x siRNA buffer to a final concentration of 
20µM and aliquotted for storage at -20°C. For transfection, the siRNA stocks were 
thawed and diluted further in 1x siRNA buffer (Thermo Fisher Scientific) to 5µM. The 
required volume of the siRNA 5µM stock was added to serum-free media, and the 
required volume of DharmaFECT 1 reagent was also added to serum-free media 
(total 200µL per well for each of the siRNA and DharmaFECT tubes. These tubes 
were incubated for 5 minutes at room temperature before combining, mixing by 
gentle pipetting and incubating for a further 20 minutes at room temperature. The 
total volume of transfection mix at this point was 400µL per well. After the 
incubation, 1600µL serum-full media per well was added and 2mL of this final mix 
was added to each well. All control wells were treated with DharmaFECT reagent 
alone.  
Plates were incubated for 24 hours at 37°C with 5% CO2 to allow for the transfection 
to take place.  
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For preliminary experiments to determine whether 10nM siRNA could sufficiently 
down-regulate target expression, after 24 hours of transfection these cells were 
harvested, lysed and analysed by immunoblotting as is described in section 2.5.  
For comet assay experiments to determine the effect of STAT3, EME1 and MUS81 
siRNAs on cisplatin and melphalan DNA-ICL repair, immediately after the 24 hour 
transfection period, media was replaced by either fresh serum-full media for control 
wells or cisplatin or melphalan containing media for 1 hour. After 1 hour of drug 
treatment media was replaced on all wells again, and plates incubated at 37°C with 
5% CO2 until harvesting at the ICL peak and then again at 24 hours post ICL peak. 
The ICL peak occurs at 9 and 16 hours post treatment for cisplatin and melphalan 
ICL peaks respectively. The rest of the comet assay was performed as is described 
in section 2.9.  
2.14 Whole genome screening of STAT3 binding sites 
To investigate the possibility of STAT3 regulating the transcription of ICL repair 
genes by directly binding to promoter regions, the UCSC Human Genome Browser 
was utilised (Kent et al., 2002). This online database of the human genome is 
annotated with results from the ENCODE (Encyclopedia of DNA Elements) project 
(Rosenbloom et al., 2013) which set out to characterise the functional elements of 
the human genome. This data includes results from chromatin immunoprecipitation 
sequencing (ChIP-seq) experiments for many transcription factors in various cell 
lines. For STAT3, data is available from seven ChIP experiments across three cell 
lines (GM12878, HeLa-S3 and MCF-10A-ER-Src).  The raw data for all STAT3 
binding sites found in these experiments was downloaded from the database and 
subsequently sorted into a comprehensive list of genes in which STAT3 may bind 
the promoter region (defined as <4kb upstream of the transcription start site). To 
refine search results, only hits present in 4 or more of the ChIP data sets were 
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shortlisted. From this list, genes known to be involved in DNA ICL repair were 
identified. This work was performed by John Ambrose and Javier Herrero of the Bill 
Lyons Informatics Center, UCL.  
2.15 Chromatin Immunoprecipitation (ChIP) Assay 
The ChIP-IT® Express Enzymatic kit (Active Motif) was used to asses the binding of 
STAT3 to the EME1 and MUS81 promoter regions. Components of the kit were 
stored at 4°C or -20°C according to the manufacturers guide. All buffers referred to 
in this method are included in the kit.    
2.15.1 Design of primers 
Primers flanking the putative STAT3 binding sites upstream of the EME1 and 
MUS81 genes were designed using Primer3 version 4.0 (Koressaar and Remm, 
2007; Untergasser et al., 2012). The following primers were ordered from 
Thermofisher Scientific as 100µM in water.  
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Table 2-3: List of ChIP primers and their sequences. 
Primer Name Sequence 5’-3’ 
cFOS Forward CGAGCAGTTCCCGTCAATC 
cFOS Reverse TCGTGAGCATTTCGCAGTTC 
NEGATIVE Forward CCCTGGACTCCTCATCTGTA 
NEGATIVE Reverse GGAAGAGCCCTGGTGATTCT 
EME1 Forward AGCCAAGTCTTCACGTTTTC 
EME1 Reverse GGTGGGTCCTTTCTCTGTAG 
MUS81 Forward CCATCTCCAGCCTCCTTCAA 
MUS81 Reverse TTGTGTAGGCGAGAGGAAGG 
MUS81 Region 2 Forward CCTGGGCAAGCTACATAACC 
MUS81 Region 2 Reverse GGAGCCGAGTTTAGGGAAGT 
EME1 Region 2 Forward TTGTTCACCAGCAAGCTCTG 
EME Region 2 Reverse TTGTGGTGGCAGTGAACTTG 
 
2.15.2 Seeding, treatment and harvesting of cells 
DU145 cells were seeded in 15cm dishes and allowed to reach 70% confluency. 
Two 15cm dishes were used for each chromatin preparation. Cells were either 
harvested untreated, or after various drug treatments. Drug treatments included 
100µM cisplatin for 1 hour, or 1.5µM VS-43 for 18 hours followed by cisplatin for 1 
hour. All drug treatments were carried out in a volume of 20mL per 15cm dish.  
After drug treatment, cells were fixed for 5 minutes with 1% formaldehyde in 20mL 
minimal cell culture media. Fixation was performed at room temperature with gentle 
rocking. Plates were then washed with PBS and the fixation reaction stopped by the 
addition of glycine buffer for 5 minutes at room temperature. Plates were again 
washed with PBS. Cells were collected in 6mL PBS containing PMSF using cell 
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scrapers, and subsequently centrifuged for at 4°C for 10 minutes at 2500rpm. After 
centrifugation the supernatant was aspirated.  
2.15.3 Shearing of chromatin and chromatin immunoprecipitation 
To obtain cellular chromatin, cells were first lysed by resuspending the pellets in 
lysis buffer containing both a protease inhibitor cocktail and PMSF. Lysis was 
performed for 30 minutes on ice with frequent agitation. To ensure complete nuclei 
release, lysates were transferred into a 2mL dounce homogenizer and dounced on 
ice for 50 strokes. Lysates were then centrifuged at 4°C for 10 minutes at 5000rpm. 
The supernatant was removed and the remaining pellet was resuspended in 
digestion buffer containing a protease inhibitor cocktail and PMSF. The samples 
were warmed to 37°C before incubation with the enzymatic shearing cocktail for 10 
minutes at 37°C. During this incubation the samples were vortexed every 2 minutes 
to increase the shearing efficiency. The shearing reaction was stopped by adding 
ice cold EDTA and after a 10 minute incubation on ice, nuclear debris was pelleted 
by centrifugation at 4°C for 10 minutes at full speed. The supernatant containing the 
chromatin was transferred into a new tube and stored at -80°C until the time of 
immunoprecipitation. 50µL of the chromatin was removed to analyse shearing 
efficiency by electrophoresis on a 1% agarose gel. Enzymatic shearing produced 
fragment sizes of predominantly 150bp, with 300bp and 450bp fragments also 
present (due to enzymatic cleavage occurring between nucleosomes).    
For immunoprecipitation, 10µL of chromatin was set aside as the “input” sample. 
ChIP reactions were performed with 25µg chromatin and 3µg of either STAT3 
(Santa Cruz Biotechnology) or rabbit IgG antibody (Cell Signaling). Tubes were 
incubated at 4°C on an end-to-end rotator for 4 hours. A magnetic stand was 
subsequently used to pellet the magnetic protein G beads used in the ChIP reaction, 
and beads were washed with the kit wash buffers. Chromatin was eluted from the 
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beads and reverse cross-linked using the kit buffers. Immunoprecipitated chromatin 
was isolated by pelleting the magnetic beads using the magnetic stand and 
collecting the supernatant.  
Both the immunoprecipitated and input chromatin were incubated for 15 minutes at 
95°C and subsequently incubated with proteinase K for 1 hour at 37°C. After this 
incubation the chromatin was purified using the Chromatin IP DNA Purification Kit 
(Active Motif) before use in PCR. 
2.15.4 PCR and analysis 
Input chromatin was diluted 1:10 for PCR whereas immunoprecipitated chromatin 
was not diluted. 2µL of chromatin was used for each PCR reaction. Primers were 
diluted 1:10 with water and used at a final concentration of 0.75µM. Power SYBRTM 
Green 2x Master Mix (Thermofisher Scientific) was used for PCR reactions. The 
PCR was performed using an Applied Biosystems 7500 RT-PCR machine. The 
PCR cycle consisted of an initial 10 minutes at 95°C followed by 45 cycles of 
95°C/60°C for 15 seconds and 1 minute respectively.  CT values were calculated 
using a threshold of 0.1. Primer efficiencies were previously calculated using a serial 
dilution of input DNA ranging from 0.005ng to 50ng. All primers had efficiencies of 
100% ± 10%.   
To calculate fold enrichment, the relative quantity of DNA amplified in each reaction 
was calculated using the following formula:  
𝐷𝑁𝐴 𝑞𝑢𝑎𝑛𝑡𝑖𝑡𝑦 = 2!!! 
The DNA quantity in each reaction was calculated as a percentage of the quantity of 
input DNA, accounting for the 10-fold dilution factor. 
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The fold enrichment was calculated using the following formula: 
𝐹𝑜𝑙𝑑 𝑒𝑛𝑟𝑖𝑐ℎ𝑚𝑒𝑛𝑡 =  𝑆𝑇𝐴𝑇3 𝐶ℎ𝐼𝑃 % 𝑖𝑛𝑝𝑢𝑡 𝐼𝑔𝐺 𝐶ℎ𝐼𝑃 % 𝑖𝑛𝑝𝑢𝑡  
This fold enrichment for the negative control region was then subtracted from the 
fold enrichment for the target regions in order to normalise for the variation in off-
target immunoprecipitation between experiments. Data was presented as mean ± 
SEM using GraphPad Prism 6. 
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2.16 Statistical Analysis 
GraphPad Prism 6 was utilised for statistical analysis.  
For assessing statistical difference between cytotoxicity data sets, the one-tailed 
unpaired students t-test was performed. For comet assays, statistical difference was 
assessed using the two-tailed unpaired students t-test.  
For determining statistical difference between a control group and more than two 
further groups of data analysis of variance (one-way ANOVA) was employed with a 
Dunnett’s post-hoc test. For determining statistical difference between all groups the 
Tukey’s post-hoc test was used. P values and their corresponding significance for 
all statistical tests are shown in Table 2-4. 
Table 2-4: P values and the corresponding significance levels. 
P Value Significance 
<0.0001 **** 
0.0001-0.001 *** 
0.001-0.01 ** 
0.01-0.05 * 
≥0.5 ns 
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Chapter 3 A Novel, Selective STAT3 Inhibitor: VS-43.  
3.1 Introduction 
In this chapter, the novel STAT3 inhibitor VS-43 is investigated in terms of potency, 
selectivity and effect on cancer cell growth.  
3.1.1 Rationale for the design of a novel STAT3 inhibitor, VS-43 
STAT3 is constitutively active in many cancer types, and its downstream targets 
feed the development of cancer by controlling cell survival, angiogenesis, 
metastasis and proliferation. It has been suggested that some cancers which 
harbour constitutively active STAT3 develop a phenomenon known as oncogene 
addiction (Frank, 2007; Masuda et al., 2010). This is where a cancer cell with an 
activated oncogene driving its survival becomes dependent on the activity of that 
oncogene to continue proliferating. Removal of that driving force results in the death 
of the cancer cell (Weinstein, 2002). Therefore, this transcription factor is a viable 
target for inhibition by novel anti-cancer drugs. 
Additionally, STAT3 inhibitors are chemosensitisers to various chemotherapy 
agents, including cisplatin. As acquired resistance to chemotherapeutics is common, 
a compound that can effectively re-sensitise patients when given in combination 
with the chemotherapy agent would be desirable. The most effective combinations 
will result in a synergistic interaction whereby the effect on cell growth is greater 
than the effect of the two drugs independently. This will allow for the use of lower 
doses of each component of the combination, resulting in decreased adverse 
effects. Therefore, a potent STAT3 inhibitor that is able to chemosensitise cancer 
cell lines to cisplatin is of clinical interest.  
Inhibitors of the EGFR pathway have been successful anti-cancer agents for many 
years now. As STAT3 lies downstream of EGFR in the EGF signalling pathway one 
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question that might be asked is: why target STAT3 instead of EGFR? However, 
several pathways feed into STAT3 activation, not just the EGF pathway. STAT3 can 
be phosphorylated through the IL-6 cytokine pathway or by individual kinases such 
as Src (Cao et al., 1996; Zhong et al., 1994). In fact, development of feedback-
related resistance has been reported with EGFR inhibitors (reviewed in (Zhao et al., 
2016)). In this model, resistance to EGFR inhibitors is said to occur via 
compensatory activation of STAT3 through the alternative cytokine pathway. 
Therefore, targeting the central node that is the STAT3 transcription factor itself may 
overcome these feedback-related issues.    
The inhibition of STAT3 has been documented using various natural and novel 
synthetic inhibitors, however, these are rarely particularly potent, requiring long 
exposure times and high doses (often above 10μM) to reach 50% cell growth 
inhibition. Additionally, selectivity for STAT3 is an issue that is extremely important 
and yet is rarely addressed.  Therefore, the need for a STAT3 inhibitor that can act 
alone, or as a sensitising agent, with improved potency and selectivity is required.  
3.1.2 Why is there a need for selectivity with STAT3 inhibitors?  
There are seven STAT family members, STAT3 being the predominant target for 
novel anti-cancer drugs due to its function as an oncogene. Other members of the 
STAT family can, however, function as tumour suppressor genes. For example, 
STAT1 acts to induce apoptosis through the transcriptional regulation of caspase-8 
(Fulda and Debatin, 2002). STAT1 also inhibits the progression of the cell cycle 
through the p21 CDK inhibitor (Chin et al., 1996). These processes stimulated by 
STAT1 are in direct contrast to the actions of STAT3 (Regis et al., 2008). STAT1 
also actively represses genes stimulated by STAT3 including c-Myc and the bcl-2 
family of anti-apoptotic proteins (Ramana et al., 2000; Stephanou et al., 2000), as 
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well as directly interacting with cyclin D1 to inhibit cell cycle progression (Dimco et 
al., 2010). 
STAT3 is closely related to STAT1, sharing 50% amino acid similarity (Szelag et al., 
2015). The x-ray structure of a STAT3 dimer binding to DNA, and the location of the 
SH2 and DNA binding domains is shown in Figure 3-1A for reference. The SH2 
domains of STAT3 and STAT1 have 59% homology at the sequence level (Mankan 
and Greten, 2011), and residues are highly conserved in both the SH2 and DNA 
binding domains of STAT3 and STAT1 (Figure 3-1B (Szelag et al., 2015)). 
Therefore, the design of STAT3 inhibitors must address selectivity in order to avoid 
inhibition of the tumour suppressor function of STAT1.   
Curcumin (Figure 3-2) has been shown to lack selectivity for STAT3, also targeting 
STAT1 and STAT5 activation (Bill et al., 2009). Conflicting opinions exist on the 
selectivity of stattic (Figure 3-2) for STAT3, with some groups observing no inhibition 
of STAT1 activation by stattic (Schust et al., 2006) and other groups reporting that 
stattic does in fact target STAT1 activation (Sanseverino et al., 2012). Szelag et al. 
suggest that the small size of stattic would allow for binding to all STAT proteins, 
reducing its selectivity significantly (Szelag et al., 2015). Even the most successful 
direct STAT3 inhibitor in clinical trials to date, OPB-31121, was shown to lack 
selectivity for STAT3, down-regulating STAT1 and STAT5 phosphorylation (M. J. 
Kim et al., 2013). Therefore, selectivity must be addressed at earlier phases of 
STAT3 inhibitor development.  
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Figure 3-1: Crystal structure of a STAT3 Dimer binding to DNA, and amino 
acid conservation between STAT1 and STAT3. A) The SH2 domain 
(yellow/orange) is immediately adjacent to the DNA binding domain (red/green). 
Taken from (Becker et al., 1998). B) purple regions in the SH2 and DNA binding 
domains are well conserved. Taken from (Szelag et al., 2015). 
 
STAT1                                      STAT3 
DNA binding Domain 
SH2 Domain 
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B
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Figure 3-2: Structures of curcumin and stattic.  
 
3.1.3 Design of VS-43 
VS-43 was designed and synthesised by collaborator Professor Moses Lee and 
colleagues (Georgia State University, Atlanta, Georgia, USA).  
Curcumin has been repeatedly demonstrated to have substantial anti-tumourigenic 
activity in many different cancer cell line models (Dhandapani et al., 2007; Goel and 
Aggarwal, 2010; Notarbartolo et al., 2005; Yallapu et al., 2010), however, its poor 
absorption and low bioavailability hamper the use of curcumin in patients (Anand et 
al., 2007). Therefore, the development of synthetic curcumin analogues through 
structural modifications improving both the potency and the bioavailabilty of this 
compound have been of significant interest in recent years.  
The diarylidene piperidone (DAP) class of compounds are one such group of 
curcumin derivatives. These compounds have a piperidone ring in place of 
curcumin’s β-diketone moiety (Adams et al., 2004). Two such derivatives, HO-3867 
(Figure 3-3) and H-4073, have been shown to inhibit the JAK/STAT pathway in 
ovarian cancer murine xenografts (Selvendiran et al., 2011, 2010).  
Aiming to further improve curcumin’s potency and bioavailability, Moses Lee and 
colleagues have synthesised two groups of curcumin analogues: NH and N-methyl 
DAPs (Gregory et al., 2013), and 2,6-bis(arylidene)-4-phenylcyclohexanone 
H3CO
HO
OCH3
OH
O OH
N
O
F F
N
OH
HO-3867
O
H3CO
H3CO
OCH3
OCH3
OCH3
OCH3
O
R3
R2
R1
R3
R2
R1
N
O
R
R4
R3
R2
R4
R3
R2
R4
R
R4
R
2(a-h)-6(a-h)
R5
R1
R5
R1
A
B C
2:R=H; 3:R=CH3; 4:R=iso-pr; 5:R=Ph; 6:R=-CH2Ph
Curcumin Stattic 
O2N S
O
O
Stattic
  155 
analogues (Davis et al., 2008). Of the second class, one compound (compound 9, 
Figure 3-3) exhibited excellent cytotoxicity in preliminary MTT cytotoxicity studies 
with GI50 values of 0.51 and 1.2µM against the murine B16 and L1210 cancer cell 
lines respectively. The chemical structure of compound 9 was, therefore, further 
developed in order to optimise binding to the polar regions of STAT3’s DNA binding 
domain. In VS-43, the N-phenyl moiety was introduced to enhance the interaction of 
the molecule with the non-polar pocket in this domain. In a bid to address 
bioavailability, the N-phenyl group also provides the potential for improved water 
solubility through salt formation. The N-phenyl-DAP design is considered relatively 
novel as only one such analogue has been reported (identified through SciFinder in 
March 2016), with no biological results published with this compound as of yet 
(Yuan et al., 2008). The structural similarities between curcumin, HO-3867, 
compound 9 and VS-43 can be seen in Figure 3-3. The full synthesis of VS-43 can 
be found in Appendix B. 
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Figure 3-3: The molecular structures of curcumin, HO-3867, compound 9 and 
the novel STAT3 inhibitor VS-43.  
 
3.2 Aims 
The aims regarding the initial investigation of VS-43 were as follows: 
1. To determine whether VS-43 inhibits the activation and DNA binding ability 
of STAT3.  
2. To test VS-43 for selectivity with respect to other STAT proteins.  
3. To investigate whether VS-43 can induce apoptosis in cancer cell lines.  
4. To compare VS-43 against other widely used STAT3 inhibitors.  
H3CO
HO
OCH3
OH
O OH
N
O
F F
N
OH
HO-3867
O
H3CO
H3CO
OCH3
OCH3
OCH3
OCH3
O
R3
R2
R1
R3
R2
R1
N
O
R
R4
R3
R2
R4
R3
R2
R4
R
R4
R
2(a-h)-6(a-h)
R5
R1
R5
R1
A
B C
2:R=H; 3:R=CH3; 4:R=iso-pr; 5:R=Ph; 6:R=-CH2Ph
Curcumin 
Compound 9 
H3CO
HO
OCH3
OH
O OH
N
O
F F
N
OH
HO-3867
O
H3CO
H3CO
OCH3
OCH3
OCH3
OCH3
O
R3
R2
R1
R3
R2
R1
N
O
R
R4
R3
R2
R4
R3
R2
R4
R
R4
R
2(a-h)-6(a-h)
R5
R1
R5
R1
A
B C
2:R=H; 3:R=CH3; 4:R=iso-pr; 5:R=Ph; 6:R=-CH2Ph
HO-3867 
N
O
OCH3
OCH3
OCH3OCH3
H3CO
H3CO
VS-43 
O
OCH3
OCH3
OCH3
OCH3
H3CO
H3CO
Compound 9
  157 
3.3 Results 
3.3.1 STAT3 is constitutively activated in cancer cell lines 
To select cancer cell lines for use in this thesis, basal STAT3 activation was 
considered. Cell lines with constitutively active STAT3, that is, high levels of 
pSTAT3Tyr705 without pathway stimulation, would be good models to test the STAT3 
inhibitor VS-43.  
Previous research suggests that the DU145 prostate cancer cell line and the A549 
NSCLC cell line both express constitutively active STAT3 (Ni et al., 2000; Song et 
al., 2003), therefore, these cell lines were grown and harvested at two growth 
phases: exponential (E, 50-60% confluency) and confluent (C, 100% confluency).  
Western blot analysis of the cell extracts illustrated that both of these cell lines 
harbour constitutively activated STAT3. DU145 cells express higher levels of 
pSTAT3Tyr705 than A549 cells, and in both cell lines a direct relationship between 
confluency and pSTAT3Tyr705 expression was observed (Figure 3-4). These results 
suggested that cell confluency must be kept constant for all experiments where 
STAT3 inhibition is studied so that the level of activated STAT3 remains constant. 
Therefore, a confluency level of 70% was chosen for all further studies.   
 
Figure 3-4: Expression of pSTAT3Tyr705 in the A549 and DU145 cell lines. Cell 
density is indicated by E = exponential and C = confluent. Blot is representative of 
more than 1 experiment. 
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3.3.2 VS-43 inhibits pSTAT3Tyr705 protein levels 
To establish whether VS-43 has inhibitory activity on pSTAT3Tyr705 levels in the 
DU145 and A549 cell lines, these cells were treated for 18 hours with increasing 
concentrations of VS-43.  Immunoblot analysis confirmed that pSTAT3Tyr705 is down-
regulated by an 18 hour treatment with VS-43 at concentrations including and lower 
than 2μM (Figure 3-5).  
The potency of VS-43 is cell line specific as A549 cells require higher doses of VS-
43 to inhibit pSTAT3Tyr705. In A549 cells, inhibition of pSTAT3Tyr705 is not seen until 
1.2μM, where a dose-dependent inhibition is then present. Approximately 50% 
pSTAT3Tyr705 inhibition occurs at 1.5μM. At 2μM the majority of pSTAT3Tyr705 is 
depleted. In the DU145 cell line a more gradual inhibition of pSTAT3Tyr705 is 
observed. From 0.5μM moderate inhibition can be seen, with approximately 50% 
pSTAT3Tyr705 inhibition occurring at 1μM. This inhibition is also dose-dependent and 
by 2μM VS-43, pSTAT3Tyr705 is almost completely depleted. The requirement for 
higher concentrations of VS-43 in A549 cells is not understood but could be related 
to differences in uptake or efflux of the inhibitor.  
To determine whether VS-43 specifically inhibits the activation of STAT3, un-
phosphorylated STAT3 was also probed for with the conclusion that whole STAT3 
levels are unaffected by VS-43 (Figure 3-5), therefore, VS-43 specifically down-
regulates constitutively active STAT3 in the DU145 and A549 cell lines, without 
altering the cellular stability of the STAT3 protein. 
Confocal microscopy was also employed to visualise the effect of VS-43 on 
pSTAT3Tyr705 cellular levels and localisation. This was performed in the A549 cell 
line. Figure 3-6 shows that with VS-43 treatment, the pSTAT3Tyr705 staining 
  159 
decreases, confirming that this inhibitor can block the activation of STAT3 and thus 
decrease the amount of transcriptionally active STAT3.  
 
Figure 3-5: VS-43 inhibits pSTAT3Tyr705 levels in a dose-dependent manner in 
both the DU145 and A549 cell lines. STAT3 expression is unaffected. Blots are 
representative of more than 1 experiment. 
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Figure 3-6: Confocal microscopy showing pSTAT3Tyr705 levels in A549 cells 
treated with VS-43 for 18 hours. pSTAT3Tyr705 is decreased upon treatment with 
VS-43. Images are representative of more than 1 experiment.  
 
3.3.3 VS-43 is more potent than stattic or curcumin 
In order to compare the potency of VS-43 as a STAT3 inhibitor with other 
compounds, two commercially available STAT3 inhibitors were used: stattic, a 
synthetic inhibitor and curcumin, the natural compound which is also the parent 
compound of VS-43. The ability of these compounds to inhibit pSTAT3Tyr705 levels in 
both the DU145 and A549 cell lines was assessed by immunoblotting. Figure 3-7 
shows that both stattic and curcumin are capable of completely diminishing 
pSTAT3Tyr705 levels in both cell lines. Drug treatments were carried out for 18 hours, 
as with VS-43 in Figure 3-5. Concentrations of approximately 7μM and 20μM were 
required for stattic and curcumin respectively, in order to see approximately 50% 
inhibition of pSTAT3Tyr705 expression in both cell lines. These concentrations are 
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much higher than the doses of VS-43 required to observe a similar degree of 
pSTAT3Tyr705 inhibition – approximately 1μM and 1.5μM in the DU145 and A549 cell 
lines respectively (Figure 3-5). Therefore, these inhibitors are considerably less 
potent than VS-43. Curcumin, the parent compound of VS-43, is approximately 10-
fold less potent than VS-43 in terms of pSTAT3Tyr705 inhibition. 
3.3.4 VS-43 inhibits STAT3 DNA binding 
The ability of STAT3 to regulate transcription depends on its ability to bind 
consensus DNA binding sites located in the promoter regions of its target genes. 
This is in part regulated through the phosphorylation status of STAT3 as only 
phosphorylated monomers may dimerise and translocate into the nucleus. However, 
measuring pSTAT3Tyr705 levels does not directly measure STAT3 DNA binding, 
therefore, an EMSA was performed to measure binding of STAT3 to a consensus 
STAT3 binding site located in the c-fos promoter region. This EMSA was also 
performed with stattic. This experiment was performed by Dr Konstantinos Kiakos in 
the research group.  
Figure 3-8 shows that while VS-43 can inhibit STAT3 DNA binding at concentrations 
of 0.8μM, stattic requires up to 7μM to significantly inhibit STAT3 DNA binding. 
These concentrations correlate well with the concentrations required to inhibit 
STAT3 phosphorylation discussed previously, therefore, the level of pSTAT3Tyr705 is 
a good indicator of DNA binding ability.  
However, to complete this experiment, a super-shift using a STAT3 antibody must 
be performed to confirm the identity of the indicated band as DNA-bound STAT3.  
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Figure 3-7: Stattic and curcumin inhibit pSTAT3Tyr705 levels in the DU145 and 
A549 cell lines. Blots are representative of more than 1 experiment. 
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Figure 3-8: VS-43 inhibits binding of STAT3 (indicated by arrowhead) to the 
hSIE consensus binding sequence from the c-fos promoter region, and did so 
at lower concentrations than stattic. This experiment was carried out with DU145 
cell nuclear extract. C = cold oligonucleotide, M = non-specific competitor. Figure 
supplied by Dr Konstantinos Kiakos. 
 
3.3.5 VS-43 action is dependent on confluency, treatment time and dose 
The ability of VS-43 to inhibit pSTAT3Tyr705 has already been shown to be dependent 
on the cell line. The extent of inhibition has also been demonstrated to be dose-
dependent in both cell lines tested, with a direct relationship between dose and 
extent of pSTAT3Tyr705 inhibition as confirmed by immunoblotting (Figure 3-5).  
Next, the effect of the length of drug treatment time and the cell confluency at the 
time of drug treatment was investigated in the DU145 cell line by immunoblotting. 
Inhibition of pSTAT3Tyr705 by VS-43 was found to be dependent on the drug 
treatment time, with a shorter 6 hour exposure requiring 1.5-2μM to down-regulate 
pSTAT3Tyr705 levels in comparison to an 18 hour drug treatment where down-
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regulation of pSTAT3Tyr705 can be seen with concentrations as low as 0.8μM (Figure 
3-9A).  
VS-43 was also tested for its ability to inhibit pSTAT3Tyr705 at two different 
confluencies of DU145 cells:  low (~30%) and high (~100%). At the lower 
confluency, 0.5μM VS-43 completely depleted activated STAT3 levels whereas at 
the higher confluency pSTAT3Tyr705 levels were not affected until approximately 1.5-
2µM (Figure 3-9B). This is likely due to the relationship between confluency and 
STAT3 activation levels that was demonstrated in section 3.3.1. At a higher 
confluency there is more target present in the cell and therefore, a higher 
concentration of inhibitor is required to see a reduction in pSTAT3Tyr705.  
 
 
Figure 3-9: pSTAT3Tyr705 inhibition by VS-43 is dependent on A) exposure time 
and B) confluency of DU145 cells. Blots are representative of more than 1 
experiment. 
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3.3.6 Inhibition of pSTAT3Tyr705 by VS-43 is persistent 
In order to establish whether inhibition of pSTAT3Tyr705 by VS-43 is reversible or 
irreversible, immunoblotting was performed after an 18 hour treatment period and 
then after a further 24 hours in drug-free media. In both cell lines 24 hours after the 
end of the VS-43 drug treatment period, the levels of pSTAT3Tyr705 remain 
suppressed (Figure 3-10). This suggests that inhibition of STAT3 by VS-43 is 
persistent and may be irreversible.  
 
 
Figure 3-10: Inhibition of pSTAT3Tyr705 by VS-43 persists for at least 24 hours 
after drug treatment (18 hours) in both the DU145 and A549 cell lines. Blots are 
representative of more than 1 experiment. 
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3.3.7 VS-43 is a selective STAT3 inhibitor 
As has been discussed in the introduction to this chapter, selectivity with STAT3 
inhibitors is an important factor that must be considered. This is because all STAT 
proteins do not regulate the same targets. In particular, STAT1 is a tumour 
suppressor protein and therefore, inhibition of STAT1 in addition to STAT3 would be 
counterproductive for an anti-cancer drug. To determine the specificity of VS-43, 
both immunoblotting and ELISA techniques were employed.  
Immunoblot analysis revealed that where pSTAT3Tyr705 levels were down-regulated 
by VS-43 in DU145 cells, pSTAT1Tyr701 and pSTAT5Tyr694 levels were not down-
regulated (Figure 3-11A). The phospho-tyrosine residues observed are the 
equivalent activating phosphorylations.  
The TransAM® STAT Family ELISA was used to establish the selectivity of VS-43 
for STAT3 over STAT1α, STAT5a and STAT5b. This kit analyses the activity of 
STAT proteins by quantifying their binding to a STAT binding consensus 
oligonucleotide, therefore, it also indirectly observes STAT DNA binding. When 
incubated with VS-43 for 18 hours, DU145 cells show a significant dose-dependent 
reduction in STAT3 activation/DNA binding (Figure 3-11B). By 2µM VS-43 only 
31.4% of control STAT3 DNA binding remains. Whilst a significant effect on STAT1α 
and STAT5a DNA binding is also observed, these effects are small. At 2µM VS-43, 
STAT1α DNA binding is decreased to 92.8% of control binding, and STAT5a DNA 
binding is decreased to 88.5% of control binding. The DNA binding of STAT5b is not 
affected by VS-43. Therefore, VS-43 has considerable selectivity for STAT3 over 
STAT1 or STAT5 and is able to block STAT3 DNA binding.   
A shorter drug treatment of 1 hour was also performed for analysis with the STAT 
Family ELISA. 1 hour treatment of DU145 cells was sufficient to inhibit the 
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activation/DNA binding of STAT3 by approximately 50% but had no effect on 
STAT1α, STAT5a and STAT5b activation (Figure 3-12).  
 
 
Figure 3-11: VS-43 is a specific pSTAT3Tyr705 inhibitor as shown by A) 
immunoblotting and B) STAT family ELISA assay. VS-43 selectively inhibits 
activation and DNA binding of STAT3. Blots are representative of more than 1 
experiment. For the ELISA, the average of two experiments is presented with the 
SEM represented as error bars. One-way ANOVA was performed to calculate 
statistical significance. * = P<0.05, ** = P<0.01. 
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Figure 3-12: Treatment of DU145 cells with VS-43 for 1 hour selectively 
inhibits STAT3 activation and DNA binding. Data displayed is from one 
experiment. 
 
3.3.8 VS-43 down-regulates STAT3 target genes 
As STAT3 is reported to regulate the transcription of several pro-survival and 
antiapoptosis genes, the effect of VS-43 on the expression of these proteins was 
assessed by immunoblotting. Bcl-2 and survivin were both down-regulated in a 
dose-dependent manner after the treatment of DU145 cells with VS-43 for 18 hours. 
Survivin inhibition mirrors that of pSTAT3Tyr705 inhibition by VS-43, whereas bcl-2 
inhibition requires greater doses of VS-43 (Figure 3-13). Therefore, VS-43 
successfully down-regulates STAT3 target expression and may therefore, affect 
cellular survival.  
3.3.9 VS-43 induces apoptosis and inhibits cell growth 
STAT3 inhibitors have been shown to act as stand-alone agents, capable of 
inducing apoptosis and cell growth inhibition in many cancer cell lines. To test 
whether VS-43 inhibits the growth of cancer cell lines, the SRB assay was 
employed. This assay was chosen as it is reported to have a greater sensitivity than 
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the alternative MTT assay (Keepers et al., 1991). The assay also has a greater 
linearity and therefore, is capable of detecting sub-confluent and supra-confluent 
cell populations. The varying ability of cells to reduce MTT can affect comparisons 
of MTT data across cell lines however, as the SRB stain is reliant only on protein 
content, comparability across cell lines is more accurate with this assay (Keepers et 
al., 1991).  
After an 18 hour treatment with VS-43, SRB analysis determined that VS-43 inhibits  
the growth of these cancer cell lines. GI50 concentrations were calculated to be 
1.43µM and 2.53µM for the DU145 and A549 cell lines respectively (Figure 3-14).  
The difference between the GI50 of VS-43 in different cell lines has not been 
investigated further; however, this is in agreement with immunoblot analysis where it 
was found that higher concentrations of VS-43 are required in A549 cells to achieve 
pSTAT3Tyr705 inhibition (section 3.3.2). Both cell lines are, however, sensitive to the 
cell growth inhibitory effects of VS-43.  
 
Figure 3-13: VS-43 down-regulates bcl-2 and survivin expression in the DU145 
cell line. Blots are representative of more than 1 experiment. 
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Figure 3-14: VS-43 inhibits cell growth in the DU145 and A549 cancer cell 
lines. GI50 values for DU145 and A549 are 1.43µM and 2.53µM respectively, 
obtained by SRB assay. Data is the average of at least 3 independent repeats, with 
SEM calculated for error bars.  
To test whether VS-43 inhibits cell growth by inducing apoptosis, after an 18 hour 
treatment with VS-43, immunoblotting was performed to probe for cleaved Poly 
ADP-Ribose Polymerase (PARP), a widely accepted marker of apoptosis. 
PARP plays a crucial role in the repair of DNA. It catalyses its own ADP-ribosylation 
which allows it to bind to SSBs in the early stages of the DNA repair process (Davar 
et al., 2012; Herceg and Wang, 2001). PARP is also thought to be important in the 
recognition of other DNA damage that requires BER and NER. In the apoptosis 
pathway, PARP is cleaved by upstream caspases such as caspase-3, which are 
themselves activated by cleavage due to extrinsic or intrinsic apoptosis signals. This 
cleavage inactivates PARP, and results in two products: a 24kDa and an 89kDa 
fragment. The 24kDa fragment is said to inhibit DNA repair by irreversibly binding 
SSBs whereas the 89kDa fragment has been suggested to be excluded from the 
nucleus into the cytosol where it binds un-cleaved PARP, preventing the formation 
of functional PARP homodimers. These events trigger apoptosis due to unrepaired 
DNA damage (Chaitanya et al., 2010; Soldani and Scovassi, 2002).    
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In both the DU145 and A549 cell lines, VS-43 treatment induces cleaved PARP 
expression. This expression exhibits an inversely proportional relationship with 
pSTAT3Tyr705 inhibition by VS-43 (Figure 3-15). Therefore, inhibition of pSTAT3Tyr705 
by VS-43 induces apoptosis in these cancer cell lines. 
 
 
Figure 3-15: Treatment of DU145 and A549 cells with VS-43 for 18 hours 
results in a dose-dependent increase in cleaved PARP expression, indicative 
of apoptosis. This expression is inversely proportional to STAT3 inhibition by VS-
43. Blots are representative of more than 1 experiment. 
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3.4 Discussion 
As STAT3 is frequently constitutively activated in cancer cell lines and involved in 
the regulation of many oncogenic pathways, it is a viable target for novel anti-cancer 
therapeutics.  
Here, the initial investigation of a novel synthetic compound, VS-43, has yielded 
promising results. VS-43 has been shown to specifically inhibit activated STAT3 at 
low micromolar concentrations in both prostate and lung cancer cell lines, inducing 
apoptosis and cell growth inhibition. 
Studies using proteasome inhibitors and/or protein synthesis inhibitors would aid in 
confirming that the decrease in pSTAT3Tyr705 seen in this chapter is due to inhibition 
of STAT3 activation rather than an effect on the stability of the STAT3 protein. 
However, given whole STAT3 levels are unaffected by VS-43 treatment, this is 
unlikely. 
Cell confluency directly correlates with pSTAT3Tyr705 levels and therefore, also with 
the efficacy of inhibition by VS-43. This effect was first noted in 2003 and was 
attributed to cell-cell interactions and lower CDK2 levels rather than external 
cytokines or growth factors. CDK2 is hypothesised to inhibit STAT3 activation 
through interaction with STAT3 inhibitory proteins such as SOCS3 (Steinman et al., 
2003), however, this hypothesis has not been proven. In confluency, STAT3 
activation acts to promote survival rather than proliferation (Steinman et al., 2003). 
Due to this effect, a confluency of 70% was chosen for all experiments where cells 
were to be drug treated. This percentage was chosen so that a significant amount of 
target, pSTAT3Tyr705, would be present whilst allowing cells to maintain their 
proliferative phenotype. The effect of confluency on pSTAT3Tyr705 expression is 
scarcely mentioned in studies investigating novel STAT3 inhibitors.  Certainly, for in 
vivo studies with STAT3 inhibitors, the effect of cell density and 3D organisation 
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within the organism must be considered and potentially higher doses of the inhibitor 
used to account for this should the same relationship be found.  
3.4.1 How does VS-43 bind to STAT3? 
Whilst no modelling of VS-43 binding the STAT3 monomer has yet been completed, 
the mechanism by which VS-43 inhibits STAT3 can be predicted based on structural 
similarities with other STAT3 inhibitors. 
Many novel STAT3 inhibitors, including VS-43, are derived from curcumin which 
exists in both keto and enol forms. However, only the diketone form of curcumin can 
interact with the STAT3 SH2 domain (Lin et al., 2010a). The design of the 
JAK2/STAT3 inhibitor FLLL32 (Figure 3-16) utilised this property by locking its 
structure in the diketone formation. This inhibitor has been shown to bind the SH2 
domain of STAT3 and thus block dimerisation, like many STAT3 inhibitors (Bill et al., 
2012).  
As described in the introduction to this chapter, VS-43 was rationally designed, 
starting with the DAP class of compounds. Two of these compounds, HO-3867 and 
H-4073, have been shown to bind to the DNA binding domain of STAT3, directly 
blocking DNA binding and thus downstream activation of the STAT3 pathway (Kalai 
et al., 2011; Rath et al., 2014). HO-3867’s arylidene groups preferentially bind to 
pockets within the DNA binding domain lined with polar amino acids whereas it’s 
pyrroline-nitroxide group binds in a non-polar pocket (Kalai et al., 2011). Kalai et al. 
performed molecular modelling of HO-3867 bound to the STAT3 DNA binding 
domain (Figure 3-17A), and in this model the hydrophobic binding pocket is seen 
clearly. Another STAT3 inhibitor, inS3-54, has also been demonstrated to bind the 
DNA binding domain, with its phenyl group binding in the same hydrophobic pocket 
as was identified for HO-3867 (Figure 3-17B) (Huang et al., 2016, 2014).  
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Figure 3-16: Structures of curcumin and FLLL32.  
This group also modelled the interaction of their inhibitor with the STAT1 DNA 
binding domain (Figure 3-17C) and found that the natural conformation of binding 
was strikingly different to that seen with STAT3. This fit had an unfavourable binding 
energy, and if the STAT3 binding confirmation of inS3-54 is adopted, a steric clash 
between the inhibitor and residues T327 and P326 occurs, therefore, binding of this 
structure to STAT1 is not favourable. This could account for the selectivity seen with 
STAT3 DNA binding domain inhibitors. While curcumin has been shown to inhibit 
pSTAT1Tyr701 (Bill et al., 2012), both inS3-54 and HO-3867 demonstrated selectivity 
for STAT3 over STAT1 (Huang et al., 2016; Rath et al., 2014). VS-43 also 
demonstrates STAT3 selectivity. Interestingly the selectivity of the H-4073 
compound has not been addressed in the literature. 
H-4073 lacks a central, axial bulky group (see structures in Figure 3-18) therefore, 
whether this reduces the selectivity of H-4073 due to a loss of interaction with 
STAT3’s hydrophobic pocket would be an interesting observation. 
In these docking models, the orientation of the inhibitors represents a “chair” 
conformation, with an axially orientated hydrophobic group binding to the 
hydrophobic binding pocket. Computational 3D modelling of VS-40, a compound 
similarly structured to VS-43, was performed in order to determine the conformation 
of this novel class of compounds in 3D space. Figure 3-17D and Figure 3-17E show 
the 3D structure of VS-40 from the front and side views, respectively. VS-40 adopts 
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a structure that would likely be capable of binding the STAT3 DNA binding domain – 
with the N-phenyl group positioned axially, maximising interaction with the 
hydrophobic binding pocket. VS-43 is very similar in structure to VS-40, with the 
only modifications being the substitution of the phenyl groups with trimethoxyphenyl 
groups. The structure of VS-43 was chosen with a view to increasing the interaction 
of the compound with both the polar and non-polar regions of the STAT3 DNA 
binding domain through the modification of the bis(arylidene) groups and the 
incorporation of an N-phenyl group.  
Therefore, VS-43 most likely inhibits STAT3 via an analogous mechanism of action 
to the similarly structured compounds discussed here, binding to the STAT3 DNA 
binding domain rather than the commonly targeted SH2 domain. The structures of 
HO-3867, H-4073, inS3-54 and VS-43 for comparison are shown in Figure 3-18.  
Interestingly, STAT3 inhibitors targeting the DNA binding domain are often seen to 
down-regulate STAT3 Tyr705 phosphorylation (Huang et al., 2016; Rath et al., 
2014). This is also the case for VS-43, despite the phosphorylation event occurring 
in the SH2 domain. A possible explanation could be that binding of a compound to 
the DNA binding domain of STAT3 renders the activating phosphorylation site 
inaccessible to kinases. As the DNA binding domain is located adjacent to the SH2 
domain in STAT3 (Figure 3-1A), inhibitor-induced conformational changes in the 
DNA binding domain could be transferred to the SH2 domain. However, detailed 
modelling of the full STAT3 protein bound to a DNA binding domain inhibitor would 
be required to confirm this. Another explanation could be that these inhibitors are 
actually capable of binding to two sites on the STAT3 monomer – the DNA binding 
domain and the SH2 domain. The relatively similar chemical structures of the SH2 
domain inhibitors curcumin and FLLL32 with the DNA binding inhibitors such as 
those discussed here could suggest a model where one inhibitor can target the 
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STAT3 protein in two ways, blocking both phosphorylation and DNA binding.  This 
has, however, not yet been investigated for any STAT3 inhibitor.  
Therefore, it is proposed here that VS-43 acts to inhibit STAT3 activation and DNA 
binding through inhibition of the DNA binding domain. This may result in a decrease 
in pSTAT3Tyr705 levels through conformational changes in the STAT3 protein or a 
dual binding mechanism. Further investigation would be required to confirm this. 
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Figure 3-17: Molecular modelling and conformation of inhibitors targeting the 
STAT3 DNA binding domain. A) molecular modelling of HO-3867 binding to the 
DNA binding domain of STAT3 (Kalai et al., 2011). B) molecular modelling of inS3-
54 binding to the DNA binding domain of STAT3 (Huang et al., 2014). C) molecular 
modelling of inS3-54 binding to the DNA binding domain of STAT1 – purple 
represents the natural fit with an unfavourable binding energy. Yellow represents 
forced binding of inS3-54 in the same conformation as for STAT3 binding (Huang et 
al., 2014). D) 3D structure of VS-40, a compound related to VS-43, from the front 
and side (E) view, (unpublished data, courtesy of M. Lee, April 2016). 
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Figure 3-18: The molecular structures of STAT3 DNA-binding domain 
inhibitors: HO-3867, H-4073 and inS3-54, and the structure of VS-43 for 
comparison.  
 
3.4.2 How does VS-43 compare to other STAT3 inhibitors? 
Direct comparison of inhibitor potency is complex. Here the influence of cell line, cell 
confluency and duration of treatment on inhibitor potency has been highlighted 
(section 3.3.5). These factors almost always vary between experiments with novel 
STAT3 inhibitors. Therefore, this must be kept in mind when making direct 
comparisons relating to inhibitor potency.  
First, a comparison with the similarly structured DNA binding domain inhibitors will 
be made. Approximately 50% pSTAT3Tyr705 inhibition was observed after treatment 
of cells with 1-1.5µM VS-43 for 18 hours (Figure 3-5). For the HO-3867 and H-4073 
analogues, a 24 hour treatment with 10-20µM was required for inhibition of the 
pSTAT3Tyr705 pathway (Selvendiran et al., 2011, 2010). This is both a higher 
concentration and a longer duration of drug treatment.  
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The inS3-54 derivative, A18, exhibited GI50 values of 3.2-4.7µM after treatment of 
cancer cell lines for 72 hours continuously (Huang et al., 2016). This is a much 
longer duration of drug treatment and again at higher concentrations than was 
observed for VS-43. The GI50 range for VS-43 was between 1.4-2.5µM after 18 
hours of drug treatment (Figure 3-14). It should be noted that the inS3-54 derivative 
was tested with A549 cells, with a resulting GI50 of approximately 4µM therefore, 
these results are comparable with the GI50 obtained for VS-43 in A549 cells which 
was lower at 2.53µM. As VS-43 has been shown here to be more potent than these 
similarly structured curcumin analogues, the structural modifications made during 
the design of VS-43 may have enhanced binding to the STAT3 DNA binding 
domain. Additionally, VS-43 exhibits superior water solubility over BB-IV-101, 
another DAP compound (200µM versus 70µM, M. Lee personal communication) 
(structure shown in Figure 3-19). Structurally, VS-43 is identical to BB-IV-101 except 
for the addition of N-phenyl group. Therefore, this group may enable salt formation 
as predicted, and could allow VS-43 more favourable pharmacokinetics than have 
been seen with curcumin in clinical trials.  
 
 
Figure 3-19: Structures of BB-IV-101 and VS-43.  
 
N
O
OCH3
OCH3
OCH3OCH3
H3CO
H3CO
VS-43 
N
H
O
OCH3
OCH3
OCH3OCH3
H3CO
H3CO
BB-IV-101BB-IV-101 
  180 
Next, a comparison of VS-43 against the more common class of SH2 domain 
STAT3 inhibitors will be made. The S3I-201 derivative S3I-1757 was used for an 18 
hour treatment period as used for VS-43 in this study. Concentrations of 50-200μM 
were required for pSTAT3Tyr705 inhibition by S3I-1757 which is much higher than the 
low micromolar doses of VS-43 used here (Zhang et al., 2013). A second 
comparison can be made to the dual JAK2/STAT3 inhibitor cucurbitacin I where with 
an 18 hour treatment, the median GI50 value across a panel of six patient-derived 
leukemia cell lines was 5μM (Ishdorj et al., 2010). Cryptotanshinone, the natural 
STAT3 inhibitor, has been studied in DU145 cells and was found to have a GI50 of 
7μM after a 24 hour treatment period (Shin et al., 2009). Many other synthetic 
STAT3 inhibitors are administered for 24, 48 or 72 hours (Bill et al., 2012; Huang et 
al., 2016; Hutzen et al., 2009; Lin et al., 2010b; Page et al., 2011; Selvendiran et al., 
2011, 2010; Siddiquee et al., 2007; Song et al., 2005; Uehara et al., 2009) The 
longest drug treatment with VS-43 carried out here was 18 hours. Therefore, a 72 
hour exposure time with VS-43 would likely require sub-micromolar doses.  
These studies indicate that VS-43 is considerably more potent than many other 
synthetic STAT3 inhibitors. However, in order to make a conclusive and true 
comparison between VS-43 and other inhibitors, the same cell line, treatment time 
and cell confluency would have to be employed, therefore, these comparisons are 
somewhat useful but more detailed and controlled comparisons would be required. 
For example, the studies performed in this thesis with stattic and curcumin are 
directly comparable to the results presented for VS-43 and it can therefore, be 
concluded that VS-43 is a more potent STAT3 inhibitor than either of these 
compounds. 
The dependency of efficacy on exposure time indicates that other drug treatment 
regimes could be investigated. For example, a shorter exposure time to a higher 
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concentration of VS-43 may be more or less detrimental to cell growth. In this 
chapter this concept has begun to be investigated – the ability of VS-43 to 
specifically inhibit STAT3 activation and DNA binding after just a 1 hour drug 
treatment time has been shown using the TransAM® STAT Family ELISA assay 
(Figure 3-12). Different treatment regimes will be investigated further in the 
combination studies included in the next chapter.  
In section 3.3.6, the inhibition of pSTAT3Tyr705 by VS-43 is demonstrated to persist 
for at least 24 hours post-treatment, suggesting that VS-43 may bind to STAT3 
irreversibly. Stattic has been suggested to be an irreversible STAT3 inhibitor, 
possibly through covalent binding to the STAT3 monomer (Heidelberger et al., 2013; 
Schust et al., 2006). The inhibition of STAT3 activation by curcumin has however, 
been shown to be reversible, with pSTAT3Tyr705 levels returning to normal after 24 
hours in drug free media (Bharti et al., 2003a). Therefore, the structural 
modifications made during the design of VS-43 may have increased the interaction 
with STAT3 sufficiently to allow for irreversible binding.  
3.4.3 Why is VS-43 potency cell line dependent? 
In this chapter, differences between cell line sensitivity to VS-43 have been 
observed. The DU145 cell line is more sensitive to VS-43 than the A549 cell line. 
This is the opposite of what would be expected as DU145 cells express higher 
levels of pSTAT3Tyr705 than A549 cells. Therefore, if the same rule were to apply as 
for confluency, higher doses of VS-43 should be required to induce pSTAT3Tyr705 
inhibition and cell growth inhibition in DU145 cells. This is, however, not the case, 
implying that other factors determine a cell line’s sensitivity to VS-43. This may be 
related to impaired drug uptake or enhanced drug efflux. Considering drug efflux 
mechanisms, the multidrug resistance transporter P-glycoprotein (P-gp) is 
expressed at high levels in A549 cells (Hamilton et al., 2001; Xu et al., 2014) and 
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low to undetectable levels in DU145 cells (Brussel et al., 1999). P-gp is a broad 
specificity ABC transporter that uses energy from ATP to shuttle compounds, 
including synthetic drugs as well as natural toxins, across the cell membrane.  This 
transporter is known to participate in the resistance to natural product-based anti-
cancer agents such as doxorubicin and paclitaxel, through facilitating efflux of the 
drug (Mechetner et al., 1998; Sarkadi et al., 2006). Therefore, a higher expression 
level of P-gp may contribute to the lower sensitivity of A549 cells to VS-43 seen 
here if this compound is a substrate for P-gp mediated efflux. If indeed VS-43 is a 
substrate for P-gp then sensitivity to this compound could be predicted based on P-
gp expression levels.  
3.4.4 How does STAT3 inhibition induce apoptosis? 
In this chapter, VS-43 is confirmed to induce cellular apoptosis through the induction 
of cleaved PARP expression (Figure 3-15). As STAT3 activation promotes cell 
survival, inhibition of this pathway blocks these survival signals, allowing for 
apoptosis. STAT3 promotes survival through the transcriptional regulation of anti-
apoptotic genes such as bcl-xl and survivin (Buettner et al., 2002; Gritsko et al., 
2006). Bcl-xl is a member of the bcl-2 family of proteins which act to inhibit 
apoptosis by preventing the release of mitochondrial cytochrome C into the 
cytoplasm – an event that leads to activation of the apoptotic caspase cascade 
(Kharbanda et al., 1997). Survivin is a member of the Inhibitor of Apoptosis (IAP) 
family of proteins. Survivin acts alongside a cofactor to directly bind and inhibit 
caspase-9 in the apoptosis cascade. Survivin also plays an essential role in mitosis, 
ensuring the correct separation of the chromosomes in cytokinesis (Mita et al., 
2008). Both bcl-xl and survivin have been shown here to be down-regulated by 
treatment of DU145 cells with VS-43 (Figure 3-13). 
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Other survival genes proposed to be regulated by STAT3 but not investigated here 
also include Mcl-1 (Epling-Burnette et al., 2001), a member of the bcl-2 anti-
apoptotic protein family, and bcl-2 itself (Choi and Han, 2012). Additionally, genes 
driving proliferation which are regulated by STAT3 include cyclin D1 (Bromberg et 
al., 1999) and c-Myc (Kiuchi et al., 1999). Therefore, the overall effect of inhibiting 
STAT3 activation would be a decrease in cell proliferation and induction of 
apoptosis.  
The induction of apoptosis seen here by VS-43 can therefore, be attributed to the 
down-regulation of the anti-apoptotic, survival, and proliferation-stimulating genes 
regulated by STAT3.  
3.5 Conclusion 
In conclusion, the novel compound VS-43 has been shown to successfully down-
regulate pSTAT3Tyr705 levels in both DU145 and A549 cells at concentrations of 2µM 
and below. VS-43 also inhibits STAT3’s ability to bind to consensus DNA binding 
sites and its action on STAT3 is specific: this compound does not inhibit STAT1 or 
STAT5. Inhibition of STAT3 phosphorylation and DNA binding is achieved at lower 
doses than with stattic or curcumin, indicating that VS-43 is a potent STAT3 
inhibitor.  
VS-43 induces programmed cell death in the DU145 and A549 cell lines with GI50 
values of 1.43µM and 2.53µM, respectively, and does so by down-regulating STAT3 
target genes including bcl-xl and survivin. 
Therefore, VS-43 is a novel, potent and selective STAT3 inhibitor, and a valid 
compound for potential use as an anti-cancer therapeutic. Further investigation into 
the use of VS-43 in combination with chemotherapy agents will be described in the 
following chapter. 
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Chapter 4 STAT3 inhibitors sensitise cancer cells to cisplatin 
4.1 Introduction 
The chemotherapy platinum drug cisplatin has been used in the clinic for nearly 40 
years since it was approved in 1978 to treat cancer. Unfortunately, resistance to 
cisplatin therapy is a common occurrence either as intrinsic resistance or as 
acquired resistance after an initial period of sensitivity to cisplatin.  Understanding 
why resistance occurs is essential in the design of novel sensitising agents that may 
help to overcome cisplatin resistance.  
4.1.1 Resistance mechanisms to Cisplatin 
There are many factors that contribute towards cisplatin resistance; the key 
concepts will be discussed here.  
Resistance can occur through the altered accumulation of cisplatin within tumour 
cells. As for all drugs delivered systemically, the patient’s pulse and blood pressure, 
as well as tumour location and type, can affect the accumulation of cisplatin at the 
tumour site itself. This can directly impact the concentration of cisplatin in tumour 
cells. Cisplatin accumulation at the tumour site can also be affected by diet as this 
regulates the extracellular pH and only an acidic extracellular pH is favourable for 
cisplatin uptake into cells (Stewart, 2007). Additionally, cisplatin binds plasma 
proteins irreversibly which lowers its activity due to reduced uptake (Vermorken et 
al., 1984), and the composition of the plasma membrane has also been postulated 
to play a role in resistance, as membranes with a higher cholesterol content are 
more rigid and therefore, allow less cisplatin into the cell via passive diffusion (Todor 
et al., 2012). Consequently, there are many patient specific physiological and 
genetic factors that can reduce cisplatin efficacy before it has even reached the 
tumour cells.   
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Cisplatin uptake at the cellular level is also believed to contribute to clinical 
resistance. The effectiveness of cisplatin as a chemotherapy agent has been 
directly linked to cellular cisplatin concentration in both in vitro and in vivo studies 
(Andrews et al., 1988; Kim et al., 2012). Uptake is, in part, mediated via the copper 
membrane transporter CTR1 therefore, resistance to cisplatin can occur when the 
expression of this transporter is reduced (Kilari, 2016). Cells deficient in CTR1 are 
less sensitive to cisplatin (Ishida et al., 2002).  However, resistance is more 
commonly associated with drug efflux. The CTR2 copper transporter has been 
suggested to be involved in cisplatin efflux. Whilst closely related to CTR1, opposite 
functionality has been observed, with decreased expression of CTR2 resulting in 
higher cellular cisplatin levels (Blair et al., 2009). Another transporter involved in 
cisplatin efflux is the Multidrug Resistance Protein 2 (MRP2), an ABC transporter 
membrane pump. One study demonstrated a 10-fold increase in resistance 
following transfection of MRP2 (Cui et al., 1999).  
The copper transporter proteins ATP7a and ATP7b have also been shown to have 
similar effects on cisplatin resistance in human cell lines – the overexpression of 
both of these transporters correlates with poor cisplatin sensitivity (Komatsu et al., 
2000; Samimi et al., 2004; Siddik, 2003).  
The inactivation of cisplatin inside the cell can also contribute to resistance. Higher 
cellular glutathione levels have been reported to correlate with cisplatin sensitivity 
(Fokkema et al., 2002; Meijer et al., 1992). Glutathione is thought to bind to 
cisplatin, preventing it binding the DNA therefore, lowering platination. Glutathione-
S-transferase (GST) levels have also been shown to correlate with cisplatin 
resistance (Byun et al., 2005). The GST-π isoform is considered the main isoform 
involved in resistance to cisplatin. A greater clinical response to cisplatin has been 
linked to lower GST-π levels (Nishimura et al., 1996), and gene amplification of 
GST-π has been reported in head and neck cancer (Cullen et al., 2003). It has been 
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suggested that this enzyme may catalyse the addition of glutathione to cisplatin, 
resulting in its inactivation (Stewart, 2007). The cellular level of metallothionines has 
also been linked to cisplatin resistance (Kelley et al., 1988). These thiol-containing 
species, like GSH, bind to and inactivate cisplatin directly, preventing the formation 
of cisplatin-DNA adducts.  
Cisplatin binding to DNA can also be affected by intra-cellular pH, with a more acidic 
environment favouring DNA binding. Accordingly, resistant cell lines have been 
shown to harbour up-regulated proton pumps which increase cellular pH (Urakami 
et al., 2001). 
Some resistance mechanisms act indirectly. The MAPK pathway has been 
investigated as a mediator of cisplatin resistance as several of its target genes are 
anti-apoptotic (c-Myc), regulate DNA repair (ERCC1) or increase intracellular thiol 
levels (GST, Metallothionine) which can all individually contribute to cisplatin 
resistance (Dempke et al., 2000). Other examples include inhibiting apoptosis by 
suppressing caspase activation or increasing anti-apoptotic Bcl-2 family proteins – 
in ovarian cancer Bcl-xL expression correlates with resistance to cisplatin and a 
reduction in disease-free survival (Williams et al., 2005). The STAT3 pathway has 
also been suggested to be involved in cisplatin resistance through the regulation of 
apoptosis (Stewart, 2007), and mutation or loss of p53 functionality has been 
reported to be involved in resistance; half of all cancers and 60% of NSCLCs have 
p53 mutations (Giaccone, 2000; Siddik, 2003; Stewart, 2007).  Some less well 
characterised factors contributing to clinical cisplatin resistance include the heat-
shock proteins, cyclooxygenase-2 and the kinase SRPK1 (Stewart, 2007).   
Heightened repair of cisplatin-DNA adducts has also been reported as a mechanism 
of resistance. In ovarian cancer, patients with higher levels of platinated DNA 
showed the best responses to cisplatin (Reed et al., 1987), and cell lines which 
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exhibited reduced removal of platinum from DNA after treatment also showed 
greater sensitivity to cisplatin (Köberle et al., 1997).  A more recent study on patient 
derived ovarian tumour cells showed that repair of cisplatin-induced ICLs is 
enhanced in cells taken from patients previously exposed to cisplatin which may 
indicate the development of acquired resistance through enhanced DNA repair 
(Wynne et al., 2007). Genetic mutations and protein over-expressions for various 
factors involved in DNA repair processes including BER, NER, MMR, TLS, and HR 
have been connected to cisplatin resistance, however, these will be discussed in 
detail in Chapter 5.  
Therefore, many different factors contribute to cellular cisplatin resistance, and there 
are subsequently many opportunities to intervene in these processes in order to re-
sensitise to cisplatin.  
4.1.2 Cisplatin-based combination treatments in cancer 
The use of a combination of drugs rather than a single agent to treat cancer is 
common. The idea behind combination therapy is that two or more pathways driving 
the cancer are interfered with, thus increasing the overall effect of the treatment. 
Additionally, combining drugs with non-overlapping toxicities are often used so that 
if one drug has a dose-limiting adverse effect, combination therapy can enhance the 
overall chemotherapeutic effect without increasing that toxicity. Currently, cisplatin is 
given in combination with a large number of other drugs including gemcitabine, 
flurouracil, topotecan, docetaxel, etoposide, vinorelbine, pemetrexed, capecitabine 
and trastuzumab (Macmillan.org.uk). These drug combinations are beneficial for the 
treatment of many different cancer types; however, the drugs combined with 
cisplatin often have independent mechanisms of action rather than targeting 
cisplatin resistance. In order to circumvent cisplatin resistance, the additional drug 
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used should interfere with resistance mechanisms, thereby having a synergistic 
effect in combination with cisplatin.  
One such combination that uses this approach is the use of DNA damage response 
inhibitors with cisplatin. Mohni et al. demonstrated that ATR inhibitors synergise with 
cisplatin in human cancer cell lines (Mohni et al., 2015). There are currently three 
phase I clinical trails investigating the combination of the ATR inhibitor VX-970 with 
cisplatin (trial identifiers: NCT02723864, NCT02567409, NCT02567422). 
The PARP inhibitor olaparib has also demonstrated synergy in combination with 
cisplatin in vitro (Evers et al., 2008) and has had positive results as a combination in 
a Phase I trial for advanced breast and ovarian tumours with BRCA1/2 mutations 
(Balmaña et al., 2014). This combination is currently in several other trials including 
a Phase I clinical trail for advanced solid tumours (trial identifier: NCT00782574). 
PARP inhibitors act to block the function of PARP in single strand break DNA repair, 
therefore, in a homologous recombination deficient background (such as BRCA1/2 
mutated individuals), these breaks persist and manifest into double strand breaks 
which causes cellular apoptosis. This is known as synthetic lethality.  However, the 
mechanism by which PARP inhibitors synergise with cisplatin is not clear, as 
cisplatin does not induce SSBs. Studies regarding the selectivity of PARP inhibitors 
for other DNA repair proteins may give further information on a mechanism for 
synergy.  
As well as DNA repair, combinations targeting cisplatin cellular uptake have been 
investigated. The problem of cellular pH in cisplatin resistance is addressed in a 
phase II clinical trial of the proton pump inhibitor esomeprazole in combination with 
cisplatin. This combination improved time to progression and overall survival in 
patients with metastatic breast cancer (Wang et al., 2015). As cisplatin uptake and 
efflux mechanisms overlap with the transport of copper ions, a phase I clinical trial of 
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a copper chelator in combination with cisplatin has been carried out. This trial also 
yielded some promising results, with one patient demonstrating a partial response 
(S. Fu et al., 2012).  
With the knowledge of resistance mechanisms continually increasing, cisplatin-
based combination regimens will improve with the use of drugs that target these 
pathways. 
4.1.3 STAT3 Inhibitors and Cisplatin 
The relationship between STAT3 inhibition and cellular sensitivity to cisplatin is one 
that has been reported frequently. As mentioned in the previous section, whilst no 
direct effect of STAT3 inhibitors on cisplatin resistance mechanisms has been 
reported as of yet, the involvement of STAT3 in the regulation of apoptosis makes 
STAT3 a promising target for combination with cisplatin. Compounds that target 
STAT3 directly or indirectly through the inhibition of upstream factors or negative 
regulators have been described to enhance cisplatin sensitivity.  
There are several natural STAT3 inhibitors that have been show to act as 
chemosensitisers to cisplatin both in vitro and in vivo. These include curcumin (Goel 
and Aggarwal, 2010; Notarbartolo et al., 2005; Yallapu et al., 2010; Ye et al., 2012) 
and resveratrol (Weiguo Zhao et al., 2010). Cucurbitacin I is another natural 
compound reported to sensitise cancer cells to cisplatin in mouse tumour models. In 
this study enhanced reductions in tumour volume and prolonged survival were 
demonstrated with the combination therapy (Tseng et al., 2012).  
Synthetic inhibitors of STAT3 activity have also been reported to sensitise cells to 
cisplatin. Many synthetic curcumin analogues including HO-3867 (Selvendiran et al., 
2011), H-4073 (Kumar et al., 2014), and FLLL32 (Abuzeid et al., 2011) have 
demonstrated reduced cell viability and increased apoptosis when combined with 
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cisplatin treatment. Other synthetic STAT3 inhibitors shown to enhance cisplatin 
sensitivity include Stattic (Ji et al., 2013; Pan et al., 2013), 5,15-DPP (Huang et al., 
2012), YC-1 (Lau et al., 2007), and OPB-31121 (M. J. Kim et al., 2013).  
Compounds targeting upstream activators of STAT3 have demonstrated success in 
combination with cisplatin. These include inhibitors of JAK2 (Catlett-Falcone et al., 
1999; Hu et al., 2014; Zhang et al., 2015) and EGFR (Feng et al., 2007). The 
negative regulation of STAT3 has been targeted using adenoviral delivery of the 
SOCS1 gene, a suppressor of cytokine signalling. SOCS1 delivery was shown to 
down-regulate STAT3 signalling and to enhance cisplatin-mediated apoptosis in 
vitro. Additionally this combination inhibited tumour growth in mouse xenografts, 
although this was also in combination with pemetrexed (Iwahori et al., 2013).  
The sheer number of studies reporting positive outcomes from combination of 
STAT3 inhibitors and cisplatin reinforces the potential for this combination in the 
clinic. A novel STAT3 inhibitor with increased potency and selectivity would be most 
beneficial in combination with cisplatin to combat resistance. In this chapter the 
interaction of STAT3 inhibitors with cisplatin will be investigated. The novel inhibitor 
VS-43 will be compared against stattic and curcumin in terms of the outcome of 
combination with cisplatin, and the wider range of use for STAT3 inhibitors in 
chemotherapy combinations will be investigated through the combination of VS-43 
with another chemotherapy agent, doxorubicin. 
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4.2 Aims 
The aims regarding the investigation of STAT3 as a chemosensitising agent were as 
follows: 
1. To determine whether STAT3 inhibitors enhance the cell growth inhibitory 
effect of cisplatin on cancer cell lines and whether these combinations are 
synergistic. 
2. To compare VS-43 against stattic and curcumin as a chemosensitising 
agent.  
3. To determine whether combination treatment with STAT3 inhibitors and 
cisplatin enhances apoptosis in cancer cell lines as opposed to single drug 
treatment.  
4. To investigate the ability of VS-43 to chemosensitise cells to doxorubicin. 
 
4.3 Results 
4.3.1 Stattic and Curcumin inhibit the growth of cancer cell lines 
The effect of the combination treatment of cells with STAT3 inhibitors and cisplatin 
will first be observed using the commercially available STAT3 inhibitors stattic and 
curcumin. As Chou-Talalay analysis of a combination treatment consisting of two 
drugs requires the dose-effect curves of each drug alone to be known (Chou, 2010), 
first the growth inhibition induced by stattic and curcumin alone was determined by 
SRB assay. 
As with VS-43 in Chapter 3, the DU145 cell line is more sensitive to growth inhibition 
by both stattic and curcumin than the A549 cell line. Cells were treated with the 
STAT3 inhibitors for a period of 18 hours before media replacement and incubation 
for 96 hours.  
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Figure 4-1: A) Stattic and B) curcumin inhibit cell growth in the DU145 and 
A549 cancer cell lines. Data plotted was obtained by SRB assay and is the 
average of at least three individual experiments with SEM calculated for error bars. 
The GI50 values for stattic are 8.21µM and 11.2µM in the DU145 and A549 cell lines, 
respectively (Figure 4-1A). The GI50 values for curcumin are 44.2µM and 48.6µM in 
the DU145 and A549 cell lines, respectively (Figure 4-1B). 
4.3.2 Cisplatin inhibits growth of DU145 and A549 cancer cell lines 
The growth inhibition induced by treatment of cells with cisplatin was also assessed 
by SRB assay. Two treatment schedules were tested: an acute 1 hour treatment 
and a continuous treatment whereby cisplatin was present for the duration of the 
SRB assay incubation time (96 hours). In the A549 cell line GI50 values were 
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57.5µM and 4.00µM for the 1 hour and continuous treatments, respectively (Figure 
4-2A). In the DU145 cell line GI50 values were 49.8µM and 3.00µM for the 1 hour 
and continuous treatments, respectively (Figure 4-2B). As the aim of this chapter 
was to observe sensitisation to cisplatin, the acute 1 hour cisplatin treatment was 
chosen for the combination studies. This was to aid the observation of any benefit of 
the combination by using a treatment regime with a lower initial effect on cell growth.  
 
Figure 4-2: Cisplatin inhibits cell growth in the A) A549 and B) DU145 cancer 
cell lines. Data plotted was obtained by SRB assay is the average of at least three 
individual experiments with SEM calculated for error bars. 
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4.3.3 Stattic and curcumin sensitise cancer cell lines to cisplatin with 
moderate synergy 
The fixed ratio drug combination regime was chosen to observe the interaction 
between STAT3 inhibitors and cisplatin. This ratio is recommended when both drugs 
have a similar dose-effect curve. Here, the dose-effect curves for stattic, curcumin 
and cisplatin are all growth inhibitory and are sigmoidal in shape (Bijnsdorp et al., 
2011). Ratios of 1:5 for stattic:cisplatin and 4:5 for curcumin:cisplatin were chosen 
based on the approximate GI50 values of the drugs alone. Cells were treated with 
one of the STAT3 inhibitors for 18 hours, followed by a 1 hour treatment with 
cisplatin. After drug treatment, the media was replaced and cells were incubated for 
96 hours before SRB staining. The decision to treat cells with the STAT3 inhibitors 
first was made based on the hypothesis that if STAT3 inhibitors interact with one of 
the cisplatin resistance mechanisms, this pathway would need to be down-regulated 
prior to cisplatin entering the cell. Therefore, STAT3 inhibitors were given as a pre-
treatment to cisplatin.  
Figure 4-3 details the combination of stattic and cisplatin in the A549 cell line. The 
GI50 value for cisplatin was reduced from 82.1µM to 27.8µM after pre-treatment with 
stattic (Figure 4-3A). This is a 66.1% decrease in cisplatin GI50. By observing 
changes in GI50 values, it can be determined whether a drug combination is more 
efficient at cell growth inhibition than a single drug, however, this does not tell us 
whether the drug combination is synergistic. This is a factor that many studies 
stating chemosensitisation to one drug by another do not address. CI value analysis 
is required to determine whether a drug combination is synergistic, additive or 
antagonistic. Synergy occurs when the overall effect is greater than the sum of the 
effect of the two drugs individually. If the effect is equal to the sum of the individual 
effects then the drug combination is additive and if the combinatory effect is less 
than the sum of the individual effects then the drug combination is antagonistic. A 
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synergistic effect is desirable as this allows for a greater therapeutic benefit with 
lower drug doses, which may reduce adverse effects. CI value analysis was carried 
out using the Calcusyn software as detailed in section 2.6.4. 
Figure 4-3B shows the CI values for this combination. The majority of CI values are 
in the “slight synergism” to “moderate synergism” range (see section 2.6.4 for 
synergy range definitions), with the lowest CI value of 0.802 occurring at 50µM 
cisplatin.  
Isobolograms for fixed ratio combinations are interpreted through the relative 
position of the data points in relation to each of the effect level lines. The effect level 
lines are drawn between the doses of each drug alone required to achieve that 
effect. A data point located below and to the left of the associated line implies 
synergy at that effect level. If the point is above and to the right of the associated 
line, there is antagonism at that effect level. An additive interaction is indicated by 
the data point residing close to or on the associated line. The isobologram plot 
shown in Figure 4-3C indicates that synergy is present between stattic and cisplatin 
at the 50%, 75% and 90% effect levels in the A549 cell line.  
Figure 4-4 shows the same combination of stattic and cisplatin in the DU145 cell 
line.  The cisplatin GI50 is reduced from 60.7µM to 25.8µM which is a 57.5% 
decrease. The CI values for this combination are moderately synergistic between 
50-70µM cisplatin, with the lowest CI value of 0.752 occurring at 60µM cisplatin. 
Some additive and mildly antagonistic CI values are seen at the upper and lower 
extremities of the dose-effect curve (Figure 4-4B). The isobologram plot indicates 
that at the 90% effect level synergy is observed between stattic and cisplatin in the 
DU145 cell line. At the 50% and 75% effect levels, additivity is observed (Figure 
4-4C). 
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Curcumin is the parent compound of the novel STAT3 inhibitor presented in this 
thesis, VS-43. Therefore, the interaction of curcumin with cisplatin was also 
assessed by fixed ratio combination SRB assays.  
Figure 4-5A illustrates the shift in GI50 for cisplatin after combination treatment with 
curcumin in the A549 cell line. The GI50 is reduced from 88.0µM to 35.0µM (a 60.2% 
decrease). The CI values for this combination are predominantly synergistic, falling 
into the  “synergism” to “moderate synergism” categories. The lowest CI value is 
0.579, achieved at 70µM cisplatin (Figure 4-5B). The isobologram depicted in Figure 
4-5C indicates synergy at the 75% and 90% effect levels, and additivity at the 50% 
effect level.  
The combination of curcumin and cisplatin was also performed in the DU145 cell 
line. The GI50 for cisplatin was decreased by 45.6% from 67.3µM to 36.6µM by 
combination with curcumin (Figure 4-6A). The CI values calculated for this 
combination fall into the “synergism”, “moderate synergism” and “slight synergism” 
categories, with the lowest CI value of 0.611 noted at 60µM cisplatin (Figure 4-6B). 
The isobologram shown in Figure 4-6C indicates synergy at the 90% effect level and 
additivity at the 50% and 75% effect levels.  
A summary of the GI50 values for combination of stattic or curcumin with cisplatin is 
presented in Table 4-1. The P values for GI50 pairs (cisplatin alone and combination 
treatment) are all P<0.0001 as determined by non-linear regression analysis.   
Clearly the combination of stattic or curcumin with cisplatin is able to produce 
synergy. Different treatment schedules and doses could be investigated in order to 
maximise the synergy observed here, as the combinations investigated here 
produced predominantly moderate synergism. It appears curcumin produces slightly 
stronger synergy than stattic in combination with cisplatin. This may bode well for 
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the novel STAT3 inhibitor, VS-43, in combination with cisplatin as the structure of 
VS-43 is derived originally from curcumin. Therefore, in the following section, the 
combination of VS-43 with cisplatin will be investigated using similar methods.   
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Figure 4-3: Combination of stattic and cisplatin in A549 cells. A) stattic plus 
cisplatin combination treatment results in increased cell growth inhibition. Data 
plotted was obtained by SRB assay and is the average of at least three individual 
experiments with SEM calculated for error bars. Students t-test was carried out to 
determine statistical significance with * = P<0.05, ** = P<0.01. B) Combination 
indices are predominantly below 1 and C) isobologram plot quantifying drug 
interactions at the 50%, 75% and 90% effect levels.  
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Figure 4-4: Combination of stattic and cisplatin in DU145 cells. A) stattic plus 
cisplatin combination treatment results in increased cell growth inhibition. Data 
plotted was obtained by SRB assay and is the average of at least three individual 
experiments with SEM calculated for error bars. Students t-test was carried out to 
determine statistical significance with * = P<0.05, ** = P<0.01, **** = P< 0.0001. B) 
Combination indices between 50-70µM fall below 1 and C) isobologram plot 
quantifying drug interactions at the 50%, 75% and 90% effect levels.  
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Figure 4-5: Combination of curcumin and cisplatin in A549 cells. A) curcumin 
plus cisplatin combination treatment results in increased cell growth inhibition. Data 
plotted was obtained by SRB assay and is the average of at least three individual 
experiments with SEM calculated for error bars. Students t-test was carried out to 
determine statistical significance with * = P<0.05, ** = P<0.01, *** = P<0.001 **** = 
P< 0.0001. B) Combination indices are predominantly below 1 and C) isobologram 
plot quantifying drug interactions at the 50%, 75% and 90% effect levels.  
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Figure 4-6: Combination of curcumin and cisplatin in DU145 cells. A) curcumin 
plus cisplatin combination treatment results in increased cell growth inhibition. Data 
plotted was obtained by SRB assay and is the average of at least three individual 
experiments with SEM calculated for error bars. Students t-test was carried out to 
determine statistical significance with * = P<0.05, ** = P<0.01, *** = P<0.001. B) 
Combination indices are predominantly below 1 and C) isobologram plot quantifying 
drug interactions at the 50%, 75% and 90% effect levels.  
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Table 4-1: GI50 values for cisplatin alone and in combination with stattic or 
cisplatin, in the A549 and DU145 cell lines. 
 Cisplatin GI50 (µM) 
Drug treatment A549 DU145 
Cisplatin 82.1 60.7 
Stattic + Cisplatin 27.8 25.8 
Cisplatin 88.0 67.3 
Curcumin + Cisplatin 35.0 36.6 
 
4.3.4 VS-43 sensitises cancer cell lines to cisplatin with greater synergy than 
other STAT3 inhibitors 
As synergy has been observed between the STAT3 inhibitors, stattic and curcumin, 
and cisplatin in the previous section, the interaction of the novel STAT3 inhibitor VS-
43 with cisplatin was investigated. Two drug treatment regimes were tested – the 
fixed ratio and non-fixed ratio combinations.  
4.3.4.1 Fixed Ratio Combination of VS-43 and Cisplatin 
For comparison of VS-43 with stattic and curcumin in combination with cisplatin, the 
“fixed ratio” combination regime was used. As with stattic and curcumin in section 
4.3.3, VS-43 drug treatment was carried out for 18 hours prior to a 1 hour cisplatin 
drug treatment. The ratio of VS-43:cisplatin used was 1:50 based approximately on 
the preliminary GI50 values of the two drugs independently in the DU145 cell line.  
In the A549 cell line, the cisplatin GI50 is reduced from 77.8µM to 45.7µM which is a 
41.3% change (Figure 4-7A). The CI values shown in Figure 4-7B are all less than 1 
therefore, synergy is evident between VS-43 and cisplatin between 40-100µM 
cisplatin. The lowest CI value achieved is 0.566 at 100µM cisplatin. These CI values 
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span the “synergism” to “moderate synergism” range. The isobologram analysis 
illustrates synergy at the 50%, 75% and 90% effect levels (Figure 4-7C). 
For the DU145 cells, combination of cisplatin with VS-43 reduces the GI50 from 
49.2µM to 30.8µM (a 37.4% decrease) (Figure 4-8A). The CI value analysis 
indicates synergy between 40-100µM cisplatin, reaching “synergism” and “moderate 
synergism” on the Chou scale. The lowest CI value obtained was 0.644 at 60µM 
cisplatin (Figure 4-8B). The combination of VS-43 and cisplatin in the DU145 cell 
line produces one antagonistic CI value at 20µM cisplatin. Figure 4-8C shows the 
isobologram analysis for this combination, which indicates synergy at the 75%, 90% 
and slight synergy at the 50% effect levels. 
These results indicate that there is synergy between VS-43 and cisplatin in both the 
DU145 and A549 cell lines, as has been shown with stattic and curcumin in the 
previous section. As these cell lines differ in their sensitivity to STAT3 inhibitors and 
to cisplatin (section 3.3.2, section 4.3.1, and section 4.3.2), this indicates that 
STAT3 inhibitors are able to produce chemosensitisation despite varied sensitivities 
to each drug alone. 
Table 4-2 summarises the GI50 values for the fixed ratio combination of VS-43 and 
cisplatin in the A549 and DU145 cell lines. The P values for each GI50 pair is 
<0.0001, as determined by non-linear regression analysis. 
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Figure 4-7: Combination of VS-43 and cisplatin in A549 cells using the fixed 
ratio method. A) VS-43 plus cisplatin combination treatment results in increased 
cell growth inhibition. Data plotted was obtained by SRB assay and is the average of 
at least three individual experiments with SEM calculated for error bars. Students t-
test was carried out to determine statistical significance with ** = P<0.01, *** = 
P<0.001 **** = P< 0.0001. B) Combination indices are all below 1 and therefore, 
synergistic C) isobologram plot quantifying drug interactions at the 50%, 75% and 
90% effect levels.  
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Figure 4-8: Combination of VS-43 and cisplatin in DU145 cells using the fixed 
ratio method. A) VS-43 plus cisplatin combination treatment results in increased 
cell growth inhibition. Data plotted was obtained by SRB assay and is the average of 
at least three individual experiments with SEM calculated for error bars. Students t-
test was carried out to determine statistical significance with * = P<0.05, ** = 
P<0.01, *** = P<0.001 **** = P< 0.0001. B) Combination indices are predominantly 
below 1 and C) isobologram plot quantifying drug interactions at the 50%, 75% and 
90% effect levels.  
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Table 4-2: Fixed Ratio GI50 values for cisplatin alone and VS-43 plus cisplatin 
combination treatment in the A549 and DU145 cell lines.  
 Cisplatin GI50 (µM) 
Drug treatment A549 DU145 
Cisplatin 77.8 49.2 
VS-43 + Cisplatin 
(Fixed Ratio) 
45.7 30.8 
 
4.3.4.2 Non-Fixed Ratio Combination of VS-43 and Cisplatin 
As was discussed in section 3.3.5, the inhibition of pSTAT3Tyr705 by VS-43 is 
dependent on several factors, including dose and treatment time. In section 3.3.7 
treatment of DU145 cells with VS-43 for 1 hour was able to selectively inhibit STAT3 
DNA binding. In this section, the use of VS-43 for an acute period of 1 hour is 
investigated further.  
Immunoblot analysis of cellular pSTAT3Tyr705 levels after 1 hour treatment with VS-
43 illustrated that an acute VS-43 exposure can also inhibit levels of STAT3 
activation in both cell lines. As with an 18 hour VS-43 treatment, a higher 
concentration of VS-43 is required to achieve pSTAT3Tyr705 inhibition in the less 
sensitive A549 cell line than in the DU145 cell line using this 1 hour treatment. 
Inhibition of pSTAT3Tyr705 is seen at 5µM and 10µM VS-43 in the DU145 and A549 
cell lines, respectively (Figure 4-9A), with a dose-dependent effect clear in both cell 
lines. pSTAT3Tyr705 expression is almost completely eliminated at 10µM and 20µM in 
the DU145 and A549 cell lines, respectively. 
Cell growth inhibition studies with 1 hour VS-43 treatments illustrated that an acute 
exposure to VS-43 results in minimal cell growth inhibition. DU145 cells are more 
sensitive to this acute VS-43 treatment than A549 cells as is also the case for the 18 
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hour exposure but neither cell line reaches 50% growth inhibition at the doses 
tested (Figure 4-9B). As these doses inhibit pSTAT3Tyr705 expression but are less 
detrimental to cell growth, the effect of an acute 1 hour pre-treatment of VS-43 on 
cisplatin sensitivity was investigated to see if this would provide a more or less 
synergistic combination.  
For the combination of the acute VS-43 treatment with cisplatin, the fixed ratio 
combination was not appropriate as the dose-response curves for the two drugs are 
not alike. The non-fixed ratio is the preferable method for combination of drugs 
where one drug is more active than the other (Bijnsdorp et al., 2011) – in this case 
cisplatin has a greater effect on cell growth than VS-43 therefore, the non-fixed ratio 
is appropriate. 
A set dose of 5µM and 10µM of VS-43 was chosen for the combination studies in 
DU145 and A549 cells, respectively, as these doses exhibited substantial 
pSTAT3Tyr705 inhibition in each cell line. This dose was applied to cells for 1 hour 
before treatment with increasing doses of cisplatin for 1 hour as for the fixed ratio 
combination.  
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Figure 4-9: A) Acute 1 hour exposure of DU145 and A549 cells to VS-43 down-
regulates pSTAT3Tyr705. B) Treatment with 1 hour VS-43 exhibits minimal cell 
growth inhibition on DU145 and A549 cells, as determined by SRB assay. All 
data plotted is the average of at least three individual experiments with SEM 
calculated for error bars. Error bars are present for all data points, including those 
that are not visible. 
In A549 cells the GI50 decreases from 64.6µM to 39.8µM - a 38% decrease, similar 
to what is achieved when a fixed ratio combination is used. The bar chart plot in 
Figure 4-10A illustrates that 10µM VS-43 alone has no detrimental effect on cell 
growth in this combination. Therefore, each difference between the cisplatin alone 
and combination bars is a result of synergy between VS-43 and cisplatin. These 
differences are not statistically significant across some doses, however, at the 
beginning and end of the dose-response curve these differences are significant and 
through CI analysis are shown to be synergistic (Figure 4-10B). The lowest CI value 
was 0.437, attained at 15µM cisplatin.  
Non-fixed ratio combinations use normalised isobolograms, where each axis plots 
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drug to give X% effect alone. The line of additivity is drawn between 1 on the Y axis 
and 1 on the X axis – where the dose of each drug to have a given effect is the 
same alone and in combination. Any data points to the left and below the line are 
synergistic and any data points to the right and above the line are antagonistic due 
to this normalisation.  
The isobologram in Figure 4-10C shows all data points to be synergistic for the non-
fixed ratio combination of VS-43 and cisplatin in the A549 cell line.   
In DU145 cells, the GI50 drops from 49.3µM to 19.5µM (Figure 4-11A). This is a 60% 
change. This difference between the percentage GI50 change in A549 and DU145 
cells may be attributed to the higher sensitivity of DU145 cells to VS-43 in terms of 
growth inhibition. At the doses of VS-43 chosen for combination with cisplatin, 
DU145 cells exhibit 15.4% growth inhibition whereas A549 cells exhibit 5.5% (Figure 
4-9B). This sensitivity to VS-43 alone is also evident in Figure 4-11A where at 0µM 
cisplatin there is already 22.7% growth inhibition by VS-43 alone. Therefore, the 
increased shift in GI50 is likely the result of growth inhibition caused by VS-43 alone 
in DU145 cells. Table 4-3 summarises the GI50 values for the non-fixed ratio 
combination of VS-43 and cisplatin.  
Combination index analysis of the DU145 combination indicates synergy across the 
full range of cisplatin doses tested, with the greatest synergy achieved at 40µM 
cisplatin with a CI value of 0.596. The isobologram in Figure 4-11C indicates that at 
all effect levels, the interaction between VS-43 and cisplatin in this combination is 
synergistic.  
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Figure 4-10: Combination of VS-43 and cisplatin in A549 cells using the non-
fixed ratio method. A) VS-43 plus cisplatin combination treatment results in 
increased cell growth inhibition. Data plotted was obtained by SRB assay and is the 
average of at least three individual experiments with SEM calculated for error bars. 
Students t-test was carried out to determine statistical significance with * = P<0.05, 
** = P<0.01, *** = P<0.001. Absorbance was normalised to 10µM VS-43 alone. B) 
Combination indices are all below 1 and C) combination data points are mostly left 
of the line on the isobologram plot. 
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Figure 4-11: Combination of VS-43 and cisplatin in DU145 cells using the non-
fixed ratio method. A) VS-43 plus cisplatin combination treatment results in 
increased cell growth inhibition. Data plotted was obtained by SRB assay and is the 
average of at least three individual experiments with SEM calculated for error bars. 
Students t-test was carried out to determine statistical significance with * = P<0.05, 
** = P<0.01, *** = P<0.001. Absorbance was normalised to 5µM VS-43 alone. B) All 
combination indices are below 1 and C) all combination data points are left of the 
line on the isobologram plot. 
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Table 4-3: Non-fixed ratio GI50 values for growth inhibition by cisplatin alone 
and VS-43 plus cisplatin combination treatment in the A549 and DU145 cell 
lines. 
 Cisplatin GI50 (µM) 
Drug treatment A549 DU145 
Cisplatin 64.6 49.3 
VS-43 + Cisplatin 
(Non-fixed ratio) 
39.8 19.5 
 
 
4.3.5 STAT3 inhibitor and Cisplatin Combination therapy Enhances 
Apoptosis in Cancer Cell Lines 
Both STAT3 inhibitors and cisplatin are known to inhibit cell growth, and VS-43 has 
been shown in the previous chapter to induce cellular apoptosis via cleaved PARP 
induction (section 3.3.9). Therefore, the effect of the combination treatment of cells 
with STAT3 inhibitors and cisplatin on apoptosis induction was investigated.  
Immunoblot analysis of key apoptosis markers, cleaved PARP and cleaved 
caspase-3, was performed for cells treated with STAT3 inhibitors alone, cisplatin 
alone, and the combination treatment using the fixed ratio combination regime. In 
the DU145 cell line, whilst some expression of cleaved PARP and cleaved caspase-
3 is observed in cells treated with VS-43 and cisplatin alone, the combination 
treatment enhanced the expression of both of these factors (Figure 4-12A). In the 
A549 cell line cleaved caspase-3 expression was induced in the combination treated 
cells where expression was minimal for cells treated with VS-43 and cisplatin alone 
(Figure 4-12B).  DU145 cells treated with stattic and curcumin in combination with 
cisplatin also increased cleaved PARP expression (Figure 4-12C). The observed 
changes in protein level are visibly greater than additive. This indicates that 
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combination of STAT3 inhibitors with cisplatin results in enhanced apoptosis of 
cancer cell lines, and that the synergy observed in terms of growth inhibition is 
translated into enhanced expression of apoptotic factors at the protein level.  
 
Figure 4-12: Combination of STAT3 inhibitors and cisplatin enhances 
apoptosis. VS-43 enhances cleaved PARP and cleaved caspase-3 expression is 
cisplatin treated A) DU145 cells and B) A549 cells. C) Stattic and curcumin enhance 
cleaved PARP expression in cisplatin treated DU145 cells. Blots are representative 
of more than 1 experiment. 
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4.3.6 VS-43 can also chemosensitise DU145 cells to doxorubicin 
STAT3 inhibitors have been reported to sensitise cancer cells to many other 
chemotherapy agents, not just cisplatin. One of the more frequently reported drugs 
used in combination with STAT3 inhibitors is doxorubicin (Couto et al., 2012; Lin et 
al., 2010b; Notarbartolo et al., 2005; Rajendran et al., 2011). Like cisplatin, 
doxorubicin also targets the cancer cell DNA, but through intercalation rather than 
crosslinking. This intercalation stabilises the topoisomerase II complex, resulting in 
DNA damage and inhibited DNA replication. Doxorubicin has also been suggested 
to act via free radical generation (Thorn et al., 2011).  
In order to determine whether VS-43, like other STAT3 inhibitors, can synergise with 
a broader range of chemotherapy drugs, the SRB assay and calcusyn analysis 
method was used to investigate the interaction of VS-43 and doxorubicin in the 
DU145 cell line.  
Cells were treated with doxorubicin for 1 hour, or in combination with an 18 hour VS 
43 pre-treatment at a fixed ratio of 1:1.6. Combination of VS-43 with doxorubicin 
reduces the GI50 from 6.42µM to 1.96µM (Figure 4-13A) and results in synergistic CI 
values where statistically significant differences in cell growth inhibition are 
observed (Figure 4-13B). The point of greatest synergy is at 5µM doxorubicin where 
a CI value of 0.411 is achieved. The isobologram shown in Figure 4-13C 
demonstrates that this combination is synergistic at the 50%, 75% and 90% effect 
levels.  
Therefore, VS-43, like many other STAT3 inhibitors, is capable of synergising with 
multiple chemotherapy agents, including doxorubicin.  
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Figure 4-13: Combination of VS-43 and doxorubicin in DU145 cells using the 
fixed ratio method. A) VS-43 plus doxorubicin combination treatment results in 
increased cell growth inhibition. Data plotted was obtained by SRB assay and is the 
average of at least three individual experiments with SEM calculated for error bars. 
Students t-test was carried out to determine statistical significance with * = P<0.05, 
** = P<0.01. B) Combination indices are all below 1 and C) isobologram plot 
quantifying drug interactions at the 50%, 75% and 90% effect levels. Synergy is 
observed between VS-43 and doxorubicin in DU145 cells at all effect levels.  
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4.4 Discussion 
In this chapter, STAT3 inhibitors are shown to sensitise both the DU145 and A549 
cell lines to cisplatin in a synergistic manner. The combination of STAT3 inhibitors 
with cisplatin results in a synergistic enhancement in apoptosis in these cell lines. 
Additionally, the novel STAT3 inhibitor described in chapter 3, VS-43, is 
demonstrated to produce greater synergy with cisplatin at lower doses than stattic or 
curcumin.  
4.4.1 How does VS-43 compare to other STAT3 inhibitors as a 
chemosensitiser? 
In this chapter, the ability of three STAT3 inhibitors to sensitise cancer cell lines to 
cisplatin has been investigated: stattic, curcumin and VS-43. All three inhibitors 
demonstrated synergy in combination with cisplatin as determined by CI analysis. 
As similar fixed ratio combinations were used to study each of the inhibitors ability to 
sensitise cancer cell lines to cisplatin, a direct comparison can be made between 
VS-43 and the commercially available STAT3 inhibitors. A higher percentage 
decrease in cisplatin GI50 values was observed by combination of cisplatin with 
stattic and curcumin than was observed in combination with VS-43 (sections 4.3.3 
and 4.3.4). However, GI50 values alone do not take into account the effect of the 
second drug, i.e. the STAT3 inhibitor, on cell growth. CI value analysis determines 
the interaction of the two drugs using the dose-effect curves of each drug alone. 
Here, a fixed ratio combination of VS-43 with cisplatin produced lower CI values 
than the combination of stattic with cisplatin. The level of synergy seen with VS-43 is 
similar to that seen with curcumin in combination with cisplatin, however, VS-43 is 
able to produce synergy over a greater dose range of cisplatin. These observations 
are summarised in Table 4-4. The greater GI50 reduction but lower synergy seen 
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with combination of stattic or curcumin with cisplatin may be explained through the 
contribution of the STAT3 inhibitors alone to cell growth inhibition.   
Additionally, the dose of each STAT3 inhibitor used must not be overlooked. VS-43 
is used at much lower concentrations than either stattic or curcumin. Five times as 
much stattic is required to achieve a much lower level of synergy with cisplatin, and 
40 times as much curcumin is required to equal the synergy between VS-43 and 
cisplatin. Therefore, using the fixed ratio combination method, VS-43 is able to 
sensitise cancer cell lines to cisplatin with greater synergy than stattic or the parent 
compound curcumin and is clearly a more potent chemosensitiser.  
Table 4-4: Summary table for combination of STAT3 inhibitors with cisplatin. 
The lowest achieved CI value and the number of synergistic CI values is indicated 
for each combination. 
 
 
 
  Lowest CI 
value 
Number of 
synergistic CI 
values  
 
A549 
Stattic + Cisplatin 0.802 5 
Curcumin + Cisplatin 0.579 5 
VS-43 + Cisplatin 0.566 6 
 
DU145 
Stattic + Cisplatin 0.752 3 
Curcumin + Cisplatin 0.611 4 
VS-43 + Cisplatin 0.644 6 
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Many other STAT3 inhibitors have been reported in the literature to synergise with 
cisplatin including both natural (curcumin and resveratrol) and synthetic compounds 
(stattic, HO-3867, and FLLL32 for example). However, in many combination studies 
the STAT3 inhibitor is given for a minimum of 24 hours, with some inhibitors being 
present for the duration of the growth assay, which can be up to 96 hours (Table 
4-5). VS-43 was able to synergise with cisplatin after both an 18 hour and an acute 
1 hour pre-treatment, indicating that VS-43 can be used in a variety of drug 
schedules in order to maximise synergy. VS-43 has proved potent enough to allow 
for the possibility of very short drug treatment schedules – an attractive feature for 
an agent in a clinical setting. This has not yet been demonstrated for any other 
novel STAT3 inhibitor. Additionally, most of the combination studies referenced in 
Table 4-5 use doses of STAT3 inhibitors higher than those used for VS-43 here. 
The majority of these studies do, however, use a wide range of cell lines, which will 
influence the doses of inhibitors required as well as treatment times as was 
demonstrated in Chapter 3. Therefore, a truly direct comparison between VS-43 and 
many of these inhibitors cannot be made, as they did not use either the DU145 or 
A549 cell lines. The study observing curcumin in combination with cisplatin did use 
the A549 cell line so this is more comparable, however, within this chapter curcumin 
has been combined with cisplatin in identical studies to those carried out with VS-
43, so a comparison to the work carried out by Ye et. al (2012) does not yield much 
additional information. Further work in order to verify the activity of VS-43 in a wider 
panel of cell lines would be necessary to make true comparisons between VS-43 
and other STAT3 inhibitors.  
A compound that can enter the cell and take effect in as short a time as 1 hour is 
likely very potent. 1 hour treatment with VS-43 at a high dose is capable of 
sufficiently down-regulating pSTAT3Tyr705 levels in both cell lines tested here with 
limited longer term cell toxicity. This acute exposure chemosensitised cells to 
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cisplatin and achieved similar levels of synergy to that of the fixed ratio combination. 
Therefore, investigation into the use of short drug treatment times, and possibly 
repeated pulses of VS-43 exposure could be of interest in the future. 
 
Table 4-5: STAT3 inhibitors reported to sensitise cancer cell lines to cisplatin. 
The dose range and treatment time are reported. 
STAT3 Inhibitor Inhibitor Dose 
range (μM) 
Inhibitor 
Treatment Time 
Reference 
5,15-DPP 50 24 hours (Huang et al.,) 
2012) 
Curcumin 5-20	 48 hours (Ye et al., 2012) 
Dihydroartemisinin 
 
10-20 24 hours (Jia et al., 2016) 
Diindolylmethane 
 
20-50 24 hours (Kandala and 
Srivastava, 2012) 
FLLL32 0.85-1.4 96 hours (Abuzeid et al., 
2011) 
H-4073 0.6-5 72 hours (Kumar et al., 
2014) 
HO-3867 1-10 24 hours (Selvendiran et 
al., 2011) 
LY5 2.5 24 hours (Xiao et al., 2015) 
OPB-21121 0.15-1 72 hours (M. J. Kim et al., 
2013) 
Resveratrol 25-100	 48 hours (Weiguo Zhao et 
al., 2010) 
Stattic 2-8	 48 hours (Pan et al., 2013) 
WP1066 5  48 hours (Zhou et al., 2014) 
YC-1 5-10 24 hours (Lau et al., 2007) 
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4.4.2 Which drug treatment schedule produces the greatest synergy?  
In this chapter, two drug treatment schedules were tested for VS-43 in combination 
with cisplatin: the fixed ratio and the non-fixed ratio methods. Figure 4-14 shows 
overlays of the CI value plots for the two drug treatment schedules (fixed and non-
fixed) for VS-43 in combination with cisplatin. In both cell lines the degree of synergy 
obtained is similar for both schedules, with similar CI values being reached. The 
non-fixed ratio combination does, however, reach slightly lower CI values which is 
indicative of marginally greater synergy. In terms of consistency of synergy, the non-
fixed ratio combination results in universal synergy in the DU145 cell line whereas in 
the A549 cell line this synergy is interrupted. This is because CI analysis was not 
carried out for the data points in the centre of the dose-response curve due to the 
lack of statistical significance. Therefore, the fixed-ratio combination produces more 
consistent synergy in the A549 cell line here.  
For the fixed ratio combination in both cell lines the greatest synergy occurs in the 
post-GI50 range. The lack of synergy at the lower end of the dose-response curves 
is due, in part, to the very low doses of VS-43 used. The combination of VS-43 and 
cisplatin in the DU145 cell line produces one antagonistic CI value at 20µM cisplatin. 
Chou explains that at the extremities of a dose-response curve, where cell kill is 
either very high or very low, CI values are less accurate as they lie beyond the 
sensitivity of the assay used to detect drug effect. This accounts for the antagonistic 
and additive CI values found at the beginning and end of the dose-response curves 
presented in this chapter. The synergy begins to appear mid-way through the dose-
response curves as the STAT3 inhibitor reaches the dose required to exert the 
required molecular effect. Synergy in the fixed ratio combination for both cell lines 
begins at 40µM cisplatin where a dose of 0.8µM VS-43 was used. Doses of VS-43 
lower than 0.8µM did not inhibit cell growth (Figure 3-14) and did not produce high 
levels of pSTAT3Tyr705 inhibition (Figure 3-5) therefore, synergy would likely not 
  221 
occur at those doses as VS-43 is not having a molecular effect. Chou states that in 
this latter half of the dose-response curve any synergy observed is more relevant to 
the therapeutic use of anti-cancer drugs (Chou, 2010), therefore, for the remainder 
of this thesis, the combination of STAT3 inhibitors with cisplatin will be carried out in 
a fixed ratio combination as this regime produces the most consistent synergy at the 
relevant effect levels in both cell lines. 
 
Figure 4-14: CI plots for the fixed and non-fixed ratio combination of VS-43 
and cisplatin, in the A549 and DU145 cell line. 
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4.4.3 Why is the synergy between VS-43 and cisplatin not greater?  
CI value analysis has determined that the interaction between cisplatin and VS-43 is 
synergistic. However, as such large shifts in the GI50 values for cisplatin are seen in 
the combination treated cells, why is this synergy not greater? Chou states that 
strongly synergistic drug interactions will have a CI in the range of 0.1-0.3 (Chou, 
2006). The combination of VS-43 and cisplatin falls into the “synergistic” and 
“moderately synergistic” CI ranges (0.3-0.7 and 0.7-0.85), as do the combinations of 
stattic and curcumin with cisplatin. An explanation for this lies in the effect of the 
STAT3 inhibitor alone which has been discussed for VS-43 in Chapter 3.  
Treatment of cells with VS-43 alone can induce apoptosis as STAT3 regulates anti-
apoptotic and survival genes. Inhibition of STAT3 action suppresses these survival 
signals and drives the cancer cell into programmed cell death. VS-43 is a potent 
inducer of apoptosis. Therefore, when cells are treated with VS-43 in combination 
with cisplatin, they are experiencing two mechanisms of apoptosis induction: one 
from the DNA damage signalling response induced by cisplatin-DNA adducts, and 
the other from the withdrawal of anti-apoptotic and survival signals when STAT3 is 
inhibited by VS-43. These effects are independent. If these were the only effects of 
cisplatin and VS-43 administration, the CI value upon combination of these 
compounds would be additive. However, synergy is observed. The effect of 
treatment with cisplatin plus VS-43 is greater than the sum of each individual effect. 
This implies a crossover in the effect of the two drugs.  
This concept is represented diagrammatically in Figure 4-15. The moderate synergy 
levels observed between these two drugs is a consequence of the ability of VS-43 
itself to induce apoptosis independently of cisplatin (right hand path). Where 
inhibition of STAT3 impacts the cisplatin-induced apoptosis pathway (interrupted 
lines), synergy is observed. The CI value analysis method takes into account the 
dose-effect curves of each drug alone and therefore, if both drugs inhibit cell growth 
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the synergy observed is more likely to be moderate as is seen here with the fixed 
ratio combinations. The non-fixed ratio combination of VS-43 and cisplatin resulted 
in slightly greater synergy, which under this hypothesis would be expected due to 
the lower cell growth inhibition by VS-43 alone when cells are treated for just 1 hour. 
As cisplatin causes cell death via DNA damage, and repair of these adducts can 
result in resistance, it is hypothesised here that VS-43 inhibition of STAT3 may 
regulate either the accumulation of DNA damage or inhibit the DNA repair process. 
This will be addressed in the next chapter.  
 
 
Figure 4-15: Cisplatin and VS-43 independently induce cellular apoptosis. 
Repair of cisplatin-induced DNA damage leads to resistance and cell survival. 
Interaction between the two pathways results in synergy and this may occur via 
STAT3-mediated regulation of DNA damage or DNA repair. 
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Another factor which may influence the degree of synergy observed in a 
combination is the treatment scheduling itself. Here, STAT3 inhibitors are given as a 
pre-treatment, prior to cisplatin treatment. However, many combination studies treat 
with both drugs simultaneously. Cisplatin treatment could also precede STAT3 
inhibitor treatment. The dependence of synergy on drug scheduling has been 
demonstrated for many combinations. One example being the combination of 
edatrexate with cisplatin where synergy was exclusively observed when edatrexate 
was administered as a pre-treatment to cisplatin (Perez et al., 1993). The logic for 
using the STAT3 inhibitors as pre-treatments to cisplatin was that any cellular 
changes due to inhibition of STAT3 would need to take effect prior to cisplatin-DNA 
adduct formation in order to have the greatest effect on cisplatin sensitivity. This 
idea was adopted by Esaki et al. when they demonstrated reversal of cisplatin 
resistance by a pre-treatment with 5-FU. This effect was not observed when 5-FU 
was administered after cisplatin. They suggest that this is due to the effects of 5-FU 
on cisplatin-ICL repair mechanisms including regulation of ERCC1 mRNA levels, as 
well as regulation of cellular glutathione content (Esaki et al., 1996). 
However, the pre-treatment style sequential scheduling does not always prove to be 
the best schedule for cisplatin combinations. Combination of histone deacetylase 
inhibitors with cisplatin was shown to produce the best synergy with simultaneous 
addition of both drugs. Sequential drug treatments in either order resulted in some 
additivity and antagonism (Luchenko et al., 2011). Combination of cisplatin with 
topoisomerase I inhibitors also demonstrated a schedule dependence where the 
greatest synergy was observed when cisplatin was given as a pre-treatment 
followed by the topoisomerase I inhibitor (Ma et al., 1998). Similarly, data from our 
group has demonstrated that cisplatin and gemcitabine only synergise when 
gemcitabine is given following cisplatin, and not in the reverse order (personal 
communication, Professor John Hartley). Therefore, further investigation into 
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whether the sequential method used here produces the greatest synergy could be 
performed in order to optimise drug scheduling. This is, however, beyond the scope 
of this thesis.  
4.4.4  How Do STAT3 Inhibitors Sensitise Cells to Cisplatin? 
Chemosensitisation by STAT3 inhibitors is mostly attributed to deregulation of the 
anti-apoptotic transcriptional targets of STAT3. However, as has been discussed 
already, this alone cannot be responsible for synergy between STAT3 inhibition and 
cisplatin. STAT3 is likely involved in the regulation of one or more cisplatin 
resistance mechanisms. 
The synthetic STAT3 inhibitor, 5,15-DPP, which was demonstrated to sensitise 
gastric cancer cell lines to cisplatin, was also found to decrease levels of cellular V-
ATPase (Huang et al., 2012), a cell membrane proton pump, which has been 
connected with resistance to several chemotherapy agents including cisplatin. The 
V-ATPase pumps protons from the cytoplasm to the extracellular environment using 
the energy from ATP (Pérez-Sayáns et al., 2010). As cisplatin binds DNA more 
favourably in acidic conditions, increase of cellular pH by up-regulation of proton 
pumps would have a detrimental effect on cisplatin sensitivity. Accordingly, proton 
pump inhibitors can sensitise cells to cisplatin (Luciani et al., 2004). Therefore, if a 
link exists between STAT3 and V-ATPase transcription, this may account for some 
of the synergy seen between STAT3 inhibitors and cisplatin. However, no other 
STAT3 inhibitors have been reported to regulate the V-ATPase.  
The chemosensitisation to cisplatin by curcumin was hypothesised to be an effect of 
curcumin-induced Hypoxia Inducible Factor-1α (HIF-1α) protein degradation. Ye et 
al. reported that HIF-1α transfection reduced cellular sensitivity to cisplatin and HIF-
1α siRNA enhanced sensitivity (2012). HIF-1α is a transcription factor induced by 
hypoxia that regulates angiogenesis and also the P-glycoprotein (P-gp) gene MDR-
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1 (Comerford et al., 2002). P-gp is a membrane drug efflux transporter associated 
with multidrug resistance. Curcumin has been shown to down-regulate P-gp protein 
levels in several studies (Ampasavate et al., 2010; Anuchapreeda et al., 2002; Ye et 
al., 2012), therefore, a link between curcumin, HIF-1α and cisplatin efflux by P-gp 
may exist. However, the argument for the involvement of P-gp in cisplatin efflux is 
weak. Some studies have reported that P-gp expression enhances cisplatin 
resistance (Gibalová et al., 2012), however, others have stated that cisplatin, being 
a synthetic compound, is not a substrate for P-gp mediated export and that P-gp 
does not influence cisplatin resistance (Stordal et al., 2012). However, Gibalová et 
al. reported that the cisplatin resistance incurred by P-gp was not due to efflux, as 
the presence of a transport inhibitor did not affect cisplatin sensitivity. Instead, they 
suggest a mechanism whereby P-gp expression can alter the sensitivity to non-P-gp 
substrates through the modulation of apoptosis signalling pathways (Gibalová et al., 
2012). 
As curcumin is a naturally occurring compound and is relatively unspecific, the 
regulation of P-gp by curcumin cannot be assumed to be a direct effect of STAT3 
inhibition. Curcumin also targets other transcription factors including NF-κB and AP-
1 as well as a host of growth factors, enzymes and cytokines (Goel and Aggarwal, 
2010; Shehzad et al., 2012). However, STAT3 decoy oligonucleotides and the 
STAT3 inhibitor cucurbitacin I were also shown to down-regulate P-gp protein and 
MDR-1 gene expression (Zhang et al., 2011). In addition, another STAT3 inhibitor, 
YC-1, also down-regulates HIF-1α expression (Kong et al., 2014).  Therefore, the 
regulation of cisplatin resistance by P-gp through STAT3 is a possible mechanism of 
sensitisation.  
As of yet, there have been no direct reports of a connection between STAT3 activity 
and DNA repair in studies discussing chemosensitisation by STAT3 inhibitors to 
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cisplatin. However, several groups have reported that curcumin sensitises cells to 
cisplatin through the inhibition of FANCD2 monoubiquitination – a crucial event in 
early ICL repair (P. Chen et al., 2015; Chirnomas et al., 2006). The effect of other 
cisplatin sensitising compounds on DNA repair has also been documented. For 
example cyclosporin A and herbimycin A have been reported to sensitise cancer 
cells to cisplatin through the down-regulation of ERCC1, a nuclease involved in ICL 
repair (Li et al., 1999). Therefore, if STAT3 were to regulate the expression of key 
DNA repair genes, this may contribute to the chemosensitisation produced by 
STAT3 inhibitors. This will be investigated in the following chapter. 
4.4.5 Combination of STAT3 inhibitors with other chemotherapy drugs 
In this chapter, the combination of VS-43 with doxorubicin is also investigated using 
the SRB assay and calcusyn combination index analysis. The interaction between 
VS-43 and cisplatin is shown to be synergistic at the doses tested (Figure 4-13). 
STAT3 inhibitors have been previously reported to sensitise cancer cell lines to 
doxorubicin. The curcumin derivatives FLLL31 and FLLL32 were demonstrated to 
interact synergistically with doxorubicin in breast cancer cell lines (Lin et al., 2010c), 
as was the synthetic STAT3 inhibitor LLL12 in canine osteosarcoma cells (Couto et 
al., 2012). The JAK inhibitor AZD1480 also produced synergy in combination with 
doxorubicin in myeloma cells (Scuto et al., 2011), contributing further evidence to 
the JAK/STAT pathway being involved in doxorubicin sensitivity. 
Doxorubicin is a DNA intercalator which disrupts topoisomerase II action leading to 
DNA damage in the form of single and double strand breaks (Tewey et al., 1984; 
Thorn et al., 2011). STAT3 inhibitors derived from curcumin have also been 
reported to sensitise cells to etoposide, camptothecin, 5-fluorouracil, gemcitabine, 
paclitaxel, oxaliplatin and radiotherapy (Aggarwal et al., 2005; Lev-Ari et al., 2007; 
Pan et al., 2013; Yallapu et al., 2010). Almost all of these agents act by targeting the 
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cancer cell DNA – either the integrity or the ability of it to replicate. The exception is 
paclitaxel, which is a microtubule inhibitor. One group did report an increase in DNA 
damage following paclitaxel treatment of peripheral blood lymphocytes (Branham et 
al., 2004). This DNA damage could, however, be a result of paclitaxel-induced 
apoptotic DNA fragmentation. Nevertheless, there is a clear link between STAT3 
inhibitors and sensitivity to DNA-interacting chemotherapeutics, including cisplatin 
and doxorubicin as shown in this chapter. Consequently, STAT3 may regulate the 
accumulation of DNA damage or efficiency of DNA repair. This will be investigated 
in the following chapter. 
Clearly, the use of STAT3 inhibitors extends beyond that of combination with 
cisplatin. STAT3 inhibitors may prove useful in combination with many other 
chemotherapy drugs in the clinic.  
4.5 Conclusion 
In conclusion, this chapter investigates the chemosensitisation properties of STAT3 
inhibitors. Stattic, curcumin and VS-43 are able to sensitise cancer cell lines to 
cisplatin and increase the level of apoptosis in cisplatin-treated cells. VS-43 
produces greater synergy in combination with cisplatin than either stattic or 
curcumin. Two treatment schedules were tested for the VS-43 combination, with the 
acute 1 hour VS-43 pre-treatment able to synergise with cisplatin as well as the 18 
hour pre-treatment. The combination of VS-43 with doxorubicin was also found to be 
synergistic. Therefore, STAT3 inhibitors, particularly more potent compounds such 
as VS-43, are promising candidates for combination with chemotherapy agents 
including cisplatin and doxorubicin. 
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Chapter 5 STAT3 modulates the repair of cisplatin-induced 
DNA damage  
5.1 Introduction 
STAT3 inhibitors have been shown to sensitise cancer cell lines to cisplatin in a 
synergistic manner. For synergy to arise, some crossover between the action of 
STAT3 inhibitors and cisplatin must occur. Therefore, this chapter investigates 
whether STAT3 inhibitors affect the DNA damage induced by cisplatin. This will help 
elucidate the mechanism of sensitisation to cisplatin by STAT3 inhibitors.  
5.1.1 γH2AX as a marker of the crosslinker-induced DNA damage response 
DNA is packaged into nucleosomes consisting of 145 base pairs of DNA wrapped 
around a core of eight histone proteins: two each of H2A, H2B, H3 and H4. H2AX is 
a member of the H2A family, accounting for 2-25% of the H2A protein in mammalian 
nucleosomes (Rogakou et al., 1998).  
Upon DNA damage, thousands of H2AX proteins are phosphorylated at serine-139 
by ATM, ATR and DNA-PKc. The phosphorylated form, known as γH2AX, is able to 
recruit DNA repair factors (MRN, BRCA1, FANCD2, RAD51, MDC, cohesins) to 
damage sites (Kuo and Yang, 2008; Lyakhovich and Surrallés, 2007; Paull et al., 
2000; Rogakou et al., 1998). Therefore, the phosphorylation of H2AX is essential for 
the DNA damage response to be triggered effectively. 
γH2AX forms foci in response to DNA damage. Foci persistence has been shown to 
be effective at predicting patient sensitivity to radiation (Olive and Banáth, 2004). 
More recently γH2AX has been found to form foci after treatment with ICL-inducing 
agents such as cisplatin, mechlorethamine and mitomycin C (Clingen et al., 2008; 
Huang et al., 2004; Mogi and Oh, 2006). Positive correlation has been found 
between the number of γH2AX foci 24 hours after cisplatin treatment and cell 
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survival (Olive and Banàth, 2009). γH2AX foci have also proven useful in the 
determination of DNA damage following treatment with the novel cross-linker SJG-
136 in clinical samples (Wu et al., 2013). It is generally accepted that γH2AX 
indicates DSB sites; therefore, this suggests that for the detection of crosslink-
induced DNA damage, a DSB must arise for γH2AX foci to form. This may occur if a 
replication fork encounters an ICL resulting in replication fork collapse, or in the 
downstream repair of ICLs where nuclease action instigates DSB formation. 
However, the activation of the ATR kinase occurs through interaction with another 
protein, ATRIP, which binds to single stranded DNA. Therefore, ATRIP may 
accumulate at stalled replication forks or at regions where there has been recent 
repair of a bulky adduct, leaving a single stranded region to fill in (Kinner et al., 
2008). Activation of ATR, and subsequently γH2AX phosphorylation, may therefore, 
occur without the presence of a DSB, and so γH2AX foci should be considered as a 
general DNA damage marker rather than specifically a marker of DSBs. 
Therefore, for the purposes of this project, levels of γH2AX will be used as a marker 
of the DNA damage response induced by the crosslinking drug cisplatin.  
5.1.2 The key stage of ICL repair: crosslink unhooking 
The mechanism by which ICLs are repaired is not fully understood but is thought to 
involve an initial unhooking stage, followed by translesion synthesis and in 
replicating cells, homologous recombination to reassemble the replication fork 
(Clauson et al., 2013).  
The critical stage of this process is the unhooking of the ICL from one of the two 
DNA strands. 
The process of ICL unhooking is performed by nuclease action either side of the 
lesion. There is much debate over the identity of the nuclease complexes involved in 
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this process, however, it is generally accepted that at least one of the incisions is 
performed by the XPF-ERCC1 complex. This is supported by evidence showing that 
XPF or ERCC1 knockout cells are highly sensitive to cross-linkers and are deficient 
in the unhooking stage of ICL repair (De Silva et al., 2000). Additionally, both XPF 
and ERCC1 expression have been shown to correlate directly with cisplatin 
sensitivity in patients (Chiu et al., 2011; Dabholkar et al., 1992; Reed et al., 2003; 
Ting et al., 2013; Vaezi et al., 2011).  
Models for ICL unhooking exist with XPF-ERCC1 performing incisions either side of 
the lesion (Kuraoka et al., 2000), however, ERCC1-/- cells are still capable of DSB 
formation after treatment with MMC (Niedernhofer et al., 2004). Additionally, data 
suggesting that a second nuclease complex, MUS81-EME1, could perform one of 
the incisions contradicts models where XFP-ERCC1 is the sole ICL unhooking 
nuclease.  MUS81-EME1 is structurally similar to XPF-ERCC1, belonging to the 
same group of nucleases, and shares the ability of XPF-ERCC1 to cleave branched 
structures, which are likely to be found at replication forks stalled by ICLs. EME1-/- 
and MUS81-/- cells are hypersensitive to ICL-inducing agents (Abraham et al., 2003; 
Hanada et al., 2006; McPherson et al., 2004) and some cisplatin resistant cells 
express higher levels of MUS81 when compared with parental cells. Knockdown of 
MUS81 in those cells rescues cisplatin sensitivity (Xie et al., 2016). Further 
evidence suggests that the level of EME1, like ERCC1, correlates with cisplatin 
sensitivity in vitro (Tomoda et al., 2009). Like ERCC1, EME1 is a stabilising factor 
required for MUS81 nuclease activity (Haber and Heyer, 2001). Therefore, all four 
components of these nuclease complexes are important for the unhooking step.  
If indeed both XPF-ERCC1 and MUS81-EME1 are required for ICL unhooking, one 
possible model for this process involves the MUS81-EME1 nuclease nicking the 
DNA on the 3’ side of the ICL first, followed by XPF-ERCC1 nuclease action 5’ to 
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the ICL (Rahn et al., 2010). However, which nuclease complex performs the first 
incision and to which side of the ICL is not yet fully agreed on with some suggesting 
that the roles of MUS81-EME1 and XPF-ERCC1 are reversed (Zhang and Walter, 
2014), and others claiming that MUS81-EME1 is instead required for the removal of 
ICLs via an insurance pathway should ERCC1-XPF incision fail (Wang et al., 2011). 
The SLX4 (FANCP) protein has drawn much interest in recent years with regard to 
ICL unhooking. SLX4 negative cells are 10-fold more sensitive to cisplatin than 
control cells. Interestingly, a function as a molecular scaffold has been suggested 
for SLX4 as this protein interacts with XPF-ERCC1 and MUS81-EME1 along with a 
nuclease SLX1 (although this nuclease is not thought to actively participate in ICL 
unhooking).  Additionally, XPF and MUS81 nuclease activity is enhanced by SLX4. 
However, the formation of DSBs is not impaired in cells deficient in SLX4, therefore, 
it is possible that it may act downstream of unhooking (Muñoz et al., 2009). 
Conversely, extracts from ERCC1 depleted cells with added recombinant XPF-
ERCC1 do not incise ICL-containing substrates unless SLX4 is also present 
(Klein Douwel et al., 2014). Therefore, the role of SLX4 in ICL unhooking is still 
undecided.  
Another protein important in the process of ICL unhooking is the Fanconi Anemia 
(FA) factor FANCD2. FANCD2 ubiquitination at lysine 561 is carried out by FANCL, 
a FA core complex protein and E3 ligase. In a cell-free system, Xenopus egg 
extracts with depleted FANCD2 do not repair ICLs and specifically, cannot incise the 
DNA around the lesion. This is rescued by reintroduction of FANCD2 but not by 
reintroduction of a mutated FANCD2 incapable of ubiquitination (Knipscheer et al., 
2009).   
As SLX4 contains a UBZ ubiquitin-binding domain, this led to studies where 
FANCD2 was demonstrated to interact with and recruit SLX4 to ICL damage sites. 
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Both the SLX4 UBZ domain and FANCD2 ubiquitination are required for the 
recruitment of SLX4 to damage foci by FANCD2 (Klein Douwel et al., 2014; 
Yamamoto et al., 2011). XPF-ERCC1 was found to be required for the efficient 
processing of ICLs, however, it is not required for FANCD2 monoubiquitination, 
implying that XPF-ERCC1 acts in a FA-independent way, and that this modification 
could occur prior to the recruitment of nucleases to an ICL. In the absence of XPF-
ERCC1, FANCD2 ubiquitination persists suggesting that FANCD2 acts upstream of 
XPF-ERCC1 but that nuclease action is required for the repair of ICLs (Bhagwat et 
al., 2009). Together, this evidence indicates a direct role of FANCD2 in the ICL 
unhooking process, possibly through the recruitment of nuclease complexes to the 
ICL via the scaffold protein SLX4.  
FANCD2 has also been found to interact with BRCA1, a protein classically involved 
in homologous recombination. FANCD2 and BRCA1 co-localise in foci after 
irradiation or MMC treatment (Garcia-Higuera et al., 2001; Taniguchi et al., 2002), 
siRNA depletion of BRCA1 significantly decreases FANCD2 ubiquitination (Bruun et 
al., 2003), and  BRCA1-/- cells display the same phenotype as FA cells - 
hypersensitivity to ICL-inducing agents (Moynahan et al., 2001). Defective BRCA1 
in cisplatin sensitive cells causes a reduction in FANCD2 foci formation after 
treatment, and exogenous BRCA1 introduction to these cells increases resistance to 
cisplatin implying a key role for BRCA1 alongside FANCD2 in the repair of cisplatin-
induced DNA damage (Burkitt and Ljungman, 2007).  
Whether BRCA1 interacts with FANCD2 directly is unknown. However, through 
yeast two hybrid and co-immunoprecipitation assays BRCA1 has been shown to 
bind FANCA, a component of the FA core complex (Folias et al., 2002). More recent 
research has suggested opposite roles for BRCA1 and the NHEJ end binding 
Ku70/80 complex.  In BRCA1-/- cells where FANCD2 foci formation is impaired, 
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depletion of Ku70/80 restores FANCD2 foci. Additionally, depletion of Ku70/80 
enhances cell survival in BRCA1-/- cells (Bunting et al., 2012). It is not yet 
understood why Ku70/80 inhibits FANCD2 foci formation but this could suggest a 
mechanism whereby Ku70/80 has inhibitory action on the recruitment of FANCD2 to 
ICLs, and BRCA1 inhibits Ku70/80 action. It is likely therefore, that BRCA1 affects 
FANCD2 recruitment to ICL damage sites in an indirect manner, either through 
direct interaction with the core FA complex or through inhibition of Ku70/80.  BRCA1 
has also been shown to be involved in the unloading of the replicative helicase at 
replication forks stalled at ICL. This role of BRCA1 allows progression of the 
replication fork to within 1 nucleotide of the lesion, which was shown to be required 
for ICL incisions to take place (Long et al., 2014). 
More recently, a role for the ubiquitin-like with PHD and RING finger domain 1 
(UHRF1) protein in ICL unhooking has been identified. This protein was found to 
directly bind an ICL-containing substrate and is required for FANCD2 foci formation. 
Knockdown of UHRF1 causes hypersensitivity of cells to MMC and psoralens, and 
also mildly increases sensitivity to cisplatin (Liang et al., 2015). Liang et al. propose 
that UHRF1 acts as a sensor of ICL damage and allows for FANCD2 recruitment 
and further downstream processing. Another group simultaneously identified 
UHRF1 as an ICL-interacting protein. Tian et al. found that UHRF1 was able to 
immunoprecipitate XPF-ERCC1 and MUS81-EME1 in the absence of SLX4, 
suggesting a direct interaction of UHRF1 with these nuclease complexes. However, 
UHRF1 deficient cells retain functional FA pathway activation after MMC treatment, 
and double knockout of the FA pathway and UHRF1 results in enhanced sensitivity 
to MMC. Therefore, the role of UHRF1 in ICL repair may be distinct from that of the 
FA pathway. For this reason, they suggest that UHRF1 functions dually to promote 
FANCD2 recruitment to the ICL site as well as a molecular scaffold parallel to SLX4 
for nuclease recruitment (Tian et al., 2015). However, currently these are the only 
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two reports linking UHRF1 to ICL repair, therefore, further investigation is required 
to elucidate the detailed role of this protein in the unhooking process. 
Taking into consideration all of the components described here, Figure 5-1 
illustrates a possible model for the coordination of ICL unhooking during replication. 
BRCA1 and the FA core complex are involved in the recruitment of FANCD2 to 
damage sites. FANCD2, once ubiquitinated by the FA core complex, can recruit the 
scaffold protein SLX4 via interaction with SLX4’s UBZ domain. The nuclease 
complexes XPF-ERCC1 and MUS81-EME1 are brought to the ICL site through their 
interaction with SLX4. UHRF1 may also stimulate both FANCD2 and nuclease 
recruitment to the ICL site. This allows for incision reactions, unhooking and 
progression of ICL repair. 
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Figure 5-1: Model for initiation of replication-dependent ICL unhooking by 
BRCA1, FANCD2, SLX4, XPF-ERCC1, MUS81-EME1 and UHRF1. 
 
 
5.1.2.1 The comet assay as a read-out for ICL unhooking 
For many years, the detection of DNA interstrand crosslinks required the use of the 
alkaline filter elution technique. This technique involved monitoring the elution rates 
of radiolabelled DNA from a column. Elution time is proportional to DNA fragment 
size and the presence of ICLs makes DNA fragments behave as if they were larger, 
therefore, decreasing the elution rate (Kohn, 1991). However, this assay requires 
large amounts of DNA, collection of fractions is lengthy, radiolabelling is usually 
required and this technique cannot observe crosslinking in individual cells. 
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The comet assay was originally utilised to observe strand breaks in cells (Ostling 
and Johanson, 1984) but was later adapted for use in the detection of ICLs. This 
assay involves denaturation of cellular DNA in alkaline conditions and 
electrophoresis to separate the DNA into a “head” region where the main body of 
intact DNA lies, and a “tail” region where fragmented DNA migrates further (Figure 
5-2). Fragmentation of DNA may be caused by irradiation, lesion specific nucleases, 
DSB-inducing drugs, or apoptosis. Therefore, the comet assay can act as a read-out 
for several types of DNA damage (Collins, 2004).  
To detect ICLs, drug-treated cells are first exposed to a fixed dose of irradiation to 
induce DSBs, which allows a long “tail” to be seen after alkaline denaturation and 
electrophoresis.  Cells with ICLs will result in a reduction in the amount of DNA in 
the “tail” region and an increase of DNA in the “head” region of the comet. This is 
because covalently linking DNA strands with ICLs reduces the ability of fragments to 
migrate through the agarose gel that the cells are embedded in. When the repair 
process begins and ICLs are unhooked from one strand, this effect is removed and 
fragments are able to migrate forming increasingly large tails depending on the 
extent of ICL unhooking (Spanswick et al., 2010).  
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Figure 5-2: Single cell electrophoresis results in “head” and “tail” DNA, for 
each cell. Image as seen on Komet 6.0 software. 
A clear advantage of the comet assay over other methods of crosslink detection is 
that monoadducts and intra-strand crosslinks do not interfere with the ability of the 
DNA to migrate through the agarose gel. Therefore, this assay observes solely the 
ICL lesion. Additionally, the comet assay is more sensitive than the alkaline elution 
method, capable of detecting lower levels of crosslinking (Wu et al., 2009), and is 
able to detect crosslinking in single cells. Radiolabelling of DNA is not required for 
the comet assay and so this technique can be applied to patient samples, extending 
its use to clinical trials (Hartley et al., 1999; Hochhauser et al., 2009; Spanswick et 
al., 2012, 2002).  
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5.2 Aims 
The aims regarding the investigation of the DNA repair pathways following STAT3 
inhibition were as follows: 
1. To determine whether STAT3 inhibitors affect the levels of cellular DNA 
damage caused by cisplatin.  
2. To investigate the effect of STAT3 inhibition on the unhooking of cisplatin-
induced ICLs. 
3. To determine whether STAT3 inhibitors affect the cellular DNA damage 
response. 
4. To investigate whether STAT3 regulates the expression of DNA repair 
factors, specifically those involved in ICL repair.  
5.3 Results 
5.3.1 VS-43 inhibits the unhooking of cisplatin-induced ICLs 
In the previous chapter, STAT3 inhibitors were demonstrated to sensitise cancer cell 
lines to cisplatin in a synergistic manner. As cisplatin exerts its cytotoxic effects 
through the adducts it forms with DNA, it is logical that the synergy noted between 
STAT3 inhibitors and cisplatin may arise from an enhancement of DNA damage or 
reduction of DNA repair in response to cisplatin treatment. 
Cisplatin forms several adducts with the DNA – monoadducts, intrastrand crosslinks 
and interstrand crosslinks (ICLs).  As ICLs covalently link the two DNA strands 
together these are considered highly cytotoxic as they cannot be bypassed in 
replication or transcription. Therefore, to test the hypothesis that STAT3 inhibitors 
may affect the level or the repair of cisplatin-induced DNA damage, the formation 
and repair of cisplatin-ICLs, was followed in cells treated with cisplatin alone, and 
cells treated with VS-43 followed by cisplatin.  
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To observe the formation and repair of ICLs in cell culture, the modified single cell 
gel electrophoresis or comet assay was employed. The tail moment, as discussed in 
the introduction of this chapter, is a direct measure of the ability of the DNA to 
migrate. This parameter will be used to determine the amount of ICLs in the DNA of 
cells treated with either cisplatin alone or cisplatin in combination with STAT3 
inhibitors. The data analysis for the comet assay uses one of two equations 
depending on whether the second drug (the STAT3 inhibitors) cause DNA strand 
breaks. If the second drug produces strand breaks these must be compensated for 
in the final calculations. Therefore, to determine whether STAT3 inhibitors induce 
strand breaks the comet assay was performed on DU145 cells treated with VS-43, 
stattic and curcumin alone, without irradiation. Figure 5-3 shows that no DNA strand 
breaks are induced by VS-43, stattic or curcumin, as the tail moments observed are 
between 0.3-0.5, similar to the untreated cells.  
The modified comet assay was then performed with cells treated with cisplatin alone 
or cisplatin in combination with VS-43 using the fixed ratio combination method.  
 
Figure 5-3: STAT3 inhibitors do not induce DNA damage. Cells treated with VS-
43, stattic or curcumin did not exhibit any DNA strand breaks as determined by the 
modified comet assay. Data plotted is the average of at least three individual 
experiments with SEM calculated for error bars. 
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Cells were harvested immediately after cisplatin treatment, 9 hours post-treatment 
(the peak of cisplatin crosslinking), 24 and 48 hours post-treatment. This was to 
follow the formation and repair of ICLs.  
In the DU145 cells, cisplatin alone (Figure 5-4A, solid line) induces a 53.7% 
decrease in tail moment at the 9 hour ICL peak. By 24 hours post-cisplatin 
treatment, the decrease in tail moment is less than 10% and this is maintained at 48 
hours post-cisplatin. As the decrease in tail moment is representative of the extent 
of DNA interstrand crosslinking, a reduction in the percentage decrease therefore, 
indicates that repair to at least the ICL unhooking stage has occurred. Any further 
repair is not distinguishable from this assay. 
In contrast, DU145 cells pre-treated with 1.2μM VS-43 before cisplatin exposure 
(Figure 5-4A, interrupted line) do not unhook the ICLs. The ICLs peak at 9 hours as 
with cisplatin-treated cells, indicating that VS-43 does not affect the overall level of 
ICLs at the peak (although a slightly higher level of crosslinking is observed, 
however, given the results in the rest of this chapter this is not considered to be a 
real effect). However, the tail moment remains decreased by between 72-73% for at 
least 48 hours after cisplatin treatment. Representative comet images at 48 hours 
post-cisplatin are shown in Figure 5-5. Cells treated with cisplatin exhibit visible 
comet tails similar in size to those of the untreated-irradiated cells. In comparison, 
VS-43 pre-treated cells have minimal comet tails and the majority of the DNA is in 
the head of the comet – indicative of high levels of interstrand crosslinking. This 
same effect is obtained in A549 cells (Figure 5-4B), although the repair of cisplatin-
induced ICLs is incomplete in this cell line, where at 48 hours post-cisplatin 
treatment, a 30% decrease in tail moment is still present. Nonetheless, pre-
treatment with VS-43 results in a maintained percentage decrease of 76.9% at 48 
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hours, indicating inhibition of ICL repair in this cell line also. P values and their 
corresponding significance levels are displayed in Table 5-1.  
 
Figure 5-4: VS-43 inhibits ICL unhooking. Fixed ratio combination of VS-43 
with cisplatin in the A) DU145 and B) A549 cell lines. VS-43 inhibited cisplatin-
ICL repair, as determined by the modified comet assay. Data plotted is the average 
of at least three individual experiments with SEM calculated for error bars. 
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Figure 5-5: Representative comet images for DU145 cells treated with VS-43 
and cisplatin.  
 
Table 5-1: Fixed ratio comet assay P values and statistical significance. The 
students t-test was used as a measure of statistical significance, with the test 
comparing the % decrease in tail moment at each time point for cells treated with 
cisplatin alone and with the combination. 
 DU145 A549 
Time 
(Hours) 
P Value Significance P Value Significance 
0 0.0441 * 0.0115 * 
9 0.0074 ** 0.1126 ns 
24 0.0017 ** 0.0107 * 
48 0.0077 ** 0.0237 * 
 
 
Untreated 
Unirradiated 
Untreated 
Irradiated 
Cisplatin 
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Irradiated 
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As the non-fixed ratio combination of VS-43 and cisplatin produced similar synergy 
to that of the fixed ratio combination in the previous chapter, the non-fixed ratio was 
also tested for its ability to inhibit ICL unhooking using the modified comet assay.  
In the DU145 cells, cisplatin alone (Figure 5-6A, solid line) induces a 60.4% 
decrease in tail moment at the 9 hour ICL peak. By 24 hours post-cisplatin 
treatment, the decrease in tail moment is reduced to below 10%. In contrast, DU145 
cells pre-treated with 5μM VS-43 before cisplatin exposure (Figure 5-6A, interrupted 
line) do not unhook the ICLs, as with the fixed ratio combination. The tail moment 
remains decreased by between 60-65% for at least 48 hours after cisplatin 
treatment. This same effect is obtained in A549 cells (Figure 5-6B), although again, 
the cisplatin-induced ICLs do not fully repair, as a 20.2% decrease in tail moment 
persists at 48 hours post-cisplatin treatment. Even so, the cells given a 10μM VS-43 
pre-treatment have significantly inhibited ICL repair – the percentage decrease in 
tail moment is 67.1% at 48 hours. P values and their corresponding significance 
levels are displayed in Table 5-2.  
Therefore, both the fixed and non-fixed ratio combination of VS-43 and cisplatin are 
able to significantly inhibit the unhooking of cisplatin-induced ICLs, which 
demonstrates persistent DNA damage, and therefore, is likely responsible for the 
sensitisation of cells to cisplatin by VS-43.  
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Figure 5-6: VS-43 inhibits ICL unhooking. Non-fixed ratio combination of VS-
43 with cisplatin in the A) DU145 and B) A549 cell lines. VS-43 inhibited 
cisplatin-ICL repair, as determined by the modified comet assay. Data plotted is the 
average of at least three individual experiments with SEM calculated for error bars. 
 
Table 5-2: Non-fixed ratio comet assay P values and statistical significance. 
The students t-test was used as a measure of statistical significance, with the test 
comparing the % decrease in tail moment at each time point for cells treated with 
cisplatin alone and with the combination. 
 DU145 A549 
Time 
(Hours) 
P Value Significance P Value Significance 
0 0.4774 ns 0.3134 ns 
9 0.3640 ns 0.1026 ns 
24 0.0005 *** 0.0043 ** 
48 0.0197 ** 0.0049 ** 
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5.3.2 Stattic and Curcumin also inhibit cisplatin-induced DNA-ICL unhooking 
In order to determine whether the inhibition of ICL unhooking seen by VS-43 is a 
property of all STAT3 inhibitors rather than an off-target effect of VS-43, comet 
assays were performed with cells treated with stattic or curcumin in combination 
with cisplatin.  
Figure 5-7A shows that cisplatin-ICL unhooking in the DU145 cell line is completely 
inhibited by pre-treatment with stattic. The ICLs peak at 9 hours post-cisplatin 
treatment at approximately 60% decrease in tail moment. By 24 hours the cells 
treated with just cisplatin (solid line) have repaired the majority of the ICLs – a 
12.3% decrease in tail moment is observed. However, cells treated with a 
combination of stattic and cisplatin (interrupted line) do not repair the ICLs - a 56.7% 
decrease in tail moment is still present at 24 hours. This is maintained at 48 hours 
post-cisplatin treatment.  
Similar results were obtained in the A549 cell line, as is shown in Figure 5-7B. At 48 
hours cells treated with cisplatin only have a 22.5% decrease in tail moment 
compared with 55.8% for cells pre-treated with stattic. The P values and their 
corresponding significance values are shown in Table 5-3. 
The combination of curcumin with cisplatin was also tested in the DU145 cell line. 
Again, the ICL peak at 9 hours is similar between the two treatment groups. The 
cells treated with cisplatin alone then repair the ICLs, reaching an 11.4% decrease 
in tail moment by 48 hours (Figure 5-8, solid line). In contrast, cells pre-treated with 
curcumin (Figure 5-8, interrupted line) do not repair the ICLs and instead an 
increase in the percentage decrease in tail moment is seen. By 48 hours post-
cisplatin a 75.6% decrease in tail moment is seem for the combination treated cells. 
The P values and their corresponding significance values are shown in Table 5-4.  
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These results indicate that inhibition of ICL unhooking is a property of all the STAT3 
inhibitors tested. Therefore, STAT3 itself may be involved in the regulation of DNA 
repair factors. This will be investigated in the next section.  
 
Figure 5-7: Stattic inhibits ICL unhooking. Fixed ratio combination of stattic with 
cisplatin in the A) DU145 and B) A549 cell lines inhibited cisplatin-ICL repair, as 
determined by the modified comet assay. Data plotted is the average of at least 
three individual experiments with SEM calculated for error bars. 
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Table 5-3: Stattic and cisplatin comet assay P values and statistical 
significance. The students t-test was used as a measure of statistical significance, 
with the test comparing the % decrease in tail moment at each time point for cells 
treated with cisplatin alone and with the combination. 
 DU145 A549 
Time 
(Hours) 
P Value Significance P Value Significance 
0 0.3589 ns 0.3900 ns 
9 0.4389 ns 0.8182 ns 
24 0.0154 * 0.0125 * 
48 0.0062 ** 0.0026 ** 
 
 
 
Figure 5-8: Curcumin inhibits ICL unhooking. Fixed ratio combination of 
curcumin with cisplatin in the DU145 cell line inhibited cisplatin-ICL repair, as 
determined by the modified comet assay. Data plotted is the average of at least 
three individual experiments with SEM calculated for error bars. 
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Table 5-4: Curcumin and cisplatin comet assay P values and statistical 
significance. The students t-test was used as a measure of statistical significance, 
with the test comparing the % decrease in tail moment at each time point for cells 
treated with cisplatin alone and with the combination. 
 DU145 
Time 
(Hours) 
P Value Significance 
0 0.0413 * 
9 0.6329 ns 
24 0.0063 ** 
48 0.0008 *** 
 
5.3.3 STAT3 inhibition alters the DNA damage response after treatment with 
cisplatin 
As STAT3 inhibitors have been shown to inhibit cisplatin-ICL repair, the effect of 
STAT3 inhibition on the cellular DNA damage response after cisplatin treatment was 
next observed. The phosphorylated version of histone H2AX (γH2AX) was 
employed as a marker of the DNA damage response, as it is recruited to sites of 
DNA damage. Levels of γH2AX were assessed by confocal microscopy. Cells were 
treated with cisplatin, VS-43 or a combination of VS-43 and cisplatin using the fixed 
ratio treatment method, at concentrations that produced synergy as reported in the 
previous chapter. The cells were then fixed and stained for γH2AX at 0, 9, 24 and 
48 hours after cisplatin treatment.  
Figure 5-9 shows representative images from these experiments in DU145 cells. 
The top panels show untreated control cells and cells treated with VS-43 alone, 
neither of which have γH2AX staining. The lower left panel shows cells treated with 
cisplatin alone, which do have increasing γH2AX foci over time. The lower right 
panel shows cells pre-treated with VS-43 before cisplatin treatment.  
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Figure 5-9: VS-43 enhances cisplatin-induced γH2AX expression in the DU145 
cell line. Confocal microscopy showing DU145 cells stained with γH2AX antibody at 
four time points: 0, 9, 24 and 48 hours. Top left panel shows control cells 
(untreated). Top right panel shows cells treated with VS-43 for 18 hours. Bottom left 
panel shows cells treated with cisplatin for 1 hour, and bottom right panel shows 
cells treated with a combination of VS-43 and cisplatin. Images are representative of 
more than 1 experiment. 
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These cells display greater γH2AX staining at every time point when compared to 
the cells treated with cisplatin alone. This staining was quantified for three repeats 
using the Cell Profiler software, which counts the number of γH2AX foci per nucleus. 
Figure 5-10 shows that there is a statistically significant increase in γH2AX staining 
in combination treated cells at 9, 24 and 48 hours when compared with cells treated 
with cisplatin alone. The greatest difference occurs at 24 hours; where cisplatin 
treated cells show an average of 15.5 foci per cell compared with 52.7 foci per cell 
for the combination treated cells. 
 
Figure 5-10: Quantification of γH2AX staining in the DU145 cell line after 
treatment with VS-43, cisplatin or the combination treatment. Quantification 
was performed by Cell Profiler with a threshold of 0.3. Data is the average of three 
independent experiments with the SEM calculated for error bars. Statistical 
significance was calculated using the one-way ANOVA with * = P<0.05 and ** = 
P<0.01.  
 
 
 
 
Quantification of γH2AX Foci in VS-43 and 
Cisplatin Treated DU145 Cells
0 9 24 48
0
20
40
60
80
Control
1.2µM VS-43
60µM Cisplatin
1.2µM VS-43 + 
60µM Cisplatin
Time (Hours)
N
um
be
r o
f
 γH
2A
X 
Fo
ci
 P
er
 C
el
l
*
* **
  252 
As the dose of cisplatin used (60µM) induces approximately 50% cell growth 
inhibition in DU145 cells, γH2AX staining was also performed for cells treated with a 
low-dose of cisplatin (6µM) in combination with VS-43. This was to lower the amount 
of DNA damage that may be occurring due to cisplatin-induced apoptosis. The 
combination of a low-dose cisplatin treatment with VS-43 resulted in a similar 
pattern as was seen for the higher dose. Whilst VS-43 itself did not result in γH2AX 
staining, in combination with cisplatin, VS-43 enhanced cisplatin-induced γH2AX 
staining (Figure 5-11). This effect was most striking at 48 hours post-cisplatin 
treatment where the combination treatment resulted in an average of 25.6 foci per 
cell compared with 0.51 foci per cell in cells treated with low-dose cisplatin alone 
(Figure 5-12).  
γH2AX staining was also carried out in A549 cells treated with VS-43 and cisplatin. 
Figure 5-13 shows that cells treated with VS-43 and cisplatin in combination exhibit 
a greater degree of γH2AX staining. The effect in this cell line is not so clear, 
however, as there was more non-specific background binding. For this reason, 
quantification of γH2AX foci was not possible in this cell line.  
In order to test whether other STAT3 inhibitors can enhance the number of γH2AX 
foci after cisplatin treatment, curcumin was used in combination in the DU145 cells. 
Figure 5-14A shows representative images of cells treated with curcumin, cisplatin 
or the combination at 48 hours post cisplatin. Again, curcumin did not induce γH2AX 
foci, and cisplatin treatment resulted in an average of 17.3 foci per cell. When cells 
were treated with curcumin and cisplatin in combination, this increased to 28.6 foci 
per cell (Figure 5-14B). This is a 40% increase in γH2AX staining.  
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Figure 5-11: VS-43 enhances γH2AX expression after a low dose of cisplatin in 
the DU145 cell line. Confocal microscopy showing DU145 cells stained with γH2AX 
antibody at four time points: 0, 9, 24 and 48 hours. Top left panel shows control cells 
(untreated). Top right panel shows cells treated with VS-43 for 18 hours. Bottom left 
panel shows cells treated with cisplatin for 1 hour, and bottom right panel shows 
cells treated with a combination of VS-43 and cisplatin.  Images are representative 
of more than 1 experiment. 
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Immunoblotting for γH2AX after VS-43 and cisplatin combination treatment in the 
A549 cell line was performed in addition to confocal microscopy (Figure 5-15A). This 
shows clearly that γH2AX expression is greatly increased in the combination treated 
cells over cells treated with cisplatin alone, where some γH2AX is detectable. The 
same immunoblotting was also carried out for combination of stattic and curcumin 
with cisplatin in the DU145 cell line (Figure 5-15B). Treatment of cells with cisplatin 
induces γH2AX expression, whereas treatment with stattic or curcumin does not. 
The combination of either stattic or curcumin with cisplatin results in an enhanced 
γH2AX expression in both instances, however, curcumin appears to have a greater 
effect in combination with cisplatin than stattic at the equitoxic doses used. 
Therefore, as γH2AX is considered an accepted marker of the DNA damage 
response, there is a clear link between STAT3 inhibition and the extent of damage 
response invoked by cisplatin and this is likely to contribute towards the synergy 
observed between these two agents.  
 
Figure 5-12: Quantification of γH2AX staining in the DU145 cell line after 
treatment with VS-43, low-dose cisplatin or the combination treatment. 
Quantification was performed by Cell Profiler with a threshold of 0.3. Data is the 
average of three independent experiments with the SEM calculated for error bars. 
Statistical significance was calculated using the one-way ANOVA with * = P<0.05. 
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Figure 5-13: VS-43 enhances cisplatin-induced γH2AX expression in the A549 
cell line. Confocal microscopy showing A549 cells stained with γH2AX antibody at 
four time points: 0, 9, 24 and 48 hours. Top left panel shows control cells 
(untreated). Top right panel shows cells treated with VS-43 for 18 hours. Bottom left 
panel shows cells treated with cisplatin for 1 hour, and bottom right panel shows 
cells treated with a combination of VS-43 and cisplatin.  Images are representative 
of more than 1 experiment. 
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Figure 5-14: Curcumin enhances cisplatin-induced γH2AX expression. A) 
Confocal microscopy showing DU145 cells stained with γH2AX antibody at 48 hours 
post-drug treatment. Curcumin enhances cisplatin-induced γH2AX expression. 
Images are representative of more than 1 experiment. B) Quantification of the above 
γH2AX staining. Quantification was performed by Cell Profiler with a threshold of 
0.3. Data is the average of three independent experiments with the SEM calculated 
for error bars. Statistical significance was calculated using the one-way ANOVA with 
* = P<0.05. 
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Figure 5-15: STAT3 inhibitors increase cisplatin-induced γH2AX expression, 
as shown by immunoblot analysis. A) VS-43 in combination with cisplatin in the 
A549 cell line and, B) stattic and curcumin in combination with cisplatin in the 
DU145 cell. Blots are representative of more than 1 experiment. 
 
 
5.3.4 VS-43 regulates the expression of DNA repair proteins 
STAT3 inhibitors, including VS-43, have been demonstrated to inhibit the unhooking 
event involved in ICL repair, and also enhance the DNA damage response. 
Therefore, DNA repair factors involved in this process may be regulated by STAT3. 
As STAT3 is a transcription factor, initially the mRNA levels of DNA repair factors 
were investigated, followed by observation of protein levels. 
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5.3.4.1 Array analysis of DNA damage signalling factors reveals up-
regulation of the stress response and down-regulation of DNA repair 
following VS-43 treatment. 
To determine if any DNA repair genes are regulated by STAT3 inhibition, an initial 
screen using a PCR array with 84 genes involved in DNA damage and damage 
signalling was employed. DU145 cells were treated with two doses of VS-43 for 18 
hours: 1μM and 2μM. This would allow for the determination of genes regulated in a 
dose-dependent manner. 
The array chosen contained groups of genes involved in apoptosis, cell cycle control 
and several DNA repair pathways including BER, DSB repair, MMR, and damage 
binding. The full list of genes can be found in Appendix A. 
CT analysis on the three independent repeats was performed. To be considered a 
significant change in mRNA expression the following criteria were applied: 
1. A dose-dependency in fold regulation must be seen. 
2. At 1µM VS-43, a fold regulation of >±1.2 must be seen.  
3. At 2µM VS-43, a fold regulation of >±2.0 must be seen. 
4. P value at both doses tested must be significant (<0.05). 
Candidate genes fitting this selection process were then separated into up and 
down-regulated pools, and ordered from the largest to smallest fold regulation at 
1µM VS-43. This is because 1µM is closer to the concentration used in the comet 
assays where unhooking of ICLs was shown to be inhibited. The results are 
displayed in Table 5-5.  
Transcription of four genes was up-regulated by VS-43. These include DDIT3 
(GADD153) and GADD45a – two stress sensor proteins involved in endoplasmic 
reticulum stress-mediated apoptosis (Liebermann and Hoffman, 2008; Oyadomari 
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and Mori, 2004), and CDKN1A (p21) – a cell cycle regulator, considered a marker of 
cell cycle arrest (Gartel et al., 1996). These genes therefore, are most likely related 
to the cellular stress induced by exposure to VS-43 and are not involved in DNA 
damage repair. MLH1, the mismatch repair protein, is also up-regulated by VS-43. 
No other significant up-regulations were observed. 
All of the genes found to be down-regulated by VS-43 treatment are involved in 
DNA repair pathways (Table 5-5). The top hit was LIG1, a ligase involved in 
replication and BER. FANCD2 and BRCA1 mRNA were also down-regulated in a 
dose-dependent manner. These factors have both been linked to ICL repair and 
therefore, they are viable targets for further investigation. Other down-regulated 
repair factors with connections to ICL repair include FANCA and BRIP1 (FANCJ), 
however, these were found to be affected less by VS-43 treatment.  
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Table 5-5: DNA damage signalling array: fold regulation and P value for genes 
up or down-regulated by a 1µM and 2µM 18 hour VS-43 treatment. 
  1µM VS-43 2µM VS-43 
Gene 
Fold 
Regulation P value 
Fold 
Regulation P value 
Up-regulated  
DDIT3 2.98 0.0232 9.44 0.0332 
GADD45A 2.02 0.0480 7.96 0.0027 
CDKN1A 2.01 0.0492 5.21 0.0052 
MLH1 1.69 0.0155 2.01 0.0436 
Down-regulated 
LIG1 -1.97 0.0043 -5.70 0.0001 
FANCD2 -1.40 0.0222 -2.91 0.0059 
BRCA1 -1.34 0.0431 -4.74 0.0005 
XRCC1 -1.27 0.0120 -4.75 0.0001 
FANCA -1.26 0.0335 -3.19 0.0000 
OGG1 -1.26 0.0391 -2.94 0.0019 
RPA1 -1.23 0.0043 -2.72 0.0002 
BRIP1 -1.22 0.0067 -4.57 0.0002 
MDC1 -1.21 0.0255 -4.33 0.0004 
 
Investigation of every DNA repair factor modulated by VS-43 is beyond the scope of 
this thesis therefore, only the top hits most relevant to the unhooking of ICLs will be 
investigated further – these are FANCD2 and BRCA1.  
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5.3.4.2 VS-43 does not affect levels of XPF-ERCC1 or SLX4 
The PCR array used in section 5.3.4.1 did not contain several factors thought to be 
involved in ICL repair. Namely, the nucleases XPF and MUS81-EME1, and the 
scaffolding protein SLX4, all thought to play roles in ICL unhooking. Therefore, a 
combination of immunoblotting and single gene RT-PCR was employed to observe 
any changes in the protein and/or mRNA levels of these genes after VS-43 
treatment. 
The primary nuclease complex believed to be involved in ICL unhooking is XPF-
ERCC1 (Zhang and Walter, 2014). The PCR array included ERCC1 but did not 
include XPF therefore, both of these proteins were analysed by immunoblot in cells 
treated with increasing concentrations of STAT3 inhibitors for 18 hours. 
Figure 5-16A illustrates that in the DU145 cell line, protein levels of XPF and 
ERCC1 are not affected by treatment with VS-43, stattic or curcumin.  In agreement 
with this, the DNA damage signalling RT-PCR array determined the fold regulation 
of ERCC1 to be 1.11 and -1.46 for 1µM and 2µM VS-43, respectively. This does not 
fit the criteria for a significant result. Therefore, STAT3 inhibitors do not inhibit ICL 
unhooking through the regulation of the XPF-ERCC1 nuclease.  
A second factor considered important in the orchestration of ICL unhooking is the 
scaffold protein SLX4. Immunoblotting for this factor after VS-43 treatment in the 
A549 and DU145 cell lines showed no effect on cellular SLX4 levels (Figure 5-16B).  
Therefore, neither the depletion of XPF, ERCC1 or SLX4 contributes to the inhibition 
of ICL unhooking seen by STAT3 inhibition.  
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Figure 5-16: A) STAT3 inhibitors do not regulate ERCC1 or XPF expression. B) 
VS-43 does not regulate SLX4 expression. Blots are representative of more than 
1 experiment. 
 
 
5.3.4.3 VS-43 affects cellular EME1, FANCD2, BRCA1 and MUS81 mRNA and 
protein levels 
The RT-PCR array identified two key ICL repair genes as being significantly down-
regulated by VS-43: FANCD2 and BRCA1. To confirm this result, single gene RT-
PCR was performed using Taqman gene assays.  FANCD2 mRNA levels were 
down-regulated to 0.806, 0.751 and 0.644 of the control mRNA level by increasing 
concentrations of VS-43. BRCA1 mRNA levels were down-regulated to 0.623, 0.558 
and 0.381 of the control mRNA level by increasing concentrations of VS-43 (Figure 
5-17). Therefore, down-regulation of both of these genes at the mRNA level is 
confirmed.  
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MUS81-EME1 is thought to be involved in one of the incision reactions during ICL 
unhooking (Hanada et al., 2006). Therefore, the mRNA level of these targets after 
VS-43 treatment was also analysed. EME1 mRNA was down-regulated by 
increasing concentrations of VS-43 to 0.417, 0.427 and 0.270 of the control mRNA 
level. The changes in MUS81 mRNA after VS-43 treatment were 1.34, 1.07 and 
0.633. Therefore, at the higher doses of VS-43, down-regulation of MUS81 mRNA 
was observed, however, this was not to the same extent as EME1, FANCD2 and 
BRCA1 mRNA (Figure 5-17).  
The protein levels of FANCD2, BRCA1, EME1, and MUS81 were also investigated 
to observe whether the effect of VS-43 on mRNA levels translates into cellular 
protein levels of these targets. Figure 5-18 shows that in both DU145 (A) and A549 
(B) cells the protein levels of FANCD2, BRCA1, EME1 and MUS81 are down-
regulated by 18 hour treatment with increasing concentrations of VS-43. This down-
regulation is maintained for at least 24 hours post VS-43 removal, indicating that 
during the 1 hour cisplatin treatment and the following 23 hours, these repair factors 
are depleted. Comet assays have shown that the majority of cisplatin-ICL repair 
occurs within the first 24 hours after cisplatin treatment therefore, lower levels of 
these factors may impair the unhooking process.  
It appears that EME1 is the most heavily down-regulated factor, particularly in the 
DU145 cell line, where as little as 0.5µM VS-43 almost completely abolishes EME1 
expression. BRCA1, FANCD2 and MUS81 are all, however, dose-dependently 
inhibited by VS-43 treatment.  
Therefore, VS-43 regulates the cellular levels of BRCA1, FANCD2, EME1 and 
MUS81 mRNA and protein levels in the cell lines tested here. This may contribute 
towards the inhibition of ICL unhooking and sensitivity to cisplatin induced by VS-43 
treatment.  
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Figure 5-17: VS-43 inhibits FANCD2, BRCA1, EME1 and MUS81 mRNA 
expression in the DU145 cell line.  Data is the average of three independent 
experiments with SEM calculated for error bars. One-way ANOVA was used to 
determine statistical significance with * = P<0.05, ** = P<0.01, and ****  = P<0.0001. 
mRNA level was normalised to untreated cells and GAPDH. 
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Figure 5-18: VS-43 inhibits expression of BRCA1, FANCD2, EME1 and MUS81 
in the A) DU145 and B) A549 cell lines. This effect persists at least 24 hours after 
VS-43 removal. Blots are representative of more than 1 experiment. 
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5.3.4.4 Stattic and curcumin also down-regulate mRNA and protein 
expression of FANCD2, EME1 and BRCA1 
In order to establish whether the effects seen on BRCA1, FANCD2, EME1 and 
MUS81 mRNA and protein expression by VS-43 were due to STAT3 inhibition 
rather than off-target effects of this compound, immunoblotting and RT-PCR was 
performed for these factors after the treatment of DU145 cells with stattic and 
curcumin for 18 hours.  
Figure 5-19A shows that both stattic and curcumin dose-dependently down-regulate 
BRCA1, FANCD2, EME1 and MUS81 protein expression. This correlates with 
inhibition of pSTAT3Tyr705 by these compounds. As with VS-43 treatment, EME1 
protein expression is down-regulated to the greatest extent, particularly with 
curcumin where 30µM almost completely abolishes EME1 expression.  
Figure 5-19B shows the relative mRNA levels for the four DNA repair factors after 
treatment with two doses of stattic: one sub-GI50 dose and one supra-GI50 dose. 
FANCD2 and EME1 mRNA expression are down-regulated by treatment of cells 
with stattic, however, this effect is not dose-dependent. EME1 mRNA level is 
decreased to 0.41 and 0.44 of the control cells for 10µM and 20µM stattic, 
respectively. FANCD2 mRNA is decreased to 0.716 and 0.767 of the control cells at 
the two doses. BRCA1 does display a dose-dependent inhibition in mRNA 
expression, with 10µM stattic reducing mRNA to 0.776 that of control cells, and 
20µM stattic reducing mRNA to 0.422 that of control cells. The results obtained for 
MUS81 mRNA expression after stattic treatment demonstrated dose-dependency 
but no statistically significant change.  
The relative mRNA levels of FANCD2, EME1, BRCA1 and MUS81 after treatment of 
cells with curcumin can be seen in Figure 5-19C. As with stattic, two doses of 
curcumin were used: one sub-GI50 dose and one supra-GI50 dose. Curcumin has the 
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greatest effect on mRNA expression when compared with either stattic or VS-43, 
which may be due to curcumin’s lack of specificity. All four DNA repair factors 
display a dose-dependent decrease in mRNA expression after treatment with 
curcumin. As with VS-43, This is strongest for EME1, where at 60µM curcumin, 
mRNA expression is reduced to 0.154 that of control cells. MUS81 mRNA 
expression is also significantly down-regulated by the higher dose of curcumin, 
reaching 0.42 relative to control mRNA expression.  
Therefore, as STAT3 inhibitors have been demonstrated here to down-regulate the 
mRNA and protein levels of BRCA1, FANCD2, EME1 and MUS81, it is possible that 
STAT3 may directly regulate the transcription of these DNA repair factors.  
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Figure 5-19: A) Stattic and curcumin inhibit the expression of BRCA1, 
FANCD2, EME1 and MUS81. B) Stattic and C) curcumin inhibit the mRNA 
expression of FANCD2, BRCA1, EME1 and MUS81. Blots are representative of 
more than 1 experiment. Data is the average of three independent experiments with 
SEM calculated for error bars. One-way ANOVA was used to determine statistical 
significance with * = P<0.05, ** = P<0.01, *** = P<0.001 and ****  = P<0.0001. 
mRNA level was normalised to untreated cells and GAPDH. 
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5.3.5 STAT3 inhibition blocks G1 to S phase cell cycle progression 
Next, the effect of STAT3 inhibition on the cell cycle was assessed by flow 
cytometry. This was required in order to determine whether the down-regulation of 
DNA repair factors by STAT3 inhibition is a result of cell cycle phase.  
First, asynchronous DU145 cells were treated with VS-43 for 18 hours at increasing 
doses, and then harvested and stained for cell cycle analysis. Representative cell 
cycle plots are shown in Figure 5-20A. Treatment with VS-43 does not appear to 
have a large effect on the cell cycle; however, there does appear to be a lower 
proportion of cells in S-phase (yellow). These plots were quantified for the 
percentage of cells in each cell cycle phase using Flowjo v10 (Figure 5-20B). This 
revealed that the percentage of cells in S phase dose-dependently decreases with 
VS-43 treatment. There is also a dose-dependent increase in the G1 population, 
although this is not statistically significant, and also a slight increase in the G2 
population. 
Identical experiments were performed in DU145 cells treated with stattic and 
curcumin at equipotent doses to those used for VS-43. The representative cell cycle 
plots show a similar slight decrease in S phase cells (yellow) after treatment with 
stattic (Figure 5-21A and Figure 5-21B). Whilst a slight increase in the percentage of 
G1 phase cells is seen, this is not statistically significant.  
For curcumin treated cells, again a dose-dependent decrease in S phase cells is 
seen on the representative cell cycle plots with increasing doses of curcumin (Figure 
5-22A and Figure 5-22B). 
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Figure 5-20: VS-43 decreases the percentage of S-phase cells. A) 
Representative cell cycle plots of DU145 cells treated with increasing doses of VS-
43 (µM). B) Quantification of the percentage of cells in each cell cycle phase, 
performed by Flowjo v10.  Data is the average of three independent experiments 
with SEM calculated for error bars. One-way ANOVA was used to determine 
statistical significance with * = P<0.05, ** = P<0.01, *** = P<0.001 and ****  = 
P<0.0001. 
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Figure 5-21: Stattic decreases the percentage of S-phase cells. A) 
Representative cell cycle plots of DU145 cells treated with increasing doses of 
stattic (µM). B) Quantification of the percentage of cells in each cell cycle phase, 
performed by Flowjo v10.  Data is the average of three independent experiments 
with SEM calculated for error bars. One-way ANOVA was used to determine 
statistical significance with * = P<0.05. 
 
0µM 5µM 
10µM 15µM 
A 
B 
0 50K 100K 150K 200K 250K
YG 610_20-A
0
100
200
300
400
500
Co
un
t
du145 stattic_15_004.fcs
Cell Cycle
7372
RMSD : 2.44
%G1 : 54.8
%S : 26.1
%G2 : 14.8
0 50K 100K 150K 200K 250K
YG 610_20-A
0
100
200
300
400
500
Co
un
t
du145 stattic_10_003.fcs
Cell Cycle
7583
RMSD : 2.82
%G1 : 51.9
%S : 19.9
%G2 : 23.8
0 50K 100K 150K 200K 250K
YG 610_20-A
0
100
200
300
400
500
Co
un
t
du145 stattic_5_002.fcs
Cell Cycle
7052
RMSD : 3.04
%G1 : 52.9
%S : 22.2
%G2 : 21.0
0 50K 100K 150K 200K 250K
YG 610_20-A
0
100
200
300
400
500
Co
un
t
du145 stattic_0_001.fcs
Cell Cycle
7673
RMSD : 2.92
%G1 : 48.0
%S : 28.0
%G2 : 18.1
0 50K 100K 150K 200K 250K
YG 610_20-A
0
100
200
300
400
500
Co
un
t
du145 stattic_15_004.fcs
Cell Cycle
7372
RMSD : 2.44
%G1 : 54.8
%S : 26.1
%G2 : 14.8
0 50K 100K 150K 200K 250K
YG 610_20-A
0
100
200
300
400
500
Co
un
t
du145 stattic_10_003.fcs
Cell Cycle
7583
RMSD : 2.82
%G1 : 51.9
%S : 19.9
%G2 : 23.8
0 50K 100K 150K 200K 250K
YG 610_20-A
0
100
200
300
400
500
Co
un
t
du145 stattic_5_002.fcs
Cell Cycle
7052
RMSD : 3.04
%G1 : 52.9
%S : 22.2
%G2 : 21.0
0 50K 100K 150K 200K 250K
YG 610_20-A
0
100
200
300
400
500
Co
un
t
du145 stattic_0_001.fcs
Cell Cycle
7673
RMSD : 2.92
%G1 : 48.0
%S : 28.0
%G2 : 18.1
0 50K 100K 150K 200K 250K
YG 610_20-A
0
100
200
300
4 0
500
Co
un
t
du145 stattic_15_004.fcs
Cell Cycle
7372
RMSD : 2.44
%G1 : 54.8
%S : 26.1
%G2 : 14.8
0 50K 100K 150K 200K 250K
YG 610_20-A
0
100
200
300
400
500
Co
un
t
du145 stattic_10_003.fcs
Cell Cycle
7583
RMSD : 2.82
%G1 : 51.9
%S : 19.9
%G2 : 23.8
0 50K 100K 150K 200K 250K
YG 610_20-A
0
100
200
300
400
500
Co
un
t
du145 stattic_5_002.fcs
Cell Cycle
7052
RMSD : 3.04
%G1 : 52.9
%S : 22.2
%G2 : 21.0
0 50K 100K 150K 200K 250K
YG 610_20-A
0
100
200
300
400
500
Co
un
t
du145 stattic_0_001.fcs
Cell Cycle
7673
RMSD : 2.92
%G1 : 48.0
%S : 28.0
%G2 : 18.1
0 50K 100K 150K 200K 250K
YG 610_20-A
0
100
2
300
400
500
Co
un
t
du145 stattic_15_004.fcs
Cell Cycle
7372
RMSD : 2.44
%G1 : 54.8
%S : 26.1
%G2 : 14.8
0 50K 100K 150K 200K 250K
YG 610_20-A
0
100
200
300
400
500
Co
un
t
du145 stattic_10_003.fcs
Cell Cycle
7583
RMSD : 2.82
%G1 : 51.9
%S : 19.9
%G2 : 23.8
0 50K 100K 150K 200K 250K
YG 610_20-A
0
100
200
300
400
500
Co
un
t
du145 stattic_5_002.fcs
Cell Cycle
7052
RMSD : 3.04
%G1 : 52.9
%S : 22.2
%G2 : 21.0
0 50K 100K 150K 200K 250K
YG 610_20-A
0
100
200
300
400
500
Co
un
t
du145 stattic_0_001.fcs
Cell Cycle
7673
RMSD : 2.92
%G1 : 48.0
%S : 28.0
%G2 : 18.1
  272 
 
Figure 5-22: Curcumin decreases the percentage of S-phase cells. A) 
Representative cell cycle plots of DU145 cells treated with increasing doses of 
curcumin (µM). B) Quantification of the percentage of cells in each cell cycle phase, 
performed by Flowjo v10.  Data is the average of three independent experiments 
with SEM calculated for error bars. One-way ANOVA was used to determine 
statistical significance with ** = P<0.01. 
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These experiments demonstrated the effect of STAT3 inhibitors on the cell cycle 
distribution of an asynchronous cell population. In order to view their effect on cell 
cycle progression, a similar experiment was performed in synchronised cells. 
DU145 cells were synchronised by serum starvation for 48 hours. The cell cycle 
block was then released by addition of serum-full media. This release was also 
performed in the presence of VS-43, stattic and curcumin. The results of this 
experiment are shown in Figure 5-23. 
Representative cell cycle plots show that the starvation period successfully reduced 
the percentage of cells in S and G2 phase. Once released, a large proportion of 
cells progressed through G1 to S phase. The plots showing the cells released in the 
presence of the STAT3 inhibitors demonstrate that treatment with either VS-43, 
stattic or curcumin is able to completely block cell cycle progression from G1 to S 
phase (Figure 5-23A). The quantification of these plots is shown in Figure 5-23B. 
Starvation increases the G1 population to 75.5% and decreases the S phase 
population to 12.5%. Upon release of this block, the percentage of G1 cells 
decreases to 43.1%, and the percentage of S phase cells rises to 46.9% as cells 
begin to progress through the cell cycle. Release of cells in the presence of VS-43, 
stattic or curcumin maintains the G1 population at 71.9%, 78.7% and 78.9%, 
respectively. The percentage of cells in S phase remains at 15.9%, 7.80% and 
7.08% for VS-43, stattic and curcumin treated cells, respectively. These results 
suggest that treatment with STAT3 inhibitors arrests cells in G1 phase. 
This may be carried out through the regulation of cyclin D1, which controls the G1-S 
transition, by STAT3 (Bartek and Lukas, 2011; Bromberg et al., 1999). Additionally, 
in section 5.3.4.1, p21 was shown to be up-regulated by VS-43 treatment. p21 is a 
cyclin-dependent kinase inhibitor, which acts to induce cell cycle arrest in G1 
(Harper et al., 1995). Therefore, given that STAT3 inhibition likely results in reduced 
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cyclin D1 and increased p21 levels, a G1 block by VS-43, stattic and curcumin is not 
unexpected. 
 
 
Figure 5-23: STAT3 inhibitors block the progression of cells from G1 to S 
phase. A) Representative cell cycle plots of asynchronous, serum-starved and 
serum-released DU145 cells, and cells released in the presence of STAT3 
inhibitors. B) Quantification of the percentage of cells in each cell cycle phase, 
performed by Flowjo v10.  Data is the average of three independent experiments 
with SEM calculated for error bars. One-way ANOVA was used to determine 
statistical significance with * = P<0.05 and ****  = P<0.0001. 
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5.3.5.1 Cell cycle regulation of BRCA1, FANCD2, EME1 and MUS81. 
As the inhibition of STAT3 has been demonstrated to induce cell cycle arrest in G1 
phase, the effect of the cell cycle on the expression of BRCA1, FANCD2, EME1 and 
MUS81 was investigated. This was to establish whether the regulation of these 
factors by STAT3 was a result of cell cycle dependent expression rather than direct 
transcriptional regulation. 
Three cell populations were harvested for immunoblotting: asynchronous, starved 
and released cells. The starved group contain a high proportion of G1 cells whereas 
the released group contains a high proportion of S phase cells. If these proteins are 
cell cycle regulated a difference in expression should be detectable between these 
populations.  
Figure 5-24 demonstrates that only BRCA1 is cell cycle regulated. A reduced 
expression of BRCA1 is observed in the starved cells, indicating that BRCA1 
expression is lower in G1 phase. As cells treated with STAT3 inhibitors resemble 
starved cells, it is likely that the decrease in BRCA1 expression by STAT3 inhibition 
is a result of cell cycle arrest in G1 phase. This agrees with previous reports 
demonstrating regulation of BRCA1 by the cell cycle (Ruffner and Verma, 1997). 
The expression of FANCD2, EME1 and MUS81 is not affected by cell cycle phase. 
Therefore, these factors may be regulated by STAT3 at the transcriptional level.  
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Figure 5-24: The expression of BRCA1, but not FANCD2, EME1 or MUS81 is 
cell cycle regulated. Assynchronous, serum-starved and serum-released DU145 
cells were analysed by immunoblotting for the expression of ICL repair genes. 
Samples are paired to samples analysed by FACS in Figure 5-23. Blot is 
representative of more than 1 experiment. 
  
 
5.3.6 STAT3 consensus binding sites reside within ICL repair gene 
promoters 
To investigate whether STAT3 regulates the transcription of DNA repair genes 
including FANCD2, EME1 and MUS81, the online UCSC Genome Browser was 
utilised (Kent et al., 2002). This database contains experimental data from 
chromatin immunoprecipitation experiments for many transcription factors, including 
STAT3. This enabled STAT3 binding sites to be located across the human genome. 
Bioinformatic analysis of this data identified STAT3 binding sites located in the 
promoter regions of DNA repair genes. This work was performed by John Ambrose 
and Javier Herrero of the Bill Lyons Informatics Center, UCL. 
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A full list of the DNA repair genes identified to contain STAT3 binding sites in their 
promoter regions is included in Appendix C. For the purposes of this thesis, three 
targets were of particular interest: FANCD2, EME1 and MUS81. 
FANCD2 did not contain any STAT3 binding sites in its promoter region. Therefore, 
it is possible that the regulation of FANCD2 by STAT3 inhibitors seen in this chapter 
is via an indirect mechanism. 
For the EME1 gene, one STAT3 binding site was identified spanning 662-253bp 
upstream of the EME1 transcription start site. This is shown in the first Genome 
Browser screenshot in Figure 5-25. The binding site appears as a grey box with the 
vertical red line indicating the consensus STAT3 binding sequence. Primers were 
designed to amplify the region between the two black boxes at the bottom of the 
image. 
 
Figure 5-25: EME1 STAT3 promoter binding site, shown on Genome browser. 
Annotations indicate the location of genes, ChIP fragments bound by STAT3, 
STAT3 consensus sequence and sequence to be amplified by PCR.  
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This was the only STAT3 binding site identified on Genome Browser, however, it 
has previously been reported that STAT3 can bind to a site approximately 1025bp 
upstream of the EME1 transcription start site (Vigneron et al., 2008). This site is 
shown in the second screen shot in Figure 5-26 and is labelled EME1 R2. Note that 
the grey box in this image is the first binding site; the second site is indicated by the 
location of the PCR amplified sequence. 
Two STAT3 binding sites were identified upstream of the MUS81 gene. The closest 
spans from 92bp upstream to 187bp downstream of the transcription start site. The 
second binding site, MUS81 R2, spans 3267-2992bp upstream of the MUS81 gene. 
The screenshots illustrating the locations of these binding sites relative to the 
MUS81 gene and also the regions to be amplified by PCR are shown in Figure 5-26. 
As there are putative STAT3 binding sites located upstream of both the EME1 and 
MUS81 genes, it is possible that STAT3 binds to these sites in order to directly 
regulate the transcription of these DNA repair factors. This is assessed in the next 
section. 
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Figure 5-26: EME1 and MUS81 promoter STAT3 binding sites shown on 
Genome Browser. PCR fragments are also shown. 
 
5.3.7 STAT3 binds to the promoters of EME1 and MUS81  
Chromatin immunoprecipitation (ChIP) assays were employed to study the binding 
of STAT3 to the putative binding sites identified in the previous section. These 
experiments were performed with DU145 cells. Cells were either harvested as 
untreated, cisplatin treated, or VS-43 and cisplatin treated. Immunoprecipitation of 
DNA bound by STAT3 was carried out using a STAT3 antibody, and PCRs were 
EME1 
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performed to amplify the regions shown on the genome browser screenshots. An 
IgG immunoprecipitation was also performed in order to calculate fold enrichment.   
For a positive control, primers were designed to amplify the region 305-134bp 
upstream of the cFOS gene. This region spans a STAT3 binding site identified on 
the UCSC Genome Browser (Figure 5-27). cFOS is known to be transcriptionally 
regulated at this site by STAT3 (Yang et al., 2003). A negative control region at 
chr12: 6637469-6637580 was also amplified in order to obtain a value for non-
specific binding. This region lies between the NCAPD2 and GAPDH genes and 
does not contain any STAT3 binding sites. Fold enrichments were normalised to the 
non-specific enrichment of the negative control region.  
 
 
Figure 5-27: The location of the STAT3 binding site upstream of the cFOS 
gene, and the region to be amplified by PCR.  
 
 
 
 
cFOS  
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The result of this ChIP experiment is shown in Figure 5-28. In all treatment groups 
the cFOS region was amplified in STAT3 immunoprecipitations (IP), indicating that 
the ChIP was successful. The STAT3 IP also pulled down the EME1 R2, MUS81 
and MUS81 R2 regions, which were enriched by 20.5, 8.94 and 21.4 fold, 
respectively. Upon cisplatin treatment, these regions were enriched similarly to 
control cells; therefore, cisplatin treatment does not appear to induce STAT3 binding 
to these sites. The enrichment at the EME1 region was, however, increased upon 
cisplatin treatment from 0.217 to 16.1 fold.  
VS-43 treatment causes a reduction in the fold enrichment at all four sites. The fold 
enrichment drops to -0.43 for the EME1 site, -1.84 for the EME1 R2 site, 1.21 for the 
MUS81 site and 3.71 for the MUS81 R2 site. These results are not statistically 
significant due to the variable nature of ChIP experiments, however, binding to 
regions upstream of both EME1 and MUS81 by STAT3 is likely, as treatment with 
the STAT3 inhibitor VS-43 consistently blocks the enrichment seen at these sites. 
Binding to the cFOS promoter, however, is not inhibited by VS-43 treatment.  
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Figure 5-28: Chromatin immunoprecipitation analysis of STAT3 binding sites 
in the EME1 and MUS81 promoters. Constitutive STAT3 binding was detected at 
the EME1 R2, MUS81 and MUS81 R2 sites. Cisplatin treatment induced STAT3 
binding to the EME1 site. VS-43 pre-treatment blocked STAT3 binding to both 
EME1 and MUS81 sites. The cFOS promoter region was used as a positive control. 
Data is the average of at least three independent experiments with SEM calculated 
for error bars. No statistical significance was observed. 
 
5.4 Discussion 
In this chapter the molecular mechanism behind the synergy between STAT3 
inhibitors and cisplatin is investigated. As cisplatin primarily acts through the DNA 
adducts it forms, with ICLs being amongst the most toxic of these adducts, it is 
logical that sensitisation to cisplatin may involve regulating the repair of these 
adducts.  
Here it is shown that STAT3 inhibitors block the unhooking of cisplatin-ICLs and 
alter the DNA damage response after treatment with cisplatin. Enhanced γH2AX 
staining was observed in cells treated with STAT3 inhibitors followed by cisplatin 
versus cells treated with cisplatin alone, however, comet assay analysis 
demonstrated that the level of crosslinks induced by cisplatin was not affected by 
STAT3 inhibition. Therefore, there is no evidence to suggest that the level of 
cisplatin-induced DNA damage is enhanced by STAT3 inhibition. Instead, 
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accumulation of γH2AX at unrepaired ICL sites may be responsible for the 
enhanced γH2AX staining and DNA damage response observed in this chapter. 
Through the screening of various DNA repair and signalling factors, STAT3 
inhibitors were found to down-regulate EME1, MUS81, BRCA1 and FANCD2 
expression in a dose-dependent manner in both the DU145 and A549 cell lines. 
These proteins are thought to be involved in the unhooking stage of ICL repair, as 
discussed in the introduction to this chapter, which may account for the reduced 
repair of cisplatin ICLs and increased sensitivity to cisplatin, which has been 
observed. BRCA1, FANCD2, EME1 and MUS81 have all been demonstrated to 
participate in the cellular response to cisplatin.  
Colon cancer cells with haploinsufficiency in EME1 (EME1+/-) are hypersensitive to 
cisplatin, as are EME1-deficient embryonic stem cells, and EME1 levels in cancer 
cell lines correlate with cisplatin sensitivity in vitro (Abraham et al., 2003; Tomoda et 
al., 2009). This could be a result of the interaction between EME1 and the nuclease 
MUS81. Accordingly, MUS81-/- cells are also hypersensitive to ICL-inducing agents 
such as cisplatin and MMC (Hanada et al., 2006; McPherson et al., 2004). 
McPherson et al. also reported that loss of MUS81 in mice resulted in a 
predisposition to tumours, suggesting a critical role for MUS81 in genome stability. 
However, Dendouga et al. reported contradicting evidence where MUS81-/- mice 
demonstrated hypersensitivity to crosslinking agents with no associated 
predisposition to tumour development (Dendouga et al., 2005), therefore, a tumour 
suppressor function for MUS81 is not yet confirmed.  
FANCD2 has been connected with cisplatin sensitivity in ovarian cancer cell lines as 
those that do not express mono-ubiquitinated FANCD2 are hypersensitive to 
cisplatin (Taniguchi et al., 2003), and siRNA-mediated knockdown of FANCD2 itself 
in lung cancer cells increases cisplatin sensitivity (Dai et al., 2015). Small molecule 
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inhibitors of FANCD2 have been shown to sensitise cells to cisplatin and other 
crosslinking agents (Jacquemont et al., 2012; Jun et al., 2013). These include 
curcumin, which like VS-43, is also a STAT3 inhibitor (Chirnomas et al., 2006). 
BRCA1 introduction into sensitive cells has also been shown to increase resistance 
to cisplatin (Burkitt and Ljungman, 2007).  
Therefore, EME1, MUS81 FANCD2 and BRCA1 have each been connected to 
cisplatin sensitivity, and so the regulation of these proteins by STAT3 inhibitors may 
be a likely mechanism for the increase in cisplatin sensitivity seen here.  
5.4.1 The roles of VS-43 regulated DNA repair factors 
In addition to BRCA1, EME1, MUS81 and FANCD2, several other DNA repair 
factors were shown to be up- or down-regulated by treatment with VS-43 in section 
5.3.4.1. The roles of these in ICL repair will be briefly discussed. 
MLH1 is the only DNA repair factor found to be up-regulated by VS-43. MLH1 is a 
component of the MutL complex in the mismatch repair pathway. This complex has 
been shown to be involved in sensitivity to psoralen induced-ICLs, as MLH1 
deficient cells display increased resistance to psoralen (Wu and Vasquez, 2008). 
However, another study contradicts this and reports that MLH1 negative cells are 
more sensitive to MMC and cisplatin. Williams et al. also report that MLH1 interacts 
with FANCD2, however, is not required for FANCD2 ubiquitination and foci 
formation (Williams et al., 2011).  Additionally, lower levels of MLH1 have been 
correlated with greater progression-free survival in patients after platinum based 
therapies (Ting et al., 2013). Therefore, the role for MLH1 in ICL repair is still 
confused, with no direct evidence for a function in ICL unhooking, so the slight up-
regulation (1.69 and 2.01 fold at 1µM and 2µM VS-43, respectively) may be either 
beneficial or detrimental to cisplatin sensitivity. 	
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All of the genes found to be down-regulated by VS-43 treatment are involved in 
DNA repair pathways (Table 5-5). The top hit was LIG1, a ligase involved in 
replication and BER. As this enzyme is not thought to function in the early stages of 
ICL repair, it was not investigated further in this project.  
The hits at the lower end of the table included FANCA which is also dose-
dependently down-regulated by VS-43 and has been suggested to regulate MUS81-
EME1 endonuclease activity in ICL repair (Benitez et al., 2014). BRIP1 (FANCJ) is 
also down-regulated by VS-43. BRIP1 functions as a helicase downstream of 
FANCD2 and ICL unhooking (Suhasini and Brosh, 2012). Therefore, although this 
may affect later stages of ICL repair, BRIP1 is not involved in unhooking and 
therefore, was not investigated further in this project.  
It is worthwhile noting that VS-43 has an inhibitory effect on the expression of many 
DNA repair genes. This may explain why STAT3 inhibitors are able to sensitise cells 
to many DNA damaging chemotherapeutics. For instance, in chapter 4, VS-43 was 
shown to synergise with doxorubicin, a topoisomerase II inhibitor. Doxorubicin 
induces DSBs but does not, however, cause ICLs as cisplatin does. Therefore, VS-
43 may interfere with the repair of other DNA adducts through the regulation of DNA 
repair factors involved in other repair pathways such as homologous recombination 
and non-homologous end joining.  
5.4.2 Combination of other DNA repair inhibitors with cisplatin 
In this chapter, STAT3 inhibition has been demonstrated to inhibit the repair of 
cisplatin ICLs, and this is proposed to contribute to the sensitisation to cisplatin by 
STAT3 inhibitors. The use of inhibitors to re-sensitise cancer cell lines to cisplatin 
through altering DNA repair mechanisms has been previously reported. For 
example, a topoisomerase II inhibitor was demonstrated to synergise with cisplatin 
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and it was suggested that this was in part via an inhibition of cisplatin-ICL repair (Ali-
Osman et al., 1993).  
This research group previously reported synergy between the EGFR inhibitor, 
gefitinib, and cisplatin in breast cancer cell lines. Cisplatin-ICL repair after this 
combination treatment was shown to be delayed (Friedmann et al., 2004). In this 
chapter, STAT3 inhibitors completely block cisplatin-ICL repair (sections 5.3.1 and 
5.3.2). The difference between the effect of EGFR inhibition and STAT3 inhibition 
may suggest that in order to achieve a greater effect, direct inhibition of STAT3 is 
preferable to the inhibition of upstream activators. Even with EGFR inhibition, 
STAT3 could be activated through alternative pathways, which may allow for 
delayed, but eventual repair of cisplatin-ICLs through continued STAT3 signalling.  
One of the DNA repair factors demonstrated here to be down-regulated by STAT3 
inhibition was FANCD2. mTOR, a signalling kinase, is also thought to regulate 
FANCD2 (Shen et al., 2013), and enhanced anti-tumour effect has been 
demonstrated between mTOR inhibitor rapamycin and cisplatin in mouse tumour 
xenografts (Hou et al., 2010). Several clinical trials reported promising results with 
mTOR inhibitors in various combinations with cisplatin (reviewed in (Grandis et al., 
2013)), but whether this is due to FANCD2 inhibition has not yet been determined.  
Other combinations targeting DNA repair inhibitors to enhance the efficacy of 
cisplatin include PARP inhibitors and ATR inhibitors, both of which are currently in 
clinical trials with cisplatin. These combinations were described in more detail in 
section 4.1.2. PARP inhibitors likely do not target the ICL unhooking mechanism, 
however, ATR inhibitors may act at this step. ATR acts upstream of FANCD2, 
phosphorylating its partner protein, FANCI upon DNA damage. This step is required 
to promote FANCD2 ubiquitination (Crossan and Patel, 2012), and so ATR inhibitors 
may also block ICL unhooking by interfering with FA pathway activation. 
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Therefore, research into DNA repair inhibitors for combination with cisplatin is well 
underway, and the benefit of combinations that target the ICL repair pathway will 
clearly be worthwhile. 
5.4.3 Genetic mutations in the ICL unhooking machinery and cisplatin 
sensitivity 
Identification of genetic mutations in ICL repair factors may offer some insight into 
the usefulness of an inhibitor that targets those factors as a chemosensitising agent. 
Activating mutations, increased copy number and up-regulation of gene expression 
in a particular cancer group may suggest potential for the use of a STAT3 inhibitor in 
combination with cisplatin in those patients. Alternatively, deactivating mutations or 
down-regulation of gene expression may provide information about the importance 
of these factors in sensitivity to cisplatin.  
According to the Catalogue of Somatic Mutations in Cancer (COSMIC) online 
database (Forbes et al., 2015), 96 unique mutations are found for EME1. However, 
mutations are found only at low frequencies: 1.09% of endrometrium cancers and 
1% of large intestinal cancers tested harboured EME1 point mutations. The 
mutations were predominantly missense mutations, substituting one amino acid for 
another in the final EME1 protein. The outcome of these mutations on EME1 
function and patient sensitivity to chemotherapy agents has not been examined. 
Interestingly, overexpression of EME1 is detected in 21.38% (of 1104 samples) of 
breast cancer tissues and a gain in copy number of the EME1 gene was found in 
6.62% (of 997) of breast cancer tissues. This may be an indication that targeting 
EME1 in breast cancer may be beneficial.  
For the MUS81 gene, 77 unique mutations are listed, with again the majority (65%) 
being missense mutations. The frequency of these point mutations is low; with 
1.85% of melanoma tissues tested carrying a MUS81 mutation. Copy number gains 
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have been reported in a small number of melanoma samples. As with EME1, the 
importance of these mutations on MUS81 function and patient sensitivity to cisplatin 
would need to be investigated. Additionally, overexpression of MUS81 has been 
detected in 9.4% of ovarian cancer tissue, and similar levels of overexpression have 
been documented in cervical and breast cancer studies. However, individual studies 
have reported both down- and up-regulation of MUS81 expression in different 
cancer tissues. Therefore, the role for MUS81 in tumour progression may be tissue 
specific (F. Wu et al., 2011; Xie et al., 2016).  
COSMIC identifies 297 somatic mutations in the FANCD2 gene across a broad 
range of cancer types. 55% of these substitutions are missense, again with an 
unknown outcome. 8% of these mutations are however, nonsense mutations, 
resulting in a stop codon instead of an amino acid. This truncates the protein being 
translated and can result in inactive protein product. The substitutions that lead to a 
truncated FANCD2 may predict tumours that are sensitive to cisplatin or other 
crosslinking agents however, this has not been tested yet. Around 3% of FANCD2 
mutations reported in the COSMIC database are small insertion or deletions of 1 or 
2 base pairs. These types of mutation cause a complete frame-shift, and it is likely 
that these patients also do not express functional FANCD2.  
A subset of Fanconi Anaemia patients (3.3%) also carry mutations in the FANCD2 
protein and are subsequently predisposed to developing acute lymphoblastic 
leukaemia. Fanconi Anaemia patients are also characterised by their 
hypersensitivity to crosslinking agents, such as cisplatin (Borriello et al., 2007; 
Mathew, 2006; Smetsers et al., 2012), and are often diagnosed through observation 
of chromosomal breakage after treatment with MMC or diepoxybutane, both ICL-
inducing agents (Oostra et al., 2012). Therefore, clinical evidence that an inactive 
FA pathway increases sensitivity to cisplatin and other crosslinkers is already in 
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abundance, and so pharmacological targeting of FANCD2, with perhaps a STAT3 
inhibitor, may lead to promising drug combinations.  
Hereditary BRCA1 mutations contribute towards the tumourigenesis of breast and 
ovarian cancer through promoting the genetic instability required to gain mutations 
in oncogenes and tumour suppressors.  There are 518 identified mutations in the 
BRCA1 gene identified on the COSMIC database. 59% of these are missense 
mutations, 11% account for insertion or deletion based frame-shifts, and 10% 
nonsense mutations. BRCA1 mutations in patient-derived xenografts have also 
been associated with cisplatin sensitivity (Lohse et al., 2015), and patients carrying 
germ-line BRCA1 mutations have been reported to respond well to cisplatin mono-
therapy (Moiseyenko et al., 2015).  
Tumours carrying BRCA1 mutations are often initially sensitive to cisplatin-based 
chemotherapy due to an impaired ability to remove cisplatin-DNA adducts. BRCA1 
may also be inactivated in sporadic breast and ovarian cancers through promoter 
methylation which inactivates transcription of a gene (Esteller et al., 2000). Acquired 
resistance can, however, occur. It was found that secondary mutations could 
reactivate BRCA1. Therefore, repair of cisplatin DNA adducts via reactivation of the 
BRCA1 gene is correlated with cisplatin resistance (Borst et al., 2008).  
Certainly for BRCA1 and FANCD2, and perhaps for EME1 and MUS81, correlation 
between mutation and cisplatin sensitivity is found. However, BRCA1 expression 
was demonstrated in this chapter to be regulated by cell cycle phase. As STAT3 
inhibition arrests the cell cycle, it was concluded that regulation of BRCA1 
expression by STAT3 is indirect. STAT3 is most likely to directly affect cisplatin 
sensitivity through the transcriptional regulation of EME1 and MUS81, as STAT3 
was demonstrated to bind the promoter regions of these genes. Further 
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investigation into the effect of the mutations reported for EME1 and MUS81 is, 
therefore, necessary.  
5.4.4 Does STAT3 regulate the transcription of genes involved in ICL 
unhooking?  
In this chapter, STAT3 inhibition has been shown to down-regulate the expression 
of MUS81, EME1, BRCA1 and FANCD2 as a potential mechanism for cisplatin 
sensitisation.  
The transcription factor STAT3 has previously been shown to be involved in the 
DNA damage response, transcriptionally regulating MDC1, a regulator of the ATM 
DNA damage response pathway. Additionally cells deficient in STAT3 are less 
effective at repairing damaged DNA (Barry et al., 2010). It is possible that STAT3 
may regulate transcription of other DNA damage response genes such as EME1, 
MUS81 and FANCD2.  
It has been reported that STAT3 binds to the promoter of EME1 and that inhibition 
of upstream kinases Src and EGFR resulted in down-regulation of STAT3 activation 
and EME1 expression (Vigneron et al., 2008). STAT3 does not associate with the 
EME1 promoter after IL-6 exposure but does so only after treatment with a 
Topoisomerase I inhibitor, suggesting that this effect is in response to DNA damage. 
Therefore, it is possible that DNA damage as a result of cisplatin exposure could 
activate the EGFR-Src-STAT3 pathway to up-regulate expression of EME1 in a 
similar manner. Treatment with a STAT3 inhibitor would block this feedback loop, 
inhibiting EME1 levels and subsequently inhibiting repair of cisplatin-DNA adducts. 
In agreement with this hypothesis, activation of EGFR and Src is induced by 
exposure of cells to cisplatin (Benhar et al., 2002). Interestingly, one study found 
that treatment of cells with the EGFR inhibitor, cetuximab, resulted in stimulated 
STAT3 phosphorylation and also EME1 expression. When co-treated with 
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cetuximab and stattic, EME1 levels were no longer enhanced (Weinandy et al., 
2014), further adding to the evidence for regulation of EME1 by STAT3.  
ChIP experiments performed in this chapter investigated whether STAT3 binds to 
the promoter regions of the EME1 and MUS81 genes. Enrichment of STAT3 
occurred at one site upstream of EME1 (the site identified by Vigneron et al.), and 
two sites upstream of MUS81 in unstimulated DU145 cells (although these cells do 
harbour constitutive STAT3 activation, as was shown in chapter 3). After cisplatin 
treatment, no further enrichment of STAT3 binding was seen at the EME1 site 
identified by Vigneron et al., however, cisplatin-dependent enrichment at a binding 
site closer to the EME1 transcription start site was observed, though this was not 
statistically significant. It may be possible that in cells harbouring constitutive STAT3 
activation, treatment with cisplatin does not further stimulate STAT3 binding to its 
target promoters. No reports of regulation of MUS81 by STAT3 exist as of yet, 
however, the results from this ChIP experiment do suggest that STAT3 
transcriptionally regulates both EME1 and MUS81, and that this accounts for the 
down-regulation of EME1 and MUS81 by VS-43 and other STAT3 inhibitors.   
Interestingly, the binding of STAT3 to the cFOS promoter was not inhibited by 
treatment with VS-43. This could suggest that when active STAT3 is low in the 
cancer cell, a re-distribution event occurs, with the remaining active STAT3 
regulating the transcription of the genes the cell needs to continue to survive, such 
as those involved in cell survival, including cFOS. 
A link between STAT3 and BRCA1 has also been investigated. BRCA1 expression 
was found to activate STAT3 via the direct activation of upstream kinases JAK1/2 in 
DU145 cells (Gao et al., 2001). Therefore, a possible positive feedback loop could 
exist between STAT3 and BRCA1, whereby STAT3 regulates the expression of 
BRCA1 which enhances the survival signal by further activating STAT3. Inhibition of 
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STAT3 would disrupt this feedback loop, down-regulating BRCA1 levels. However, 
as has been shown in this chapter, BRCA1 expression is cell cycle dependent, so 
STAT3-mediated regulation may be indirect via the arrest of cells in G1 phase.  
Regulation of FANCD2 expression by STAT3 has not yet been investigated. The 
only evidence connecting these two proteins currently is the finding that the natural 
STAT3 SH2 domain inhibitor Curcumin down-regulates FANCD2 
monoubiquitination, sensitising cells to cisplatin (Chirnomas et al., 2006). As 
FANCD2 mRNA and protein levels appear to be down-regulated to a lesser extent 
than BRCA1 by VS-43 inhibition of STAT3, it is possible that this is a result of loss of 
interaction with BRCA1. FANCD2 is known to require BRCA1 to associate to ICL 
sites (Bruun et al., 2003) therefore, down-regulation of BRCA1 by cell cycle arrest 
through STAT3 inhibition may destabilise FANCD2. However, whether STAT3 acts 
to directly or indirectly regulate the expression of FANCD2 is yet to be confirmed. 
A link between the ERCC1 component of the XPF-ERCC1 nuclease and STAT3 has 
also been made, with one study reporting that treatment of cells with the src inhibitor 
dasatinib, inhibits the STAT3 pathway and also expression of ERCC1 in order to 
enhance cisplatin sensitivity (J. Chen et al., 2015).  However, src acts upstream of 
STAT3 and also regulates the activation of other signalling pathways such as the 
Raf/MEK/MAPK pathway. As no down-regulation of ERCC1 was seen by treatment 
of cells with STAT3 inhibitors in this chapter, src may regulate ERCC1 through 
another pathway. No connection between any other FANC proteins or the SLX4 
scaffolding protein and STAT3 has been reported.  
Therefore, currently the strongest evidence exists for the transcriptional regulation of 
EME1 by STAT3. This combined with the evidence presented here connecting 
STAT3 to both EME1 and MUS81 expression, could suggest a mechanism whereby 
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STAT3 regulates the transcription of the MUS81-EME1 nuclease, allowing for 
STAT3 status to determine the cancer cells ability to repair cisplatin-ICLs. 
5.5 Conclusion 
In conclusion, this chapter has investigated the mechanism of sensitisation to 
cisplatin by STAT3 inhibitors. It has been shown that STAT3 inhibitors block the 
unhooking of cisplatin-ICLs, and alter the DNA damage response in both the DU145 
and A549 cancer cell lines.  
Investigation of the mRNA and protein levels of key DNA repair factors after 
treatment of cells with VS-43 and other STAT3 inhibitors has led to the hypothesis 
that STAT3 inhibitors block ICL unhooking via the down-regulation of EME1, MUS81 
BRCA1 and FANCD2. Transcriptional regulation by STAT3 seems most likely for 
EME1 and MUS81, as STAT3 was demonstrated to bind to genomic locations 
upstream of the transcription start sites for these genes.  
In the following chapter, the involvement of STAT3 in the repair of melphalan-
induced ICLs will be investigated to gain an understanding of the range of 
combinations which STAT3 inhibitors like VS-43 may be useful for in the clinic.   
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Chapter 6 Cisplatin and Melphalan DNA-ICLs repair via 
different unhooking mechanisms 
6.1 Introduction 
The results presented in this thesis so far suggest that STAT3 inhibitors are able to 
sensitise cancer cell lines to cisplatin, with the hypothesis that this is due to the 
involvement of STAT3 in ICL repair. The novel STAT3 inhibitor, VS-43, was also 
shown to synergise with doxorubicin. Therefore, STAT3 inhibitors may be able to 
synergise with other chemotherapy agents. As STAT3 inhibitors have been shown 
to block cisplatin-ICL repair, whether these inhibitors have similar effects on other 
ICL-inducing agents is of interest. This will be investigated for melphalan in this 
chapter.  
6.1.1 Rationale for investigating melphalan: chemosensitisation studies and 
ICL repair 
Melphalan belongs to the nitrogen mustard class of chemotherapy agents which 
originated from an observation that mustard gas used in the first world war acted 
through targeting the haematopoietic system, making it useful for the treatment of 
haematological cancers (Krumbhaar and Krumbhaar, 1919; Lawley and Phillips, 
1996). Melphalan is a bifunctional alkylating agent, known react with both guanine 
and adenine bases to form monoadducts and ICLs (Povirk and Shuker, 1994). 
Melphalan does not, however, form intrastrand crosslinks as cisplatin does (Bauer 
and Povirk, 1997). According to early studies, approximately 30-40% of melphalan 
adducts are ICLs (Hansson et al., 1987). 
Whilst not reported as frequently as for cisplatin, some studies have described 
sensitisation of cancer cells to melphalan by inhibition of STAT3 (Bharti et al., 
2003b; Li et al., 2010; Scuto et al., 2011), However, the studies performed by Bharti 
et al. and Li et al. do not perform combination index analysis to quantify the drug 
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interactions as synergistic, additive or antagonistic, and whilst Scuto et al. do 
demonstrate synergy with melphalan, they use a JAK2 inhibitor. As JAK2 has other 
downstream signalling pathways in addition to STAT3, such as the MAPK pathway, 
the inhibition of STAT3 may not be responsible for the synergy observed. Therefore, 
whether STAT3 inhibitors would prove beneficial in combination with melphalan 
remains to be confirmed. This will be investigated in this chapter.  
A second issue this chapter will aim to address is related to the mechanism of ICL 
repair. Previous research carried out in this group has suggested that melphalan-
ICL repair does not occur via the same mechanism as cisplatin-ICL repair. First, 
Friedmann et al. demonstrated that whilst the EGFR inhibitor, gefitinib, exhibited 
synergy in combination with cisplatin, when combined with melphalan, no synergy 
was observed. Using the modified comet assay, the formation and repair of ICLs 
after treatment of cells with cisplatin or melphalan in combination with gefitinib was 
followed. Gefitinib delayed the repair of cisplatin-ICLs but had no effect on the repair 
of melphalan-ICLs (Friedmann et al., 2004). As EGFR is one of the upstream 
activators of STAT3, it is possible that STAT3 may be selectively involved in 
cisplatin-ICL repair.  
Further evidence gathered by this group demonstrated a clear difference between 
the mechanism of unhooking for cisplatin and melphalan-induced ICLs. Using the 
modified comet assay, Spanswick et al. demonstrated that plasma cells from 
myeloma patients clinically resistant to melphalan could repair melphalan-ICLs but 
not cisplatin-ICLs. Additionally, cells from ovarian cancer patients pre-platinum 
therapy could not repair either cisplatin or melphalan ICLs, but post-platinum 
therapy they were able to repair cisplatin ICLs exclusively. Experiments with the 
RPMI8226 myeloma cell line were also carried out. These cells behaved similarly to 
the melphalan-resistant patient cells – comet assays showed successful unhooking 
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of melphalan-ICLs but persistence of cisplatin ICLs in this cell line. In this study, 
combination with gemcitabine was also shown to inhibit cisplatin-ICL unhooking but 
not melphalan-ICL unhooking (Spanswick et al., 2012).  
This research group has found two different drug combinations that specifically 
target cisplatin-ICL repair without affecting the progression of melphalan-ICL repair. 
Therefore, ICLs induced by different agents, particularly cisplatin and melphalan, 
may require different repair pathways.  
6.1.2 Structural differences between ICL agents  
If different mechanisms of repair do exist, the structure of the ICL may determine 
which repair pathway is taken. The structures of cisplatin and melphalan are very 
different (Figure 6-1). Melphalan is a more complex molecule than cisplatin, and so 
even though both link two guanine bases through the displacement of their chloride 
ions, the impact on the structure of DNA is likely to be different. In fact, the 
structures of different ICL-forming agents are quite varied. Figure 6-2 illustrates the 
diversity of crosslinkers and the ICLs they form.  
 
Figure 6-1: Structures of cisplatin and melphalan.  
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Figure 6-2: The different structures of DNA ICLs induced by various 
crosslinking agents. A) mechlorethamine, B) MMC, C) cisplatin, D) psoralen, E) 
nitrosourea, F) diepoxybutane, G) aldehydes and H) nitric oxide. Taken from 
(Lopez-Martinez et al., 2016). 
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When an agent binds to the DNA and forms an ICL, the DNA is distorted from its B-
DNA form. The degree of distortion and bending achieved will vary depending on 
the crosslinker. Some crosslinks are considered to be largely distorting whereas 
others barely distort the DNA at all. The crystal structure of DNA containing a 
cisplatin ICL was solved in 1999. This structure shows that cisplatin binds in the 
major groove and bends the DNA double helix by 47° towards the minor groove and 
unwinds the helix by 70° at the lesion and by 110° five base pairs away from the 
lesion. The now unpaired cytosine residues complementary to the crosslinked 
guanines are extruded from the DNA helix. Nine water molecules surround the 
platinum atom, and another seven water molecules make contacts with the ICL 
adduct. These water molecules link the platinum adduct to the surrounding 
phosphate backbone as well as the crosslinked guanines in order to maintain the 
distorted structure (Coste et al., 1999). The structure of the cisplatin DNA-ICL and 
the resulting distortion can be seen in Figure 6-3.  
The structure of DNA containing a melphalan-ICL has not yet been solved. 
However, some indication of the physical effect on the DNA structure may be gained 
from studies using another nitrogen mustard, mechlorethamine (shown in Figure 
6-2A). Computer modelling of DNA containing a mechlorethamine-ICL showed that 
mechlorethamine binds in the major groove, a 12.4-16.8° bend is induced and an 
over-winding of 2-6° occurs (Rink and Hopkins, 1995). This is a much smaller 
distortion than that induced by a cisplatin-ICL. However, the effect of melphalan’s 
much bulkier alkyl group on the degree of distortion compared with the single methyl 
group on mechlorethamine is not known. Other crosslinking agents include MMC 
which binds the minor groove of the DNA and which induces no detectable distortion 
of the DNA helix (Rink et al., 1996), and psoralens which have been shown to  
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induce distortion of the base stacking at the crosslink site, but this does not result in 
an overall bending of the DNA (Hwang et al., 1996; Sinden and Hagerman, 1984).  
The extent of DNA distortion has been linked to the level of lesion repair. ICLs that 
produce a greater distortion are unhooked more frequently than DNA containing 
minimally distorting ICLs (Smeaton et al., 2008). The importance of helix distortion 
on the removal of ICLs has also been highlighted for the novel crosslinker, SJG-136, 
which binds to the DNA minor groove and exhibits high cytotoxicity and slow ICL 
repair (Clingen et al., 2005). SJG-136-induced ICLs are reported to induce relatively 
little distortion to the DNA helix (Jenkins et al., 1994) therefore, this could effectively 
mask the lesion from recognition by repair proteins, resulting in the slow unhooking 
of these ICLs.  
 
Figure 6-3: Stick representation of the crystal structure of a single cisplatin 
ICL from the A) minor groove and B) 90 degrees rotated to show the bend 
induced. Taken from (Malinge et al., 1999). 
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The trans-isomer of cisplatin, transplatin, is reported to have reduced anti-tumour 
activity and increased repair of adducts (Heiger-Bernays et al., 1990). Transplatin 
crosslinks guanine with the complementary cytosine and the distortion produced by 
the resulting ICL is lower than that of cisplatin – a bend of 24° and 12° unwinding 
(Brabec et al., 1993). Therefore, the degree of distortion does not always positively 
correlate with adduct repair or toxicity. The relationship between the structure of 
ICLs and their biological effects appears to be more complex.  
As well as distortion differences, as is shown in Figure 6-2, ICL agents also differ in 
their base specificity. Cisplatin and melphalan both crosslink guanine residues by 
reacting with the N7 position, however, the sequence specificity also differs: 
cisplatin forms ICLs at 5’-GpC-3’ sites whereas nitrogen mustards form ICLs at 
5’GpNpC-3’ sites (Muniandy et al., 2010). The larger distance between guanines in 
the nitrogen mustard crosslink is possibly due to the larger distance between the 
substituted chloride ions. MMC also forms ICLs between guanine residues, though 
these ICLs crosslink the N2 atoms at 5’-CpG-3’ sites (Rink et al., 1996). In contrast, 
psoralens crosslink the thymine residues at 5’-TpA’3’ sites (Hwang et al., 1996).  
Therefore, the diverse structures of ICL-inducing agents and the distortions they 
produce in DNA, combined with the varied sequence and base specificities, results 
in a wide range of ICLs which must all be recognised and repaired by cellular 
machinery. Given the structural differences between these lesions, it is possible that 
different machinery is responsible for the repair of different ICLs.  
In this chapter the differences between cisplatin and melphalan ICL repair will be 
investigated, with an emphasis on the unhooking of these lesions.  
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6.2 Aims 
The aims of this chapter were as follows: 
1. To investigate whether STAT3 inhibitors sensitise cancer cell lines to 
melphalan, and whether this combination is synergistic.  
2. To determine whether STAT3 inhibitors block melphalan-ICL unhooking. 
3. To investigate the role of STAT3, EME1 and MUS81 in cisplatin and 
melphalan ICL unhooking. 
6.3 Results 
6.3.1 Melphalan inhibits cancer cell line growth 
In order to establish whether STAT3 inhibitors can sensitise cells to melphalan, the 
cell growth inhibition produced by melphalan alone was first determined in order to 
decide the ratio with which to carry out the combination assays. 
The effect of 1 hour of melphalan treatment on the DU145 and RPMI8226 cell lines 
was determined by SRB assay. The DU145 cell line was chosen to allow for a direct 
comparison to the cisplatin combinations in Chapter 4, and the RPMI8226 myeloma 
cell line was chosen as melphalan is widely used to treat myeloma and therefore, 
this is more clinically relevant.   
Figure 6-4 shows that in both cell lines melphalan inhibits cell growth. The GI50 for 
melphalan in DU145 cells was 110.3µM. RPMI8226 cells were considerably more 
sensitive to melphalan, with a GI50 of 43.75µM. These GI50 values were taken into 
consideration when deciding the ratios for the combination assays. 
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Figure 6-4: Cell growth inhibition by 1 hour melphalan treatment in DU145 and 
RPMI8226 cells. Determined by SRB and MTT assay for DU145 and RPMI8226 
cells, respectively. Data plotted is the average of at least three individual 
experiments with SEM calculated for error bars. 
6.3.2 STAT3 inhibitors do not chemosensitise cancer cell lines to melphalan 
The combination of STAT3 inhibitors with melphalan was first trialled in the DU145 
cell line using the novel STAT3 inhibitor, VS-43. Due to the approximate GI50 values 
of VS-43 and melphalan alone in this cell line, a ratio of 1:100 was used for VS-
43:melphalan, with an 18 hour pre-treatment of VS-43 followed by 1 hour treatment 
with melphalan. As with all other cell growth inhibition assays, the cells were then 
incubated for 96 hours before SRB staining.  
Figure 6-5A shows that combination of VS-43 with melphalan in the DU145 cell line 
reduces the melphalan GI50 by 19.8% from 91.7µM to 73.5µM. Non-linear 
regression analysis determined that these GI50 values are significantly different with 
a P value of P<0.0001.  CI value analysis was performed where the differences in 
cell growth inhibition were statistically significant. Figure 6-5B shows that the CI 
values obtained were predominantly in the additive range (0.9-1.1). One value was 
however, in the slight synergy range – a CI of 0.852 was obtained at 160µM 
melphalan. An antagonistic CI value of 1.329 was obtained at 300µM melphalan.  
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Figure 6-5: Combination of VS-43 and melphalan in DU145 cells. A) VS-43 plus 
melphalan combination treatment slightly increases cell growth inhibition. Data 
plotted was obtained by SRB assay and is the average of at least three individual 
experiments with SEM calculated for error bars. Students t-test was carried out to 
determine statistical significance with * = P<0.05, ** = P<0.01. B) Combination 
indices are predominantly in the additive region close to 1 and C) isobologram plot 
quantifying drug interactions at the 50%, 75% and 90% effect levels. Additivity and 
slight antagonism is observed between VS-43 and melphalan in DU145 cells. 
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The isobologram plot, which graphically represents drug interactions at different 
effect levels, shows that the interaction between VS-43 and melphalan in this 
particular combination is mildly antagonistic at the 50% and 75% effect levels and 
additive at the 90% effect level. Therefore, unlike with cisplatin, synergy between 
VS-43 and melphalan is not observed using the fixed ratio combination in the 
DU145 cell line.  
Next, the combination of VS-43 and melphalan was assessed in the more clinically 
relevant RPMI8226 cell line. In order to carry out this combination, assessment of 
the effect of VS-43 treatment alone was required. As RPMI8226 cells are a 
suspension cell line, the MTT assay was used instead of the SRB assay as a 
measure of cell growth inhibition.  RPMI8226 cells were treated for 18 hours with 
VS-43, and subsequently incubated for 96 hours before MTT was added.  
Figure 6-6 shows that VS-43 inhibits the growth of RPMI8226 cells with a GI50 of 
2µM. These cells are less sensitive to VS-43 and more sensitive to melphalan than 
DU145 cells, therefore, a ratio of 1:100 was not appropriate. Instead, a ratio of 1:20 
was chosen as this better represented the relative sensitivity of RPMI8226 cells 
towards VS-43 and melphalan.  
Pre-treating RPMI8226 cells with VS-43 reduces the melphalan GI50 from 51.0µM to 
26.7µM – a 47.8% decrease (Figure 6-7A). Non-linear regression analysis 
determined that these GI50 values are significantly different with a P value of 
P<0.0001. However, only the last three pairs of data points demonstrate a 
statistically significant difference. CI value analysis was performed for those 
combinations, with the results shown in Figure 6-7B. The lowest CI value obtained 
was 0.908 at 60µM melphalan, and the highest was 1.465 at 100µM melphalan. 
These values span the additive to antagonistic range. This is confirmed by the 
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isobologram plot shown in Figure 6-7C, as at all three effect levels the combination 
data points are to the right and above each line – indicative of antagonism.  
 
Figure 6-6: VS-43 inhibits growth of the RPMI8226 myeloma cell line. Data 
plotted was obtained by MTT assay and is the average of at least three individual 
experiments with SEM calculated for error bars. 
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Figure 6-7: Combination of VS-43 and melphalan in RPMI9228 cells. A) VS-43 
plus melphalan combination treatment slightly increases cell growth inhibition. Data 
plotted was obtained by MTT assay and is the average of at least three individual 
experiments with SEM calculated for error bars. Students t-test was carried out to 
determine statistical significance with * = P<0.05, ** = P<0.01 and *** = P<0.001. B) 
Combination indices are predominantly in the additive region close to 1 and C) 
isobologram plot quantifying drug interactions at the 50%, 75% and 90% effect 
levels. Slight antagonism is observed between VS-43 and melphalan in RPMI8226 
cells at all effect levels. 
 
 
0 50 100 150
0
1.0
2.0
3.0
4.0
5.0
Melpha lan
Is obolog ram
V
S
-4
3
E D50 E D75 E D90
0 10 20 30 40 60 100
0
50
100
%
 C
on
tr
ol
 A
bs
or
ba
nc
e
Effect of VS-43 18 hour Pre-treatment on 
Melphalan Sensitivity of RPMI8226 cells
Melphalan 
VS-43 + Melphalan
Fixed Ratio
combination
Dose Melphalan (µM)
Dose VS-43 (µM)  0            0.5            1            1.5            2              3             5
*
***
**
B
C
V
S
-4
3 
Melphalan 
A
Combination Indeces For Fixed Ratio Combination 
of VS-43 and Melphalan in RPMI8226 Cells
0 50 100
0.5
1.0
1.5
2.0
2.5
Dose of Melphalan (µM)
C
I V
al
ue
  307 
The combination of VS-43 with melphalan was also assessed using the non-fixed 
ratio method, as this gave slightly greater synergy for combination of VS-43 with 
cisplatin in chapter 4. DU145 cells were pre-treated with 5µM VS-43 for 1 hour, 
followed by a 1 hour melphalan treatment at a range of doses. The results of this 
experiment are shown in Figure 6-8. The GI50 for melphalan is decreased from 
109µM to 84.9µM with a VS-43 pre-treatment. This is a 22.1% change. Non-linear 
regression analysis determined that these GI50 values are significantly different with 
a P value of P<0.0001. However, the difference between the pairs of melphalan 
treated and combination treated cell growth inhibition was not statistically significant. 
Therefore, no CI analysis was performed, as this combination provided no 
significant benefit to cell growth inhibition.  
To determine whether other STAT3 inhibitors had the potential to synergise with 
melphalan, DU145 cells were also pre-treated with stattic and curcumin in 
combination with melphalan. 
The ratio of stattic:melphalan used was 1:10 and the ratio of curcumin:melphalan 
used was 1:2.5. These ratios were based on the approximate GI50 values for each 
drug alone in the DU145 cell line.  
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Figure 6-8: Non-fixed ratio combination of VS-43 and melphalan in DU145 
cells. VS-43 plus melphalan combination treatment does not significantly affect cell 
growth inhibition. Data plotted was obtained by SRB assay and is the average of at 
least three individual experiments with SEM calculated for error bars. No statistical 
significance was observed. Absorbance was normalised to 5µM VS-43 alone 
Figure 6-9A shows the cell growth inhibition for the combination of stattic and 
melphalan. The GI50 for melphalan decreases from 107.9µM to 49.2µM. This is the 
largest shift in GI50 seen yet with melphalan: a 54% reduction, however, the non-
linear regression analysis was not able to establish a P value for this difference due 
to ambiguous fitting of the curves. The CI value analysis shown in Figure 6-9B 
shows that irrespective of the GI50 shift, the interaction of stattic and melphalan is 
predominantly not synergistic. The only mildly synergistic CI value obtained is 0.866 
at 120µM melphalan. The remainder of the CI values are in the additive and 
antagonistic range. The interaction between stattic and cisplatin is further confirmed 
with the isobologram indicated in Figure 6-9C. At the 50% and 75% effect levels, the 
interaction is additive, whereas at the 90% effect level stattic exhibits slight 
antagonism in combination with melphalan.  
Figure 6-10A shows the effect on cell growth inhibition by combination of curcumin 
with melphalan. Curcumin pre-treatment lowers the melphalan GI50 by 31.2% from 
89.7µM to 61.7µM. Non-linear regression analysis determined that these GI50 values 
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are significantly different with a P value of P<0.0001. When CI value analysis was 
performed no synergistic CI values were obtained. The lowest CI value was 0.961 
and the largest was 1.194, indicating additivity and slight antagonism between 
curcumin and melphalan (Figure 6-10B). Figure 6-10C shows the isobologram 
analysis of this combination, which indicates antagonism at the 50%, 75% and 90% 
effect levels.  
Therefore, the combination of STAT3 inhibitors with melphalan does not result in 
synergy. An additive and sometimes antagonistic relationship is found between 
STAT3 inhibitors and melphalan in both the DU145 and RPMI8226 cell lines.  
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Figure 6-9: Combination of stattic and melphalan in DU145 cells. A) stattic plus 
melphalan combination treatment increases cell growth inhibition. Data plotted was 
obtained by SRB assay and is the average of at least three individual experiments 
with SEM calculated for error bars. Students t-test was carried out to determine 
statistical significance with * = P<0.05, ** = P<0.01 and *** = P<0.001. B) 
Combination indices are predominantly in the additive region close to 1 and C) 
isobologram plot quantifying drug interactions at the 50%, 75% and 90% effect 
levels. Additivity and slight antagonism is observed between stattic and melphalan 
in DU145 cells. 
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Figure 6-10: Combination of curcumin and melphalan in DU145 cells. A) 
curcumin plus melphalan combination treatment increases cell growth inhibition. 
Data plotted was obtained by SRB assay and is the average of at least three 
individual experiments with SEM calculated for error bars. Students t-test was 
carried out to determine statistical significance with * = P<0.05. B) Combination 
indices are predominantly in the additive region close to 1 and C) isobologram plot 
quantifying drug interactions at the 50%, 75% and 90% effect levels. Slight 
antagonism is observed between curcumin and melphalan in DU145 cells at all 
effect levels. 
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6.3.3 Combination with STAT3 inhibitors does not enhance apoptosis or 
DNA damage in melphalan-treated cells 
In order to determine whether combination of STAT3 inhibitors with melphalan 
enhances apoptosis induction, immunoblotting was performed 24 hours after drug 
treatment. At the same time, immunoblotting for γH2AX was performed to determine 
whether STAT3 inhibitors enhance melphalan-induced DNA damage as they do for 
cisplatin (chapter 5).  
Figure 6-11A shows that treatment of DU145 cells with VS-43 induces both cleaved 
PARP and cleaved caspase-3 expression. Melphalan treatment induced cleaved 
PARP expression but minimal cleaved caspase-3 expression. Melphalan also 
resulted in γH2AX expression. Combination treatment with VS-43 followed by 
cisplatin did not exhibit higher levels of cleaved PARP, cleaved caspase-3 or γH2AX 
expression. Therefore, VS-43 does not enhance apoptosis or DNA damage induced 
by melphalan. 
Figure 6-11B shows similar immunoblotting for DU145 cells treated with stattic and 
curcumin in combination with melphalan. The combination of stattic and melphalan 
does not increase γH2AX expression but does result in a slight increase in cleaved 
PARP, however, this looks to be no more than additive. Combination of curcumin 
with melphalan also increases cleaved PARP as well as γH2AX expression to some 
extent. However, if compared with the effect of curcumin in combination with 
cisplatin on these factors (Chapter 4, Figure 4-12), this effect is much lower.  
These results suggest that VS-43 and stattic do not enhance melphalan-induced 
apoptosis or DNA damage, and that curcumin does have some effect on melphalan-
induced apoptosis although this is much lower than the enhancement seen in 
combination with cisplatin. This is consistent with the lack of synergy observed 
between STAT3 inhibitors and melphalan.  
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Figure 6-11: Combination treatment with STAT3 inhibitors and melphalan 
does not enhance apoptosis of DNA damage in the DU145 cell line. A) VS-43 in 
combination with melphalan does not enhance expression of cleaved PARP, 
cleaved caspase-3 or γH2AX. B) combination of stattic with melphalan also does not 
enhance cleaved PARP or γH2AX expression. Curcumin slightly increases cleaved 
PARP and γH2AX expression in combination with melphalan. Blots are 
representative of more than 1 experiment. 
 
6.3.4 STAT3 inhibition has no effect on melphalan DNA-ICL repair 
In the previous chapter STAT3 inhibitors were demonstrated to enhance cisplatin-
induced DNA damage, and block cisplatin-ICL unhooking. So far, the combination of 
STAT3 inhibitors with melphalan has not resulted in enhanced DNA damage. 
Therefore, the effect of STAT3 inhibition on melphalan-ICL repair was investigated. 
First, DU145 cells were treated with VS-43 for 18 hours followed by melphalan for 1 
Cleaved PARP 
γH2AX 
β-Actin 
Cleaved Caspase-3 
1 µM VS-43    
100 µM Melphalan 
−       +      −      + 
−       −      +      + 
γH2AX 
 
β-Actin 
10 µM Stattic 
40 µM Curcumin    
100 µM Melphalan −     +    −    +     −    +     
−     −    −    −     +    +             
−     −    +    +     −    − 
Cleaved PARP 
A
B
50 kDa 
20 kDa 
15 kDa 
100 kDa 
50 kDa 
15 kDa 
100 kDa 
  314 
hour and then cells were harvested at 0, 9, 24 and 48 hours post melphalan-
treatment for analysis by comet assay. 
Figure 6-12 shows representative images of cells 48 hours after melphalan 
treatment, acquired through the Komet 6.0 software. 48 hours after melphalan 
treatment there appears to be no difference between cells treated with melphalan 
alone or cells that have been pre-treated with VS-43: both have similar comet tails, 
close in size to the comet tails of the untreated irradiated group. This suggests that 
any crosslinking induced by melphalan treatment has been repaired by 48 hours in 
both groups.  
This is in stark contrast to the representative images shown for the combination of 
VS-43 with cisplatin in Figure 5-5, where a clear difference in comet tails was 
observed. 
 
Figure 6-12: Representative comet images for the combination of VS-43 and 
melphalan. 48 hours after melphalan treatment, cells treated with either melphalan 
alone or VS-43 in combination with melphalan do not display any difference in 
extent of crosslinking – both groups have repaired melphalan-induced ICLs. 
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The representative images represent the overall outcome of the assay, however, 
this is a snapshot in time. The results from the full time-course comet assay are 
shown in Figure 6-13A. There is no difference between the formation and repair of 
melphalan-ICLs in the two treatment groups. Both groups reach the peak of ICL 
formation at 16 hours post-melphalan treatment (the 16 hour time-point for peak of 
melphalan-induced ICL formation has been previously demonstrated in this group 
(Spanswick et al., 2012)), and by 24 hours both groups have begun to repair the 
ICLs. At 48 hours post-treatment the melphalan-alone treated cells have reached 
16.8% decrease in tail moment, and the combination treated cells are at 16.2% 
decrease in tail moment. This is almost identical. As such, the differences between 
the two treatment groups were not statistically significant at any time point.  
The non-fixed ratio combination of VS-43 and melphalan was also tested for its 
effect on melphalan-ICL unhooking. Figure 6-13B shows that as with the fixed ratio 
combination, pre-treatment with 5µM VS-43 has no significant effect on the 
formation or repair of melphalan-induced ICLs.  
To determine whether the observed effects were specific for the novel STAT3 
inhibitor, VS-43, or apply to all STAT3 inhibitors, comet assays were also performed 
for cells treated with stattic and curcumin in combination with melphalan. As with 
VS-43, pre-treatment of DU145 cells with stattic (Figure 6-14A) or curcumin (Figure 
6-14B) has no effect on the formation or repair of melphalan-induced ICLs. Again, 
16 hours after drug treatment, the peak of ICL formation is observed in all treatment 
groups. By 24 hours post melphalan treatment, approximately 50% repair has 
occurred, and by 48 hours post melphalan treatment further repair is evident. 
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Figure 6-13: VS-43 has no effect on melphalan-ICL unhooking in the DU145 
cell line. A) Fixed ratio and B) non-fixed ratio combination of VS-43 with melphalan. 
Cells pre-treated with VS-43 are able to repair melphalan-ICLs as well as cells 
treated with melphalan alone. Results are an average of three independent repeats, 
with SEM calculated for the error bars. No statistical significance was observed.  
The combination of stattic and melphalan, however, results in a plateau in the 
percentage decrease in tail moment. At 24 hours post-treatment 29.6% decrease in 
tail moment is observed whereas at 48 hours post-treatment this has only reached 
25.7%. In contrast, melphalan alone treated cells exhibit a decrease in tail moment 
of 41.0% at 24 hours and 12.9% at 48 hours. This could suggest potential slowing of 
melphalan-ICL repair by stattic, however, this is not statistically significant when 
compared with the melphalan-alone treated cells.  
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Figure 6-14: Stattic and curcumin have no effect on melphalan-ICL unhooking 
in the DU145 cell line. Cells pre-treated with A) stattic or B) curcumin are able to 
repair melphalan-ICLs as well as cells treated with melphalan alone. Results are an 
average of three independent repeats, with SEM calculated for the error bars. No 
statistical significance was observed. 
As melphalan is not clinically used in prostate cancer, the DU145 cell line is not the 
most relevant model. Therefore, the effect of VS-43 on melphalan-ICL repair was 
also assessed in the RPMI8226 myeloma cell line. Figure 6-15 illustrates again that 
the combination of VS-43 with melphalan has no significant effect on the formation 
or repair of melphalan-ICLs. The tail moments are almost identical between 
melphalan-alone treated cells and cells that have been pre-treated with VS-43. 
Therefore, STAT3 inhibitors do not block the unhooking of melphalan-induced ICLs, 
in contrast to their role in cisplatin-ICL repair.  
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Figure 6-15: VS-43 has no effect on melphalan-ICL unhooking in the RPMI8226 
cell line. Cells pre-treated with VS-43 are able to repair melphalan-ICLs as well as 
cells treated with melphalan alone. Results are an average of three independent 
repeats, with SEM calculated for the error bars. No statistical significance was 
observed. 
 
6.3.5 STAT3 knockdown by siRNA blocks cisplatin but not melphalan DNA-
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been assessed through the use of pharmacological STAT3 inhibition. As 
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comet assay. 
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were then harvested at the peak of crosslinking (9 hours for cisplatin and 16 hours 
for melphalan), and 24 hours after the peak of crosslinking (33 hours for cisplatin 
and 40 hours for melphalan). This was to determine whether STAT3 siRNA affected 
either the level of interstrand crosslinking or the overall repair of those crosslinks.  
Figure 6-16B shows clearly that partial knockdown of STAT3 by siRNA had no effect 
on the level of cisplatin or melphalan ICLs at the peak of crosslinking. The 
percentage decrease in tail moment ranges from 55.0% to 59.3% across the six 
conditions, and none of these differences are statistically significant, as determined 
by one-way ANOVA. 24 hours after the ICL peak, however, cells treated with 
melphalan alone, and with luciferase or STAT3 siRNA in combination with 
melphalan show ICL repair down to 20.9%, 22.7% and 21.9%, respectively. For 
cisplatin-treated cells there is a significant difference between the cells treated with 
cisplatin alone and luciferase siRNA transfected cells, and the STAT3 siRNA 
transfected cells. Cells treated with cisplatin alone exhibit a 14.7% decrease in tail 
moment and luciferase siRNA transfected cells exhibit a -1.03% decrease in tail 
moment. This difference is, however, not statistically significant. Cells transfected 
with STAT3 siRNA have a 48.4% decrease in tail moment 33 hours after cisplatin 
treatment. These differences can be seen in the representative comet images in 
Figure 6-17. At the 9 hours and 16 hours post cisplatin and melphalan treatment, 
respectively, short tails are observed in all of the cells treated with the crosslinkers, 
irrespective of siRNA treatment. The images highlighted in red indicate the visible 
difference between the cells treated with STAT3 siRNA and cisplatin, versus STAT3 
siRNA and melphalan, at 24 hours post ICL peak. The cisplatin-treated cells have 
very short tails, similar to those seen at the ICL peak, whereas the melphalan-
treated cells have larger tails, suggesting crosslink unhooking. 
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This suggests that STAT3 siRNA blocks the repair of cisplatin, but not melphalan-
ICLs.  
 
Figure 6-16: STAT3 siRNA inhibits cisplatin but not melphalan ICL repair. A) 
partial STAT3 knockdown was achieved with STAT3 siRNA in the DU145 cell line, 
as determined by immunoblotting. B) percentage decrease in tail moment at the 
peak of crosslinking (9 hours for cisplatin and 16 hours for melphalan). C) 
percentage decrease in tail moment 24 hours after the peak of crosslinking. The 
repair of cisplatin ICLs is inhibited by STAT3 siRNA. Melphalan ICLs repair 
irrespective of siRNA used. Luciferase (Luc) siRNA was used as a control. Results 
are the mean of three independent experiments with SEM displayed for error bars. 
One-way ANOVA was used to measure statistical significance. ** = P<0.01 and *** 
= P<0.001. 
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6.3.6 Knockdown of EME1 or MUS81 specifically abolishes cisplatin-ICL 
repair 
In Chapter 5, STAT3 inhibitors were identified to down-regulate expression of EME1 
and MUS81, the two components of one of the ICL unhooking nuclease complexes. 
It was hypothesised that the regulation of these DNA repair factors by STAT3 could 
be responsible for the involvement of STAT3 in cisplatin-ICL unhooking. In order to 
investigate this, siRNA knockdown of EME1 and MUS81 was carried out before 
treatment of DU145 cells with cisplatin and melphalan. The extent of ICL repair was 
quantified by comet assay. 
Figure 6-18A demonstrates that a partial EME1 knockdown was achieved in DU145 
cells using the EME1 siRNA. As with the STAT3 siRNA comets, the effect of EME1 
knockdown on ICL formation was assessed by measuring the tail moment of cells at 
the ICL peak. All three groups of cells treated with cisplatin reached between 68.7% 
and 62.1% decrease in tail moment at the ICL peak, whereas the cells treated with 
melphalan reached between 53.6% and 51.7% decrease in tail moment (Figure 
6-18B). The differences between these groups were not statistically significant, 
indicating that EME1 knockdown has no effect on the formation of cisplatin or 
melphalan ICLs. At 24 hours post ICL peak, the cisplatin treated cells exhibit 11.1%, 
15.7% and 51.9% decrease in tail moment for the cisplatin alone, luciferase siRNA 
and EME1 siRNA groups. The difference between the EME1 siRNA group was 
statistically significant when compared with either the cisplatin alone or luciferase 
siRNA cells. This indicates that EME1 siRNA blocks cisplatin-ICL unhooking, 
similarly to STAT3 siRNA. The cells treated with melphalan, however, all repaired 
the melphalan-ICLs to a similar extent: between 6.76% and 16.4% decrease in tail 
moment was observed, suggesting that melphalan-ICLs are unhooked irrespective 
of the siRNA treatment. Representative images for this experiment are shown in 
Figure 6-19. The difference between the role for EME1 in cisplatin-ICL and 
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melphalan-ICL repair is highlighted in the images outlined in red. After EME1 
knockdown, cells treated with cisplatin retain the short comet tails associated with a 
high level of crosslinking; whereas melphalan treated cells have large comet tails, 
similar to those seen in cells treated with melphalan alone.  
These results are indicative of a role for EME1 in cisplatin-ICL unhooking. 
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Figure 6-18: EME1 siRNA inhibits cisplatin but not melphalan ICL repair. A) 
partial EME1 knockdown was achieved with EME1 siRNA in the DU145 cell line, as 
determined by immunoblotting. B) percentage decrease in tail moment at the peak 
of crosslinking (9 hours for cisplatin and 16 hours for melphalan). C) percentage 
decrease in tail moment 24 hours after the peak of crosslinking. The repair of 
cisplatin ICLs is inhibited by EME1 siRNA. Melphalan ICLs repair irrespective of 
siRNA used. Luciferase (Luc) siRNA was used as a control. Results are the mean of 
three independent experiments with SEM displayed for error bars. One-way ANOVA 
was used to measure statistical significance. * = P<0.05 and ** = P<0.01. 
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Identical experiments were performed in DU145 cells transfected with MUS81 
siRNA. A partial MUS81 knockdown was achieved as is shown in Figure 6-20A, with 
the luciferase siRNA acting as a negative control. As with both STAT3 and EME1, 
knockdown of MUS81 has no significant effect on the formation of cisplatin or 
melphalan ICLs, as the percentage decrease in tail moment at the ICL peak is 
between 54.8% and 61.7% for cisplatin treated cells, and 47.9% and 51.4% for 
melphalan treated cells (Figure 6-20B). Figure 6-20C shows that MUS81 siRNA is 
also capable of inhibiting cisplatin-ICL repair: the percentage decrease in tail 
moment is 57.6% in MUS81 knockdown cells treated with cisplatin versus 21.8% 
and 15.9% for cisplatin alone and luciferase knockdown cells treated with cisplatin. 
Both of these differences are statistically significant. However, MUS81 knockdown 
has no effect on the repair of melphalan-ICLs. Regardless of siRNA treatment, cells 
treated with melphalan exhibit a percentage decrease in tail moment of 
approximately 20%, indicating that ICL unhooking has occurred. Representative 
images of this experiment are shown in Figure 6-21. Again, the difference between 
the effect of MUS81 knockdown on cisplatin and melphalan treated cells is visible. 
24 hours after the ICL peak, cisplatin treated cells also transfected with MUS81 
siRNA have comet tails similar to those seen at the ICL peak, indicating little, if any, 
repair. In contrast, melphalan treated cells also transfected with MUS81 siRNA have 
visible comet tails, similar to those seen with melphalan treatment alone or in cells 
transfected with the luciferase control siRNA.  
These results indicate that MUS81, in addition to EME1, is involved in the repair of 
cisplatin-ICLs but not melphalan-ICLs. STAT3 knockdown has a similar effect to the 
knockdown of both of these nuclease components, which supports the hypothesis 
that regulation of EME1 and MUS81 by STAT3 is responsible for the inhibition of 
cisplatin-ICL unhooking.  
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Figure 6-20: MUS81 siRNA inhibits cisplatin but not melphalan ICL repair. A) 
partial MUS81 knockdown was achieved with MUS81 siRNA in the DU145 cell line, 
as determined by immunoblotting. B) percentage decrease in tail moment at the 
peak of crosslinking (9 hours for cisplatin and 16 hours for melphalan). C) 
percentage decrease in tail moment 24 hours after the peak of crosslinking. The 
repair of cisplatin ICLs is inhibited by MUS81 siRNA. Melphalan ICLs repair 
irrespective of siRNA used. Luciferase siRNA was used as a control. Results are the 
mean of three independent experiments with SEM displayed for error bars. One-way 
ANOVA was used to measure statistical significance. *** = P<0.001 and **** = 
P<0.0001. 
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6.3.7 Expression of EME1 and MUS81 is interdependent 
In this chapter, the involvement of both MUS81 and EME1 in cisplatin-ICL repair has 
been demonstrated. In Chapter 5, VS-43 and other STAT3 inhibitors were shown to 
down-regulate the expression of both EME1 and MUS81, and this was suggested to 
be via the transcriptional regulation of these genes by STAT3.  
MUS81 and EME1 form a complex, and this interaction is essential for nuclease 
activity (Haber and Heyer, 2001), therefore, whether the down-regulation of either 
EME1 or MUS81 could affect expression of the other component of the complex 
was investigated. siRNA was used to down-regulate EME1 and MUS81 individually, 
and immunoblotting was performed for both factors at 24 hours and 48 hours post 
transfection. 
Figure 6-22A shows that cells transfected with 10, 25 and 50nM EME1 siRNA 
exhibit reduced EME1 expression, which increases from 24 to 48 hours post 
transfection. MUS81 expression is also down-regulated, and this effect is greater at 
48 hours post transfection with EME1 siRNA. There also appears to be a dose-
dependent effect. In Figure 6-22B the reverse was performed: MUS81 was knocked 
down with increasing concentrations of siRNA. Here, the effect is more striking, 
MUS81 expression is clearly reduced by transfection with MUS81 siRNA, and this is 
also able to down-regulate expression of EME1. There appears to be a dose-
dependent effect, which is, again, greatest at 48 hours post transfection. 
Therefore, the expression of EME1 and MUS81 appears to be interdependent, with 
each factor potentially stabilising the other.  
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Figure 6-22: Expression of EME1 and MUS81 is interdependent. siRNA 
knockdown of A) EME1 and B) MUS81 in DU145 cells. Immunoblotting was 
performed 24 and 48 hours after transfection with three concentrations of siRNA. A 
luciferase siRNA (L) was used as a non-targeting control. Blots are representative of 
more than 1 experiment. 
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In this chapter, the investigation into the role of STAT3 in ICL unhooking has been 
extended to include the nitrogen mustard crosslinking chemotherapy drug, 
melphalan. Whereas in Chapter 4 the combination of STAT3 inhibitors with cisplatin 
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combination with inhibition of STAT3. CI values obtained for the combination of 
melphalan with STAT3 inhibitors were predominantly additive and at very high effect 
levels, mildly antagonistic (although the accuracy of the CI values at high effect 
levels is diminished, as discussed in Chapter 4). In addition, the repair of melphalan-
ICLs was not affected by STAT3 inhibitors or STAT3 siRNA knockdown, suggesting 
that the role of STAT3 in ICL unhooking is not a universal one.  
ICLs are considered to be the most toxic of the lesions formed by crosslinkers such 
as cisplatin and melphalan and, accordingly, the level of these adducts has been 
shown to correlate with the anti-cancer activity of the crosslinker (Hansson et al., 
1987; Kothandapani et al., 2011; Sunters et al., 1992; Zhen et al., 1992). The results 
presented in this thesis are in agreement with these findings, as the ability of STAT3 
inhibitors to block ICL repair correlates with their chemosensitising properties. For 
melphalan, where ICL repair proceeds in the presence of STAT3 inhibitors, no 
sensitisation is observed.   
Clearly, if STAT3 inhibitors are able to block cisplatin-ICL, but not melphalan-ICL, 
unhooking, these events must occur via separate pathways, as has been reported 
by this group previously (Spanswick et al., 2012).  
6.4.1 Differences between cisplatin and melphalan-ICL repair 
Studies investigating the mechanism for ICL repair often use different crosslinking 
agents, as the repair pathway is generally considered universal. If, as is 
demonstrated in this thesis, the repair of different ICLs takes place via different 
mechanisms, this approach is not appropriate. Experiments performed with the 
same crosslinking agents should be compared together and the differences and 
similarities between experiments using different crosslinkers should be noted.   
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In this chapter, the MUS81-EME1 endonuclease is demonstrated to play a key role 
for the unhooking of cisplatin-ICLs, but not melphalan-ICLs. Investigations into ICL 
repair have most frequently used cisplatin, mitomycin C or psoralen. Melphalan is 
rarely used in these studies. However, work from our laboratory has demonstrated 
that ERCC1 and XPF mutant cell lines are hypersensitive to melphalan whereas 
these mutants display only slight increased sensitivity to mono-functional melphalan, 
indicating the importance of XPF-ERCC1 in melphalan ICL repair (Clingen et al., 
2005). Also, another study investigated the role of ERCC1 in melphalan sensitivity 
and showed ERCC1-/- cells to be hypersensitive to melphalan (Al-Minawi et al., 
2009). However, no studies have yet been carried out describing the involvement of 
MUS81-EME1 in melphalan sensitivity or melphalan-ICL repair.  
The role of the MUS81-EME1 endonuclease in cisplatin-ICL repair is more 
frequently studied. There are several reports of hypersensitivity to cisplatin in cancer 
cell lines lacking MUS81 or EME1 (Abraham et al., 2003; Hanada et al., 2006; 
McPherson et al., 2004), as was discussed in Chapter 5. In addition, mouse 
embryonic stem cells lacking MUS81 expression do not generate DSBs in response 
to cisplatin whereas wild-type cells do, suggesting that MUS81-EME1 is involved in 
incising the cisplatin-ICL (Hanada et al., 2006).  
In Chapter 5, as well as MUS81-EME1, FANCD2 was shown to be down-regulated 
by treatment with STAT3 inhibitors. FANCD2 has been reported to be involved in 
the repair of both cisplatin and melphalan-induced ICLs. Inhibitors of the FANCD2 
protein increase sensitivity to cisplatin (Chirnomas et al., 2006) and in myeloma 
cells a proteasome inhibitor which down-regulates FANCD2 levels is able to 
sensitise cells to melphalan. In that same study, siRNA directed against FANCD2 
was shown to increase the percentage of melphalan-ICLs (Yarde et al., 2009), and 
Knipsheer et al. have demonstrated that FANCD2 is essential for the incision 
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reactions to take place on a synthetic cisplatin-ICL (Knipscheer et al., 2009). This 
evidence combined with the knowledge that FANCD2 acts very early in the ICL 
repair process suggests that FANCD2 acts in a general ICL repair role. Indeed, the 
FA core complex protein FANCF, involved in FANCD2 monoubiquitination has also 
been tied to both cisplatin and melphalan sensitivity, and also melphalan ICL repair 
(Chen et al., 2005; Dai et al., 2015).  
BRCA1 was also shown to be down-regulated by STAT3 inhibition in this thesis. As 
with FANCD2, the involvement of BRCA1 in both cisplatin and melphalan ICL repair 
has been proposed. BRCA1-/- cells are hypersensitive to cisplatin, and do not form 
FANCD2 foci after treatment with cisplatin (Bhattacharyya et al., 2000; Bunting et 
al., 2012). BRCA1 levels have also been found to be up-regulated in melphalan-
resistant cell lines (Chen et al., 2005). These studies do not demonstrate a direct 
relationship between BRCA1 status and ICL unhooking, however, as BRCA1 is also 
involved in homologous recombination (Valerie and Povirk, 2003), which occurs 
downstream of the unhooking process in ICL repair after the lesion has been 
removed, it is likely to also be involved in the general ICL repair mechanism.  
Therefore, the very early stages of ICL repair (FA pathway activation) and later 
stages (homologous recombination) are possibly the same for all ICLs. What may 
differ is the initial recognition of the ICL, and the incisions required either side of the 
ICL for unhooking, as the various ICL structures and distortions produced could 
influence which proteins are able to bind to the site.  
This group has previously reported evidence that the repair of cisplatin and 
melphalan ICLs occurs via a different mechanism. Friendmann et al. demonstrated 
that inhibition of EGFR delays cisplatin-ICL but not melphalan-ICL unhooking. They 
suggested that this effect is due to the inhibition of the NHEJ protein DNA-PK, as an 
inhibitor of DNA-PK also sensitised cells to cisplatin and delayed cisplatin-ICL 
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unhooking, but not melphalan-ICL unhooking. EGFR was shown to interact directly 
with DNA-PK and the possibility of inhibition by sequestration was suggested 
(Friedmann et al., 2004). The effect of STAT3 inhibition on DNA-PK levels is not 
reported, however, DNA-PK was one of the genes analysed by RT-PCR array in 
Chapter 5. DNA-PK was down-regulated by 1.32 and 1.54 fold at 1µM and 2µM VS-
43, respectively. However, neither of these values were statistically significant as P 
values greater than 0.05 were calculated by the analysis software. Therefore, DNA-
PK was not shortlisted as a STAT3 target. It is possible that EGFR may therefore, 
inhibit cisplatin-ICL unhooking through both the regulation of DNA-PK and STAT3 
downstream targets such as MUS81-EME1. Another study, however, reported 
contradictory evidence for the role of DNA-PK in melphalan sensitivity. Sousa et al. 
observed sensitisation to melphalan by DNA-PK inhibitors (Sousa et al., 2013). 
Therefore, the mechanistic role for DNA-PK in ICL unhooking, and whether it does 
have lesion specificity, requires further investigation. The argument for a link 
between EGFR and the MUS81-EME1 endonuclease is, however, strengthened by 
the report by Vigneron et al. which suggested that EGFR regulates EME1 
expression through STAT3 (Vigneron et al., 2008).   
Spanswick et al. also presented evidence to suggest a different unhooking 
mechanism for cisplatin and melphalan ICLs. Gemcitabine was shown to selectively 
inhibit cisplatin ICL unhooking (Spanswick et al., 2012). Gemcitabine is a nucleoside 
analogue that may inhibit nucleotide excision repair through its incorporation into the 
repairing DNA patch. As cisplatin also forms intrastrand crosslinks, which are 
removed by NER (Zamble et al., 1996), Spanswick et al. suggest that the inhibition 
of intrastrand crosslink repair may sequester DNA repair proteins which also play a 
role in ICL repair, such as the XPF-ERCC1 endonuclease (Friedberg, 2001). The 
effects of STAT3 inhibition on the level of cisplatin intrastrand crosslinking could be 
investigated using adduct-specific antibodies (Liedert et al., 2006). Melphalan does 
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not form intrastrand crosslinks (Bauer and Povirk, 1997), however, monoadducts 
are formed which are also repaired by NER (Grant et al., 1998). Therefore, the 
effect of gemcitabine, and STAT3 inhibitors, on sequestration of NER proteins and 
whether this selectively targets cisplatin-ICL repair remains to be determined.  
6.4.2 The role of MUS81-EME1 in ICL repair: evidence so far 
The data presented in this chapter demonstrates the involvement of both 
components of the MUS81-EME1 endonuclease in cisplatin-ICL repair. Knockdown 
of either MUS81 or EME1 with siRNA significantly inhibits the unhooking of cisplatin-
ICLs in a similar manner to that seen with STAT3 siRNA or STAT3 pharmacological 
inhibition (Figure 6-16, Figure 6-18, Figure 6-20). However, the role for MUS81-
EME1 in ICL repair is still largely debated.  
ERCC1-/- cells are able to generate DSBs after treatment with MMC (Niedernhofer 
et al., 2004), suggesting that ERCC1-XPF may not be the only nuclease involved in 
the ICL incision reaction. Hanada et al. have demonstrated that DSBs do not form in 
response to cisplatin and MMC in mouse embryonic stem cells lacking MUS81 
(Hanada et al., 2006). However, data from our research group has demonstrated 
that DSBs do not form after treatment with cisplatin (De Silva et al., 2002). 
Nonetheless, Hanada et al. also reported that deletion of MUS81 rendered cells 
hypersensitive to both MMC and cisplatin. In normal cells, the generation of DSBs 
after cisplatin and MMC treatment was demonstrated to occur in a replication-
dependent manner, therefore, suggesting that MUS81-EME1 acts to incise ICLs at 
stalled replication forks (Hanada et al., 2006). This is in agreement with the structure 
specificity of MUS81-EME1 for replication fork structures and 3’ flaps (Ciccia et al., 
2003). Therefore, a role for MUS81-EME1 as the additional nuclease involved in 
incising cisplatin-induced ICLs remains possible. 
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Another piece of evidence linking the MUS81-EME1 nuclease to ICL repair is its 
interaction with the scaffold protein, SLX4. SLX4-/- cells are approximately 10-fold 
more sensitive to cisplatin than wild-type cells, and SLX4 directly interacts with 
MUS81, stimulating it’s nuclease activity as well as the nuclease activity of XPF 
(Muñoz et al., 2009).  
Some studies do not agree with a primary role for MUS81-EME1 in ICL unhooking. 
Kuraoka et al. demonstrated that the XPF-ERCC1 nuclease is able to incise both 
sides of the ICL, however, these experiments were performed with psoralen rather 
than cisplatin (Kuraoka et al., 2000), therefore, it cannot be assumed this is also the 
case for cisplatin ICLs. Wang et al. suggested that MUS81-EME1 was involved in 
incising the ICL as an insurance mechanism should XPF-ERCC1 and SNM1A 
action fail, however, this study did not use cisplatin either, MMC was used to induce 
ICLs (Wang et al., 2011). 
Therefore, the role of MUS81-EME1 in ICL repair remains to be confirmed. 
However, if a lesion-specific approach is taken, with the results presented in this 
chapter combined with the evidence put forward by Hanada et al., involvement of 
MUS81-EME1 in ICL unhooking is likely.  
6.4.3 Other possible combinations for STAT3 inhibitors 
In this chapter STAT3, via the regulation of the MUS81-EME1 endonuclease, is 
shown to be involved in the unhooking of cisplatin-ICLs, whilst having no influence 
on the unhooking of melphalan ICLs. The alternative unhooking mechanisms may 
be a result of the varying structure of the ICL lesion, which depends on the 
crosslinking agent used and the resulting degree of DNA helix distortion. As 
discussed in the introduction to this chapter, cisplatin-ICLs are highly distorting 
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lesions whereas nitrogen mustard-induced ICLs such as mechlorethamine-ICLs are 
considerably less distorting (Coste et al., 1999; Rink and Hopkins, 1995).  
It is therefore, possible that crosslinkers which produce ICLs with a similar level of 
DNA distortion to cisplatin-ICLs may be substrates for MUS81-EME1 cleavage, and 
so may synergise with STAT3 inhibitors. The crosslinkers most likely to produce 
similar structured ICLs are those from the same family as cisplatin, the platinum 
crosslinkers. The currently FDA approved platinum compounds other than cisplatin 
are carboplatin and oxaliplatin. The structures of these compounds are shown in 
Figure 6-23.  Unfortunately there is no structural information regarding the 
distortions that carboplatin or oxaliplatin produce when they form DNA-ICLs. 
Therefore, whether the larger size of both of these platinum compounds affects the 
structure of the DNA-ICL formed is unknown, however, the distance between the 
two crosslinked sites should be the same as with cisplatin. Sensitivity studies using 
carboplatin and oxaliplatin with STAT3 inhibitors would provide some indication as 
to whether all platinum-induced ICLs are repaired via the same unhooking 
mechanism.  One study has already reported synergy between oxaliplatin and 
curcumin, though whether this is due to STAT3 inhibition is as yet unknown (Li et 
al., 2007), as our group has previously published an antagonistic interaction 
between the EGFR inhibitor, cetuximab, and oxaliplatin (Santoro et al., 2015). For 
carboplatin, a synergistic interaction with curcumin has been described in 
retinoblastoma cell lines (Sreenivasan and Krishnakumar, 2014). Additionally, 
combination studies have shown synergy for the combination of carboplatin with 
gemcitabine (Wang et al., 2010), and the benefit of combining carboplatin with 
gemcitabine in platinum-resistant ovarian cancer patients has been demonstrated in 
a phase II trial. This trial also demonstrated a significant reduction in the repair of 
carboplatin-ICLs in patient cells treated with gemcitabine (Ledermann et al., 2010). 
As this research group has also previously described gemcitabine to inhibit cisplatin-
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ICLs in vitro (Spanswick et al., 2012), this could suggest that carboplatin-ICLs repair 
via a similar mechanism and so combination with STAT3 inhibitors may be 
beneficial. The differences between the repair of cisplatin, carboplatin and 
oxaliplatin adducts may also be inferred by the patterns of cross-resistance seen 
within this class. Cross-resistance exists between cisplatin and carboplatin, whereas 
cross-resistance is much lower between cisplatin and oxaliplatin (Eckstein, 2011; 
Raymond et al., 2002). Therefore, this would suggest that cisplatin and carboplatin 
may have similar repair mechanisms whereas oxaliplatin-induced DNA damage may 
not be repaired by the same pathway. 
Chemosensitivity studies using selective STAT3 inhibitors will determine whether 
carboplatin is a possible candidate for combination treatment, and comet assays 
with MUS81-EME1 knockdown will aid in the elucidation of the repair mechanisms 
at play for the various platinum-ICLs.  
In Chapter 4, VS-43 was shown to synergise with doxorubicin, the intercalating 
topoisomerase II inhibitor, which exerts its toxic effects on cells by inducing DSBs. 
Interestingly, Friedmann et al. previously reported synergy between the EGFR 
inhibitor, gefitinib, and etoposide, a topoisomerase II inhibitor. Gefitinib was 
demonstrated to delay the repair of etoposide-induced DSBs, as measured by 
comet assay (Friedmann et al., 2004). As discussed previously, EGFR acts 
upstream of STAT3 therefore, the effects published by Friedmann et al. could be a 
result of indirect STAT3 inhibition. 
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Figure 6-23: Structures of cisplatin, carboplatin and oxaliplatin. 
This, along with the results presented in this thesis demonstrating synergy between 
VS-43 and doxorubicin, could suggest that STAT3 regulates genes involved in DSB 
repair. Two genes involved in DSB repair via homologous recombination were 
down-regulated by VS-43 on the DNA damage signalling RT-PCR array in Chapter 
5 (section 5.3.4). These were BRCA1 and RPA1. Therefore, through the down-
regulation of homologous recombination proteins, STAT3 inhibitors may also 
chemosensitise to other agents that act via the induction of DSBs, including other 
topoisomerase inhibitors like irinotecan, or ionising radiation. In fact, previous work 
carried out by this group has demonstrated radiosensitising properties of VS-43. 
This data is included in Appendix D.  
Therefore, it is proposed here that STAT3 is able to synergise with the ICL-inducing 
agent, cisplatin, through the inhibition of MUS81-EME1 expression, which is 
required for the unhooking of cisplatin-ICLs. STAT3 may also be able to sensitise 
Cisplatin
Pt
Cl NH3
Cl NH3
Cisplatin 
Carboplatin 
Oxaliplatin 
  340 
cells to other crosslinking agents, particularly if MUS81-EME1 is involved in the 
unhooking of those lesions. Alternatively, the effects of STAT3 inhibition on other 
DNA repair proteins, including those involved in homologous recombination, may 
allow for sensitisation to agents inducing DSBs. Further investigation into the DNA 
repair mechanisms targeted by STAT3 inhibition and the possible therapy 
combinations as a result of this must be carried out.  
6.4.4 The interdependency of EME1 and MUS81 
In this chapter, the dependency of each component of the MUS81-EME1 nuclease 
on its partner protein was investigated using siRNA knockdown of each factor 
individually. Expression of EME1 and MUS81 was demonstrated to be 
interdependent, which may be expected due to the reported dependency between 
MUS81 and EME1 for nuclease activity (Haber and Heyer, 2001).  
In Chapter 5, STAT3 inhibitors were demonstrated to down-regulate the expression 
of both EME1 and MUS81, possibly by directly binding to the promoter regions of 
these genes and regulating transcription. With the observation that down-regulation 
of either MUS81 or EME1 is able to produce an effect on the expression of the 
partner protein, it follows that if STAT3 is involved in the transcription of just one of 
these genes, inhibitors of this pathway would be able to down-regulate both MUS81 
and EME1. The effect of STAT3 inhibition on mRNA expression of EME1 and 
MUS81 was analysed in sections 5.3.4.3 and 5.3.4.4, with the clear finding that 
EME1 mRNA expression is inhibited to a greater extent than MUS81 mRNA 
expression. Therefore, these results could suggest that STAT3 directly regulates the 
transcription of EME1, and through down-regulation of the EME1 protein, MUS81 
expression is also down-regulated. However, STAT3 binding to the MUS81 
promoter region was demonstrated by ChIP in Chapter 5, although whether this 
binding affects transcription of the MUS81 gene is yet to be determined. Therefore, 
  341 
STAT3 may regulate the expression of MUS81 directly, or through the regulation of 
it’s partner protein, EME1. These events lead to an inhibition in cisplatin-ICL 
unhooking when cells are treated with both a STAT3 inhibitor and cisplatin.  
6.5 Conclusion 
In this chapter, the combination of STAT3 inhibitors with melphalan has been 
investigated. STAT3 inhibitors do not chemosensitise to melphalan, and do not 
enhance melphalan-induced apoptosis or DNA damage. The pharmacological 
inhibition of STAT3 has no effect on the repair of melphalan-induced ICLs. This is in 
contrast to what was reported for cisplatin-ICLs in the previous chapter. siRNA 
knockdown of STAT3 was shown to inhibit cisplatin but not melphalan-ICL repair. 
The role of the MUS81-EME1 nuclease in the repair of these lesions was also 
investigated, and it was found that both MUS81 and EME1 are required for the 
unhooking of cisplatin-ICLs whereas neither component of the nuclease complex is 
needed for melphalan-ICL repair to proceed. Interdependency between expression 
of EME1 and MUS81 was also observed. 
Therefore, the synergy reported between STAT3 inhibitors and cisplatin is likely due 
to the regulation of the MUS81-EME1 nuclease by STAT3, which is required for the 
repair of cisplatin-ICLs. Upon STAT3 inhibition, the MUS81-EME1 nuclease is 
down-regulated, either through the transcriptional regulation of both factors, or 
through transcriptional regulation of EME1 and subsequent loss of MUS81 
expression due to the interdependency between these factors. Upon down-
regulation of MUS81-EME1, cisplatin-ICL unhooking is blocked. As the MUS81-
EME1 nuclease is not required for melphalan-ICL unhooking, this provides the 
mechanistic basis for why STAT3 inhibitors do not synergise with melphalan. 
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Chapter 7 Conclusions 
STAT3 is constitutively activated in many types of cancer, and the targets of this 
transcription factor drive tumourigenesis through cell survival, metastasis, 
angiogenesis and differentiation (Frank, 2007; Masuda et al., 2010). STAT3 
inhibitors are frequently reported to harbour chemosensitising properties, however, 
the mechanism behind this is not understood. Therefore, understanding the role of 
STAT3 and how this interacts with the mechanism of action of chemotherapy agents 
will enable the development of more successful combination therapies. 
This thesis has investigated two projects related to STAT3: the pharmacological 
characterisation of a novel STAT3 inhibitor, VS-43, and the involvement of STAT3 in 
the mechanism of ICL repair.  
Chapter 3 began with the introduction to the novel STAT3 inhibitor, VS-43. VS-43 
was derived from the naturally occurring compound, curcumin, which lacks sufficient 
potency and bioavailability to be successful in the clinic (Anand et al., 2007). VS-43 
was rationally designed by Professor Moses Lee and colleagues to inhibit the 
STAT3 DNA binding domain. The structural design of VS-43 proved successful as 
VS-43 was demonstrated to be approximately 10-fold and 40-fold more potent at 
inhibiting pSTAT3Tyr705 than the commercially available STAT3 inhibitors stattic and 
curcumin, respectively. Additionally, VS-43 may irreversibly inhibit STAT3, as the 
down-regulation of pSTAT3Tyr705 persisted after removal of the drug. As curcumin 
has been demonstrated to be a reversible STAT3 inhibitor, these results suggest 
further superiority of VS-43 (Bharti et al., 2003a). A longer duration of action for a 
compound, could allow for less frequent treatment appointments for a patient.  In 
Chapter 3, the selectivity of VS-43 was also investigated.  VS-43 is demonstrated to 
have selectivity for STAT3 over STAT1, STAT5a and STAT5b. The selectivity of 
STAT3 inhibitors is an important factor, which is surprisingly rarely addressed for 
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many novel compounds. In particular, selectivity for STAT3 over STAT1 is critical 
due to the role of STAT1 as a tumour suppressor, regulating genes involved in 
apoptosis and cell cycle arrest (Chin et al., 1996; Fulda and Debatin, 2002). The 
most developed STAT3 inhibitor to date, OPB-31121, even targets STAT1 and 
STAT5 in addition to STAT3 (M. J. Kim et al., 2013). The clinical consequences of 
the lack of selectivity and whether it will hamper further clinical development of 
OPB-31121 remains to be seen. However, it is possible that inhibition of STAT1 
could dampen the anti-cancer benefit of a STAT3 inhibitor.  
The various factors influencing the activity of a STAT3 inhibitor were also 
investigated in Chapter 3. Drug treatment times, the confluency of cells and the cell 
line used were all shown to contribute to the evaluation of potency when treating 
with a STAT3 inhibitor. These are factors that complicate the comparison of inhibitor 
potencies from data reported in the literature. A true direct comparison cannot be 
made unless each of these factors is controlled for. This should be taken into 
consideration in future studies investigating and comparing inhibitor potencies.  
Whilst VS-43 has been demonstrated to have many qualities suitable for a stand-
alone anti-cancer agent, today, many chemotherapy regimens consist of a 
combination of drugs. This provides the rationale for Chapter 4.  
In Chapter 4, the combination of STAT3 inhibitors with cisplatin was investigated. 
Curcumin has been frequently reported to enhance cisplatin sensitivity in cancer cell 
lines (Goel and Aggarwal, 2010; Notarbartolo et al., 2005; Yallapu et al., 2010). 
Given VS-43 has been proven to be a more potent STAT3 inhibitor than curcumin, 
whether this affects the interaction with cisplatin was of interest. VS-43 was 
compared directly to stattic and curcumin in terms of its interaction with cisplatin. 
Whilst all three STAT3 inhibitors were able to sensitise cancer cell lines to cisplatin, 
VS-43 produced greater synergy with cisplatin than either of the commercial STAT3 
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inhibitors. These results strengthen the argument for the development of more 
potent STAT3 inhibitors, as they can be used at lower doses to produce greater 
synergy in combination with cisplatin. Additionally, treatment with VS-43 for just 1 
hour was enough to synergise with cisplatin, suggesting that alternative treatment 
regimes could be investigated to maximise this synergy and perhaps manage side 
effects in the clinic, as the 1 hour VS-43 treatment was considerably less toxic than 
the longer 18 hour treatment. A drug that has the flexibility to be used for shorter 
treatment periods may be beneficial for clinical use, should this observation 
translate across into clinical trials.   
Whilst the combination of VS-43 with cisplatin did result in synergy, this was not 
considered “strong synergism”, as defined by Chou et al. (Chou, 2010). The effect of 
VS-43 alone contributed to some of the cell growth inhibition observed in the 
combination. Therefore, as the analysis of drug combinations takes into account the 
dose-response curves of both drugs alone, the higher the toxicity of the individual 
drugs, the lower the synergy observed is likely to be. As such, the non-constant 
combination of VS-43 and cisplatin produced slightly greater synergy, as VS-43 
itself is not particularly toxic after a 1 hour exposure. This should be considered 
when designing novel combination treatment schedules in the future, and possible 
alterations in the drug treatment times made in order to obtain the greatest degree 
of synergy. 
Chapter 5 addressed the question of how STAT3 inhibitors synergise with cisplatin. 
The rationale for looking at DNA repair came from the hypothesis that for synergy to 
occur between two drugs, their mechanisms of action must overlap. Cisplatin is a 
DNA-damaging chemotherapy agent, and DNA damage response inhibitors such as 
ATR inhibitors have previously been shown to synergise with cisplatin (Mohni et al., 
2015). Additionally, resistance to cisplatin can occur via the repair of cisplatin-DNA 
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adducts (Wynne et al., 2007). Therefore, it was logical to observe the effects of 
STAT3 inhibition on cisplatin-induced DNA damage.  
The DNA damage marker, γH2AX, was significantly increased in cells treated with 
the combination of STAT3 inhibitor and cisplatin, indicating that cisplatin-induced 
DNA damage is enhanced by inhibition of STAT3. STAT3 inhibitors were then 
demonstrated to block the repair, specifically the unhooking, of cisplatin-ICLs, 
without affecting the initial formation of these adducts. This implied that STAT3 
could have a role in the early stages of ICL repair.  
As STAT3 is a transcription factor, it was hypothesised that STAT3 may regulate the 
expression of ICL repair genes. Therefore, inhibition of STAT3 could down-regulate 
those factors and subsequently block ICL repair. RT-PCR revealed several DNA 
repair factors to be down-regulated by VS-43 treatment. These included FANCD2 
and BRCA1, two proteins known to be involved in the ICL unhooking process, as 
well as MUS81 and EME1, both components of the MUS81-EME1 endonuclease, 
which is reported to be involved in incising the ICL site to allow for unhooking (Rahn 
et al., 2010).  
In Chapter 5, STAT3 inhibitors were demonstrated to cause a G1-phase cell cycle 
arrest. Of the four ICL-repair factor targets, only BRCA1 was found to be cell cycle 
regulated, consistent with current literature (Ruffner and Verma, 1997). This 
suggested that the regulation of FANCD2, EME1 and MUS81 by STAT3 may be 
transcriptional and so the online UCSC Genome Browser database was utilised to 
identify possible STAT3 binding sites upstream of the MUS81 and EME1 
transcription start sites. No STAT3 binding sites were identified upstream of 
FANCD2. Using ChIP-PCR with a STAT3 antibody, STAT3 was found to be 
enriched at two sites upstream of the MUS81 gene and one site upstream of the 
EME1 gene. VS-43 pre-treatment effectively abolished STAT3 binding to these 
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sites. This data suggested that STAT3 directly regulates the expression of the 
MUS81-EME1 nuclease, which is in agreement with a study suggesting 
transcriptional regulation of EME1 by the EGFR-STAT3 axis (Vigneron et al., 2008). 
These results have expanded the understanding of the synergistic interaction 
between STAT3 inhibitors and cisplatin, providing a possible mechanistic basis for 
the frequently reported beneficial co-administration of these drugs. As well as 
enhancing apoptosis in cisplatin-treated cells, STAT3 inhibitors directly interfere with 
the cisplatin-ICL repair pathway. This raised the possibility that other ICL-inducing 
agents may synergise with cisplatin due to the regulation of DNA repair by STAT3.   
Therefore, the aim of Chapter 6 was to investigate the use of STAT3 inhibitors in 
combination with another crosslinking drug, melphalan. Melphalan was chosen as 
previous data from this group suggested that melphalan and cisplatin have different 
mechanisms of ICL unhooking, and that EGFR inhibitors synergise with cisplatin but 
not melphalan (Friedmann et al., 2004; Spanswick et al., 2012). Whereas cisplatin is 
used to treat lung, head and neck, testicular and cervical cancer, melphalan is 
predominantly used in myeloma patients (as well as some ovarian and breast 
cancer patients) (Cancer Drugs, Cancer Research UK webpage, available from: 
http://www.cancerresearchuk.org/about-cancer/cancers-in-
general/treatment/cancer-drugs/ [accessed August 2016]), therefore, understanding 
which chemotherapy drugs STAT3 inhibitors are successful in combination with 
would indicate which patients would be most likely to benefit from the development 
of STAT3 inhibitors. 
In agreement with the previous findings of this group, STAT3 inhibitors did not 
synergise with melphalan. Additionally, pre-treatment with a STAT3 inhibitor had no 
effect on the repair of melphalan-induced ICLs, suggesting that STAT3 is not 
involved in melphalan-ICL unhooking. Non-pharmalogical inhibition of STAT3 was 
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performed by siRNA knockdown, and the effect of this, as well as siRNA knockdown 
of MUS81 and EME1, on cisplatin and melphalan ICL unhooking was observed. 
STAT3, MUS81 and EME1 siRNA knockdown had equivalent effects on ICL repair: 
cisplatin-ICL repair was inhibited, whereas melphalan-ICL repair was unaffected. 
Given the potential transcriptional regulation of the MUS81-EME1 nuclease by 
STAT3 (either by regulation of both components of the nuclease or by regulation of 
EME1 followed by down-regulation of MUS81 expression due to the 
interdependency in expression demonstrated between these factors in Chapter 6), 
these results suggested first that MUS81-EME1 is specifically involved in cisplatin-
ICL unhooking, and second, that STAT3 inhibitors synergise with cisplatin through 
the regulation of the MUS81-EME1 nuclease. This confirms the mechanistic basis 
for why STAT3 inhibitors synergise with cisplatin, but not melphalan, as MUS81-
EME1 is only required for efficient cisplatin-ICL repair. 
This data highlights the need for mechanistic ICL repair studies to use the same 
crosslinking agents in order to elucidate the agent-specific ICL repair pathways. 
Currently the role of MUS81-EME1 in ICL repair is debated, with some studies 
suggesting MUS81-EME1 is involved in ICL repair whereas others disagree 
(Hanada et al., 2006; Kuraoka et al., 2000). However, these studies use different 
crosslinking agents to make conclusions about ICL repair, and as has been shown 
in this thesis, this approach is not appropriate as there is not a completely universal 
ICL repair pathway. Instead, studies using different crosslinkers with select repair 
proteins knocked out could be compared and contrasted in order to identify which 
stages of ICL repair are universal and which are variable. Once the differences in 
ICL repair are established, this will aid in the determination of the most beneficial 
drug combinations. For instance, here the mechanistic rationale behind combination 
of STAT3 inhibitors and cisplatin is suggested to be through the MUS81-EME1 
nuclease. Combination of STAT3 inhibitors with melphalan in the clinic is not a 
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viable option as there is no interaction between the STAT3 pathway and melphalan-
ICL repair. 
7.1 Future work 
Several findings presented in this thesis could be carried forward in future work. 
Each of these areas will be discussed briefly.  
7.1.1 Further development of VS-43 as a therapeutic agent 
The data presented in this thesis has demonstrated promising results regarding the 
novel STAT3 inhibitor, VS-43. VS-43 is potent and selective, and has been shown to 
be a superior chemosensitiser when compared with other STAT3 inhibitors. 
Therefore, further preclinical development of this compound should be carried out. 
This will consist of mouse xenograft experiments, initially testing the toxicity of VS-
43 in vivo and the ability of VS-43 to reach the tumour site and down-regulate 
STAT3 activation in the tumour. If these studies are successful, combination 
treatments with cisplatin would be performed to determine whether the synergy 
demonstrated in vitro can be achieved in animal models. After preclinical research, if 
promising data has been obtained with VS-43, the process of testing VS-43 in 
clinical trials would begin in order to determine tolerability, dose ranges, treatment 
schedules and anti-cancer activity. This is, however, a lengthy process. The STAT3 
inhibitor, OPB-31121, entered clinical trials in 2010 (Oh et al., 2010) and, 6 years 
later, is still in phase I/II clinical trials.  
7.1.2 Optimisation of combination schedules  
The combination of STAT3 inhibitors and cisplatin was reported to be synergistic in 
this thesis. As discussed in Chapter 4, however, the drug treatment schedule used 
can affect the degree of synergy achieved. In this thesis, the STAT3 inhibitors were 
administered as pre-treatments to the crosslinking agents, and synergy was 
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observed in combination with cisplatin. However, even greater synergy may be 
obtainable using a different drug schedule, for example simultaneous treatment with 
both the STAT3 inhibitor and cisplatin.  
VS-43 was demonstrated to synergise with cisplatin with both an 18 hour pre-
treatment and a 1 hour pre-treatment. Therefore, the length of inhibitor treatment 
time could also be investigated in order to find the most synergistic treatment 
scheduling. The importance of the length of time between treatment with the first 
drug and the second in a combination was demonstrated by Lee et al. Treatment of 
breast cancer cells with erlotinib followed by doxorubicin was shown to be more 
beneficial than delivery of the two drugs together or in the opposite order, and a 
treatment delay of 24 hours was optimal for apoptosis induction when compared 
with a 4, 8 and 48 hour pre-treatment (Lee et al., 2012).  
Whether the best in vitro treatment schedules are also the best in vivo and even in 
patients would also need to be addressed.  
7.1.3 Combination of STAT3 inhibitors with other chemotherapy agents 
STAT3 inhibitors have been described to sensitise cancer cells to various 
chemotherapy agents, not just cisplatin. This thesis demonstrated that the 
combination of STAT3 inhibitors with melphalan is not a viable one, however, 
combination with other crosslinking chemotherapy drugs must be tested. In 
particular, as discussed in Chapter 6, the combination of STAT3 inhibitors with other 
platinum crosslinkers should be investigated. Both oxaliplatin and carboplatin are 
used in the clinic today, and acquired resistance can develop in response to either 
of these compounds (Giaccone, 2000; Mishima et al., 2002). In the case of 
oxaliplatin, the extent of DNA platination is lower in more resistant cell lines 
(Mishima et al., 2002), therefore, if STAT3 inhibitors can sensitise cells to oxaliplatin 
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or carboplatin, this may overcome resistance through the regulation of ICL repair. 
As VS-43 is not able to synergise with melphalan, whether this applies to the whole 
class of nitrogen mustards must also be determined. This will also help to elucidate 
the differences in ICL repair due to the regulation of MUS81-EME1 by STAT3. 
In this thesis, VS-43 is also demonstrated to synergise with the topoisomerase II 
inhibitor doxorubicin, and it was hypothesised that this may be through the 
regulation of DSB repair by STAT3. Interestingly, Friedmann et al. previously 
reported synergy between gefitinib and etoposide, another topoisomerase II 
inhibitor, and showed that gefitinib can delay the repair of etoposide-induced strand 
breaks (Friedmann et al., 2004). As gefitinib acts to inhibit EGFR, upstream of 
STAT3, this suggests that STAT3 inhibitors may also be able to sensitise cells to 
etoposide. This has, in fact, already been reported for curcumin (Dhandapani et al., 
2007). Sensitisation of cancer cell lines to etoposide could possibly occur through 
the regulation of the DSB repair process, for instance via the transcriptional 
regulation of factors involved in homologous recombination such as BRCA1 and 
RPA1, which was demonstrated by VS-43 in Chapter 5. If STAT3 inhibitors are able 
to sensitise to other DSB-inducing agents, such as IR, whether this is via inhibition 
of homologous recombination will need to be determined, particularly as melphalan-
ICL repair may involve homologous recombination, therefore, why STAT3 inhibitors 
cannot sensitise to melphalan would also need to be investigated further. 
7.1.4 Further investigation of the ICL unhooking mechanism 
In this thesis, the differences between cisplatin and melphalan ICL repair have 
begun to be investigated, with the main finding being that the MUS81-EME1 
nuclease is required for the efficient unhooking of cisplatin-ICLs but is not involved 
in melphalan-ICL repair. In addition to the ERCC1-XPF nuclease, which was 
  351 
demonstrated to not be regulated by STAT3 in this thesis, there are several other 
nucleases which have been suggested to play a role in the ICL unhooking process. 
SNM1A, a 5’-3’ exonuclease, is one candidate. SNM1A has been shown to be 
capable of digesting past an ICL after an initial incision by ERCC1-XPF - described 
as an “ICL trimming” activity (Sengerová et al., 2011; Wang et al., 2011). This 
activity could allow for the unhooking of an ICL in the absence of a second incision. 
However, the issue of different repair pathways for different crosslinks is evident 
again, as SNM1A knockout cells are sensitive to MMC and SJG-136, but not 
melphalan or cisplatin (Dronkert et al., 2000; Wang et al., 2011). Therefore, the role 
for this nuclease and whether it, as well as MUS81-EME1, acts in a lesion-specific 
manner, must be investigated further.  
The Fanconi Anemia associated nuclease (FAN1), which interacts with FANCD2, 
has also been suggested to harbour ICL trimming activity due to its 5’ nuclease 
action on nicked DNA, as well as a potential role in the initial ICL incision 
(Sengerová et al., 2011; Smogorzewska et al., 2010). However, the interaction of 
FAN1 with FANCD2 is not required, and it has been suggested that FAN1 is not 
involved in ICL repair, but is instead involved in genomic stability following ICL-
inducing agents (Lachaud et al., 2016). Additionally, DSBs are able to form after 
treatment of FAN1-deficient cells with cisplatin, however, this was demonstrated 
using immunofloresence staining of γH2AX foci therefore, this may not correlate 
directly with DSB induction (MacKay et al., 2010). Therefore, which nucleases are 
involved in ICL repair for which types of ICL remains to be investigated, and whether 
SNM1A or FAN1 are regulated by STAT3 must also be determined.  
In this thesis, STAT3 inhibitors have been shown to inhibit cisplatin-ICL unhooking, 
and it was proposed that this is through the down-regulation of the MUS81-EME1 
nuclease. The modified comet assay was utilised to observe ICL formation and 
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repair in these studies. This assay is capable of detecting ICLs up until the point at 
which they unhook from the DNA double helix. Therefore, any stage of repair prior 
to ICL unhooking may have been affected by STAT3 inhibition in order to achieve 
the observed block in ICL unhooking. Therefore, it is possible that STAT3 also 
influences repair factors further upstream to the ICL incisions.  This could include 
the machinery that initially recognises the ICL for repair.  
The recognition of cisplatin and carboplatin ICLs has been reported to require the 
mismatch repair pathway, whereas oxaliplatin ICLs are not recognised by this 
machinery (Fink et al., 1998). The fanconi anemia protein, FANCM, has also been 
suggested to be involved in ICL recognition. Along with its partner protein FAAP24, 
FANCM is able to bind unwound DNA at an ICL site and bring with it the FA core 
complex (Niedernhofer, 2007). Cells deficient in FANCM are not capable of 
ubiquitylating FANCD2 and demonstrate hypersensitivity to MMC (Meetei et al., 
2005). The UHRF1 protein was more recently identified as a potential ICL 
recognition factor due to its ability to directly bind ICL-containing DNA substrates, as 
well as the ERCC1 and MUS81 nuclease components (Tian et al., 2015), this study 
was, however, performed using psoralen-induced ICLs, so again the question of 
agent-specific ICL repair pathways arises. 
As the distortions produced by different ICLs are extremely varied, different 
mechanisms of ICL recognition are likely to exist, in addition to replication-
dependent and independent ICL recognition. Whether STAT3 regulates the 
expression of ICL-recognition factors should be investigated. 
Therefore, much remains to be determined regarding ICL repair, but by using 
STAT3 inhibitors, and understanding which ICL repair proteins STAT3 regulates, the 
different pathways within ICL repair may begin to emerge.  
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7.1.5 Clinical relevance of MUS81-EME1  
The MUS81-EME1 nuclease has been demonstrated to be essential for the repair of 
cisplatin-ICLs, however, the relevance of this nuclease in the clinical setting is not 
yet known. As discussed in Chapter 5, the COSMIC online database indicates that 
mutations in EME1 and MUS81 do occur, although the functional consequences of 
these mutations is unknown. Over-expression of these proteins occurs at greater 
frequency (21.38% of breast cancer tissues for EME1 and 9.4% of ovarian cancer 
tissues for MUS81) (Forbes et al., 2015). However, whether this overexpression 
correlates with resistance to cisplatin in patients is yet to be determined.  
If expression of MUS81 or EME1 is correlated with response to cisplatin in patients, 
as ERCC1 has been suggested to (Chiu et al., 2011; Ting et al., 2013), the 
expression of either component of the MUS81-EME1 nuclease could be developed 
as a novel biomarker for cisplatin sensitivity. Additionally, patients expressing high 
levels of MUS81 or EME1 may respond well to cisplatin combined with a STAT3 
inhibitor. Therefore, the potential exists to expand on the findings in this thesis 
regarding the involvement of MUS81-EME1 in cisplatin-ICL repair, in terms of 
patient response to platinum-based therapy.  
Additionally, a compound which targets the MUS81-EME1 nuclease may be of 
interest for use in patients with particular genetic backgrounds. MUS81-EME1 has 
been shown to be synthetically lethal with a number of DNA repair factors such as 
BLM and other RecQ helicases (Trowbridge et al., 2007).  
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7.2 Final conclusion 
This thesis presents a novel STAT3 inhibitor, VS-43, and demonstrates it to have 
superior potency and selectivity over other STAT3 inhibitors. VS-43 is also able to 
produce greater synergy in combination with cisplatin than other STAT3 inhibitors. 
The second finding of this thesis is that the synergy between STAT3 inhibitors and 
cisplatin is achieved, in part, through the transcriptional regulation of the MUS81-
EME1 endonuclease by STAT3. This nuclease is required for the successful 
unhooking and downstream repair of cisplatin-ICLs; therefore, down-regulation of 
MUS81-EME1 by inhibition of STAT3 effectively blocks ICL unhooking. 
Contrastingly, STAT3 inhibitors do not synergise with melphalan, and do not block 
melphalan-ICL unhooking, as the MUS81-EME1 nuclease is not essential for 
melphalan-ICL repair. These findings provide a mechanistic basis for the successful 
combination of STAT3 inhibitors with cisplatin in the clinic, and also highlight the 
differences between crosslinking chemotherapeutics, which will be useful in 
determining successful anti-cancer combination therapies. 
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Appendices 
Appendix A: Gene list for DNA damage signalling arrays 
Position Symbol Description Gene name 
A01 ABL1 
C-abl oncogene 1, non-
receptor tyrosine kinase 
ABL/JTK7/bcr/abl/c-ABL/c-
ABL1/p150/v-abl 
A02 APEX1 
APEX nuclease 
(multifunctional DNA repair 
enzyme) 1 
APE/APE1/APEN/APEX/A
PX/HAP1/REF1 
A03 ATM Ataxia telangiectasia mutated 
AT1/ATA/ATC/ATD/ATDC/
ATE/TEL1/TELO1 
A04 ATR 
Ataxia telangiectasia and 
Rad3 related 
FCTCS/FRP1/MEC1/SCK
L/SCKL1 
A05 ATRIP ATR interacting protein - 
A06 ATRX 
Alpha thalassemia/mental 
retardation syndrome X-
linked 
ATR2/JMS/MRXHF1/RAD
54/RAD54L/SFM1/SHS/X
H2/XNP/ZNF-HX 
A07 BARD1 
BRCA1 associated RING 
domain 1 - 
A08 BAX BCL2-associated X protein BCL2L4 
A09 BBC3 BCL2 binding component 3 JFY-1/JFY1/PUMA 
A10 BLM 
Bloom syndrome, RecQ 
helicase-like 
BS/RECQ2/RECQL2/REC
QL3 
A11 BRCA1 Breast cancer 1, early onset 
BRCAI/BRCC1/BROVCA1
/IRIS/PNCA4/PPP1R53/P
SCP/RNF53 
A12 BRIP1 
BRCA1 interacting protein C-
terminal helicase 1 BACH1/FANCJ/OF 
B01 CDC25A 
Cell division cycle 25 
homolog A (S. pombe) CDC25A2 
B02 CDC25C 
Cell division cycle 25 
homolog C (S. pombe) CDC25/PPP1R60 
B03 CDK7 Cyclin-dependent kinase 7 
CAK1/CDKN7/HCAK/MO1
5/STK1/p39MO15 
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Position Symbol Description Gene name 
B04 CDKN1A 
Cyclin-dependent kinase 
inhibitor 1A (p21, Cip1) 
CAP20/CDKN1/CIP1/MDA
-
6/P21/SDI1/WAF1/p21CIP
1 
B05 CHEK1 
CHK1 checkpoint homolog 
(S. pombe) CHK1 
B06 CHEK2 
CHK2 checkpoint homolog 
(S. pombe) 
CDS1/CHK2/HuCds1/LFS
2/PP1425/RAD53/hCds1 
B07 CIB1 
Calcium and integrin binding 
1 (calmyrin) 
CIB/CIBP/KIP1/PRKDCIP/
SIP2-28 
B08 CRY1 
Cryptochrome 1 (photolyase-
like) PHLL1 
B09 
CSNK2A
2 
Casein kinase 2, alpha prime 
polypeptide CK2A2/CSNK2A1 
B10 DDB1 
Damage-specific DNA 
binding protein 1, 127kDa 
DDBA/UV-
DDB1/XAP1/XPCE/XPE/X
PE-BF 
B11 DDB2 
Damage-specific DNA 
binding protein 2, 48kDa DDBB/UV-DDB2 
B12 DDIT3 
DNA-damage-inducible 
transcript 3 
CEBPZ/CHOP/CHOP-
10/CHOP10/GADD153 
C01 ERCC1 
Excision repair cross-
complementing rodent repair 
deficiency, complementation 
group 1 (includes overlapping 
antisense sequence) COFS4/RAD10/UV20 
C02 ERCC2 
Excision repair cross-
complementing rodent repair 
deficiency, complementation 
group 2 COFS2/EM9/TTD/XPD 
C03 EXO1 Exonuclease 1 HEX1/hExoI 
C04 FANCA 
Fanconi anemia, 
complementation group A 
FA/FA-
H/FA1/FAA/FACA/FAH/FA
NCH 
C05 FANCD2 
Fanconi anemia, 
complementation group D2 
FA-
D2/FA4/FACD/FAD/FAD2/
FANCD 
C06 FANCG Fanconi anemia, FAG/XRCC9 
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Position Symbol Description Gene name 
complementation group G 
C07 FEN1 
Flap structure-specific 
endonuclease 1 FEN-1/MF1/RAD2 
C08 
GADD45
A 
Growth arrest and DNA-
damage-inducible, alpha DDIT1/GADD45 
C09 
GADD45
G 
Growth arrest and DNA-
damage-inducible, gamma 
CR6/DDIT2/GADD45gam
ma/GRP17 
C10 H2AFX 
H2A histone family, member 
X H2A.X/H2A/X/H2AX 
C11 HUS1 
HUS1 checkpoint homolog 
(S. pombe) hHUS1 
C12 LIG1 
Ligase I, DNA, ATP-
dependent - 
D01 MAPK12 
Mitogen-activated protein 
kinase 12 
ERK3/ERK6/P38GAMMA/
PRKM12/SAPK-3/SAPK3 
D02 MBD4 
Methyl-CpG binding domain 
protein 4 MED1 
D03 MCPH1 Microcephalin 1 BRIT1/MCT 
D04 MDC1 
Mediator of DNA-damage 
checkpoint 1 NFBD1 
D05 MLH1 
MutL homolog 1, colon 
cancer, nonpolyposis type 2 
(E. coli) 
COCA2/FCC2/HNPCC/HN
PCC2/hMLH1 
D06 MLH3 MutL homolog 3 (E. coli) HNPCC7 
D07 MPG 
N-methylpurine-DNA 
glycosylase 
AAG/ADPG/APNG/CRA36
.1/MDG/Mid1/PIG11/PIG1
6/anpg 
D08 MRE11A 
MRE11 meiotic 
recombination 11 homolog A 
(S. cerevisiae) 
ATLD/HNGS1/MRE11/MR
E11B 
D09 MSH2 
MutS homolog 2, colon 
cancer, nonpolyposis type 1 
(E. coli) 
COCA1/FCC1/HNPCC/HN
PCC1/LCFS2 
D10 MSH3 MutS homolog 3 (E. coli) DUP/MRP1 
D11 NBN Nibrin 
AT-V1/AT-
V2/ATV/NBS/NBS1/P95 
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Position Symbol Description Gene name 
D12 NTHL1 
Nth endonuclease III-like 1 
(E. coli) NTH1/OCTS3 
E01 OGG1 
8-oxoguanine DNA 
glycosylase 
HMMH/HOGG1/MUTM/O
GH1 
E02 PARP1 
Poly (ADP-ribose) 
polymerase 1 
ADPRT/ADPRT 
1/ADPRT1/ARTD1/PARP/
PARP-1/PPOL/pADPRT-1 
E03 PCNA 
Proliferating cell nuclear 
antigen - 
E04 PMS1 
PMS1 postmeiotic 
segregation increased 1 (S. 
cerevisiae) HNPCC3/PMSL1/hPMS1 
E05 PMS2 
PMS2 postmeiotic 
segregation increased 2 (S. 
cerevisiae) 
HNPCC4/PMS2CL/PMSL
2 
E06 PNKP 
Polynucleotide kinase 3'-
phosphatase EIEE10/MCSZ/PNK 
E07 PPM1D 
Protein phosphatase, 
Mg2+/Mn2+ dependent, 1D PP2C-DELTA/WIP1 
E08 
PPP1R1
5A 
Protein phosphatase 1, 
regulatory (inhibitor) subunit 
15A GADD34 
E09 PRKDC 
Protein kinase, DNA-
activated, catalytic 
polypeptide 
DNA-
PKcs/DNAPK/DNPK1/HY
RC/HYRC1/XRCC7/p350 
E10 RAD1 RAD1 homolog (S. pombe) HRAD1/REC1 
E11 RAD17 RAD17 homolog (S. pombe) 
CCYC/HRAD17/R24L/RA
D17SP/RAD24 
E12 RAD18 
RAD18 homolog (S. 
cerevisiae) RNF73 
F01 RAD21 RAD21 homolog (S. pombe) 
CDLS4/HR21/HRAD21/M
CD1/NXP1/SCC1/hHR21 
F02 RAD50 
RAD50 homolog (S. 
cerevisiae) NBSLD/RAD502/hRad50 
F03 RAD51 
RAD51 homolog (S. 
cerevisiae) 
BRCC5/HRAD51/HsRad5
1/HsT16930/MRMV2/RAD
51A/RECA 
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Position Symbol Description Gene name 
F04 RAD51B 
RAD51 homolog B (S. 
cerevisiae) R51H2/RAD51L1/REC2 
F05 RAD9A RAD9 homolog A (S. pombe) RAD9 
F06 RBBP8 
Retinoblastoma binding 
protein 8 
COM1/CTIP/JWDS/RIM/S
AE2/SCKL2 
F07 REV1 
REV1 homolog (S. 
cerevisiae) REV1L 
F08 RNF168 Ring finger protein 168 hRNF168 
F09 RNF8 Ring finger protein 8 hRNF8 
F10 RPA1 
Replication protein A1, 
70kDa 
HSSB/MST075/REPA1/R
F-A/RP-A/RPA70 
F11 SIRT1 Sirtuin 1 SIR2L1 
F12 SMC1A 
Structural maintenance of 
chromosomes 1A 
CDLS2/DXS423E/SB1.8/S
MC1/SMC1L1/SMC1alpha
/SMCB 
G01 SUMO1 
SMT3 suppressor of mif two 
3 homolog 1 (S. cerevisiae) 
DAP1/GMP1/OFC10/PIC1
/SENP2/SMT3/SMT3C/S
MT3H3/UBL1 
G02 TOPBP1 
Topoisomerase (DNA) II 
binding protein 1 TOP2BP1 
G03 TP53 Tumor protein p53 BCC7/LFS1/P53/TRP53 
G04 
TP53BP
1 
Tumor protein p53 binding 
protein 1 53BP1/p202 
G05 TP73 Tumor protein p73 P73 
G06 UNG Uracil-DNA glycosylase 
DGU/HIGM4/HIGM5/UDG/
UNG1/UNG15/UNG2 
G07 XPA 
Xeroderma pigmentosum, 
complementation group A XP1/XPAC 
G08 XPC 
Xeroderma pigmentosum, 
complementation group C RAD4/XP3/XPCC 
G09 XRCC1 
X-ray repair complementing 
defective repair in Chinese 
hamster cells 1 RCC 
G10 XRCC2 X-ray repair complementing defective repair in Chinese - 
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Position Symbol Description Gene name 
hamster cells 2 
G11 XRCC3 
X-ray repair complementing 
defective repair in Chinese 
hamster cells 3 CMM6 
G12 XRCC6 
X-ray repair complementing 
defective repair in Chinese 
hamster cells 6 
CTC75/CTCBF/G22P1/KU
70/ML8/TLAA 
H01 ACTB Actin, beta BRWS1/PS1TP5BP1 
H02 B2M Beta-2-microglobulin - 
H03 GAPDH 
Glyceraldehyde-3-phosphate 
dehydrogenase G3PD/GAPD 
H04 HPRT1 
Hypoxanthine 
phosphoribosyltransferase 1 HGPRT/HPRT 
H05 RPLP0 Ribosomal protein, large, P0 
L10E/LP0/P0/PRLP0/RPP
0 
H06 HGDC 
Human Genomic DNA 
Contamination HIGX1A 
H07 RTC 
Reverse Transcription 
Control RTC 
H08 RTC 
Reverse Transcription 
Control RTC 
H09 RTC 
Reverse Transcription 
Control RTC 
H10 PPC Positive PCR Control PPC 
H11 PPC Positive PCR Control PPC 
H12 PPC Positive PCR Control PPC 
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Appendix B: Synthesis of VS-43 
Synthesis of VS-43 ((3E,5E)-3,5-Bis-(3,4,5-trimethoxybenzylidene)-1-phenylpiperid-
4-one) was as follows: 
A solution of appropriate N-phenyl-4-piperidone (100 mg, 0.6 mM) and 3,4,5-
trimethoxybenzaldehyde (235 mg, 1.2 mM) in glacial acetic acid (2.0 mL) was 
purged with dry hydrogen chloride gas for 20-25 minutes. The reaction mixture was 
stirred at room temperature for 16 hours, poured into ice-water, and neutralised with 
solid sodium carbonate. The organic product was extracted with ethyl acetate (3 x 
10 mL), which was combined and dried with anhydrous sodium sulfate. Removal of 
the drying agent and solvent gave a residue that was purified by silica gel column 
chromatography. The desired product, drying in vacuum at 40-45 °C, was isolated 
as a yellow solid (100 mg, 33%), Mp = 134-136 °C, Rf = 0.55 [ethyl acetate:hexane 
(2:3)]; FT-IR (KBr) n 3473, 3020, 2935, 2834, 1659, 1594, 1577, 1497, 1450, 1415, 
1385, 1360, 1241, 1213, 1186, 1120, 1046, 1038, 996, 963, 835, 793, 764, 734, 
720; 1H NMR (CDCl3) δ 7.82 (s, 2H), 7.16 (t, J = 8.0 Hz, 2H), 6.81 (t, J = 8.0 Hz, 
1H), 6.74 (d, J = 8.0 Hz, 2H), 6.66 (s, 4H), 4.67 (s br, 4H), 3.86 (s, 6H), 3.84 (s, 
12H); 13C NMR (CDCl3) δ 186.9, 153.2, 148.7, 139.3, 137.9, 132.3, 130.6, 129.3, 
120.2, 116.5, 107.9, 61.0, 56.3, 51.3; LRMS (EI) m/z 531 (M+, 100%). HRMS (EI) 
calcd for C31H33NO7 531.2257, found 531.2254. 
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Appendix B Figure 1: Synthesis of VS-43. 
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Appendix C: STAT3 binding sites upstream of DNA repair genes 
identified by UCSC Genome Browser 
GENE STAT3 binding site 
EME1 chr17 48449918 48450328 
chr17 48449918 48450328 
chr17 48449918 48450328 
chr17 48449918 48450328 
chr17 48449918 48450328 
chr17 48449918 48450328 
chr17 48449918 48450328 
chr17 48449918 48450328 
MUS81 chr11 65627711 65628059 
chr11 65627711 65628059 
chr11 65627711 65628059 
chr11 65627711 65628059 
chr11 65627711 65628059 
chr11 65627711 65628059 
chr11 65627711 65628059 
chr11 65627711 65628059 
chr11 65627711 65628059 
BRCA1 chr17 41276552 41276828 
chr17 41277280 41277690 
FANCG chr9 35079960 35080310 
chr9 35079960 35080310 
chr9 35079960 35080310 
chr9 35079960 35080310 
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GENE STAT3 binding site 
chr9 35079960 35080310 
chr9 35079960 35080310 
FANCM chr14 45646302 45646637 
FANCI chr15 89786961 89787287 
chr15 89786961 89787287 
CHEK2 chr22 29108348 29108722 
chr22 29108348 29108722 
chr22 29108348 29108722 
chr22 29108348 29108722 
chr22 29138506 29138750 
chr22 29138506 29138750 
chr22 29138506 29138750 
chr22 29138506 29138750 
chr22 29138506 29138750 
chr22 29138506 29138750 
chr22 29138506 29138750 
chr22 29138506 29138750 
chr22 29138506 29138750 
chr22 29138506 29138750 
chr22 29138506 29138750 
chr22 29138506 29138750 
chr22 29138506 29138750 
H2AFX chr11 118966349 118966670 
chr11 118966349 118966670 
MDC1 chr6 30685155 30685510 
chr6 30685155 30685510 
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GENE STAT3 binding site 
MSH6 chr2 48010135 48010490 
chr2 48010135 48010490 
chr2 48010135 48010490 
chr2 48010135 48010490 
RAD51AP1 chr12 4647486 4647896 
chr12 4647486 4647896 
chr12 4647486 4647896 
chr12 4647486 4647896 
chr12 4647486 4647896 
chr12 4647486 4647896 
chr12 4647486 4647896 
chr12 4647486 4647896 
chr12 4647486 4647896 
chr12 4647486 4647896 
chr12 4647486 4647896 
chr12 4647486 4647896 
chr12 4647486 4647896 
chr12 4647486 4647896 
RAD51B chr14 69010937 69011262 
RAD54B chr8 95385447 95385727 
CHEK1 chr11 125491913 125492229 
chr11 125491913 125492229 
chr11 125491913 125492229 
chr11 125491913 125492229 
chr11 125491913 125492229 
chr11 125491913 125492229 
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GENE STAT3 binding site 
chr11 125491913 125492229 
chr11 125491913 125492229 
chr11 125491913 125492229 
chr11 125491913 125492229 
ERCC1 chr19 45927618 45927952 
chr19 45927618 45927952 
chr19 45927618 45927952 
chr19 45927618 45927952 
chr19 45927618 45927952 
chr19 45927618 45927952 
chr19 45927618 45927952 
chr19 45982169 45982495 
HMGB1P27 chr2 192036449 192036910 
MDM2 chr12 69202547 69202858 
chr12 69202547 69202858 
chr12 69202547 69202858 
chr12 69202547 69202858 
chr12 69202547 69202858 
chr12 69202547 69202858 
chr12 69202547 69202858 
chr12 69202547 69202858 
chr12 69202547 69202858 
chr12 69202547 69202858 
chr12 69202547 69202858 
chr12 69202547 69202858 
chr12 69202547 69202858 
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GENE STAT3 binding site 
chr12 69202547 69202858 
chr12 69202547 69202858 
chr12 69202547 69202858 
chr12 69202547 69202858 
MLH3 chr14 75516304 75516585 
chr14 75516304 75516585 
chr14 75516304 75516585 
chr14 75516304 75516585 
chr14 75516304 75516585 
chr14 75516304 75516585 
MRE11A chr11 94182617 94182941 
chr11 94183305 94183585 
RAD52 chr12 1023485 1023789 
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Appendix D: Radiosensitisation by VS-43 
VS-43 can radiosensitise DU145 cells. Cells were treated with VS-43 for 18 hours 
and subsequently irradiated. Cell survival was assessed by colony formation assay 
(supplementary methods). Pre-treatment with VS-43 resulted in a dose-dependent 
decrease in colony formation following irradiation. 
 
Appendix D Figure 1: Radiosensitisation by VS-43.  
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